P00001606T0076|0 9|Comparison
P00008171T0000|0 19|Pharmacologic aspects
P00008997A0472|4 6|CSF
P00010943A0733|0 9|Flurazepam
P00012653T0045|0 3|Beta
P00013683A0210|4 27|extracorporeal CO2 removal
P00015731A0090|0 24|Intravenous administration
P00022143T0000|0 17|Teratological study
P00023348A0601|0 15|Colorectal polyps
P00024600A0522|3 26|variable HMG dosage regimen
P00025557A0100|7 16|CO2 content
P00027739T0000|0 28|Serum gamma glutamyltransferase
P00027967A0207|11 31|secretory HI antibodies
P00029555A0861|18 27|virus assay
P00029953T0045|0 14|Characteristics
P00030183T0000|0 7|Takayasu
P00030937A0119|0 3|SGPT
P00033873T0001|0 26|Gamma glutamyl transpeptidase
P00034935A0545|0 7|Patients
P00038408T0000|0 19|Selective stimulation
P00039271T0000|0 17|Anti-anxiety action
P00041512T0067|0 8|Abstracts
P00048373A0377|0 6|Removal
P00050628A0202|2 24|IgG monoclonal gammopathy
P00052597T0000|0 6|Studies
P00054900A0226|0 23|Peroxydase reaction stains
P00055040A0000|3 14|out-patients
P00056837A0000|5 21|mediastinoscopies
P00056901A0308|10 21|human albumin
P00060529A0695|12 23|control group
P00061478T0000|4 16|complications
P00063680T0000|0 16|Prenatal diagnosis
P00064414A1098|0 4|Sings
P00066874T0000|0 47|False positive amniotic fluid alpha fetoprotein levels
P00072928T0000|0 13|Serum-ferritin
P00073344A0367|3 10|subjects
P00074758T0000|0 7|Patients
P00083846T0000|0 6|Albumin
P00084275T0063|0 6|Preface
P00086313A0000|11 17|strains
P00088391A0181|5 19|other hand factor
P00089778A0000|18 37|alpha 2-macroglobulin
P00092689A0352|6 6|%
P00094639A0313|0 7|Prazosin
P00096241A0087|0 1|T4
P00097989A0106|1 20|three-phased analysis
P00100540T0000|0 17|Aspirin intolerance
P00100791A0425|5 11|results
P00101300A0257|2 6|cases
P00105401A0635|11 13|CBZ
P00105903A0288|3 17|present research
P00111174A0351|16 35|functional properties
P00112627A0542|0 12|Pentobarbital
P00113657A0628|0 5|Pb foil
P00114144A0189|2 11|anatomical
P00115974A0576|3 8|groups
P00117748T0000|0 11|Erythromycin
P00118044A0000|7 26|angular displacements
P00118810T0001|0 15|Hemolytic disease
P00119339A0400|55 66|less virulent
P00122718A0500|13 20|MRF units
P00129659T0000|0 10|Variability
P00130573T0054|0 2|VII
P00131739T0001|0 24|Several demographic indices
P00133214T0064|4 11|concepts
P00136175A1137|25 50|myocardial capillary density
P00137671A0896|5 16|observations
P00139624A0318|5 9|hours
P00139827A0000|0 16|Radioimmunoassays
P00142718A0156|9 16|patients
P00146327A0147|13 18|tumors
P00149899T0001|0 9|Prediction
P00150066A0100|0 20|Native human fibrinogen
P00150066A0554|2 27|post-operative haemorrhages
P00154430A0906|3 19|Southern technique
P00155973A0387|26 31|limits
P00159600A0871|0 1|SV
P00163384A0000|3 9|carcass
P00167544A0067|3 11|inner ears
P00168176A0000|0 6|Patulin
P00168431T0000|0 18|Steroid glucuronides
P00172199A0270|3 8|matrix
P00173860A0475|0 9|Riboflavin
P00176742T0000|0 10|Polyglactin
P00183063A0300|3 11|incidence
P00188387A0975|0 6|Studies
P00193088A0196|7 25|other normal subjects
P00193587T0000|0 12|EEG theta waves
P00196255A0000|0 14|REM dream content
P00198510T0000|0 10|Innervation
P00199012T0000|0 18|Ectopic ACTH syndrome
P00201881A0487|1 15|striking finding
P00205074A0000|0 22|Chronic hypophosphatemia
P00209664A0836|28 34|serum LH
P00210220X0000|0 22|Molecular neurochemistry
P00211881A0602|0 6|Efforts
P00216939T0001|0 5|Effect
P00219533T0001|0 11|Distribution
P00219565A0172|3 11|incidence
P00219674A0000|0 55|Technetium-99m stannous pyrophosphate myocardial scintigrams
P00221136A0984|1 17|similar phenomenon
P00221725A0523|25 41|cytochrome oxidase
P00222102A0227|0 8|Treatment
P00222827A0000|0 6|Workers
P00224013A0661|0 7|Total VO2
P00225352T0000|0 31|Phenobarbital-induced alterations
P00227393T0000|0 9|Modulation
P00227610A1593|11 18|respects
P00231555T0001|0 5|Effect
P00232354A0286|0 8|Serum ACTH
P00232456T0000|0 6|Anatomy
P00234206T0000|0 7|Bertioga
P00234264A0164|0 34|Gamma glutamyl transpeptidase activity
P00234626T0036|0 2|XXI
P00239014A0000|1 31|gas-liquid chromatographic method
P00239169T0000|0 23|Dopamine receptor blockade
P00240016T0033|0 1|V.
P00240518A0000|1 26|rapid fluorimetric procedure
P00242427T0001|23 38|supervisory nurse
P00254537T0000|5 13|graduates
P00261981A0434|10 34|maternal serum somatomedin A
P00264240A1843|3 11|sequences
P00265964A0562|34 46|grain boundary
P00267764A0651|30 36|reasons
P00294502T0001|0 8|Diagnosis
P00300314A0132|9 25|serious infections
P00303189A0247|24 28|drugs
P00304240A0369|7 23|conventional tests
P00304310A0000|3 11|end-stage
P00304806A0760|12 36|serum alpha1AT quantitation
P00313766A0666|2 9|patients
P00316723A0558|0 6|Changes
P00321261A0104|3 17|uterine response
P00330364A0132|10 19|BCG strains
P00331128A0000|0 9|High levels
P00331936T0000|0 8|Detection
P00336354A0543|13 19|serum GH
P00336547A0000|3 15|mortality rate
P00337102T0058|0 7|Williams
P00339289T0049|0 2|Use
P00340692T0033|1 8|Emeritus
P00342623A0228|9 16|vaccines
P00350465T0000|0 17|Antenatal diagnosis
P00352569A0000|0 18|Hepatic oxygen supply
P00354315T0000|0 17|Gonadal dysfunction
P00358945A0225|3 15|maximum period
P00361059T0000|11 29|comparative efficacy
P00361340A0529|0 3|Most
P00369397A0280|0 7|Basal FSH
P00369683T0000|0 9|Adriamycin
P00377466A0188|0 16|Follow-up controls
P00378492A0475|0 11|Renin studies
P00378735A0000|11 23|clinical trial
P00381783T0000|0 29|Bone marrow transplantation-1979
P00383169A0000|17 31|clinical actions
P00384744T0000|3 34|unilateral vestibular hypofunction
P00385457A0187|8 17|inhibition
P00386251A0899|3 19|IDF standard method
P00390932T0001|0 15|Capsular antigens
P00393598A0198|11 24|endotoxin fever
P00397806T0039|1 16|new Algerian cases
P00401521A0138|11 17|percent
P00401676A0414|0 24|Accurate pathologic staging
P00406585T0001|0 17|Inherent hematology
P00409927A0570|0 7|Neomycin
P00411465A0142|42 45|cent
P00413854A0958|0 6|Changes
P00414575T0000|0 19|Ultrasonic evaluation
P00415543A0320|0 10|Recognition
P00416758T0001|0 8|Isolation
P00417166T0000|0 21|Pharmacokinetic profile
P00417301T0001|0 20|Immunologic mechanisms
P00418341T0000|0 19|Intestinal adaptation
P00420460A0291|2 9|patients
P00423649A0259|5 14|techniques
P00425547A0000|2 9|patients
P00427715A0000|10 17|patients
P00429151T0000|0 3|Year
P00429893A0000|4 26|multiple-electrode array
P00429949A0000|17 58|World Health Organization 29th Expert Committee
P00430889T0001|0 22|Biliary-enteric fistulas
P00431832T0001|0 15|Plasma ion changes
P00432615A0541|0 20|Such marked differences
P00435187T0000|14 25|flowers bloom
P00437749A0242|0 25|Various treatment modalities
P00439618T0001|0 15|Lethal Tachmalcor
P00439716T0001|0 29|Ophthalmosonographic evaluation
P00445259T0000|0 25|Serum ferritin concentration
P00445720A0263|3 26|systolic pressure gradient
P00450367T0000|1 16|prospective trail
P00450559A0269|33 51|inaccurate Clinitemp
P00450760T0001|0 15|Cryoglobulinemia
P00451192A0248|0 3|Data
P00453780A0430|3 30|preferential serum IgA response
P00454780A0340|0 17|Ultimate strengthes
P00456424A0000|3 9|effects
P00463973A0000|0 13|Platelet number
P00464387A1185|0 17|Serial measurements
P00465223A0373|6 13|patients
P00465681A0000|7 29|hemoglobin concentration
P00465829T0000|0 5|Nernst
P00473229T0000|0 6|Effects
P00473249T0000|0 5|Effect
P00474064A0205|18 36|convlusion threshold
P00476020T0000|3 14|biochemistry
P00476572A0139|24 29|lesion
P00477794T0000|0 6|Effects
P00478714T0000|0 7|Efficacy
P00479222A0682|0 9|Resistance
P00479246T0000|8 40|calcaneal tuberculous osteomyelitis
P00481612A1121|17 31|opiate receptors
P00483716A0366|23 47|convoluted internal carotid
P00484177A0242|26 43|laminar flow regimen
P00485615A0935|30 56|hyperlipemic abdominal crisis
P00488534A0308|11 48|significant Treatment X Strain interaction
P00490336A0181|5 22|conduction velocity
P00493818A0422|3 10|failures
P00494659A0391|3 25|major urinary metabolites
P00495097A0663|5 19|characteristics
P00497494A0112|3 13|ventilation
P00499588T0000|0 21|Carbohydrate metabolism
P00503336A0285|16 19|CAEC
P00506559A0000|3 29|sub-acute inhalation toxicity
P00506649T0000|0 6|Changes
P00509703A0581|5 15|differences
P00510341T0036|11 20|E.O.R.T.C.
P00512215A0000|3 14|present study
P00513284A0000|2 23|intravenous preparation
P00513284A1255|14 17|days
P00516545T0001|0 24|Structural characteristics
P00517890A0468|3 14|enteric route
P00519173A0126|5 12|patients
P00521732T0000|0 15|Urinary excretion
P00524451A0136|11 38|spontaneous locomotor activity
P00528144T0000|11 21|transferrin
P00534613A0000|0 10|Irradiation
P00535520A0239|4 20|certain exceptions
P00540707A0255|12 30|satisfactory results
P00541752A1032|7 20|determinations
P00550399A0615|6 20|commonest causes
P00553858A0000|8 12|Grice
P00555492A1034|5 11|changes
P00555495T0000|0 4|Study
P00555583T0000|0 15|Pharmacokinetics
P00557559A0170|5 13|compounds
P00564032A0724|0 6|Changes
P00564943A0444|0 5|Calves
P00565136T0000|18 21|mice
P00565314A0293|0 9|Guinea pigs
P00569989A0239|5 23|halothane anesthesia
P00574222T0000|0 14|Sensory kindling
P00574956A0304|17 26|stereotypy
P00575231A0422|0 3|None
P00577440A0298|5 12|duodenum
P00578648T0048|0 16|Functional effects
P00580106T0000|0 8|Treatment
P00580151A0706|61 72|testosterone
P00583004A0445|0 7|Contrary
P00583522T0001|0 15|Etiopathogenetic
P00587791T0054|0 6|Nursing
P00589073A0000|10 43|basal plasma prolactin concentrations
P00590594T0000|0 25|Ovarian allotransplantation
P00592887T0000|0 15|Allergic reaction
P00593119T0001|0 8|Screening
P00594466T0001|3 11|induction
P00594617A0192|7 28|significant correlation
P00597715A0256|0 8|One-third
P00598012A0174|2 21|girls prolactin levels
P00599601A0260|29 46|surgical procedures
P00600943T0001|1 5|cases
P00601401A0181|6 23|hemoglobin solution
P00602622A0362|1 20|one-week ulcer therapy
P00602702A0309|16 29|severe diarrhea
P00603783A0647|0 10|Serum levels
P00606849T0000|0 31|Experimental ischemic heart disease
P00614915T0001|0 9|Vitrectomy
P00616575A0000|27 48|central brain structures
P00617815A0215|2 25|systematic L-R differences
P00618078A0367|14 29|lysozyme activity
P00619305A0759|18 23|groups
P00619782A0058|0 7|Deep tans
P00619948A0000|4 10|effects
P00621626T0000|0 12|Stress effects
P00622556A0111|16 23|collagen
P00623361A0221|0 6|Smoking
P00626014T0001|3 11|malignity
P00627039T0000|0 10|Elimination
P00627129A0944|5 13|responses
P00627202T0000|0 8|Diuretics
P00628990A0000|5 12|patients
P00630713T0000|0 9|Evaluation
P00633909A0000|18 25|patients
P00635143T0001|0 5|Action
P00635194A0093|0 12|Kodak XV-2 film
P00636526T0033|0 8|Diagnosis
P00637637T0000|3 17|multiple factors
P00639410T0000|0 8|Cortisone
P00640584A0250|5 25|time-sharing principle
P00641395A0441|4 15|blood samples
P00644314T0000|7 22|hypersensitivity
P00644539A0783|18 27|inhalation
P00646023T0058|0 18|Experimental studies
P00646193T0000|0 6|Potency
P00656008T0000|0 9|Prevention
P00657551T0000|0 10|Measurement
P00659962T0000|9 34|urinary riboflavin excretion
P00663166A0000|0 22|Radionuclide angiography
P00664320T0000|7 15|detectors
P00665053A0276|14 37|single sero-anzymatic type
P00665214A0374|45 54|physiology
P00665336A0908|5 12|same time
P00668122A0414|0 7|Analysis
P00669800A0579|0 9|Female mice
P00676416A0320|22 26|years
P00676790T0000|0 16|Angiotensin effect
P00681550A0000|0 12|Procion yellow
P00681571T0028|0 17|Incidental findings
P00682762T0001|0 17|Silicosis mortality
P00685922A0451|26 35|strictures
P00686836A0000|0 6|Pentane
P00693987T0001|0 13|Thromboplastic
P00696680A0000|3 9|authors
P00696858A0000|11 36|pure natural porcine secretin
P00701144T0000|0 16|Biometric analysis
P00701462A0722|0 14|Urine antibodies
P00702773A0327|0 9|Althoug RBF
P00703350A0418|0 11|99mTc phytate
P00703932A0000|3 10|patients
P00704675A0199|9 11|UO2
P00710217T0001|0 12|Synovial cysts
P00710372A0302|10 32|hypothalamic dysfunction
P00712117A0521|1 13|sharp outbreak
P00713525A0268|7 15|decreases
P00715180T0074|0 5|Effect
P00715753A0241|2 22|biopsies CK-MB fraction
P00716366T0001|0 4|Value
P00722298A0619|1 15|one-way analysis
P00722652A0118|0 33|Several free 2nd-generation schizonts
P00725257A0452|13 21|pD2 values
P00725336T0000|0 32|Newcastle disease virus surveillance
P00725534A0888|19 37|persistent challenge
P00725752T0001|0 8|Treatment
P00726581T0122|0 5|Orthop
P00728718T0000|0 13|Thyroid disease
P00729003A1182|0 7|Residues
P00733067A0188|10 15|reflux
P00736376A0371|15 35|eventual high mortality
P00737422A0832|0 8|Pathogens
P00740409A0000|3 16|histochemistry
P00741476A0000|3 15|year-old woman
P00743335T0001|0 12|Reaction times
P00745775A0170|12 19|patients
P00747722A0486|16 34|three-phase reaction
P00748978T0000|0 17|Serum relaxin levels
P00753237A0000|4 31|natural hydrostatic phenomenon
P00755245A0000|0 5|Effect
P00755671A0485|14 20|heparin
P00755869A0216|0 21|Contingency contracting
P00756511T0036|0 8|Dietetics
P00757244A0000|3 9|results
P00759049A0185|3 13|micromethod
P00759400T0000|0 16|Platelet serotonin
P00762763A0253|3 18|overall incidence
P00764737X0000|3 15|vigilance task
P00767155T0001|3 21|December armed revolt
P00767161A0837|0 19|Significant increases
P00768220X0000|3 11|motor unit
P00771729X0000|0 22|Avian reproductive system
P00775582T0000|0 19|Biological properties
P00779272T0001|0 17|Serological studies
P00780639X0000|0 22|Carcinoembryonic antigen
P00792847A0000|21 42|antilymphocyte globulin
P00799988A0554|13 36|global assessment patients
P00803867A0315|0 7|Patients
P00806295A0193|0 9|Absorption
P00807356T0001|0 13|Bacteriostatic
P00808266T0000|0 7|Advances
P00808898A0000|3 26|clinico-pathological data
P00811852T0001|0 19|Personal satisfaction
P00812183T0000|0 23|Dialyzable transfer factor
P00818380A0239|0 15|Rheumatoid factor
P00819176T0001|11 29|hydrostatic pressure
P00821833A0000|33 47|vocal repertoire
P00822611A0467|18 25|patients
P00823087A0608|0 7|Deflunia
P00825571T0031|0 2|III
P00827364A0000|1 13|new instrument
P00830568A0000|0 9|Pancreatic
P00832096T0000|0 24|Abnormal calcium metabolism
P00833472A0907|35 44|gallstones
P00836637A0000|1 20|five-phase experiment
P00837262A0000|3 16|responsiveness
P00837811A0675|12 13|MS
P00838152A0863|14 32|mean temperature rise
P00839378A0649|3 15|elevated Viso V
P00842406A0771|3 20|psychological tests
P00842522T0000|0 27|Selective bronchial intubation
P00843232A0100|36 52|etiological factor
P00846559A0000|6 12|strains
P00847967T0000|0 20|Current diagnostic uses
P00851041A0000|1 14|follow-up study
P00851286A0375|0 5|Deaths
P00857024A0888|0 9|Recurrence
P00863184T0043|0 9|Adaptation
P00863773T0000|0 6|Dangers
P00866577A0579|0 8|Treatment
P00868301A0043|2 21|diethyl ether solution
P00868903A0000|0 7|Amikacin
P00870859A0121|27 38|insufficient
P00871237A0601|37 42|angina
P00872442T0000|0 9|Estimation
P00872922A0204|3 7|acids
P00874942T0000|0 21|Unrecognized amnionitis
P00875778T0000|0 9|Evaluation
P00876722T0000|0 27|Bacterial meningitis secondary
P00877857A0763|0 11|Serum amylase
P00879329A0176|5 22|control preparation
P00879829A0564|0 6|Infants
P00881630A0000|3 22|morphological effects
P00885562A0281|5 8|GAGs
P00890028A0507|3 14|length scales
P00891370A0000|0 26|Well-visualised arteriograms
P00892353A0686|2 12|hypotension
P00898500A0246|3 6|sera
P00903772A0359|0 7|Wherever
P00909114A0000|0 17|Diallylnitrosamine
P00910823A0196|14 35|experimental conditions
P00911590T0000|0 20|Haemodynamic responses
P00913623A0242|19 32|large molecules
P00915090A0536|11 14|days
P00916099A0000|0 16|Self-emasculation
P00917572T0001|0 10|Possibility
P00917721A0484|23 38|reliable evidence
P00918556A0000|3 12|prevalence
P00918965A0728|18 25|patients
P00920381T0000|9 23|cardiac glycogen
P00921032T0000|0 19|Biological evaluation
P00921911A0159|0 5|Levels
P00926272A0000|7 17|common cause
P00926604A0504|0 10|Propranolol
P00926751A0000|0 12|Recent studies
P00927633T0001|8 40|electron microscopic investigations
P00928529T0001|0 14|Feeding behavior
P00929418T0001|0 3|Role
P00930947A0629|13 28|drug interactions
P00931089T0001|0 16|Circulatory arrest
P00932738A0116|3 23|systolic blood pressure
P00932817A0499|0 9|Iodine-123
P00933251T0000|0 16|Petrous meningioma
P00935526A0000|3 14|difficulties
P00938594A0149|2 10|cessation
P00941050T0000|17 38|procainamide absorption
P00947327A0000|34 53|antibiotic resistance
P00947834X0000|0 6|RESULTS
P00951909X0001|4 23|afferent loop syndrome
P00952734T0000|0 5|Letter
P00954819A1041|20 38|spontaneous recovery
P00956364A0138|0 12|Batch cultures
P00956554A0414|5 11|samples
P00958550T0001|0 5|Crisis
P00959656A0250|0 12|Pregnant women
P00961711T0000|0 16|Hematology problem
P00962222A0633|16 31|cyclic variations
P00962277T0000|0 12|Haemodilution
P00964758T0001|0 25|Extramedullary plasmacytoma
P00967223T0059|0 1|I.
P00968181A0264|12 17|calves
P00970320A0000|33 60|chemical cartridge respirators
P00970488A0105|3 29|neuroleptic-induced increase
P00970839A0118|0 11|Rainbow trout
P00974901A0080|0 10|Stimulation
P00975314T0001|0 17|Primary amenorrhoea
P00975540T0000|6 20|absolute methods
P00980255T0000|0 10|Application
P00984209A0614|0 17|Serum gastrin levels
P00985110T0001|0 18|Efferent projections
P00985276A0000|0 8|Preflight
P00985279A0493|0 38|Mean corpuscular hemoglobin concentrations
P00986800A0325|3 10|Cu values
P00986925A0002|11 20|calcitonin
P00987649T0001|0 4|State
P00988572A0000|0 12|Oxygen tension
P00989973A0000|16 36|plasma fibrinogen level
P00992316A0178|10 34|rectilinear pressure curves
P00993176A0066|5 13|myoglobin
P00996272A0397|16 22|sources
P00996364X0000|0 0|E
P00999494A0000|3 10|patients
P01000378T0000|0 5|Effect
P01003819A0498|14 24|nomogram one
P01004298A0744|4 13|up-grading
P01009451A0728|10 17|controls
P01009739T0001|0 5|Effect
P01009841T0001|0 14|Dual innervation
P01010638A0161|34 34|%
P01012640T0001|0 21|Certain characteristics
P01012904A0333|3 30|color-word interference effect
P01019207A0232|30 39|conditions
P01021091T0000|14 29|adrenergic nerves
P01027644T0001|0 13|Potscoital test
P01030985T0090|0 1|I.
P01035457A0623|5 10|tumour
P01036714A0072|0 6|Studies
P01044338A0240|0 19|Infrared measurements
P01047417T0000|8 32|National Health Dis-service
P01047895T0001|13 32|patient care justified
P01048020T0000|0 7|Critique
P01048968A0152|5 11|studies
P01050144A0297|11 23|steep decrease
P01050400T0000|0 10|Improvement
P01057137A0192|17 37|clinical acceptability
P01064124A0560|7 7|d
P01067493A0119|3 22|contraceptive pattern
P01071715A0903|0 24|Plethysmographic technique
P01075075T0038|0 1|I.
P01078982A0227|44 67|combined cyclophosphamide
P01080374A0709|0 7|Evidence
P01081904A0198|0 5|Fibrin
P01082726A0248|15 25|mobile pupil
P01082833A0000|17 38|anti-inflammatory agent
P01083321X0000|2 7|stands
P01083375T0000|0 17|Alpha-1 antitrypsin
P01083784T0000|0 23|Lymphocyte subpopulations
P01084413A0271|8 36|normal ventricular measurements
P01087288T0000|24 43|cytogenetic estimates
P01088654T0001|0 8|Technique
P01090210A0417|0 20|Mean total lung capacity
P01092248T0000|0 12|Current status
P01093055T0000|0 6|Calcium
P01093845A0208|0 12|Modern studies
P01093847A0000|21 44|tropatepine hydrochloride
P01096741X0000|0 15|Epididymal growth
P01097100A0217|3 10|patients
P01098179A0167|0 6|Results
P01098592A0567|0 8|IgG levels
P01099693T0000|0 5|Letter
P01101272T0000|0 9|Assessment
P01103390A0149|3 21|discordant behaviour
P01107226A0808|0 20|Residual amphotericin B
P01113908A0475|9 22|slight increase
P01116254A0000|9 33|intravenous administration
P01116466A0185|0 17|Thromboplastin time
P01118293A0150|27 37|suppression
P01119586A0337|0 18|Glycogen utilization
P01119658A0000|3 9|records
P01122015A0467|7 9|vol
P01123658A0000|3 9|authors
P01124944A0830|7 22|parental attitude
P01125117A0183|18 24|attacks
P01128985A0000|11 32|useful diagnostic method
P01130186A0568|3 27|other hypoglycaemic patient
P01130531A0224|0 15|Nerve stimulation
P01131946T0001|0 5|Effect
P01138215T0001|0 3|Risk
P01138330A0204|0 12|Bulbar pouches
P01140184A0342|0 14|Liver microsomes
P01141114A0188|0 17|Prolonged heavy work
P01145884T0028|10 20|serological
P01147436T0000|3 33|American Burkitt Lymphoma Registry
P01147502T0000|0 9|Vitrectomy
P01148868A0284|3 24|metabolic clearance rate
P01150658A0683|63 68|Sairam
P01156631A0658|3 31|mean plasma sodium concentration
P01156814T0000|0 8|Editorial
P01157191A0536|9 22|high dose levels
P01157614T0000|0 6|Effects
P01158512T0000|0 31|Glucose-6-phosphate dehydrogenase
P01158838A0438|3 16|eluting solvent
P01159822A0353|3 20|bronchial epithelia
P01168607A0672|3 23|routine administration
P01168908A0000|0 14|Prostaglandins F
P01168956A0552|38 52|fetal weight gain
P01170143A0247|0 5|Groups
P01171020A0711|3 9|effects
P01171935A0313|15 41|dyskinetic movement disorders
P01172734T0035|0 10|Association
P01172917T0000|0 5|Letter
P01174873T0000|0 13|Retinoblastoma
P01176905A0094|4 18|pineal melatonin
P01178153A0056|0 1|D.
P01178637T0001|0 14|Atherosclerosis
P01185956A0722|3 9|authors
P01186344A0303|3 12|attainment
P01190120A0832|15 26|% lengthening
P01190251A0335|0 6|Caution
P01191955A0077|12 18|new test
P01191964A0000|5 10|groups
P01193458T0001|0 24|Routine isotope cystography
P01193770T0000|0 11|Air ion action
P01194673A0652|28 46|negative chemography
P01201977T0000|19 45|antibiotic disc sensitivities
P01202616A0466|9 21|retransfusion
P01206772T0000|8 18|chromosomes
P01206896T0001|0 14|Characteristics
P01208811T0001|0 4|Study
P01209618A0409|0 9|Tobramycin
P01211754A0192|20 24|cases
P01215067A0000|3 30|specific electrical resistance
P01217450A0295|2 18|Chemical occlusion
P01224116A0576|18 25|patients
P01225339A0590|13 26|such occlusions
P01228258A0000|0 23|Streptococcal preparation
P01228882A0437|40 60|highest concentrations
P01233561T0001|0 16|Maternal lactation
P01235347T0001|0 25|Experimental cardiotoxicity
P01236224T0001|0 16|Muscular pathology
P01237206A0199|0 12|Demonstration
P01241437A0152|3 10|patients
P01241588A1470|3 13|alterations
P01241866A0682|15 30|leukocyte-counts
P01242636A0678|3 9|results
P01243628A0286|6 10|cases
P01244236A1122|3 9|results
P01245162A0262|0 8|Reduction
P01246210A0648|3 14|calcium ratio
P01247475A0000|1 13|late diagnosis
P01248124A0281|0 15|Total cholesterol
P01249198A1097|3 23|serum FT3 concentration
P01252223A0347|3 9|authors
P01253191T0000|10 43|phase-plane technique representation
P01256410T0001|1 10|activities
P01259027A0416|13 37|structural identifiability
P01261005A0711|19 37|lot-to-lot variation
P01262596T0000|3 20|cochlear compromise
P01264640T0028|15 20|Saigon
P01265443A0159|0 16|Hypertonic glucose
P01265887T0001|8 26|factor VIII inhibitor
P01267446A0210|0 15|Biohydrogenation
P01272816A0000|10 26|calcium metabolism
P01275335A0158|0 15|Chlamydial agents
P01275541A0405|21 31|CPK activity
P01276105A0313|14 28|insulin response
P01278251A0000|3 9|authors
P01279197T0000|0 17|Mutational analysis
P01279352A0297|8 10|PAL
P01279352A0473|0 14|Nuclear extracts
P01279352A1197|16 17|NF
P01279374A0396|23 34|more new genes
P01279696A0862|0 14|Previous studies
P01280413T0001|0 8|Treatment
P01280807A0575|3 12|apparent Kd
P01281322A0604|1 29|significant direct relationship
P01281472T0000|0 29|Rabbit skeletal muscle glycogenin
P01281771T0000|0 15|Characterization
P01282014A0275|0 6|Animals
P01282638A0934|3 17|prophylactic use
P01284032A0213|0 1|AP
P01284595A0102|54 64|Y-231 cosmid
P01284828T0001|0 25|Tissue plasminogen activator
P01285009A0000|0 13|Gene constructs
P01285358A0396|0 11|Serum gastrin
P01285554T0000|0 8|Prospects
P01285807A0365|11 12|SD
P01286732A0572|6 17|hepatomegaly
P01287197A0761|6 15|first group
P01292230A0283|6 10|drugs
P01294345A0591|14 38|significant improvement due
P01295373A0651|17 29|early response
P01295500A0366|0 3|Most
P01296815A0059|11 24|third human gene
P01297332A0983|44 47|SCBs
P01297332T0000|0 17|Mutational analysis
P01298173A0153|3 16|natural history
P01298398A0461|40 55|nadolol racemate A
P01299489A0788|35 48|little evidence
P01300914A1066|14 33|histological criteria
P01301171A0979|6 10|cases
P01302765A0999|5 14|components
P01304515A0178|11 17|results
P01304809T0001|3 7|years
P01309244A0798|25 33|positions
P01309587A0715|0 25|Synergistic transactivation
P01309593A0095|3 17|UCR core sequence
P01309593A1092|5 11|studies
P01309815A0972|12 25|scr1-1 mutation
P01309860A0559|3 19|cellular sequences
P01309894A0807|4 8|Rep78
P01309910A0428|0 25|Nucleotide sequence analysis
P01310154A0879|5 11|results
P01310178A0876|3 27|JS78 mutation changes Gln243
P01310879A0000|1 16|patient suffering
P01310899A0339|12 28|receptor structure
P01310935T0000|10 14|UbcD1
P01312005A0600|0 7|Analysis
P01313715A0461|12 23|present study
P01313846A0850|0 9|Comparison
P01313894A1179|7 20|similar pattern
P01313909A0526|3 12|phenotypes
P01314457T0000|0 7|Analysis
P01314841A0724|0 8|Treatment
P01314953A1266|11 37|gel mobility shift experiments
P01315706A0000|0 22|Myogenic differentiation
P01316125A0176|37 39|1O2
P01316125A0382|3 8|points
P01316459A0311|0 3|Acad
P01316461A1083|6 31|vitro-synthesized S2 protein
P01316476A0842|0 25|Many canonical TATA sequences
P01316476A1428|3 5|ORF
P01316680A0643|17 22|IR5 ORF
P01316900A0000|3 13|DNA sequence
P01316903A0296|3 22|unphosphorylated form
P01316903A1040|0 15|RNA polymerase IIA
P01317376A0981|0 19|Fructokinase activity
P01318310A0000|0 14|Plasma membranes
P01318739A0410|15 33|patients vincristine
P01320255A0795|5 11|results
P01320640A0336|0 9|Tumor cells
P01321277A0342|1 11|recombinant
P01321277A0664|0 2|ROS
P01321280A0494|31 32|E6
P01321332A0970|0 26|Transient transfection assays
P01321336A0000|3 16|enhancer region
P01321336A0731|3 16|splice variants
P01321337A0318|1 23|third prominent component
P01321337A1161|26 50|MATa cna1 cna2 double mutants
P01324172A0880|0 9|Antibodies
P01324385A0329|0 6|METHODS
P01324404A0813|1 36|position-independent activation domain
P01324404A1208|0 31|HNF-3 beta amino-terminal sequences
P01324406A1250|0 12|Possible roles
P01324639T0000|0 15|Susceptibilities
P01325221A0870|0 15|Nocodazole arrest
P01325386A0766|3 16|hit1-1 mutation
P01326329A0703|6 19|base pair region
P01326557T0000|0 6|Cloning
P01327280A0000|2 5|rats
P01327758A0000|0 10|Replication
P01327967A0668|0 22|Insertional inactivation
P01328197A0985|5 12|findings
P01328219A1397|0 5|NSCL-1
P01328681A0149|0 24|Labile LTR-binding proteins
P01328681A0348|0 6|Ruddell
P01328854T0000|1 15|single MEF-2 site
P01328884T0000|0 17|Truncation variants
P01329039A0239|11 24|E-box consensus
P01329039A0951|0 17|Intermediate levels
P01330077A0000|0 17|T-cell receptor beta
P01330309A1134|3 14|CANNTG motifs
P01330975T0000|0 23|Peripheral polyneuropathy
P01331057A0000|24 28|COX12
P01331060A0768|17 32|calcineurin A gene
P01331086T0000|3 23|basal promoter elements
P01331292A1425|15 31|multiple instances
P01331501A0397|14 35|short synthetic peptides
P01331516A0103|5 11|mutants
P01332589A0666|3 6|MICs
P01332964A0247|3 17|minimal promoter
P01333035T0000|0 6|Mapping
P01333047A0404|14 34|epidermal growth factor
P01333053A0110|1 14|major mechanism
P01333125A0000|14 40|comparative sequence analysis
P01333317A1008|38 40|Sp1
P01334428A1102|0 1|Km
P01334493A0289|4 14|soluble form
P01334518T0000|0 9|Strategies
P01337142A2043|8 45|human glycoprotein alpha-subunit promoter
P01338867A0503|0 9|Comparison
P01339125A0153|0 16|Laboratory studies
P01339373T0000|0 8|Structure
P01339391A0000|29 39|55-kb region
P01339468A0272|3 13|ORF1 protein
P01339773A0000|11 18|patients
P01339773A0778|3 15|relationships
P01339815A1545|2 24|significant correlations
P01340470A0000|2 23|RNA-binding protein gene
P01341119A0450|4 18|research studies
P01346262A0377|1 16|comparative study
P01346534T0000|0 15|Characterization
P01347476T0000|0 6|Mapping
P01347664A1026|4 11|mutation
P01347908T0000|3 11|rationale
P01347944A0964|0 16|Mutational studies
P01348504A0757|8 30|pol alpha-primase complex
P01348508A0313|17 25|positions
P01348590A0000|3 23|retrospective analysis
P01349705T0000|0 6|Effects
P01349837T0000|0 9|cDNA clones
P01350780A0184|0 26|Amino acid sequence comparison
P01350932A1123|3 12|single site
P01352113A0002|3 22|pulmonary toxic events
P01352113A0231|3 18|pulmonary effects
P01353478T0000|0 10|Interaction
P01354506T0000|0 31|Gestational trophoblastic diseases
P01357190A0726|18 24|mutants
P01357528A0084|3 16|subunit protein
P01358190A0654|0 11|Substitution
P01358592A0752|4 28|negative regulatory pathway
P01358758A0000|3 15|distal portion
P01358880A0251|10 26|amino acid sequence
P01359588A0375|4 14|computation
P01360180A0513|0 14|Repeated efforts
P01360180A1568|27 42|P68 amino terminus
P01360294A0000|4 9|August
P01363080A0710|0 11|Visual acuity
P01363166T0001|0 14|Currents aspects
P01364100A0377|12 35|21-mer subrepeat structure
P01370281A0461|0 9|Sequencing
P01370446A0818|5 9|sites
P01371181A0688|13 20|plasmids
P01371272A1167|0 11|Perturbation
P01371275T0000|0 21|Differential expression
P01371413A0742|14 23|hGCSFR gene
P01371863A0000|31 64|differentially-regulated gene family
P01372365A1202|6 10|sites
P01372456A0426|0 7|Necrosis
P01372802A1481|13 20|segments
P01372900A0448|5 9|exons
P01372900A1017|19 48|complete structural organization
P01373374A0735|0 9|Homodimers
P01374331A0636|21 52|distinct transcriptional start site
P01374392A0341|3 20|hydrophobicity plot
P01374398A0951|3 27|initial translation protein
P01374688A0471|19 23|ml/kg
P01375224A0152|0 6|Genetic
P01375913A0484|23 50|synthetic DNA oligonucleotides
P01376319T0000|0 3|Gene
P01377696A0000|3 52|chick axon-associated surface glycoprotein neurofascin
P01377764A0309|3 11|carcinoma
P01377818A0468|11 19|C/EBP beta
P01377962A1012|11 21|tobacco GS-2
P01378052A0594|7 10|acoR
P01378127A0841|11 17|effects
P01378431A0202|0 1|C.
P01378506A0884|16 34|full-deletion mutant
P01378526A0535|29 45|FK506 plasma levels
P01379032A0495|6 12|percent
P01379150A0996|5 15|cibenzoline
P01380062A0097|0 7|T antigen
P01380076A0165|18 37|reversed-phase column
P01380454A0451|24 37|protein product
P01380716A0174|3 15|pulpal tissues
P01380825A0622|0 19|Northern blot analyses
P01383690A1023|3 14|ARG SH2 domain
P01383695A0100|12 25|EBV B-cell clone
P01384040A1043|18 27|activation
P01384165A0000|2 5|rats
P01384229A0175|8 29|possible functional role
P01385462A0151|13 61|separate high-performance liquid chromatographic runs
P01386210A0293|11 23|successful use
P01386897A0000|0 4|Entry
P01387105A0933|7 26|Southern blot analyses
P01388160A1102|5 18|residue Glu-381
P01389362T0000|0 8|Porcelain
P01389573A1071|0 3|TBPf
P01389585A0825|18 27|Scotchbond
P01391001A0583|17 38|important yeasts species
P01392012A0228|3 29|neurohypophysial vasopressin
P01392277A0000|0 7|Comments
P01392358A0389|21 36|telephone contact
P01394200A0592|3 16|treatment group
P01394655A0615b|0 13|Urease activity
P01395755A1023|13 34|significant differences
P01396432A0388|9 17|wide range
P01396444A0934|3 13|experiments
P01396572A0320|10 32|supercoiled plasmid pUC19
P01396583A0204|1 11|cDNA library
P01396592A1113|3 13|experiments
P01396601A0986|14 27|lumenal domains
P01398068A0948|0 8|Complexes
P01398071A0526|20 40|cold-sensitive strains
P01398073A0986|5 11|results
P01398074A0697|3 14|gene sequence
P01398074A1081|3 17|RNase MRP RNA gene
P01398098A0770|0 17|Clone pSRc200 hybrid
P01398104A0834|9 15|results
P01398106A0754|0 7|Cleavage
P01398140A0488|16 28|Xenopus U7 gene
P01399206A0375|3 9|results
P01400217T0000|0 17|Mutational analysis
P01400396A1265|3 10|promoter
P01400401A0065|2 7|humans
P01400401A0854|0 18|Western blot analyses
P01400775A0435|5 11|results
P01402647A0114|0 11|DR1 molecules
P01403222A0391|23 39|collaborative care
P01403391T0000|0 16|Chronic hepatitis B
P01404401A0740|9 21|ATPase cluster
P01404612A0303|10 28|recombinant human Ads
P01406630A0545|0 8|Alignment
P01406630A0965|12 14|p50
P01406656A1075|9 19|cosmid clone
P01406677A0000|8 48|transcriptional control elements responsible
P01406688A0898|0 17|Sequencing analysis
P01406703A1435|12 28|Y1 cell cDNA library
P01407286A0427|0 6|Autopsy
P01408090A0572|17 32|TEE visualization
P01408137A0974|28 41|high G+C content
P01408219A0670|10 17|patients
P01408474A0531|0 12|PaO2 threshold
P01409581A0206|18 38|E26 virus-encoded v-ets
P01409643A0618|7 26|lambda gt11 expression
P01410071T0000|0 10|Blood levels
P01413984A0737|27 46|n-3 FA supplementation
P01414219A0319|3 19|healthy volunteers
P01418272A1072|6 10|ng/mL
P01418494T0000|0 13|Rolandic spikes
P01418542A0000|19 36|beta-glycyrrhetate
P01418834A0987|5 29|chronic hematocrit decrease
P01418860A0797|3 9|effects
P01419945A1386|0 11|Localization
P01420177A1065|0 11|Substitution
P01420223T0000|0 11|Significance
P01420363A0818|3 6|TIMP
P01420363T0000|0 10|Involvement
P01420579A0292|5 21|serum neutralizing
P01421145A1190|0 12|Fractionation
P01421390T0000|1 15|controlled trial
P01421609A1067|24 27|DMVA
P01422265A0263|3 20|IgG subclass profile
P01423454A0309|0 10|Examination
P01423738A0639|5 13|other hand
P01424674A0000|0 20|Cicatricial pemphigoid
P01425653T0000|3 9|effects
P01425921A1286|17 24|features
P01426635A0496|18 22|ZFH-2
P01427034A0440|9 15|introns
P01427457A0000|3 13|prospective
P01428490A0671|3 19|highest prevalence
P01428513A0440|19 30|advantageous
P01429596A1669|17 32|unique properties
P01429624A0328|13 36|nonpermissive temperature
P01429714A0730|0 3|Clin
P01429724A0664|22 43|minimal catalytic domain
P01429740A1065|18 49|complete mitochondrial presequence
P01429768T0000|0 22|Human neutrophil response
P01429836A0457|0 9|Disruption
P01429836A1205|1 10|mutant form
P01431380A0244|14 26|field research
P01431602A0229|3 14|second method
P01431809T0000|0 17|Nucleotide sequence
P01432453T0000|0 9|Validation
P01433391A0594|16 26|dark rearing
P01433502A1163|5 11|results
P01433524A0788|1 12|second domain
P01435698A0000|23 40|blood compatibility
P01436261A0145|0 25|Subcutaneous administration
P01437562A0462|0 17|Anti-CRK antibodies
P01438224A0749|49 50|J.
P01438287T0000|14 27|vaccinia vector
P01441120T0000|0 2|Use
P01441818T0001|0 13|Interferon type
P01443047A0773|2 13|other changes
P01443745T0000|0 21|Respiratory interaction
P01443748A1190|3 17|pressure greater
P01446132A0328|3 13|air embolism
P01446828A1088|13 16|ADH5
P01447139A0208|0 1|V.
P01447189A1546|21 29|RNK-Met-1
P01447189T0000|0 11|Purification
P01448107A0361|16 36|dominant GCN2 mutations
P01448806A0135|0 13|Administration
P01448917A0775|0 10|Comparisons
P01448932T0000|0 41|Rice dwarf phytoreovirus segment S12 transcript
P01449183A0795|23 26|beta
P01449301A0710|0 15|Cold cardioplegia
P01450815A0337|13 23|diatrizoate
P01451771A0619|12 19|analyses
P01452037A0000|3 17|structural genes
P01452584T0000|21 29|exotoxin A
P01452703A0782|0 16|Laboratory studies
P01454518A0336|29 35|domains
P01454819A0000|0 20|Mono-ADP-ribosylation
P01456888A0074|42 52|derivatives
P01457380A0000|3 11|tramtrack
P01457695T0000a|0 6|Removal
P01457695T0000b|0 6|Removal
P01458170A0155|0 9|Adapromine
P01459447A0484|5 13|sequences
P01459451A0478|0 31|GAL4-VP16-mediated antirepression
P01459885A0705|7 10|days
P01459921A0000|36 51|Hampshire wethers
P01460054A0478|9 13|ICSBP
P01460054A0968|10 14|ICSBP
P01460772T0001|7 23|chronic hepatitis C
P01462786T0000|0 20|Dynamic decision making
P01464329T0000|1 33|coiled-coil related protein specific
P01464606A0344|0 16|Comparable amounts
P01467088T0075|0 8|Abstracts
P01467828A0542|5 11|results
P01468625A0282|16 19|LEU2
P01468625A1080|11 14|ACT1
P01469042A0355|5 14|CENP-B gene
P01469047A1606|27 36|tail domain
P01470243A0871|13 20|subgroup
P01470741T0062|0 11|Distribution
P01471602A0362|3 16|appropriate use
P01473196A1016|15 30|more reabsorption
P01473207A0582|3 27|major pathological findings
P01473234A1001|0 10|Green pepper
P01474990A0000|1 12|genomic clone
P01475381T0001|0 10|Brucellosis
P01476376T0000|0 4|Assay
P01477021A0394|0 6|RESULTS
P01478672A0795|3 12|phage clone
P01480183A0000|6 19|flanking region
P01480183A1689|13 31|molecular mechanisms
P01480470A0323|0 5|BiP670
P01482912A0617|3 5|CEM
P01483755A0000|0 28|Magnetic resonance spectroscopy
P01483771A1335|15 23|greater NA
P01485648A0000|17 31|diagnostic value
P01486836A0774|0 7|Patients
P01487144A0505|14 24|gene segment
P01490493A0416|10 25|large examination
P01492463T0001|0 4|Alena
P01493864A0619|0 14|Dopamine neurons
P01495069A0392|0 3|DIBA
P01496348A0000|0 5|Caries
P01496784A0939|3 9|results
P01497582A0593|1 16|second large group
P01498607A0000|4 27|short nucleotide sequences
P01499213A0185|25 38|72-year-old man
P01499616A0136|3 15|mean blood flow
P01502157A0000|0 4|ME1a1
P01504178T0000|13 17|years
P01504853A0299|0 12|Exogenous LHRH
P01505488A0231|11 29|consecutive patients
P01505516A0928|12 23|aspartic acid
P01506705A0282|6 14|V-A bypass
P01506746A0476|0 18|Greater rupture force
P01509798A0520|2 8|rest AFF
P01511231A0085|17 29|smoking habits
P01511950T0000|0 7|Exposure
P01512259A0867|13 28|latter phenomenon
P01512654A0503|5 13|other hand
P01512941A0000|15 43|broad-spectrum fluoroquinolone
P01513114A1133|3 27|mean serum creatinine levels
P01513213A0231|0 15|Model predictions
P01516427T0000|0 14|High-resolution
P01516829A0113|23 26|SNF2
P01516829A0460|10 18|LexA-GAL4
P01518396T0000|0 7|George T.
P01518833A0397|1 21|lambda gt10 cDNA library
P01518849A0165|0 1|NE
P01518926T0000|8 13|topics
P01522699A0092|0 6|Methods
P01523111A0769|0 6|Factors
P01524549A0241|4 15|GH deficiency
P01525153A0359|11 11|d
P01525966T0000|20 30|renal stones
P01526658A0454|0 2|IFI
P01526690T0000|0 23|Mitochondria-lytic action
P01527020A0511|0 19|Exon-intron junctions
P01529530T0000|0 37|Interferon-alpha-induced gene expression
P01531086A0127|3 6|cDNA
P01531214A0885|9 12|LD50
P01531632A0000|8 18|few proteins
P01532229A1264|41 56|ubiquitous factor
P01532796A0107|0 8|Mutations
P01532914A0067|0 6|Expense
P01533760T0000|0 25|Estrogen replacement therapy
P01535242A0557|9 14|FDC-P1
P01536153A0574|18 38|significant difference
P01536575A1213|2 18|unexpected finding
P01537334A0507|15 23|TRP-2 maps
P01537845A0571|5 10|bovine
P01538401A1244|3 26|base-pair oligonucleotide
P01538403A1058|12 25|reconstitution
P01539996A0588|16 32|amino acid sequence
P01541556A1040|0 21|Radiolabelled palmitate
P01541577A0000|2 16|volunteer deaf Ss
P01542565A0220|0 22|Mature tobacco L12 protein
P01542565T0000|0 44|Nuclear-encoded chloroplast ribosomal protein L12
P01542667A0125|15 23|IFN-gamma
P01542686A0000|0 15|Molecular cloning
P01542730A1982|7 45|single-chamber rate-adaptive atrial pacing
P01543909A0787|30 38|K562 cells
P01544854A0699|5 9|drugs
P01544918A1240|0 15|Characterization
P01544928A1252|0 9|Comparison
P01545523A0000|16 30|quantifications
P01545787A0345|9 21|human enhancer
P01545792A0000|3 27|cardiac myosin light chain-2
P01545792A0492|0 18|Deletion mutagenesis
P01545797A0587|0 18|Disruption mutations
P01545806T0000|0 8|Molecular
P01545818A0696|3 6|p130
P01546522A0000|0 47|Probable progressive multifocal leukoencephalopathy
P01547775A1024|17 46|possible biological significance
P01547787A0548|0 19|Proprotein processing
P01547942A0120|1 25|32P-labeled LAP DNA-binding
P01547957A1083|6 39|degenerate oligodeoxyribonucleotide
P01548756A1102|0 21|Stringent hybridization
P01548891A0635|10 44|carboxyl-terminal parathyroid hormone
P01549118A0000|3 40|Caenorhabditis elegans vitellogenin genes
P01549123A0480|3 10|MET4 gene
P01549125A0140|3 11|functions
P01549129A0356|21 27|domains
P01549346A0000|3 20|c-Ets-1 oncoprotein
P01549465A0122|0 33|Previous transactivation experiments
P01551176A0000|0 7|GR63178A
P01551568A1476|0 19|Marker rescue analysis
P01551898A1084|4 9|vector
P01551910A0313|0 18|Competition analysis
P01551910A0978|4 11|DNA motif
P01552052A0139|0 8|OBJECTIVE
P01552457T0000|0 22|Intrapocket chemotherapy
P01552662A0398|0 23|Electromagnetic blood flow
P01552853A1377|19 22|virF
P01553407T0000|0 7|Problems
P01554334A0000|20 35|gamma-interferon
P01555556A0565|0 13|Control Tmuscle
P01556068A0000|3 29|Klebsiella aerogenes gene maoA
P01556111A0241|8 19|other regions
P01557217A0272|9 18|infectious
P01557411A1282|8 19|human D1A gene
P01558942A1369|0 18|Similar observations
P01559209T0000|0 12|Preceptorship
P01560021A0379|14 25|genetic basis
P01560774A0885|6 7|kb
P01562659A0676|0 10|Institution
P01563343A0548|0 11|Lac operators
P01563635T0000|0 13|Overproduction
P01564653A0307|0 15|Various companies
P01565093A0179|4 8|March
P01565882A0737|14 20|changes
P01566576A0605|0 3|Keck
P01567649A0139|16 16|%
P01568960A1129|1 17|possible mechanism
P01569015A0120|0 13|Computer-aided
P01569102A0708|0 5|Domain
P01569344A0404|6 11|cities
P01569581A0482|38 41|mRNA
P01569584A0672|0 16|Hybridization data
P01569945A0529|3 10|SEN1 gene
P01572549A0000|0 21|Protein tyrosine kinases
P01573270A0000|3 8|IA4 mAb
P01577056A0178|13 39|double-blind cross-over study
P01577740A1111|0 14|Primer extension
P01577819A0709|3 29|variant PRP-precursor alleles
P01579472A1018|9 30|typical enhancer element
P01579537A0000|11 15|years
P01580738T0001|0 8|Allagille
P01581409A0398|0 10|Sensitivity
P01581577A1186|0 4|PSI-G
P01581965A0388|5 14|C-terminus
P01582413A0192|0 23|Site-directed mutagenesis
P01582413A0759|0 11|Dimerization
P01582500A0178|3 22|circadian rhythmicity
P01583819A0377|0 2|SEA
P01584812T0000|0 24|Neural-specific expression
P01585014A0000|23 29|effects
P01586901A0000|0 20|Drug-drug interactions
P01587267A1144|3 14|sequence data
P01587763A0402|0 19|Total body irradiation
P01588270A1029|12 24|blood pressure
P01588315A0356|0 5|AgMNPV
P01588913A0000|1 14|gene homologous
P01588961A0000|0 3|STP1
P01588963A1153|10 19|antibodies
P01588965A0000|0 15|GCR1 gene function
P01589576A0170|3 13|decay curves
P01592545A0726|13 33|systolic blood pressure
P01594554A0845|5 11|results
P01596007A0908|0 15|Most apneic events
P01597170A0000|5 11|rabbits
P01597272A0077|2 6|women
P01597462A0457|0 9|Disruption
P01600531A0483|0 11|Coronary flow
P01601181A0842|3 16|60A transcripts
P01601869A1389|1 13|724-bp segment
P01603088A1121|5 11|results
P01605038T0001|0 8|Influence
P01607223A0000|0 19|Recent investigations
P01608239T0001|6 20|natural barriers
P01611699A0000|5 25|pyridoxine derivatives
P01612085A0624|3 21|serum erythropoietin
P01613640A0158|3 18|coating materials
P01615049A0000|12 27|drinking patterns
P01615182A0206|3 14|present study
P01615493A0408|3 4|HC
P01615493A0975|0 9|Argatroban
P01616475A0756|5 11|results
P01617242T0000|0 13|FDA regulations
P01617776A0343|10 32|adrenergic nervous system
P01617801A0088|0 5|DESIGN
P01618027A1108|14 24|transcripts
P01618243T0000|0 27|Intravenous amine pressor tests
P01618256A0521|3 38|mean minimum steady-state concentration
P01619114A0383|4 15|ongoing study
P01619642A0131|4 10|parents
P01620118A0470|5 18|mutant proteins
P01620129A0417|3 30|sequence-specific interaction
P01620610A1070|31 62|TI region-based expression problems
P01620781A0611|15 22|subjects
P01621584A0183|0 23|UF-021 ophthalmic solution
P01623900A0670|5 17|blood pressure
P01624425A0907|0 15|Wild-type protein
P01625131A0452|15 20|biopsy
P01625527A0000|0 24|Whole blood serotonin levels
P01626372T0000|0 6|Tissues
P01626430A1112|3 12|homologies
P01626440A0449|6 25|application solutions
P01626631A0557|5 16|Rett syndrome
P01627106A0320|3 19|similar experiment
P01627828A0475|19 34|southern blotting
P01627830A0000|3 7|cDNAs
P01628201A0824|0 12|Incidence rate
P01628806A1347|11 27|sequence variation
P01628904A0386|3 16|final screening
P01629768A0131|0 6|Lesions
P01630454A0635|1 9|38-bp poly
P01630455A0448|27 37|NFIL-1 beta A
P01630569A0605|7 19|amphotericin B
P01631229T0000|0 11|Cutis aplasia
P01633435A0743|3 21|DRF-2 nuclear protein
P01633816A0667|7 16|15-kb clone
P01634308A0191|0 24|Cardiovascular risk factors
P01634400A1101|0 14|Production costs
P01634464A0163|26 43|factor VII inhibitor
P01634861A1336|33 52|oxygen debt hypothesis
P01636339A0200|0 6|Account
P01636714A0845|3 9|results
P01637758A0532|11 27|greater proportion
P01639092A0776|0 4|Lewis
P01639724A0452|1 12|control group
P01640778A0485|15 25|rapid method
P01641628A0869|3 12|modalities
P01642060A0471|3 21|clinical application
P01643943A0300|11 27|lung cancer tissues
P01644751A0590|4 19|open reading frame
P01644796A0374|41 56|recombinant furin
P01644814A0068|16 28|40-kDa protein
P01644821A1259|8 15|butyrate
P01644831A0824|27 42|carboxyl terminus
P01645902A1462|15 21|results
P01645905A0341|0 12|Nucleoprotein
P01646157A0414|12 52|3.6-kb full-length alpha-GalNAc cDNA sequence
P01646487A0874|0 7|Patients
P01646753A0336|20 24|oxide
P01647070A0232|3 20|mutant JCV T antigens
P01647656A0000|18 50|myocardial beta-adrenergic receptor
P01647813A0512|9 18|transcript
P01648142A1170|2 9|patients
P01648530A0000|14 20|M region
P01649173A0160|51 60|attenuator
P01649318A0734|0 5|EBNA-2
P01649318A1222|5 15|experiments
P01649539T0000|0 13|Plasma vitamin E
P01649835A0822|21 37|bovine PBR/IBP cDNA
P01650524A0837|3 14|initial phase
P01650557T0000|0 16|Discrepant results
P01651232A0152|4 7|mRNA
P01651918A0000|40 52|cDNA fragments
P01652372A0153|16 19|SWI5
P01652515A0379|12 30|behavioral deviation
P01652755A1492|2 40|similar transient transfection experiments
P01653173A0619|4 13|repression
P01653236A0895|14 16|p50
P01653238A1062|3 47|putative 12-O-tetradecanoyl-phorbol-13-acetate
P01653238A1715|0 2|TPA
P01653918A0286|45 61|ipsilateral cornea
P01654349A0327|0 9|Feed intake
P01655126T0000|0 18|Extraction procedure
P01655713A0294|49 77|exoenzyme S-deficient phenotype
P01656220T0000|0 2|axl
P01656221A1319|0 8|Alignment
P01656235A0946|13 28|important element
P01656675A0236|0 16|Capnography curves
P01657246A0325|3 29|transcription initiation site
P01657249A1019|3 8|anti-I
P01657415A0837|0 13|Intron K1 cox1.2
P01657594A0472|23 29|mutants
P01657969A1420|8 18|alterations
P01658356A1369|3 9|results
P01658356T0000|0 12|Recombination
P01658375A0854|3 21|nucleotide sequences
P01658468A0123|10 15|months
P01658741A1047|36 44|kilobases
P01659685T0000|3 22|independent promoters
P01660486A1756|3 9|results
P01660925T0000|0 15|Transfer RNA genes
P01661369A0825|13 16|strD
P01662609A0398|6 10|genes
P01662794A0640|0 9|Expression
P01662807A1182|24 46|TR promoter co-sedimented
P01662884A1029|0 11|Temafloxacin
P01664192A1577|3 22|neuromuscular effects
P01669611A0142|15 28|prolonged fever
P01671675A0483|12 21|clone pKB11
P01671675A0905|28 51|Northern blotting analysis
P01673220A0578|22 28|genomic
P01674177T0001|0 18|Histamine-2 blockade
P01674242A0358|3 11|clearance
P01674369A0417|9 22|partial element
P01674662A0000|13 45|HIV-antibody positive heroin addicts
P01674817A0862|2 9|homology
P01674817T0000|0 8|Mutations
P01675154T0000|0 19|Myocardial infarction
P01675424A0991|7 24|striking difference
P01675637T0033|1 25|single amino acid difference
P01675763A1389|2 13|such benefits
P01678287A1308|10 37|human Antp TATAA binding protein
P01678392A0648|5 21|% confidence values
P01679068A0000|8 14|infants
P01679124A1368|0 17|Biochemical studies
P01679749A1171|3 14|localization
P01681075A0429|6 8|min
P01682484A0680|6 21|coronary stenosis
P01682509A0539|25 43|major IE proteins IE86
P01682542A0690|15 34|general HIV prevalence
P01684791A0000|3 19|cis-acting element
P01686909A0299|21 36|biliary excretion
P01687050T0000|0 14|Diagnostic value
P01688841A0430|0 9|Expression
P01688972A0803|0 10|Inducible VT
P01690703A0285|0 9|Venkatesan
P01690728A1166|16 49|corresponding mature mRNA transcripts
P01690812A0000|15 15|%
P01691184A0995|0 4|Gap b3
P01692135A0783|11 34|rtFc gamma R alpha cDNA clone
P01692837A0390|4 8|genes
P01692962A0980|0 15|Stable expression
P01694009A0112|4 7|exon
P01694014A0716|0 8|Treatment
P01694280A0000|5 37|flexible fiberoptic ventriculoscope
P01694525A0000|0 22|Isopenicillin N isomerase
P01695098A1116|0 7|Serum IgG
P01695116A0078|27 43|complete remission
P01695314A0762|8 12|mg/dl
P01695314T0000|0 18|Platelet aggregation
P01695322A0000|0 4|Wnt-1
P01695378A1406|0 8|Induction
P01695905A0480|0 8|GLUT5 mRNA
P01697611A0738|20 25|tumors
P01697683T0000|0 13|Identification
P01697928A1214|22 37|sequence homology
P01698761A1059|10 31|large DNA rearrangements
P01698772A0238|6 7|J.
P01699944A1538|5 11|results
P01700272A0838|0 14|Polyadenylation
P01701088A1335|0 11|Co-existence
P01702361A0621|9 15|studies
P01702426A0196|11 24|flanking region
P01702426A1006|1 6|new set
P01702432A1296|0 23|Northern blotting analysis
P01702972A0613|7 23|cDNA hybridization
P01703335T0000|0 27|Lymphoproliferative disorders
P01703632T0000|13 22|suppressor
P01707659A0458|22 31|homologous
P01707800A0354|11 34|N13-N20 interpeak interval
P01708098A0922|5 40|avidin-biotin complex DNA binding assays
P01708771A1215|0 20|Sequence determination
P01708774A0203|3 13|DNA sequence
P01709486A0000|3 29|murine mutation dominant white
P01709933T0000|0 8|Isolation
P01710766A0349|3 10|proteins
P01710768A1172|3 9|results
P01710979T0000|3 5|SH2
P01710985A0315|0 3|Chem
P01711041A0348|5 10|clones
P01711041A0962|3 15|C5 alpha-chain
P01711048T0000|0 19|Heterozygous mutation
P01712296A0157|3 21|nucleotide sequences
P01713213A0000|37 83|human pim-1 proto-oncogene shares extensive homology
P01713213A0488|1 25|full-length human pim-1 cDNA
P01714322A0969|44 50|kDa hsps
P01714358A0990|5 18|kDa polypeptide
P01714452A0559|0 7|Homology
P01714902A0221|39 82|Ti alpha-beta CD3 gamma delta epsilon TCR complexes
P01715593A0838|4 14|desipramine
P01715975A0885|0 14|Opposite effects
P01716292A0000|1 17|segmental analysis
P01716629A0000|15 32|cDNA clones specific
P01717718A1255|12 25|point mutations
P01717833A1223|3 22|alpha inhibin promoter
P01717833T0000|0 9|Regulation
P01717925A0477|0 9|Comparison
P01717994T0000|0 6|Cloning
P01718043A0384|2 9|patients
P01718983A1640|0 1|E.
P01719684A0494|3 14|above results
P01720555A1087|15 36|2-kilobase B2 transcript
P01720843A1506|5 11|results
P01721261T0000|0 15|Pharmacokinetics
P01721884A0962|15 30|significant match
P01722319A0849|0 7|Analysis
P01722479A0302|3 27|qualitative concentrations
P01723619A0766|16 26|F absorption
P01723962A0165|13 23|serum lipase
P01724982A0237|18 25|anti-HCV
P01725547A0354|0 8|Diltiazem
P01725622A0292|3 18|first transfusion
P01726211A0502|5 15|risk factors
P01726631T0001|0 11|Epidemiology
P01727488A1146|0 21|PRDII-BF1-derived cDNAs
P01727494A0000|0 12|Vaccinia virus
P01730412T0000|0 2|Max
P01730747A0205|15 16|G1
P01731107A0928|0 12|Substitutions
P01731933T0000a|0 1|Zn
P01731933T0000b|0 1|Zn
P01731979A1408|3 19|tissue specificity
P01732033A0000|3 17|pathophysiology
P01732736A1076|0 10|Transcripts
P01732752A0156|6 16|early B cells
P01733105A0127|3 8|genome
P01733358A0240|5 10|tumors
P01734020A1318|0 13|Immunostaining
P01734283A0817|27 38|RAP74 protein
P01734570T0000|0 6|Effects
P01735347A0482|3 25|primary pancreatic insult
P01735447A0271|12 25|mutant molecule
P01735447A0833|8 26|active-site mutation
P01735721A0185|12 28|amino acid sequence
P01736093A0731|0 24|Heat-inducible CAT activity
P01736651A0104|9 13|Women
P01736844T0000|0 11|Testosterone
P01737741A0000|0 9|BACKGROUND
P01737789A0800|3 31|upstream delta-alpha breakpoint
P01738470A0441|0 7|Patients
P01738653T0014|0 3|Bone
P01738936A0292|3 10|patients
P01739439A0257|0 26|Complex repetitive discharges
P01739956A0638|0 9|Management
P01740121A0136|41 45|Kex2p
P01740330A0329|0 1|J.
P01740437A0851|3 24|major 49-kDa core protein
P01740448A1735|7 33|obvious transmembrane regions
P01740682A0703|0 7|Toxicity
P01741249A0177|0 3|W.G.
P01742341A0499|26 43|individual reaction
P01742606A0000|1 23|mouse brain beta-spectrin
P01742879A0471|0 6|RESULTS
P01744039A0511|3 11|fragments
P01744042A1355|3 12|csbA fusion
P01744119A0757|3 13|constraints
P01747972T0000|0 18|Thrombolytic therapy
P01748067A0000|1 16|prospective trial
P01748194A0767|8 14|lesions
P01748287T0000|0 23|Human SRF-related proteins
P01748292A0000|14 18|cDNAs
P01748630A0125|0 22|Growth factor stimulation
P01751163A0000|3 9|authors
P01751255A0529|0 12|Cardiac output
P01751970A0209|0 16|Amino acid residues
P01752441A0000|0 24|Transcriptional activation
P01752792A0000|10 29|quantitative evidence
P01753317A0879|5 11|results
P01754381A0000|4 14|initial step
P01756195A1117|20 38|significant increase
P01756539A0354|0 20|Pulmonary hypertension
P01757341A0591|3 16|volume fraction
P01758750A0000|0 13|Airway pressure
P01759052A0786|0 3|Appl
P01759282A0000|0 5|Issues
P01760166A0963|0 9|CONCLUSION
P01761736A0158|0 8|Diltiazem
P01762053A0557|3 10|granules
P01762914A1218|9 19|uPA promoter
P01762917A0615|13 15|Ser
P01763065A0913|0 1|P.
P01763106A0070|6 24|exploratory behavior
P01764899A0399|40 56|water fluoridation
P01765095A0680|0 34|12-O-Tetradecanoylphorbol 13-acetate
P01765266A0000|2 14|Xenopus laevis
P01765269A0308|5 11|introns
P01765375A0290|3 6|mRNA
P01765386A0305|20 21|kb
P01765407A0866|2 12|8-h exposure
P01766666A0788|0 17|Antibodies specific
P01766876A0000|38 43|events
P01766999A0000|0 17|Allergenic activity
P01767060A0000|35 53|c-DDP administration
P01767592A0682|3 30|potential regulatory sequences
P01767899A0136|0 21|Marked thrombocytopenia
P01768648A0853|12 21|properties
P01769189A0000|0 10|Plasma lipid
P01769919A0393|0 22|Auditory threshold shifts
P01770651T0001|0 10|Fundamental
P01771593A1152|14 15|TA
P01771593A1232|14 19|adults
P01771959A0442|5 8|PTCA
P01772201T0001|3 18|alcoholic patient
P01772341A0852|23 39|combined treatment
P01774062A0257|1 9|330-kb YAC
P01774063A0161|0 29|Interspecific backcross analysis
P01774093T0000|0 19|Adverse foetal outcome
P01774822A0289|7 30|image-processing computer
P01776306A0572|3 15|second patient
P01776715A0489|25 38|centrifugation
P01777841A0744|3 20|possible mechanisms
P01779299A0000|10 30|behavioral alterations
P01779433A0694|19 42|monomeric Alu family repeat
P01779769A0000|16 29|repressor locus
P01780235A0094|3 11|EPO levels
P01781923A0744|4 26|differential sensitivity
P01782424A0278|14 36|threshold concentrations
P01782669A0496|30 41|temperatures
P01782982A0155|0 9|Felodipine
P01783088A1136|10 17|patients
P01783375A1066|3 9|mapping
P01784589A0000|41 61|5-HT2 receptor activity
P01785749A0695|5 11|changes
P01786094T0001|0 14|Arsenic contents
P01787085A0331|5 20|other experiments
P01788002T0001|0 13|Magnetotherapy
P01791363A0208|5 11|results
P01791754T0000|0 17|Mutational analysis
P01792580A0198|5 15|blood donors
P01792914T0000|0 20|Extramedullary relapse
P01797459A0103|0 9|Mycoplasma
P01797467A0000|0 4|RU486
P01798407A1011|13 30|local abnormalities
P01804671A1001|13 23|small values
P01806314A0322|0 8|Many cells
P01808049A0262|0 14|CT abnormalities
P01808136T0000|3 9|effects
P01808186A0984|0 3|Pigs
P01808602A0000|9 16|patients
P01808829A0510|0 3|TPTA
P01809854A0106|0 7|Examples
P01810108A0000|4 36|phase slug flow tubular heat exchanger
P01810154A0491|7 14|children
P01811243A0000|0 24|Regional cerebral blood flow
P01811948A0289|5 16|present study
P01812102A0101|3 27|present study reports visual
P01812690A0475|8 10|SMF
P01814182A0000|0 13|Different doses
P01816655T0000|0 5|Review
P01817497A0715|0 9|Resolution
P01822581A0533|5 13|instances
P01822995T0000|0 24|Maize rbcS promoter activity
P01823520A0183|0 11|Measurements
P01823524A0238|13 24|scanty number
P01824713A0964|3 15|12S E1A product
P01824944A0988|18 28|tunicamycin
P01825027T0000|0 3|PAS1
P01826003A0694|14 22|base pairs
P01826043A0431|3 31|pp90rsk-protein kinase activity
P01827068T0000|0 10|Human GATA-3
P01827203A0136|4 37|many eukaryotic transcription factors
P01828248A0189|15 25|UvrA protein
P01829060A0649|3 12|ED30 values
P01829460A0329|0 23|Southwestern blot analysis
P01830114A1587|8 21|positive effect
P01830928A0361|3 37|minus-end-directed microtubule motors
P01832019A0265|4 14|transparent
P01832152A0000|3 33|incompatibility group W plasmid pSa
P01832152A0902|0 33|Potential translational start signals
P01832197T0001|0 6|Imaging
P01833185A0547|3 19|Thr161Val mutation
P01833637A0531|3 11|abundance
P01833716A0990|0 11|Deregulation
P01837787T0000|3 18|murine Mov-34 gene
P01837842A1410|0 3|CREB
P01839414T0000|36 53|malignant neoplasms
P01840513A1019|29 37|SL-2 cells
P01840607A0294|25 28|UTRs
P01840608A0823|3 12|N-terminus
P01840711A0000|3 11|RNA genome
P01840902A1089|57 62|plants
P01842498A0000|1 14|novel cDNA clone
P01842867A0696|24 47|great regeneration ability
P01844017A0410|14 31|linear relationship
P01844878A0000|1 6|vector
P01844982A0324|0 5|Chagas
P01845829A0158|0 15|Previous analysis
P01845885A1003|3 27|second transcriptional unit
P01845899A0000|3 23|adeno-associated virus
P01846206A0665|1 20|larger region upstream
P01846489A1119|15 47|picornaviral 3C-like protease domain
P01846491A0459|11 27|relative positions
P01846803A0688|22 36|phosphorylation
P01847464A0856|2 26|short-term cotransfections
P01847665A1079|3 10|findings
P01848300A0910|0 17|Suggestive evidence
P01848871A0392|32 44|sodium channel
P01849509T0000|0 13|Identification
P01849675A0167|33 39|viruses
P01849734A1063|8 25|PR55 beta transcript
P01850096A0662|0 11|Heterodimers
P01850105A1093|3 9|effects
P01850127A0000|0 16|Stable association
P01850893A0286|17 26|antibodies
P01851386T0092|3 28|Italian Lung Cancer Task Force
P01851527T0000|3 18|promoter activity
P01851756A0743|0 3|Biol
P01851862A0273|0 18|Nucleotide sequences
P01851876A0129|28 51|EMBL3 mouse genomic library
P01852438A0928|3 11|MVV-value
P01852603A0000|3 6|rad9
P01853796T0000|0 5|Review
P01854339A0221|16 39|strong sequence similarity
P01855255T0000|0 18|Premature initiation
P01856021A0577|69 85|reliable procedure
P01857143A0351|14 28|78-year-old male
P01857326A0160|0 9|Oculus-500
P01860846A0663|3 11|human cDNA
P01861034A0798|5 13|resection
P01861188A0000|0 10|Plate luting
P01862027A0212|5 12|features
P01862455T0000|0 14|Thyroid lymphoma
P01863768A0649|19 24|ORF113
P01863887A0174|0 15|Space limitations
P01864510A0946|0 7|Dd PK1 RNA
P01864821A0000|3 14|various forms
P01864837A1029|3 18|primary structure
P01865010A0000|0 7|Patterns
P01867069A0000|0 12|Young CD-1 mice
P01869565A1254|0 2|USF
P01869907A2146|3 21|across-fiber pattern
P01869968A0000|0 27|Arterial radioactivity content
P01869968A0673|0 23|Linear regression analysis
P01870194A0302|0 29|Human immunodeficiency virus type
P01870428A0677|0 9|Thigh girth
P01870500A0276|0 12|Contributions
P01871033A0434|0 4|Tests
P01871135A0295|3 6|cDNA
P01871971A0836|0 7|Analysis
P01872856A0277|0 7|Recovery
P01873999A0000|47 57|model system
P01874195A0139|25 34|GH receptor
P01874752A0948|22 58|certain experimental conditions cdc2/p58
P01875922A0770|0 15|Mutation analysis
P01876836T0000|0 13|Identification
P01878489A0959|3 19|enzymatic response
P01878755A0496|5 9|ileum
P01881595A0476|0 7|Formalin
P01881671T0001|0 5|Uptake
P01882240A0526|33 38|issues
P01882386A0000|18 36|alpha-mercapto-beta
P01883992A0922|5 11|results
P01884435A0088|20 26|effects
P01884998A1135|3 9|members
P01885006A0995|3 9|domains
P01885613A1298|0 10|Information
P01885752A0198|0 19|Chlamydia trachomatis
P01885915A0000|8 22|human infections
P01886043A0380|3 5|SMX
P01886368A0000|0 14|PO2 measurements
P01886774A0000|0 11|POU-specific
P01888896A0505|1 14|deletion series
P01889753A0441|3 12|nucleotide
P01890362A0305|7 14|patients
P01890989A1392|12 38|different regulatory elements
P01892680A0907|0 7|Toxicity
P01893195A0000|16 27|green monkeys
P01893927A0704|10 29|mean arterial pressure
P01894696A0301|0 1|J.
P01895358A0000|0 5|Limits
P01895370A0199|4 21|stepwise reductions
P01895384A0746|3 16|IE0 gene product
P01895393A0745|9 17|promoters
P01895555T0001|0 9|Evaluation
P01896777T0000|0 15|Ivermectin uptake
P01897515A0348|0 22|Bone marrow abnormalities
P01898113A0265|3 19|smaller uptake rate
P01898164A0839|28 37|arch repair
P01898928A0260|0 23|DNA hybridization analysis
P01899209A0883|0 8|Increases
P01899287A0726|0 9|Expression
P01899409T0000a|0 11|Determinants
P01899846A0862|13 26|rbcL-rbcS locus
P01900194T0000|0 11|Relationship
P01901405A0694|0 7|Analysis
P01901443A0297|11 18|patients
P01901664T0064|1 5|cases
P01901859A0000|0 6|UDP-Gal
P01901946A0243|1 24|synthetic oligonucleotide
P01901950T0000|0 19|Sequence requirements
P01903404A0688|0 30|Infarct regional ejection fraction
P01903841A0125|8 21|lysine residues
P01903841A1449|3 25|plasmid shuffle technique
P01904154A0164|33 48|characterization
P01904437A0000|0 12|Transcription
P01904546A0671|0 9|Disruption
P01905199A0210|11 18|ICRF-187
P01905517A1076|3 5|ORF
P01906111A1295|26 44|dose-intense regimen
P01906166A0119|0 10|Mitomycin-C
P01906509A0072|30 43|flanking region
P01906692A0321|0 12|INTERVENTIONS
P01907265A0670|0 9|Consistent
P01907941A0275|13 23|I kappa B beta
P01909027A0922|0 15|Sequence analysis
P01909621A0119|0 6|Lengthy
P01909960A0134|11 19|injection
P01910505A0000|0 21|Fufang wuzi yanzong pills
P01911767T0000|0 8|Mutations
P01913955A0177|3 19|structural changes
P01915580A0889|5 11|results
P01916168A0969|12 34|correlation coefficients
P01916405A0242|0 23|Bronchial mucosa tattooing
P01916632A0431|0 17|Anti-HBc production
P01917943A0621a|0 15|Sequence analysis
P01917943A0621b|0 15|Sequence analysis
P01917962A0152|3 13|cDNA segment
P01918010A0000|0 16|Lipoprotein lipase
P01918010A1730|0 7|Deletion
P01918070A0281|13 19|binding
P01918073A0150|0 9|Comparison
P01919831T0000|0 28|Ventilatory management casebook
P01921463T0000|2 17|ASSEMBLER routine
P01922082A0149|0 9|Expression
P01922734T0000|0 10|Habituation
P01922739A0336|17 20|ROSP
P01923167A0000|0 25|Blood flow velocity waveforms
P01923628T0001|0 19|Quantitative analysis
P01923766A0485|0 15|Sequence analysis
P01923803A0609|0 7|Position
P01923985A0111|0 10|Symptoms due
P01924315A0158|5 9|yeast
P01924920A0115|10 16|samples
P01925092A0000|0 20|Previous investigators
P01925092A0304|11 15|hours
P01927421A0181|0 27|Neuro-otological examinations
P01927845A0107|8 17|morphology
P01928923A0000|0 11|Equine amnion
P01930470A0337|10 29|current high incidence
P01930660T0000|0 23|Insulin-like growth factor
P01931966A0490|0 5|Fusion
P01932650A0435|11 18|patients
P01932695A1155|3 13|suppression
P01933614A0406|11 36|salmon calcitonin nasal spray
P01934378A1219|0 36|Skeletal muscle metaboreceptor responses
P01934378T0000|0 44|Skeletal muscle metaboreceptor exercise responses
P01936213T0000|0 9|Evaluation
P01936348A0155|3 14|examinations
P01936997A0795|0 16|RNA gel retardation
P01937790A0292|26 36|immunogenic
P01937989A0383|4 9|groups
P01938178T0000|0 11|Applications
P01939131A0871|29 34|BW2001
P01939199A0588|0 20|Recombinant human TFIID
P01939827A0150|10 21|pretreatment
P01939878A0765|14 27|solidification
P01939899A2043|32 50|satisfactory account
P01939906A0233|4 17|generalization
P01942033T0000|0 12|Determination
P01943184A1050|0 15|Endothelial cells
P01945430A0660|3 19|original technique
P01947449A0191|11 29|diffusion limitation
P01947449A1082|3 21|Diffusion limitation
P01948783A0000|3 24|antihypertensive effect
P01952827A0215|14 20|seizure
P01954355A0997|0 17|Monitoring patients
P01954835A0000|0 21|Echinococcus granulosus
P01956285A0000|30 40|nucleotides
P01956491A0095|1 14|7-day treatment
P01958368A0556|0 8|Evolution
P01958821T0000|0 29|Confocal fluorescence microscopy
P01960974A0000|0 6|Toluene
P01961213A0150|23 32|HCB-levels
P01961747A0000|1 29|herpesvirus proteinase activity
P01961996A0522|0 5|Adult H
P01963419A0501|3 25|rear silver liquid chamber
P01963438T0000|0 28|Heterogeneous electron transfer
P01963858T0001|0 18|Selective activation
P01964989A0145|0 13|Urine specimens
P01967130A0645|3 23|1489-base pair EFIA cDNA
P01968043A0908|4 29|putative positive cDNA clones
P01968061A0371|0 2|Sci
P01968156T0000|0 18|Dose standardisation
P01968224A0119|3 16|coding sequence
P01970560A1024|0 19|Translational fusions
P01970801A0925|25 29|genes
P01970926A0000|6 14|exercise K
P01970984A0668|19 38|serum estradiol levels
P01971191A1271|17 38|beta-adrenergic agonist
P01972379T0042|0 10|DNA sequence
P01973384A0206|19 39|synthetic binding sites
P01974550A0362|5 16|base-line CBF
P01974876A1051|15 51|restriction fragment length polymorphism
P01975157A0836|3 23|antilog transformation
P01975428A0151|0 8|Telomeres
P01976638A1135|12 18|located
P01977585A0222|3 14|native enzyme
P01977856A1036|21 25|BSPMs
P01978834A0076|1 35|bovine abomasum lambda gt11 cDNA library
P01978857A0504|0 11|Judicious use
P01982061A0615|9 15|TATA box
P01982061T0000|0 15|Characterization
P01982190T0001|5 13|cirrhosis
P01982997A1104|0 10|Examination
P01983026A0483|8 16|heart rate
P01984665T0000|0 9|Processing
P01985301T0000|19 24|MK-801
P01985920A0156|0 15|Initial screening
P01985920T0000|0 6|Cloning
P01985924A0554|15 30|equimolar complex
P01986225A0250|31 33|HSF
P01986241A0117|0 8|Induction
P01986254A0452|0 21|Gel mobility shift assays
P01986360A0000|5 10|clones
P01988041A0281|17 22|clones
P01989561A0100|21 31|instruments
P01989999A0000|0 25|Adenylosuccinate synthetase
P01990254A0791|0 16|Immunophenotyping
P01990266A0678|0 32|DNA-protein UV cross-linking studies
P01991521A0481|3 9|results
P01992459A0000|3 21|specific interaction
P01992742A0000|13 19|records
P01992953A0247|0 12|Cut-off levels
P01992953T0000|0 22|Alanine aminotransferase
P01993181T0000|0 25|Nucleotide sequence analysis
P01993656A1860|6 13|ARF cDNAs
P01995951A0000|3 20|long terminal repeat
P01996312A0454|7 9|PCR
P01997465A0276|0 23|Radiation-induced changes
P01999035A0383|3 16|first follow-up
P01999459A0795|0 1|A.
P01999999T0001|0 16|Perilunar luxation
P02000093A0794|0 8|Landsberg
P02001033A1907|12 39|equianesthetic concentrations
P02002051A0276|27 46|full-length cDNA clone
P02002051T0000|0 11|Isoform C beta
P02002511A0637|0 18|Salient applications
P02004521A0266|0 7|Patients
P02004705A0686|3 14|cdr1 sequence
P02005547A0121|10 27|clear understanding
P02006558A0000|0 21|Displacement thresholds
P02007045A0092|3 9|authors
P02008982A0463|0 4|ELISA
P02010912A0366|21 33|detailed study
P02011924A0729|10 20|small number
P02012097T0000|0 21|Paroxysmal fluctuations
P02012789A0051|2 22|positive family history
P02014928T0000|0 17|Occupational asthma
P02015921A0523|1 18|further subdivision
P02016053A0752|0 27|Amino acid sequence comparisons
P02016769A0720|14 30|relative strengths
P02017159A0646|0 5|Grasso
P02017271A0502|6 11|months
P02017414A0307|0 2|Age
P02019572A0000|13 24|DNA sequences
P02020082A0356|3 13|disturbance
P02020314A1290|12 34|micrograms/kg/day GM-CSF
P02021630A1104|5 15|differences
P02022188A0112|0 18|Biochemical analysis
P02022188A1463|17 28|gene products
P02022920A0334|3 15|C4BP alpha gene
P02023097A0000|3 32|human immunodeficiency virus type
P02023421A0343|7 19|proliferation
P02023904A0120|3 10|CDC7 gene
P02024252A0000|9 13|years
P02024488A0506|0 3|HeLa
P02024625A0202|0 10|Differences
P02024791A0582|0 11|MEASUREMENTS
P02024816A0521|7 11|ELISA
P02025515A0979|11 19|short t1/2
P02026144A0741|0 14|Temporal control
P02026147A0000|11 13|Ca2
P02026461A0760|2 10|most cases
P02026491A0399|3 10|patients
P02027839A0250|3 9|muscles
P02028125A0101|3 12|prevalence
P02029468A0296|0 21|Serum TNF concentrations
P02030910A0000|0 12|Genomic clones
P02030910A1070|0 30|Polymerase chain reaction analysis
P02033038A0309|0 3|Most
P02033062A1169|6 21|promotor function
P02034655A1224|3 7|alpha
P02034655T0000|0 15|Characterization
P02034669A0293|7 22|3.0-kb transcript
P02034676A0267|3 12|homologues
P02035805T0000|0 25|Angina haemorrhagica bullosa
P02036066A0000|13 19|effects
P02038293A0919|0 9|Conclusion
P02038326A0538|3 18|gcd2-503 mutation
P02038784A0317|5 12|patients
P02041088A1053|12 27|enhancer activity
P02044785A0000|1 10|single case
P02044950A0258|8 30|polymerase chain reaction
P02044975A0380|52 56|P less
P02045366A1149|0 21|Hydrophobicity analysis
P02045524A0000|29 57|important new therapeutic agents
P02045809A0331|11 22|similar rates
P02046202A0625|3 11|remainder
P02047597A0149|11 30|experimental vulvitis
P02052544A0641|15 27|DNA polymerase
P02052592A0000|18 49|mononuclear cell secretory products
P02053289A0701|15 27|nt differences
P02054754A0919|3 20|standard principles
P02055484A0538|9 19|PCR products
P02056553T0000|0 15|Hemorrhagic shock
P02060052A0954|23 28|levels
P02061282A0447|16 27|pMxL1 plasmid
P02061333A0784|26 32|introns
P02061333A1359|5 16|observations
P02062116A0688|0 8|Pargyline
P02062933A0738|27 39|estrous female
P02064119A1172|0 26|Hypoxic ventilatory responses
P02065022A0747|4 17|small deletions
P02066246A0258|4 19|computerized list
P02068085A1273|25 49|negative regulatory element
P02069738A0000|22 36|stimulus control
P02069873X0000|0 8|Mechanism
P02070227T0000|0 21|Endothelial cell seeding
P02072238T0000|0 15|Menetrier disease
P02072798A0330|5 28|hemodynamic stabilization
P02073222A0269|11 18|patients
P02075876A0408|3 19|stimulus threshold
P02075876T0001|0 7|Analysis
P02076620A0548|12 33|plasma fibrinogen levels
P02076620T0000|0 10|Gemfibrozil
P02076816T0000|2 24|RME1-independent pathway
P02077560T0000|9 32|pharmacological profiling
P02078080T0040|16 25|Madagascar
P02078570A0287|5 9|cases
P02079811A0407|3 9|authors
P02080902A0183|2 10|adulthood
P02081463A0110|28 43|Spec gene activity
P02083199A1175|0 20|Phosphopeptide mapping
P02083230A0938|27 46|typical signal peptide
P02083253A1512|3 23|TCF-1 alpha binding site
P02083546A0000|1 23|new semi-automatic method
P02088781A0653|3 9|results
P02089054A0121|0 2|IdB
P02091890A0614|12 22|eltoprazine
P02092131T0000|1 9|new method
P02093033T0001|0 5|Effect
P02093741A0211|0 13|Data collection
P02093888A0293|0 4|ARPIA
P02094221A0247|0 7|Diuresis
P02094257T0000|0 14|Diagnostic value
P02095150T0000|0 22|Femoral strain adaptation
P02099622A1046|0 19|Immuno-cytochemistry
P02102823A0492|0 17|Promoter activities
P02102831A1282|5 11|regions
P02103140A1088|8 8|%
P02103403A0149|22 40|excess alcohol intake
P02105497A1092|2 23|evolutionary comparison
P02106287A0478|0 11|Spore inocula
P02107073A0584|8 21|overexpression
P02107548A0727|0 23|Reverse transcription-PCR
P02109544A0000|20 27|benefits
P02110145T0000|0 9|Sequencing
P02110148A0423|9 23|HindIII fragment
P02111015A0574|3 12|N-terminal
P02113015A0295|0 15|Maternal seizures
P02113174A0064|26 43|zinc fingers similar
P02113174A0957|0 6|Krox-24
P02113455A0207|3 28|interindividual variability
P02113699A0372|3 10|patients
P02113901A0000|8 10|CO2
P02115111T0000|0 9|Expression
P02115115A1053|46 60|sites homologous
P02115116A1137|3 9|results
P02115118A0565|35 44|smg p25A GDI
P02115121A0000|0 11|Yeast mutants
P02115122A0562|0 15|Critical residues
P02115572A1323|17 33|V lambda pseudogene
P02115889A0436|40 48|human gene
P02116071A0000|1 18|long follow-up study
P02116537A1237|27 45|lower concentrations
P02117799T0000a|0 3|Uses
P02117799T0000b|0 3|Uses
P02118519A0516|23 46|potential consensus motifs
P02118525A0737|36 46|CCK promoter
P02118612A0629|6 12|minutes
P02119530T0000|0 8|Influence
P02119626A0471|8 12|scars
P02119946T0000|8 16|dysphagia
P02120707A0594|0 23|Gel-mobility-shift assays
P02120833A0000|2 8|Denmark
P02121371T0000|3 10|NF1 locus
P02122454A1042|22 27|Phe-62
P02123029A0478|1 13|second isotype
P02123293A0227|0 4|Petko
P02123295A0645|0 9|Disruption
P02123300T0000|0 46|Human recombinant DNA-derived antihemophilic factor
P02123466A0272|4 15|other members
P02123467A0811|27 34|promoter
P02123820A0000|0 6|Effects
P02123875A0223|10 27|structural features
P02123877A1452|21 25|c-fos
P02124433A0235|5 12|patients
P02124710A0193|3 17|nuclear proteins
P02124710A1624|11 17|further
P02125016A0145|0 3|PBSX
P02125153A0410|1 22|bacteriological relapse
P02126417A0408|5 12|controls
P02126504A0602|10 22|Rh-antibodies
P02129338A0568|10 26|amino acid sequence
P02131652A0883|0 37|Higher fasting serum gastrin concentration
P02131666A0483|3 19|experimental group
P02131902A0000|44 75|transesophageal echocardiographic
P02132636A0188|0 7|Subjects
P02133731A1572|4 5|S3
P02135343A0131|46 60|normal occlusion
P02135536A0621|21 33|brush abrasion
P02137704A0000|9 19|select group
P02138707A0198|39 65|lambda gt11 expression library
P02138915A1060|3 9|p36 gene
P02138992A0911|4 25|multimodality treatment
P02139473A1603|1 10|contiguous
P02139891A0532|3 15|major promoter
P02141425A0175|15 32|fingertip-to-floor
P02142240A0506|2 23|significant differences
P02142486A0367|0 10|Teicoplanin
P02142921T0000|11 47|hormone-releasing hormone analog therapy
P02142955A0248|2 12|Experiments
P02142993A0176|3 17|clinical picture
P02143023A0729|18 32|octamer elements
P02143186A0867|21 27|introns
P02143186A1306|0 19|Northern blot analysis
P02143768T0000|0 8|Impaction
P02143961A0400|4 18|antidepressants
P02144290A1444|0 2|Sci
P02144558A1022|1 15|needs assessment
P02144610A1306|0 7|TCR alpha
P02145195A0253|5 13|stem-loop
P02145268A0746|10 27|nucleotide sequence
P02145268A1454|5 10|losses
P02146266A0000|1 33|4.8-kilobase BamHI-HindIII fragment
P02146495A0706|3 15|other peptides
P02147223A1047|14 16|CRE
P02147422A0000|44 66|human U1-70K snRNP protein
P02148219A0508|54 66|clinical facts
P02148291A0173|5 43|appropriate synthetic HSE oligonucleotides
P02148508A0374|0 4|Fluid
P02148508A1478|3 9|results
P02148799A0000|3 9|nmr gene
P02149487A0348|4 35|days dexamethasone suppression test
P02149566A0478|10 18|P-31 NMR-S
P02149570T0000|0 16|Cutaneous necrosis
P02150473T0067|0 12|Critical study
P02151229A0000|0 24|Regional cerebral blood flow
P02151229A0921|0 15|Mean ROI-A/B ratio
P02153243A0965|29 41|normal product
P02153683A1579|23 39|separate complexes
P02153977A0364|5 9|genes
P02154467A0709|3 12|PC2 protein
P02154474A1504|20 28|sequences
P02154599A0382|18 29|footprinting
P02154599T0000|3 19|zta transactivator
P02154602A0092|7 18|human homolog
P02154686A0185|0 8|Fragments
P02154885A0153|3 7|sites
P02155017A1106|3 18|possible benefits
P02156828A0164|10 26|amino acid sequence
P02157067A0610|0 6|Summers
P02157141A0923|16 23|T antigen
P02157764A1115|1 15|rabbit antiserum
P02157882T0000|0 11|Conservation
P02158099A0487|2 30|transient cotransfection assays
P02158927A0000|19 28|nucleotide
P02159470A1432|0 14|Specific binding
P02159559A0779|13 32|specific interference
P02160502A0471|2 29|recombination signal sequences
P02160622A0000|3 27|antinociceptive properties
P02160955A0899|0 9|Constructs
P02162049A0291|29 35|factor Y
P02162103A0000|23 27|cDNAs
P02162467A0311|10 23|cytR expression
P02162754A0339|15 19|sites
P02162754A0801|0 2|PAO
P02162835A0989|17 36|sequence similarities
P02163347A0472|3 14|cDNA sequence
P02163382A0169|17 28|O7-LPS region
P02163394T0000|3 10|sacT gene
P02164585A0416|3 13|TraD protein
P02164585A0814|3 16|protein product
P02164588A0266|0 19|Various mutant HN genes
P02164604A0399|3 9|studies
P02164604A1574|25 41|E2 proteins present
P02164637A0515|0 9|Disruption
P02165181A0299|4 9|cohort
P02165589A0000|52 56|2C1-3
P02165589A0888|10 17|Region II
P02166040A0385|18 25|vanadate
P02166416A0419|14 32|miliary tuberculosis
P02166825A0198|24 41|functional elements
P02167321T0000|1 15|DNA motif related
P02167467T0000|3 42|26S rRNA binding ribosomal protein equivalent
P02167784A0109|4 22|healthy male subjects
P02168640A0268|0 22|Significant correlations
P02169887A0360|3 13|transcripts
P02170687A0000|3 15|E6/E7 promoter
P02172672T0001|7 17|Goodpasture
P02173399A0333|15 30|negative controls
P02173405A0270|2 23|symptomatic abnormality
P02174105A1232|0 26|Immunohistochemical analysis
P02174427A1574|4 10|strains
P02174861A0736|0 9|Regulation
P02174974A0000|0 12|Transcription
P02175433A0575|3 13|recombinant
P02175908A0805|9 17|mutations
P02176021T0000|0 12|Determination
P02176152A0896|14 15|RA
P02176209A0954|21 23|EFI
P02176232T0001|0 10|Risk factors
P02176822A0000|0 27|Multifunctional protein kinase
P02179052A1044|16 16|Y
P02179188A1223|22 36|motile responses
P02179815A0582|6 13|p59v-rel
P02180935A0535|0 17|Kinetic experiments
P02181760A0311|0 8|Blood flow
P02182240A0355|11 18|patients
P02182323A0121|8 25|primary transcripts
P02182618A0168|3 18|promoter activity
P02183467A0668|10 18|short ORFs
P02185140A0000|26 33|14DM gene
P02185250A0726|0 10|Truncations
P02187091A0721|0 26|Pulmonary vascular resistance
P02187871T0000|3 11|ANB1 locus
P02188096A0955|19 43|alternative splicing events
P02188168A0000|0 29|Serum beta 2-microglobulin levels
P02190122A0633|4 15|emancipation
P02190134A0572|28 38|progression
P02193033A0195|0 1|R.
P02194273A0913|0 27|Specific hyperimmune globulins
P02194972T0000|0 17|Therapeutic effects
P02195025T0000|0 9|Regulation
P02195715A0143|0 20|Homozygous individuals
P02195715T0000|0 16|Ischemic stroke due
P02196176A0749|0 4|TREB7
P02196311A1034|5 11|results
P02196450A0870|0 7|Analysis
P02196565A0606|5 28|general regulatory factor I
P02196565T0000|0 16|Yeast Gal11 protein
P02198259A0685|0 7|Deletion
P02198289A0436|6 19|larger peptides
P02199311A0620|7 27|transcription extracts
P02200150A1381|7 14|patients
P02200315A0278|0 2|IgG
P02200736A1003|5 11|factors
P02201770A0188|5 19|known flea larvae
P02201901A0229|15 30|specific antibody
P02201905A1004|5 17|latter results
P02202496T0000|0 16|Clinical nutrition
P02203672A1542|3 35|computer-programmed cytocentrifuge
P02204029A0184|0 20|RNase protection assays
P02204621T0000|0 8|Isolation
P02204623A0000|3 21|juxtamembrane region
P02204625A1130|23 27|genes
P02204810A1080|12 14|GA2
P02206430A0197|0 3|Pups
P02206789A0002|3 10|efficacy
P02206858A0000|0 17|Homozygous protein C
P02208762A0228|20 32|granddaughter
P02209237A0239|0 29|Abnormal intrapulmonary shunting
P02209243A0237|3 16|urinary protein
P02209540A1362|14 17|Ets1
P02209605A0510|21 28|MSAS gene
P02209811T0000|0 20|Horseradish peroxidase
P02212540A0473|0 31|Standardized gastric wall specimens
P02213566A0000|3 9|effects
P02217307T0000|0 7|Evidence
P02217741T0001|3 15|interrelation
P02218094A0395|33 34|Ft
P02219751A0517|9 16|saccades
P02220102A0271|0 8|Incidence
P02220304A0501|26 30|Alcoy
P02223652A0939|4 24|antithrombin unit basis
P02223773A0000|0 34|Chick brain actin depolymerizing factor
P02223928T0069|0 16|Initial experience
P02225687A0546|0 16|Comprehensive care
P02227438A0492|0 22|Primer extension analysis
P02228615A0974|3 6|85Sr
P02229068A0156|0 13|Gene constructs
P02229072A1012|4 15|growth arrest
P02229282A0454|0 7|Patients
P02229541T0000|0 4|Giant
P02231162T0000|0 13|Further studies
P02231479A0585|33 45|5-year-old son
P02233626T0000|0 39|Droperidol-induced extrapyramidal symptoms
P02233680A1115|5 11|results
P02233715A0914|3 11|induction
P02233729A1065|4 12|mutations
P02234345A0215|3 15|glial cyst wall
P02234731A0503|20 34|cytologic smears
P02236002A0958|4 10|mammals
P02236022A0000|3 20|protooncogene c-myb
P02236060A1671|0 11|Modification
P02236064A1178|0 17|S6 kinase activation
P02236276T0000|0 3|Rats
P02237431A0000|0 9|Expression
P02237431A0833|3 18|Ets-1 binding site
P02241742A0766|0 11|Cerebral flow
P02241892A0681|0 10|Utilization
P02242222T0000|0 18|Presidential address
P02243093A0000|0 27|Human T-cell leukemia virus type
P02243386A0113|27 49|serial undiluted passages
P02246362T0000|3 23|Jenkins Activity Survey
P02246447A0460|28 43|regression slopes
P02246803A0692|25 45|non-invasive TTD method
P02247069A0261|3 10|TUP1 gene
P02247072A0794|3 25|SUP44 suppressor mutation
P02247081A0223|14 23|disruption
P02247924A0078|18 35|perinephric abscess
P02248732A1113|36 46|haloperidol
P02249872A1051|26 34|wide range
P02250919A0404|0 10|Perceptions
P02251119A0319|0 6|Results
P02252891T0000|0 19|65-kilodalton protein
P02252953A0300|9 23|restrained girls
P02253274A0000|3 14|Mauriceville
P02253663A0687|3 17|circadian rhythm
P02254282T0000|0 7|Sequence
P02254418A0641|0 10|Most strains
P02254749A0133|8 12|cDNAs
P02256678A1224|9 41|complementary footprinting analysis
P02257251T0000|0 14|Pathophysiology
P02257899T0000|0 25|Auditory-visual interaction
P02258918A0242|24 29|slices
P02259334A0205|3 18|upstream promoter
P02259795A0570|55 66|calculations
P02261254A0168|0 10|Experiments
P02262439A0508|0 10|MCh infusion
P02264601A0000|0 19|Taste reactivity tests
P02265055A0417|0 19|Plasma concentrations
P02266679A0740|0 7|Plasma Al
P02268461A0224|27 34|patients
P02269281A1276|3 12|occurrence
P02269426A0428|0 2|IST
P02270096T0000|0 16|Genotoxic activity
P02270587A0000|3 25|endodontal treatment need
P02270834A0123|3 12|long method
P02272095A0832|5 11|results
P02273690T0001|0 6|Effects
P02274343A0064|0 20|Common foot pathologies
P02274509A0623|0 15|Liver dysfunction
P02276891T0000|0 10|Coenzyme Q10
P02277005A0227|3 19|CT characteristics
P02277319A0211|19 31|preservatives
P02277452A0116|4 11|patients
P02278217A0372|6 11|groups
P02278474A0000|0 29|Serum Fibrin Degradation Products
P02280777T0000|3 21|uteroglobin promoter
P02281118A1191|0 31|Prostaglandin synthesis inhibitors
P02281330A0556|3 32|inspiratory oxygen concentration
P02281948A0245|10 28|mineral oil emulsions
P02282815T0000|0 11|Significance
P02283148T0000|0 11|Significance
P02283378A0385|3 17|former procedure
P02283378T0000|0 11|Simple method
P02283873A0308|15 25|adolescents
P02284393A0751|0 14|Further research
P02284573A0943|14 17|MoAB
P02287860T0001|0 14|Ultrastructural
P02289102A0114|7 23|audiotape cassette
P02289639A0989|3 12|mean change
P02290216T0001|0 5|Effect
P02291144A0493|4 15|good accuracy
P02291628A0264|3 12|second part
P02292272T0000|0 20|Interlimb coordination
P02293019A0000|0 18|Antileukoproteinase
P02293664A0946|22 30|deletions
P02294048A0881|20 49|% amino acid sequence similarities
P02295521A0922|2 16|causal relations
P02296509A0997|18 33|household members
P02298741A0809|0 7|Analysis
P02299543A0317|36 49|present outlook
P02300541A0000|14 20|effects
P02300577A0852|3 11|beta chain
P02300759A0000|3 22|therapeutic protocole
P02303158T0000|0 28|Thyrotropin-induced expression
P02303470A0242|3 9|introns
P02303874A1643|7 28|initial titration period
P02305014A0226|5 15|first series
P02306539T0000|0 2|Use
P02307067A1348|3 13|persistence
P02307371A0263|11 30|mechanism responsible
P02307613A0783|0 37|Erythrocyte protoporphyrin concentration
P02307848A0347|9 17|sequences
P02307848T0042|3 9|genomic
P02307850A0000|6 29|RNK-16 lambda-gt11 library
P02307850A1197|3 11|induction
P02308496A0000|43 52|blood level
P02310261A0115|3 9|abscess
P02310300A0298|4 16|% lymphography
P02310350A0221|3 14|present study
P02310496X0000|0 23|Similar memory impairments
P02311544A0086|0 6|Studies
P02312470A0774|3 31|BAL-to-plasma specific activity
P02312689A0360|3 18|kappa coefficient
P02315151T0020|0 12|Senior systems
P02315472A0583|17 27|imaging time
P02317413A0364|0 7|Patients
P02317554T0000|0 12|Determination
P02318208A0817|3 19|cis-acting element
P02319610A1527|3 19|clinical relevance
P02320008A0651|0 5|TMBr-1
P02320999A0606|33 41|materials
P02322535A0658|0 5|Intron
P02323517A0557|6 6|h
P02324102A1157|0 9|Comparison
P02324104A0151|15 15|%
P02324104A0516|0 9|High levels
P02324104A0929|8 20|novel C subunit
P02324104A1195|3 17|alternative exon
P02325208A0209|7 8|M.
P02325895T0000b|19 42|mechanoreceptor discharge
P02326716A0139|0 6|Methods
P02326946T0000|0 40|Plasma lecithin/cholesterol acyltransferase
P02327159T0001|0 3|Lars
P02328328A0419|0 18|Axillary nodal status
P02329840A0383|21 35|microelectrodes
P02330041A0335|0 9|Expression
P02330110A1085|9 33|multiple laboratory studies
P02330333A0325|0 12|Accumulations
P02331361A0268|9 23|gradual increase
P02332018A0538|19 40|exercise-induced asthma
P02332798A0725|3 11|afferents
P02333239T0000|9 21|age old problem
P02333545A0313|22 37|fibrinogen levels
P02333749A0411|3 36|stepwise logistic regression analysis
P02334972A0145|38 51|different types
P02335034A0584|23 42|whole-body heat stress
P02335521T0000|2 40|NF1-related vitellogenin activator element
P02335713A0905|1 15|poor correlation
P02335815A0530|5 20|carboxyl terminus
P02336338A0931|3 9|effects
P02339005T0000|0 5|Effect
P02339447A0162|18 24|7,7-2H2
P02340595A0124|0 15|Sequence analysis
P02341669A0000|0 10|Experiments
P02342477A1292|8 11|UfAP
P02343033A0000|15 26|dates infants
P02344529T0000|8 19|renal anaemia
P02347102A0000|3 24|pseudolymphoma syndrome
P02347407A0217|5 25|local geomagnetic field
P02347655A0193|5 18|artificial lung
P02348225A0192|0 3|Mean
P02348408A0126|0 8|Attitudes
P02348728A1153|14 22|DNA ploidy
P02349827A0193|1 26|semiautomatic digital system
P02349942A0287|0 19|Environmental factors
P02349998A0297|0 18|Dopamine SERS spectra
P02351239A0693|5 12|findings
P02351297A0000|8 35|experimental toxicity research
P02353453A1249|13 25|helicase motif
P02353875A0800|3 9|results
P02354381A0207|10 19|treatments
P02355293A0749|7 28|significant differences
P02355765A0220|24 43|benzathine penicillin
P02355920A0681|1 20|consensus binding site
P02356823A0063|4 17|proposed method
P02357537A0451|3 9|effects
P02358975A0709|53 66|strong symptoms
P02360336A0574|0 3|Drug
P02361008T0000|0 6|Changes
P02361575T0000|0 13|Dermal toxicity
P02361812A1110|3 10|kg FFM SMR
P02362161T0000|0 5|MK-927
P02362803A0608|0 19|PCR-derived fragments
P02368931A0587|2 31|addition serum IgE concentrations
P02370571A0663|3 10|findings
P02371273A0144|3 21|transcriptional unit
P02371517A0747|8 15|patients
P02372496A0782|0 16|Co-administration
P02372712A0002|3 9|effects
P02373686T0000|0 18|Transient expression
P02373810A1118|19 19|%
P02374886A0305|3 26|Community Adjustment Scale
P02376023A0307|12 17|months
P02378615A0807|3 17|protein sequence
P02378945A0487|4 13|adaptation
P02383693A0301|3 8|eluent
P02383771A0544|2 22|histologic examination
P02384265A0947|5 11|results
P02384389A0854|3 11|same trend
P02386485A0554|3 20|nucleotide sequence
P02386895A0496|0 9|Toxicities
P02388685A0577|3 9|results
P02390538A0000|7 13|infants
P02390633T0000|0 16|Fatal encephalitis
P02390989A0745|29 35|GPB gene
P02391344T0000|0 15|Molecular cloning
P02392032A0657|3 9|results
P02392511T0000|0 28|Serotonin 5-HT2 receptor binding
P02393001A0324|8 10|%BF
P02393895A0918|3 10|RF values
P02394707A0789|0 15|Promoter elements
P02394718A0130|9 13|genes
P02395868A0322|13 30|catalytic zinc sites
P02396415T0001|0 6|Results
P02398897A0000|0 29|Eucaryotic transcription factors
P02399053A0153|0 24|Sprague-Dawley newborn rats
P02399053A1032|3 4|Lm
P02400070T0000|0 9|Comparison
P02400457A0469|2 11|Experiment
P02402678A0463|12 32|available formulations
P02403035A0621|9 20|reading frame
P02403634A0788|0 15|Sequence analysis
P02403926A0000|3 16|trk-2h oncogene
P02403926A0307|0 9|Antibodies
P02404451A1532|9 39|recent scanning-deletion analysis
P02405393T0000|0 8|Molecular
P02405589A0000|0 10|Information
P02405818A0550|0 14|Branch occlusion
P02406570A0466|3 19|ABFI-binding sites
P02406570A0898|18 27|properties
P02406992A0192|0 20|Nonvascular ophthalmic
P02408248A0414|24 40|hypotensive action
P02409297A0984|0 18|Polyclonal antiserum
P02411513A0667|5 19|characteristics
P02417023T0001|0 3|Role
P02417669A0218|2 24|maximum photosensitivity
P02418701A0000|26 32|tissues
P02419327A0998|3 17|priming activity
P02419588A0284|0 1|A.
P02420432A1060|12 22|conjunction
P02423533A1314|3 8|levels
P02423533A1790|3 7|cDNAs
P02423773T0001|0 17|Colorimetric method
P02423850A0292|0 15|Deletion analysis
P02424743A0280|3 4|N1
P02427024X0000|0 8|Tolerance
P02427797A0199|4 7|dogs
P02427812A0865|5 11|results
P02427869A0939|12 40|beta 2-adrenoceptor sensitivity
P02431314A0834|14 19|Hansel
P02436005A0707|5 11|results
P02437625A0197|19 22|eyes
P02437792T0000|0 9|Comparison
P02437895A0000|1 5|probe
P02438637T0000|0 16|Mucolipidosis type
P02442837A0060|13 18|groups
P02443028A0695|2 7|reflow
P02443924A0083|7 14|patients
P02444507A0240|0 15|Lysozyme activity
P02445751A0925|3 27|first involved measurements
P02446871A1021|1 18|5.8S-like structure
P02449431A1121|0 18|ATP gamma S inhibition
P02451872A0391|21 35|methoxydextrane
P02452313A0114|0 7|ASL-8123
P02454390T0000|0 7|Enhancer
P02454976A0944|12 18|results
P02455821A0099|25 72|1.8-kilobase AccI-EcoRI restriction fragment mapping
P02456827A0899|3 6|4-AP
P02457922A0991|0 12|Hybridization
P02458080T0000|0 8|Prognosis
P02458234T0000|1 9|new method
P02458699A0650|0 7|Svensson
P02459309T0000|0 16|Endogenous release
P02461368A0162|28 36|first time
P02462047A0208|0 14|Viable flap areas
P02462305A1071|3 17|size discrepancy
P02462523A0394|1 23|9.5-kb KpnI-SalI fragment
P02463050A0514|3 44|corticosterone synthesis inhibitor metyrapone
P02464097T0000|3 9|effects
P02466414A0000|4 24|pentobarbitalized dogs
P02466665A0202|3 25|small IGF-binding protein
P02468795A1086|0 34|Serum prostatic acid phosphatase levels
P02469451A0239|42 52|open fashion
P02470955A0101|5 11|studies
P02473156A0000|1 4|cDNA
P02473198A0613|0 7|Dopamine
P02473619A0202|0 23|Spontaneous sensitization
P02473693A0174|35 46|fetal protein
P02473718A0000|19 21|apt
P02473907A1338|7 10|C mAb
P02473942A1207|5 20|hydropathic plots
P02474093T0000|0 10|Angiotensin
P02474110A1039|15 34|significant reduction
P02474204A0105|0 13|Endocrine cells
P02474356A0559|10 22|radioactivity
P02475506A0878|3 6|mRNA
P02475717A0565|0 13|Tissue necrosis
P02476030A0000|10 23|retinal surface
P02476664A0563|49 56|human K14
P02477373A0930|1 16|potential TATA box
P02479635A0659|0 13|Cotransfection
P02479823A0727|0 15|Sequence analysis
P02480419A0735|13 21|cirrhosis
P02480959A0470|4 15|P-450scc mRNA
P02481230A1258|23 42|bovine alpha transgene
P02481429T0000|1 22|rapid staining technique
P02481779A0213|0 6|NIK-244
P02482293A1518|2 38|TNF-resistant T24 bladder carcinoma cells
P02482511A0860|5 31|phosphodiesterase inhibitors
P02483210A0000|3 17|diagnostic value
P02483438A0498|36 41|groups
P02484714T0000|0 21|Structural organization
P02484994T0001|0 24|Intravenous gamma globulins
P02485188A0415|9 24|chondroitinase AC
P02486634A0632|0 18|Myocardial perfusion
P02487898A0315|4 20|NGF administration
P02488148A1156|26 36|RSNA meeting
P02489032A0000|0 23|Immunoglobulin light chain
P02489753A0581|3 9|results
P02489895T0001|0 20|Muscle action potential
P02492111A0670|4 4|%
P02492111A0868|21 42|known neurotoxic effects
P02493644A0588|9 16|3T3 cells
P02495745T0000|3 21|thrombolytic effects
P02496090A0252|5 7|CO2
P02496100T0000|0 30|Enzyme-linked immunosorbent assay
P02496109A0754|8 18|experiments
P02497340A0989|0 32|Functional rearranged antibody genes
P02498322A0226|3 30|specific DNA-protein complexes
P02498652A0460|5 16|transfection
P02500432A1416|20 44|constitutive CAT expression
P02502096A0462|13 26|renal blood flow
P02502602A0323|0 8|Tonometry
P02502960A0762|8 9|p.
P02504603T0000|0 8|Isolation
P02505087A1037|15 37|dimerization specificity
P02506390T0001|0 5|Growth
P02506740A0742|0 5|Fourth
P02507523A0791|3 13|ORF1 product
P02507815A0000|0 7|Kindling
P02508306A0528|0 19|Abundant infiltration
P02508726A0498|5 15|case reports
P02509123A0371|5 12|sessions
P02510242A0313|8 12|cases
P02511069A0532|0 23|Recessive lethal mutations
P02511150T0025|0 12|Current status
P02511207A0282|0 1|K.
P02511430A0000|1 13|215-base-pair
P02511898A0000|20 26|reasons
P02512010A0801|3 19|PETCO2 measurement
P02514498A0000|0 14|Gastric CO2/HCO3
P02515953A0459|0 13|Follow-up study
P02517008A0481|3 15|other patients
P02518645T0001|0 20|Neonatal Chagas disease
P02518691A0251|12 38|IL2R alpha promoter constructs
P02519327T0001|0 20|Palindromic rheumatism
P02519679T0000|0 9|Inefficacy
P02520622A0200|5 12|patients
P02521217A1035|17 30|related protein
P02521674T0000|0 6|Mapping
P02522297A0000|14 26|thromboxane A2
P02523800A1178|36 43|CHS1 gene
P02525044A1026|3 15|recovery index
P02526165X0000|9 20|Leser-Trelat
P02527365T0000|0 13|Xenopus homolog
P02527745A0865|0 19|Southern blot analyses
P02528329A0000|5 19|missense mutants
P02528730A1073|9 15|exons 2a
P02529378A0536|0 17|S1 nuclease analysis
P02530413A0195|2 15|supine position
P02530470A0604|3 19|overall prevalence
P02531203A0241|0 22|Quantitative predictions
P02532032A0385|0 19|Plasma concentrations
P02532210A0000|3 19|adenovirus E1A gene
P02534067A0316|0 13|Administration
P02535460A1443|0 13|RNA transcripts
P02536096A0327|2 10|HeLa cells
P02536160A0518|5 30|basal unstimulated condition
P02537441A0231|0 3|None
P02537485A0841|5 16|formalin test
P02538450A0000|14 23|cDNA clones
P02538656A0172|20 35|several E1 mutants
P02538720A0582|0 3|UbiA
P02541251A1327|9 14|T2 gene
P02541882A0251|0 15|Radiation therapy
P02542194A1496|5 11|results
P02542270A0000|3 13|methylation
P02542612A0530|0 17|S1 nuclease analysis
P02543226A1559|41 49|carcinoma
P02543621A0788|0 7|Analysis
P02543679A1291|35 41|lambda O
P02543734A0414|0 24|Synthetic oligonucleotides
P02544059A0377|0 6|Effects
P02545357A0000|3 29|mustard chloroplast gene rps16
P02545903A0639|0 9|Antibodies
P02546234A1382|10 36|supraventricular tachycaydia
P02547079A0910|3 24|negative calcium balance
P02547611A0318|0 6|Clone 4c
P02547706A0928|16 18|ISH
P02547706T0001|0 7|Validity
P02547778A0786|3 14|unique nature
P02548683T0001|1 12|brief account
P02549036A0000|3 26|Bacillus subtilis phage phi
P02549343A1008|17 19|gpI
P02549417A0000|0 17|Erythrocytic stages
P02550118A0610|8 45|bilateral diffuse pulmonary infiltrations
P02550682A0411|11 19|incidence
P02551886A0332|0 14|Restriction maps
P02552143A0748|0 2|VP5
P02552316A0526|14 35|seronegative caretakers
P02554310A0419|12 26|similar fragment
P02555177A0488|7 11|pet54
P02555418A0973|0 6|Insert2
P02555519A0798|5 26|considerable variations
P02555703T0000|0 22|Tyrosine kinase oncogenes
P02556264A0278|4 16|TC-II enhanson
P02556269A0187|3 10|DNA helix
P02556603A0606|12 29|similar improvement
P02557217A0000|0 13|Beta-endorphin
P02557217A0398|19 28|calcitonin
P02557350A0632|3 14|DNA sequences
P02559630A0270|0 20|Other hemostatic values
P02560415T0012|0 18|Rare neurogenic tumor
P02562787A0637|27 37|cellular NBP
P02562825A0413|0 13|Responsiveness
P02565405T0000|0 6|Drug use
P02565683A0841|1 17|critical heart rate
P02565807A1198|14 30|neu proto-oncogene
P02566613A0831|3 15|65-bp sequence
P02566613T0000|0 25|Somatostatin gene expression
P02566680A0820|14 42|full mu-opioid agonists fentanyl
P02567030A0482|22 43|original discrimination
P02568930T0000|0 8|Isolation
P02569411A0151|5 15|termination
P02571924A0000|0 11|Haploid cells
P02572777T0000|0 19|Tumour necrosis factor
P02572928T0000|0 9|Monitoring
P02573303A0000|13 27|left ventricular
P02573336A0000|17 30|return-of-fear
P02573829T0000|0 23|Evolutionary conservation
P02573836A0244|11 30|functional importance
P02574016A0428|20 22|TOF
P02574052A0910|2 23|significant differences
P02574193A0663|0 8|Selection
P02574551T0000|0 13|Antihistamines
P02575174A0229|27 34|efficacy
P02575490A1021|0 19|Northern blot analysis
P02575567T0001|0 22|Materials science studies
P02575959A0643|3 13|latency time
P02576405A0223|2 18|patients resistant
P02577458A0412|34 43|newer drugs
P02577867T0000|3 22|avian cellular homolog
P02580830A1131|1 14|736-bp sequence
P02582240A1009|0 16|High ATP/GTP ratios
P02582918A0000|5 33|hepatitis B vaccine immunization
P02584969A0119|3 20|experimental design
P02585492A1005|0 32|Interspecific complementation tests
P02586485A0511|0 4|GN101
P02586513A0622|0 7|Analysis
P02590097A0093|0 17|Nodular involvement
P02590391A0442|0 3|None
P02590540A0741|5 9|women
P02590615A0636|16 26|steady state
P02590869A0743|3 19|GALT-primed calves
P02591078A0000|0 19|Recent investigations
P02591969A0961|3 21|elements responsible
P02592543A0106|3 16|present studies
P02592640A0466|0 9|High values
P02592961A0327|0 5|COGLAB
P02595451A1136|18 29|aniridia gene
P02595451T0000|1 25|fine-structure deletion map
P02597484A0624|13 32|effective diffusivity
P02597549A0964|10 23|recent patients
P02598034A0000|0 21|Middle-latency auditory
P02598745A0251|0 3|Most
P02599995A1031|0 27|Intracellular activity studies
P02600306A0140|48 56|detection
P02601707A0986|0 19|Gel retardation assays
P02602150A0993|0 19|Such transgenic plants
P02603374A0383|0 15|Ventral rhinotomy
P02603923A0220|4 30|full-thickness skin incisions
P02604420A0234|16 23|rebiopsy
P02605160A0000|11 20|iron intake
P02605182A0936|10 24|protein sequence
P02605679A0306|0 7|Analysis
P02607766A0000|41 56|characterization
P02609112A0000|0 12|Reagent strips
P02614668A0971|3 31|lowest detectable concentration
P02615078A0283|13 22|antibodies
P02617623A0740|0 5|LON-72
P02620085A0656|0 17|Animal experimental
P02621983T0001|0 11|Significance
P02623038A0632|2 8|changes
P02627159A0899|3 30|antigen-specific IgG4 antibody
P02629109A0000|11 26|fertility decline
P02630543A0210|16 31|staining affinity
P02631505A0382|0 9|Ampicillin
P02631566A0151|0 13|Alkoxymetgyl-3
P02631743A0275|17 25|incidence
P02631887A0000|6 13|patients
P02632904A0619|18 23|VE/VO2
P02634490A0186|3 23|differential diagnosis
P02634872A0000|0 9|Retrograde
P02636920T0001|0 17|Collaborative study
P02637597A0362|0 17|Serological studies
P02638964A0372|3 18|maximum stress due
P02641762T0001|0 19|Ischemic heart disease
P02642466T0000|0 15|Sequence analysis
P02642976A1474|0 26|Potential consensus sequences
P02644735A0427|2 9|FP mutant
P02645276T0088|0 11|Construction
P02645431A1562|20 33|hypocitraturia
P02646007T0000|0 36|Concomitant chronic lymphocytic leukemia
P02647403A0000|0 24|Vivid visual hallucinations
P02647918A0423|5 14|whole group
P02647918A0588|0 10|Application
P02647937A0191|21 36|surgical planning
P02648396A0565|2 12|Rat-1a cells
P02648396A1033|23 26|foci
P02648646A0216|0 23|Platelet activating factor
P02648646A0932|10 31|significant correlation
P02649445A0412|4 5|BG
P02649811T0000|0 22|Postcoital contraception
P02650663A0178|35 42|subjects
P02651448A0000|32 50|diffusion concurrent
P02651487A0000|25 46|calcium channel blockers
P02655381A0000|0 10|Many studies
P02656257A0000|3 36|site-specific DNA inversion system Cin
P02657388A1011|3 18|terminator region
P02657883A0000|0 9|US-Doppler
P02657883T0001|0 6|Doppler
P02664229A0138|8 15|cosmesis
P02666034A1520|12 19|patients
P02666404A0220|3 22|galactose transporter
P02666568A0000|15 31|untreated patients
P02667259A0331|20 23|cent
P02668691A0570|4 7|mRNA
P02669199A0000|0 18|Tumor necrosis factor
P02670457T0000|3 20|calcium requirement
P02674141A1202|3 24|seventh cysteine residue
P02674327A0493|3 5|p34
P02674671A0601|5 35|single-stranded DNA transformants
P02674674A1308|3 9|results
P02674679A1237|12 39|S1 nuclease protection analysis
P02675492A0806|11 18|patients
P02677002A0205|8 16|wild-type
P02677429A0366|0 12|Survival rates
P02677666A0356|0 6|Mapping
P02679804A2000|3 10|products
P02680843A0724|21 22|RS
P02684159A0870|0 20|Hybridization analysis
P02684585T0001|0 23|Agranulocytosis treatment
P02685331A0523|3 24|R. meliloti nifH promoter
P02685461A0380|0 20|Major clinical symptoms
P02685565A0165|37 53|c-myb-encoded mRNA
P02686588A0592|0 22|Routine clinical analysis
P02686749A0000|11 28|health significance
P02686980A0000|30 51|functional organization
P02686985A0811|1 33|transcription factor exclusion assay
P02688772T0000|0 9|Psychiatry
P02689136A1851|5 18|adverse effects
P02689439A0000|3 36|cytosolic glutathione S-transferases
P02689439A0402|18 36|untranslated regions
P02689544A0456|0 4|Model
P02691557A0273|3 11|incidence
P02691811A0355|15 17|min
P02691998A0672|3 13|present data
P02692881A0354|16 34|normal pregnant women
P02693208A0166|26 38|recombination
P02693593A0866|21 34|leader sequence
P02694731A0241|5 13|other hand
P02695914T0000|3 19|stereoselectivity
P02700977A0444|0 9|Scotchbond
P02702566A0000|14 22|cisplatin
P02702849A0418|0 28|Metformin plasma concentrations
P02703121T0000|0 8|Diagnosis
P02703925A0359|27 45|various subgroupings
P02704579A1078|1 23|significant relationship
P02705072A0464|0 8|End points
P02705296A0231|12 26|molecular weight
P02705556A1049|4 5|RV
P02707909A0209|2 18|alternative method
P02708288A0139|0 19|Liquid chromatography
P02708288A0621|3 17|dichloromethane
P02708353A1080|0 25|Primer extension experiments
P02708353A1452|17 39|polymerase chain reaction
P02709081T0000|0 9|Validation
P02709819A0495|7 9|ADR
P02711145T0000|0 16|HIV infectiousness
P02711167A0818|14 20|turnout
P02711601A0601|3 25|corresponding inhibition
P02712246T0042|14 43|histopathologic characteristics
P02712450A0989|0 10|Normocapnic
P02713310T0000|0 12|Fundus changes
P02713520T0000|0 17|Chronic dose effects
P02713994A0482|3 7|titer
P02714525A0529|0 11|Kidney weight
P02714852T0000|0 15|Allelic variation
P02717133T0001|21 48|optimal development conditions
P02717349A0311|0 2|Men
P02718683A0142|0 18|Handgrip dynamometry
P02720966A0455|2 19|cerebrospinal fluid
P02721169A0171|0 8|NERVTRACK
P02723503T0000|0 8|Swim-over
P02724227T0000|0 15|Perfusion washout
P02725495A0929|26 36|U2 RNA region
P02725513A0617|19 41|active CHO spacer promoter
P02727909A0383|7 15|amplitude
P02729666A0267|0 31|Significant intergroup differences
P02731611A0134|18 26|rationale
P02731671A0000|3 18|relative toxicity
P02732341A0000|0 17|Light microscopical
P02733116T0000|7 24|National Institutes
P02733690T0000|0 15|Molecular cloning
P02735364A1330|5 14|final model
P02736482A0550|18 41|external radiation therapy
P02739739T0000|0 22|COUP transcription factor
P02740196A0704|2 11|Experiment
P02740347A0644|0 11|Cosmid clones
P02740627A0137|3 14|oxygen uptake
P02740874A0957|0 15|Epithelial damage
P02740955A0333|11 18|patients
P02743842A0000|3 14|present study
P02743981A0347|0 10|Transcripts
P02744123A0237|17 23|results
P02744490A0894|0 7|Evidence
P02745280A0276|13 16|PaO2
P02745444A0391|3 29|transcription initiation site
P02745666A0000|0 18|Endometrial biopsies
P02746099A0000|3 10|mobility
P02747653A0910|1 25|larval albumin-like protein
P02748188A0091|14 31|pain-tolerant group
P02748595A0492|17 32|baboon liver class
P02749215A0000|8 18|proteinuria
P02751080A0176|4 17|individual shot
P02752303A0000|0 12|Lithium delays
P02752629A0163|0 6|Dynamic
P02752651A0480|28 36|September
P02756731T0001|0 13|Prostaglandins
P02756878A0075|32 52|successive occurrences
P02757033A0905|41 45|genes
P02757862T0000|0 16|Initial experience
P02758382A0478|0 6|Obesity
P02760922A0000|0 36|Heterogeneous nuclear ribonucleoprotein
P02761008X0000|0 26|Brain cholinesterase activity
P02761150A0000|11 24|zinc deficiency
P02761492A0124|3 10|findings
P02761537A0168|0 11|Heating cells
P02761540A0873|0 15|Deletion analysis
P02762006A0071|0 3|Cord
P02762198T0001|0 3|Reye
P02763467A0903|4 58|two-dimensional polyacrylamide gel electrophoretic patterns
P02764797A0182|0 4|PULSE
P02765001A0105|0 11|Definite JPsA
P02765214A0486|12 16|Kurti
P02766330A0779|25 37|antipsychotic
P02766508A0421|1 22|correlation coefficient
P02766745T0000|1 19|hospital-based study
P02767166A0368|17 33|lipid peroxidation
P02767733A0690|3 21|histological grading
P02772495A0641|0 5|Asthma
P02773507A0750|11 14|l/kg
P02773930T0000|3 16|solitary kidney
P02774271A0000|0 8|Halothane
P02774808A0194|3 8|values
P02775136A1151|5 11|results
P02775333A1137|0 9|Buflomedil
P02776471A0235|26 32|animals
P02776742A0000|0 8|Heart rate
P02776823A0000|3 19|clinical tolerance
P02777797A0720|0 19|DNA blot hybridization
P02778237A0585|8 37|term corticosteroid-dependent IA
P02778873A0761|16 19|CRL3
P02779752A0000|3 12|1-Naphthyl
P02779752A0776|3 16|m-Chlorophenyl
P02780157A0576|3 23|characteristic feature
P02781495T0001|0 6|Changes
P02781567A0544|18 20|v/v
P02783181A0000|3 16|cytoprotective
P02784507A0000|3 32|human immunodeficiency virus type
P02787430A0124|0 22|Histiocytic panniculitis
P02789062A0000|17 34|human 4F2 heavy chain
P02789062A1420|1 4|cDNA
P02789180A0407|0 46|Electrocardiographic right ventricular hypertrophy
P02789217A1323|6 19|IL6 mRNA species
P02790009A0375|0 17|Sequencing analysis
P02790009A1052|3 15|mature protein
P02792270A1220|0 26|Oligosynaptic EPSP components
P02792430A0000|0 10|Experiments
P02793216A0876|5 13|other hand
P02793620A0214|9 24|later-parity cows
P02793753A0354|10 13|lobe
P02794828A0214|23 39|intact canine heart
P02795923A0000|31 48|basic CT appearances
P02796216A0063|15 28|atypical course
P02796988A0735|3 24|transcription factor Sp1
P02797877A0475|3 16|combination PIP
P02798953A0307|13 19|mothers
P02799892A0154|18 38|saline-washed red cells
P02800417A0332|12 21|asthmatics
P02800435A0000|0 15|Acute experiments
P02802280A0495|2 23|significant differences
P02805945A0000|3 13|percentages
P02806916A0000|1 15|genomic DNA clone
P02807780A0143|10 28|appropriate solution
P02808232A0681|0 10|Lower limits
P02809116A0237|12 31|small negative effects
P02809651A0492|37 49|meta-analysis
P02809722A0926|5 39|acromegalic patient visual improvement
P02809831A0799|14 17|PPSF
P02810911A0372|3 12|accuracies
P02811378A0250|3 17|congenital forms
P02811378A0379|0 25|Immunohistochemical studies
P02813369A0390|18 26|same males
P02813404T0000|0 23|Male-enhanced antigen gene
P02814182A1211|2 5|rats
P02814820A0967|9 16|Roux limb
P02815229A0139|3 12|treatments
P02816251A0397|3 35|subepicardial lymphatic capillaries
P02817724A0075|25 26|T1
P02818122A0000|1 9|great deal
P02818260T0000|0 14|Low-grade glioma
P02820128A1333|9 27|sequence repetitions
P02820128A1670|22 39|palindromic domains
P02821340A0434|6 24|sub-maximal exercise
P02824334A0972|23 41|G-protein gene family
P02825139A0661|24 42|significant homology
P02825750A0260|4 20|evaluable patients
P02826127A0709|50 65|SV40 octamer motif
P02826717A0179|0 5|Anoxia
P02826729A0790|0 5|Growth
P02828926A1870|5 27|multiple myogenic factors
P02829183A0117|0 18|DNA sequence analysis
P02830214A0000|11 23|acetazolamide
P02830265A0341|0 5|RPA190
P02830282A0155|7 21|intact A1 protein
P02831398A0346|0 6|Irmiere
P02831556A0173|5 13|offspring
P02831796A0000|0 26|Simian immunodeficiency virus
P02832149A1009|40 47|products
P02832293T0000|8 13|CRF-41
P02832744A0403|10 23|mos transcripts
P02833012A0428|12 16|L mRNA
P02833021A1185|3 9|results
P02833049A0630|0 9|Variations
P02833049A1041|15 34|steady state RNA levels
P02833101T0000|0 13|Aplastic crisis
P02833517A0467|11 32|more different sequences
P02834478A0000|0 25|Low molecular weight heparins
P02834843A0000|3 22|bactericidal activity
P02836623A1094|0 1|Mo
P02837575A0979|0 36|Sodium dodecyl sulphate-induced cleavage
P02837763A0259|0 16|Amino acid sequence
P02838246A0225|0 19|Herpes virus infection
P02838319A0527|0 3|RVEF
P02838710A0299|3 8|levels
P02839488A1314|0 17|Quantitative assays
P02839716A0673|7 11|cells
P02839716A1907|19 22|E2-C
P02840034A1266|0 17|Accurate evaluation
P02840376A0461|1 8|anti-IIa
P02843495A0544|0 11|Introduction
P02843694T0001|0 23|Chronic E-B virus infection
P02844767A0191|3 18|primary structure
P02844767A0596|3 18|Nostoc petBD genes
P02844767A1022|0 20|RNA blot hybridizations
P02844797A1225|10 22|muscle isoform
P02845654A0510|0 11|Substitution
P02846640A0643|8 31|indigo-producing bacteria
P02846852A1459|11 27|polymerases active
P02848842A0643|9 20|RNA molecules
P02849100A0441|7 32|hydrophobic sequence located
P02849759A0865|3 14|SV40 enhancer
P02850472A0112|14 23|origin core
P02850967T0000|0 8|Induction
P02850971A0180|1 26|17-mer oligodeoxynucleotide
P02852805A0216|1 18|total soluble solids
P02852894T0000|0 5|Causes
P02853799T0001|3 13|progression
P02853922A0596|0 10|Elevated IOP
P02856622T0001|0 2|Use
P02859434T0000|0 11|Poor response
P02861067A0000|36 42|effects
P02861144A0242|0 14|Further analysis
P02861238T0000|0 11|Hantaan virus
P02862656T0000|0 6|Changes
P02863492A0544|2 23|significant differences
P02863747T0000|0 29|Replacement variant histone genes
P02865502T0000|0 26|Double-blind randomised trial
P02868446A0184|3 19|C-terminal domains
P02868848A0167|8 17|vancomycin
P02869125A0120|0 7|Fentanyl
P02870249T0000|0 23|Intravesical chemotherapy
P02870720A0188|0 9|Bisoprolol
P02870851A0349|0 5|Output
P02872786A0147|3 26|Hagen-Poiseuille equation
P02873593A0581|11 14|rats
P02874078A0252|2 33|endometrial luteal phase deficiency
P02874635T0000|0 15|Prenatal exposure
P02875224A1059|0 10|Reperfusion
P02875967A0377|32 41|adrenaline
P02876820A0841|2 18|metabolic acidosis
P02876899A0568|2 5|Days
P02877124A0000|0 5|Mature
P02878100A0674|0 13|Present results
P02879906A0000|0 6|Studies
P02879951T0000|0 6|Effects
P02880841A0313|19 21|TF1
P02882893A0301|0 14|Body temperature
P02883327A0413|3 22|polyadenylation sites
P02883871A1075|9 11|ISA
P02883963A0000|3 10|patients
P02884860A0329|0 8|Terazosin
P02885517T0000|7 17|blood donors
P02889352A0000|0 11|Most patients
P02889495A0000|3 29|randomised double-blind study
P02890200T0001|0 45|Somatostatin-producing endocrine pancreatic tumor
P02892762A0296|0 5|Direct
P02894689A0000|19 38|specific DNA fragments
P02894741A0000|11 28|supplementary doses
P02894789A0954|11 25|recovery indexes
P02895472A0178|11 27|bacterial colonies
P02895566A0187|0 2|DPA
P02895754A0000|0 6|Topical
P02897651A0000|0 14|Hyperthyroidism
P02898752A0683|1 17|strong correlation
P02899177A0605|27 47|low-frequency kindling
P02899792T0000|0 8|Oestrogen
P02900760A0073|5 20|sequence elements
P02901498A0354|3 14|biosynthesis
P02901763A0977|0 9|Codon usage
P02902615A0000|1 30|new physiopathological treatment
P02902656A0481|4 16|scrotal testes
P02902844A1219|3 15|subunit-a gene
P02902927A0145|29 34|bovine
P02903500A0278|12 31|functional properties
P02904322A0002|3 28|East African dik-dik antelope
P02906027A0553|2 19|sequence comparison
P02906027A1156|5 19|unusual features
P02906249A1195|5 14|first group
P02906673T0000|0 7|Efficacy
P02907308T0001|1 5|cases
P02907533A0362|24 40|drug concentration
P02907533T0000|0 6|Effects
P02909528A1081|1 22|second promoter activity
P02910496A0583|1 15|decamer sequence
P02910989T0000|0 6|Effects
P02911540A0478|14 26|infected wound
P02913368A1037|0 18|Pharmacology studies
P02914422A0409|0 15|Computer analysis
P02914492A0183|16 18|ICU
P02916764A0253|3 13|risk factors
P02918474A0817|7 15|verapamil
P02919483A0091|11 14|boys
P02919530A0000|16 38|uncontrolled reperfusion
P02919832A0144|0 13|Cardiac disease
P02920591A0251|0 20|Hemodynamic assessment
P02923687A0218|45 53|sinusitis
P02925013A1112|21 29|low levels
P02925568A0460|8 14|effects
P02926499A0340|11 42|electrical-mechanical analog model
P02927391A0238|21 30|proviruses
P02928112T0000|0 15|Molecular cloning
P02928376A0312|6 16|present work
P02929056T0000|0 12|Successful use
P02930623A0404|6 20|flexion whiplash
P02934778A0702|29 54|5-HT2 serotonergic receptors
P02934889A0558|0 10|Oxfendazole
P02934891A0845|20 35|DNA-footprinting
P02935638A0000|49 57|Spec1 gene
P02936163T0000|0 15|Platelet function
P02936284A0357|0 21|Spontaneous degradation
P02938185A0223|11 19|cell lines
P02939260A1553|0 41|Partial N-terminal amino acid sequence analysis
P02940334A0141|0 5|Group A
P02941237A0160|5 18|former instance
P02943562T0000|0 22|Penicillinase production
P02947866A1416|5 24|quantitative analysis
P02949170A0184|19 25|effects
P02950216A0084|0 13|Functional flow
P02957125A0601|6 13|patients
P02958204A0175|16 22|effects
P02958233A0123|3 17|clinical picture
P02958660A1094|44 59|conversion factor
P02959089T0000|0 15|Preventive effect
P02960012A0838|14 24|PPNG strains
P02962859A0276|0 21|Monospecific antibodies
P02963517A0453|0 19|Quantitative analysis
P02964329A0000|3 14|pathogenesis
P02965149A0727|3 15|previous study
P02966671A0151|3 23|experimental end points
P02966671A0551|0 7|Schedule
P02967496A0182|3 25|cpc-1-encoded transcript
P02967915A0000|3 44|seco-steroid hormone 1,25-dihydroxyvitamin D3
P02967915A0968|14 35|calbindin-D28K promoter
P02968055A0984|3 5|HOI
P02969316A0002|23 27|atria
P02969819A0814|0 19|Ig D-JH recombinations
P02970061A0271|3 27|RAD18 gene open reading frame
P02970640A0341|0 32|Atomic absorption spectrophotometry
P02971603A0883|0 11|Most patients
P02971710A0734|0 4|Plots
P02971957A0287|3 27|absorbable perisplenic mesh
P02973304A0000|1 17|rare chronic course
P02975680A0000|8 25|accommodation night
P02975753A1333|0 25|Oligonucleotide mutagenesis
P02976332A1277|18 21|PGI2
P02979426T0000|0 19|Organ transplantation
P02979834T0000|0 6|Effects
P02981457A0368|0 1|D.
P02981840A0907|1 20|114-base pair sequence
P02982332T0001|0 4|Phase
P02983316A0310|13 20|segments
P02983331T0000|0 7|Evidence
P02985812A0984|2 15|unusual feature
P02985820A1287|0 24|Different sequence elements
P02986279A0000|2 12|milk samples
P02987220A0472|0 9|Subcloning
P02987777A0000|5 9|cases
P02988457A0650|36 53|future potentiality
P02989637A0671|20 41|dopaminergic regulation
P02989786A0328|14 30|enhancer sequences
P02991060A0465|5 17|IgG antibodies
P02993630A1190|0 11|Fine analysis
P02994253A0482|5 11|dosages
P02994336A0864|0 1|FK
P02995967T0000|1 27|v-erbB-related protooncogene
P02995999A0000|3 18|sequence analysis
P02997622A0916|4 16|L-myc sequence
P02997777A0609|0 27|Temperature-shift experiments
P02998016A0527|3 10|homology
P02998043A1199|0 10|Examination
P02999267A0606|8 10|FAP
P02999267A0885|14 29|myocardial uptake
P03000457A1554|6 17|kDa precursor
P03000489A0822|0 18|Alveolar lymphocytes
P03001054A0703|25 29|nicks
P03001084A0406|28 40|4024-base pair
P03001086A0587|12 28|amino acid sequence
P03001110A0546|4 18|phosphorylation
P03001353A0146|2 23|temperatures permissive
P03001645A0785|3 7|pet56
P03001705T0000|0 22|Multistep transformation
P03001952A0958|19 26|patients
P03002501A1327|0 9|Comparison
P03002786A0143|9 10|n =
P03003695A0395|0 9|Comparison
P03004364A0775|25 44|biological activities
P03004739A0753|14 14|C
P03004982A0199|3 20|nucleotide sequence
P03004982A1094|3 20|N-terminal sequence
P03005231A0649|10 30|untranslated sequences
P03006066A0653|6 20|P135gag-myb-ets
P03007281A0905|3 13|Dox-A2 locus
P03008094A0697|3 15|C-terminal end
P03008405A0532|0 15|Further outbreaks
P03009366A0438|7 21|ultrastructural
P03009826A0201|11 16|clones
P03010281A0220|3 8|copies
P03011793A0582|3 19|open reading frames
P03013477A0000|28 39|iron overload
P03013841A0207|0 7|Cattaneo
P03014515T0000|0 24|Human alpha-galactosidase A
P03014593A0681|0 7|Diazepam
P03015611A0331|3 19|amino acid sequence
P03015628A1078|0 10|Osteocalcin
P03015953T0000|0 7|Analysis
P03016301A0605|8 18|v-myc codons
P03016506A0611|1 17|recombinant vector
P03016883A0000|2 4|men
P03017225A0706|9 17|carcinoma
P03017996A0731|9 20|biosynthesis
P03018491A0840|3 16|hexanucleotide
P03019505A0390|4 11|patients
P03020001A0781|3 10|smallest
P03020513T0000|3 19|52-protein subunit
P03021050A0501|22 26|peaks
P03021088A0135|3 15|latent periods
P03022129A0842|3 19|nucleosomal arrays
P03023067A0779|0 10|Translation
P03023679A0624|3 17|molecular weight
P03023682A0271|0 8|Insertion
P03023859A0000|5 8|DNAs
P03023887A0470|0 19|Nuclease footprinting
P03023970A0922|3 13|96-bp insert
P03024343A0372|3 8|tumors
P03024703A1036|21 31|nucleotides
P03025606T0000|0 28|Transcriptional control signals
P03025655T0000|1 18|noncatalytic domain
P03025661A0260|0 6|Gluzman
P03025862A0860|1 10|single exon
P03026915A1024|6 27|nontranslated sequences
P03027661A0000|3 12|activities
P03027779A0000|0 15|SPECT examination
P03027905A0632|0 18|Plasma renin activity
P03029111A0155|3 9|mutants
P03031602A1001|3 13|second group
P03032143A0218|1 10|centromere
P03032964T0000|0 19|Constitutive function
P03033283A0837|3 25|separate NF1-binding loci
P03033283A1415|26 29|sets
P03034570A0943|10 14|genes
P03034956A0666|16 41|basal adrenal androgen levels
P03035056T0000|0 11|Active lambda
P03035218T0000|0 13|Identification
P03035658A0355|6 28|pentobarbital anesthesia
P03036415T0000|0 8|Influence
P03036817A0213|0 34|Oligonucleotide-directed mutagenesis
P03036933A0774|0 10|ACTH release
P03037334A0932|25 47|upstream promoter element
P03038643A1374|20 51|mammalian erythroid alpha-spectrin
P03038891A0935|0 15|Northern analyses
P03039177A0503|13 22|cDNA clones
P03039387A0920|8 25|immunochemotherapy
P03040023A0113|0 7|Morphine
P03040403A0155|3 9|PSS gene
P03041046A0127|7 12|A-MuLV
P03041802A0975|24 41|platelet aggregates
P03042778A0643|21 41|yeast vegetative growth
P03045117A0936|13 18|values
P03045725A0872|17 27|suppression
P03046655A0000|9 23|prevalence study
P03046931A0247|13 38|eIF-4A intronless retroposon
P03048024A0418|0 19|Bacteriologic culture
P03049570A1242|5 16|similarities
P03050147A0896|19 23|cells
P03050147A1520|37 49|scanning model
P03052327A1474|13 19|results
P03052641A0204|14 32|compounds attractive
P03053713A0752|0 12|DNA sequencing
P03057259A0514|22 45|primary malignant lymphoma
P03059171A1232|0 13|Administration
P03060846T0000|0 17|Mutational analysis
P03060953A0481|0 6|Animals
P03061301A0624|0 20|Prostacyclin formation
P03061301A1409|8 16|excretion
P03061383A0000|20 29|mecillinam
P03062370A0000|0 3|GCN4
P03062370A0384|5 11|results
P03064524A0160|3 10|efficacy
P03064811A0485|3 19|amino acid sequence
P03065140A0273|5 13|mutations
P03065141A0448|3 9|results
P03065610A0375|3 9|rci gene
P03065621T0000|0 8|Structure
P03066131A0000|17 26|anatomical
P03066208A0310|0 22|Histological examination
P03066625A0756|8 32|large epidemiologic studies
P03067505A0688|5 16|prostacyclin
P03069046A0126|24 36|good precision
P03069980T0000|0 6|Factors
P03072021A0696|3 20|amino acid sequences
P03072580A0455|0 9|Van der Ende
P03073091A0338|6 20|insulin infusion
P03073091A0449|0 6|Amounts
P03073192T0000|0 49|Mycobacterium avium-intracellulare complex infections
P03075154T0000|0 9|Recurrence
P03076124A0496|3 22|bile acid sequestrants
P03078268A0529|11 35|pathophysiological aspects
P03079276T0029|0 7|Analysis
P03080793T0000|0 8|Statement
P03083441T0000|0 12|Modifications
P03088643A0000|0 18|Cocaine-treated rats
P03090237A0202|10 18|schedules
P03090372A0607|0 31|Intravenous glucose tolerance tests
P03091849A0000|3 9|effects
P03097509A0654|14 25|RNA molecules
P03097643A1357|8 17|BALB/c gene
P03098018A0139|0 15|Clinical findings
P03102289A0786|48 64|hCG administration
P03104245A0402|4 11|patients
P03104248A0322|6 12|Stage IA
P03104914T0000|0 8|Mechanism
P03104982A0690|15 30|hemoglobin levels
P03108171A0088|0 9|Ritanserin
P03109147A0000|0 13|Ethylene glycol
P03109147T0127|0 7|Research
P03109954A0945|3 9|results
P03110119A0267|6 7|BH
P03110678A0702|0 9|Comparison
P03110692A0156|11 14|mg/l
P03110746A0146|3 16|mean percentage
P03110794A0991|2 10|overdoses
P03110801A0532|20 42|plasma prolactin response
P03112028A0404|15 22|patients
P03112412A0985|12 26|wild-type strain
P03114188A0907|0 35|Significant treatment-related problems
P03114829T0000|0 7|Clinical
P03114995T0000|0 6|Effects
P03115087A0515|3 12|mean weight
P03115787A0633|3 10|patients
P03117046T0000|0 8|Isolation
P03117147A1059|1 18|complementary study
P03118631A0140|2 12|differences
P03119227A0079|3 13|DNA sequence
P03119485A0476|16 43|different essential fatty acids
P03120334A0893|4 4|%
P03123310A0000|25 32|Gart gene
P03123983T0000|9 23|neuroplasticity
P03125420A0421|0 3|Biol
P03125422A0202|3 9|results
P03126531T0000|0 7|Reversal
P03127034A0591|3 11|heart rate
P03127463A1017|0 9|Human rIL-3
P03132498A0730|4 11|patients
P03133250A0000|12 27|prospective study
P03133360A1215|3 10|findings
P03134872T0029|0 6|Apropos
P03137105A0146|1 21|prostaglandin analogue
P03137346A0319|3 15|nucleolin gene
P03137601A0212|8 36|L-threo-dihydroxyphenylserine
P03138190A0347|0 17|Substantial amounts
P03138449A0759|17 21|delta
P03139750A0000|3 14|genetic basis
P03142875A0366|15 44|complete 6-kilobase cDNA sequence
P03143048A1091|0 14|HDL-cholesterol
P03143485A0366|3 36|Euglena ribosomal protein gene cluster
P03144705A0859|20 24|sites
P03146017A0983|3 20|nucleotide sequence
P03146150T0000|0 11|Potentiation
P03146784A0158|4 12|receptors
P03147912A0422|0 26|Symptomatic hyperventilators
P03149774A0173|5 10|IA task
P03150015T0001|0 15|Clinical research
P03150296A0594|25 53|endogenous creatinine clearance
P03154072A0862|3 17|protein mixtures
P03159903A0352|28 34|located
P03166458A1356|1 16|protein footprint
P03167060A0000|0 23|Insulin-like growth factor
P03168709A0000|3 21|central visual fields
P03171221A0531|3 13|variability
P03171279A0158|29 44|metatarsal artery
P03172863T0000|0 5|Effect
P03175942A0706|32 36|doses
P03178097A0000|3 19|CHARGE association
P03178161A0000|0 34|Esophageal brush cytological screening
P03178626A0137|0 7|Aviators
P03179496T0000|0 9|Evaluation
P03180595A1040|7 30|gallbladder visualization
P03181276A0422|2 14|micrograms PAF
P03182802A0278|0 2|Sci
P03182872A1122|0 3|Chem
P03183103A0000|0 23|Sequential MR examinations
P03183127A0068|0 9|Comparison
P03184267A0000|14 33|young broiler chickens
P03185322A1305|1 15|poor correlation
P03185540T0000|0 6|Factors
P03186091T0000|0 5|Change
P03190481A0292|10 31|alpha-naphthyl esterase
P03190914A0149|12 33|migration differentials
P03192537A0370|10 28|96-residue amino acid
P03192724A0000|0 28|Interpersonal style differences
P03192799T0000|0 8|Statement
P03192950A0566|0 3|Sera
P03194410A0771|2 11|UOxase mRNA
P03195167A0104|3 22|platelet adhesion rate
P03198436T0000|0 20|Conservative treatment
P03198525A0164|3 19|112-d feedlot trial
P03199043A0248|0 8|Existence
P03199436A1060|9 20|gene clusters
P03200488A0439|3 9|results
P03200844A1211|3 17|partial sequence
P03207975A0709|11 15|hours
P03208493A0849|3 26|glomerular filtration rate
P03209019A0662|7 30|28-week promotion bioassay
P03212551T0001|3 14|pathogenesis
P03212929A0000|2 15|ELISA procedure
P03214709A0559|5 7|min
P03216131A0559|3 13|only isolate
P03218714A0000|2 17|11-month-old girl
P03219107A0212|3 11|incidence
P03220077A0274|3 16|median survival
P03223123T0001|0 17|Critical evaluation
P03227288A0542|7 13|infants
P03227568T0001|0 6|Variety
P03228518A0339|38 44|samples
P03228785A1047|0 7|Recovery
P03229917A0099|7 34|extensive pancreatic resection
P03232410A1467|30 37|new cases
P03233862T0000|0 18|Neuromyelitis optica
P03234790T0001|0 5|Effect
P03235487A0404|0 12|Incorporation
P03237446A0377|0 3|None
P03239106A0856|13 29|phosphorus content
P03243027T0000|0 29|Post-transcriptional regulation
P03243920A0591|3 10|temporal
P03246999A0483|13 22|amplitudes
P03249792A0241|0 14|Possible factors
P03249840A0411|0 19|Baseline measurements
P03251210A0981|0 11|Many children
P03253219T0000|0 12|R-wave voltage
P03256150A1866|3 9|results
P03257146A1037|5 11|results
P03258069A0000|3 10|purposes
P03259437A0140|5 43|infected neonates serum alpha-amylase value
P03261005A0216|0 6|Records
P03261223A0644|8 15|patients
P03261331A0563|0 4|SPECT
P03263357A0112|51 65|circadian rhythm
P03263465T0000|3 16|murine MHC class
P03264073A0224|3 19|active derivatives
P03264299A0679|2 14|untreated mice
P03264886A0000|24 31|children
P03267732A0788|15 32|Ga-fbg scintigraphy
P03268555T0000|22 37|biocompatibility
P03270085A0382|0 13|Hypomagnesemia
P03274204A0642|0 11|Dentalplaque
P03275867A0187|0 3|GRFI
P03275873A0379|3 9|effects
P03276246A0037|17 62|new technetium-99m-albumin colloid white blood cell
P03276924A0090|12 17|tumors
P03278829A0082|3 13|indications
P03280021A1615|3 10|SSB-poly
P03280807A0000|0 8|Mutations
P03280807A1447|13 28|suf12-null/SUF12
P03280912T0000|0 21|Antituberculosis agents
P03280946A0375|3 25|putative immunity protein
P03282232A0743|0 9|Antibodies
P03282813A0794|13 24|similar range
P03283881A0216|0 13|Stable patients
P03285764A0675|0 18|Hyperprolactinaemia
P03286611A1198|0 3|Yang
P03287597T0000|0 16|Secretory function
P03292076A0820|0 17|Chronic endotoxemia
P03292082A0486|21 38|high concentrations
P03293844T0000|0 3|Diet
P03296019T0000|0 15|Time delay effects
P03296212A0603|23 32|interferon
P03296254A0556|0 15|Minor differences
P03297181A0127|3 21|healthy male subjects
P03298134A0000|19 30|previous work
P03300118A0392|0 13|Oxygen delivery
P03304015T0000|0 16|Clinical chemistry
P03304866T0001|0 16|Revascularization
P03305875T0000|0 13|Static orthoses
P03306340A0537|3 23|intrapancreatic spread
P03308909A0485|0 15|Lysosomal enzymes
P03309892A0637|0 7|Contrary
P03311954A0000|1 16|multicentre study
P03312033A0501|0 10|Monotherapy
P03312514A0756|3 8|N3 wave
P03315359A0732|0 10|Proctoscopy
P03317796A0853|5 16|control group
P03319621A0707|16 19|mRNA
P03319646T0000|0 18|Plasma renin activity
P03319912A0000|0 9|Cephradine
P03320875A2090|8 18|unavailable
P03322829A0952|31 52|good compliance category
P03325081A0524|0 17|Bullous keratopathy
P03326381A0423|3 25|ultrastructural findings
P03329716A0187|16 34|EGF receptor promoter
P03330711T0000|7 26|antimalarial activity
P03331525T0001|16 29|dentin adhesion
P03331933T0048|2 14|Felix Lagrange
P03332022A1094|8 31|cysteine clustering region
P03332848A0000|0 8|Hand-held
P03334950A0000|3 15|German Society
P03335127A0176|27 38|generic BASIC
P03335398A0568|5 14|high levels
P03335444A0000|21 29|human male
P03335651A0000|2 15|analytic method
P03335923A0257|10 17|patients
P03337024A0000|2 16|previous studies
P03338154T0000|0 17|High concentrations
P03340548A1018|5 16|chicken liver
P03340726A1103|4 12|histology
P03340774A0328|0 18|Dosimetric estimates
P03343730A0486|1 22|significant association
P03344586T0000|0 14|New technologies
P03344812A0924|7 17|present data
P03345706A0561|21 25|PaCO2
P03346157A0000|14 18|times
P03346210A0000|3 23|epidermal growth factor
P03348382A0785|3 19|millimolar ouabain
P03351478A0371|8 14|regions
P03352254A0203|3 23|same rhythmic structure
P03352439T0000|0 31|Vocal cord abduction rehabilitation
P03352727T0000|0 1|UK
P03352947T0001|7 25|AIDS-related complex
P03354295A0157|0 12|Distant spread
P03354341A0177|3 26|glomerular filtration rate
P03355122A0238|29 47|plasma glucose levels
P03359860A0000|3 11|relations
P03360667A0000|21 28|altitude
P03360948A0477|10 12|CAP
P03361653A0459|26 51|nuclear contour digitization
P03366720A1335|30 47|mammary utilization
P03366864A0099|3 10|skin site
P03368701A0113|12 27|great reliability
P03370815T0000|0 13|Rapid detection
P03371139A0829|3 13|former group
P03371806A0000|0 23|Electronic data processing
P03371894A0355|0 17|Vimentin positivity
P03372422A0558|3 20|maximum deflections
P03373755T0001|0 17|Recent developments
P03375184A0000|3 23|spermicide nonoxynol-9
P03377864A0000|0 19|Static magnetic fields
P03377891A0652|0 23|Psychological disturbance
P03378994T0000|0 20|Chronic administration
P03379058A0188|0 19|Nucleotide sequencing
P03380547A0169|0 2|SPA
P03381039A0364|14 16|MAN
P03382310A0903|0 19|Abnormal technetium Tc
P03382772A0319|0 16|Practical interest
P03382855A0368|3 12|artery cuff
P03383897A0189|0 22|Lithium-carbonate action
P03384033A0155|7 11|units
P03384272A0145|40 48|wide range
P03387665A0000|31 51|Trypanosoma congolense
P03390074A0000|0 18|Electroglottography
P03395009A1750|0 18|Statistical analysis
P03395164A0000|3 24|pharmacological effects
P03395249A1044|0 27|Histopathological examination
P03396437A0321|7 14|problems
P03396628A0207|9 25|observation period
P03398433T0001|20 35|generalized forms
P03398714A0594|13 14|RH
P03398823A0459|3 9|effects
P03400694A0245|0 7|PATIENTS
P03401060A0000|0 12|Thin melanomas
P03402183A0171|3 10|TA muscle
P03403313A0298|3 28|actuarial local control rates
P03403412A0000|3 9|effects
P03403480A0299|0 18|Prolonged suspension
P03403826T0000|33 48|anatomic variable
P03404334T0000|0 11|Water content
P03404495A0172|0 19|Thyroid function tests
P03406054A0351|0 3|Data
P03407676A0585|0 15|Primary infection
P03407843T0000|0 5|Papers
P03413681A0659|0 19|Ischemic heart disease
P03413890T0001|0 8|Prognosis
P03417104A0536|17 23|results
P03417588T0000|0 26|Liquid chromatographic method
P03417668A1233|5 12|findings
P03418727A0992|12 31|extensive penetration
P03420266A0000|28 39|hyperthermia
P03420324A0178|0 11|Pregnant rats
P03420466A0000|3 11|incidence
P03421425A0878|5 12|patients
P03423732A0341|0 7|Addition
P03427474A0853|15 25|control rats
P03427613A0659|19 35|specialized system
P03428084A0430|4 17|degrees stimuli
P03428274A0000|0 12|Nuclear factor
P03429306T0000|1 10|Golgi study
P03429371A1051|14 33|cephalothin clearance
P03430221A1236|3 10|findings
P03434347A0358|0 7|Mean rCBF
P03436119A0000|0 29|Quantitative computed tomography
P03436529A1066|17 24|enhancer
P03436877A0950|0 1|Kf
P03439248A0000|3 22|scintigraphic methods
P03440780A0779|9 15|results
P03441587A0000|0 7|Research
P03443144A0409|1 26|low aspirin esterase activity
P03443566A0675|6 16|experiments
P03443573A0329|0 19|Overall least-squares
P03443609A0000|9 40|supercritical fluid chromatography
P03446332A0831|0 12|Nitrofurazone
P03448035T0000|0 12|Ovarian tumors
P03449358T0001|0 19|Ultrastructural study
P03450438A0446|0 5|X2 test
P03451761A0215|6 18|baseline study
P03452920T0001|0 2|Man
P03457330A0271|3 10|patients
P03459385T0000|0 6|Allergy
P03459736A0184|3 11|criterion
P03463537T0001|0 13|Clinical method
P03463543A1613|0 7|Enoxacin
P03465957A1008|0 18|Mean fluorosis scores
P03466730A0210|0 20|Autonomic dysfunctions
P03473253A0000|2 47|industry-wide retrospective cohort mortality study
P03473379A0183|14 24|amyloidosis
P03476002A0148|0 3|Hair
P03478354A0436|9 13|herds
P03479897A0961|5 13|other hand
P03484075T0001|0 17|Emergency treatment
P03484894A0782|4 8|cases
P03485064A0135|11 23|EVS treatments
P03486405A0341|0 3|Most
P03487348A0000|1 17|stochastic version
P03488532A0235|3 23|previous interim report
P03491190A0233|3 15|detectability
P03493240T0000|0 22|Pharmacologic properties
P03494649A0472|4 28|brief hypercapnic challenge
P03499608A1054|35 42|reagents
P03499657A0000|0 10|Osteocalcin
P03499822A0182|0 37|Multivariate logistic regression analysis
P03504971A0000|0 5|Hexsyn
P03507689A0000|0 37|Chimeric phage-plasmid expression vectors
P03508698A0535|24 36|finger flexors
P03510185A0187|0 4|Natl.
P03513989A0580|7 13|ethanol
P03513989A1149|57 67|disturbance
P03515840A0000|14 29|consecutive cases
P03516189A0406|3 10|patients
P03517388A0763|3 32|highest postoperative CK-MB level
P03520729A0381|2 16|relevant changes
P03522105A1011|0 31|High trough serum TOB concentrations
P03526279T0000|0 20|State-approved schools
P03528748A0414|3 16|maxicell system
P03531317A0930|22 31|recessives
P03534581A0976|3 11|incidence
P03536682A0572|0 8|Ovulation
P03536864A0000|2 13|previous work
P03537686A0099|3 11|small size
P03537711A0181|0 1|W.
P03537721A0491|0 13|Tetrad analysis
P03537721A0876|10 21|observations
P03537727A0243|3 6|poly
P03540591A0330|20 22|RNA
P03540853A0652|3 29|N-terminal amino acid sequence
P03541263A0368|0 19|Several new techniques
P03542945T0000|0 12|Ciprofloxacin
P03543485A0069|0 29|Possible pathogenetic mechanisms
P03543936A0000|3 10|rho genes
P03544858A0374|49 55|insulin
P03545955A0751|3 14|glucose areas
P03545955A1378|3 22|serum insulin response
P03549045A0878|0 2|SCL
P03550444T0000|0 10|Development
P03552363A0568|0 28|Postglucose serum insulin levels
P03553149A0299|6 40|oligonucleotide-directed mutagenesis
P03553439A0404|32 53|Type I-solid tumor tissue
P03555318T0000|3 14|pharmacology
P03556834T0000|0 22|Acute inhalation toxicity
P03559193A0000|3 22|present investigation
P03559232T0000|1 16|preliminary study
P03559287T0000|0 9|Legionella
P03561036T0000|0 9|Lymphatics
P03561622A0659|3 12|last resort
P03563399A0534|3 21|signal durations less
P03563604A1075|3 12|spleen rate
P03567017A0000|0 13|Multiple dosing
P03568311A0273|4 11|patients
P03568311A1361|12 20|tamponade
P03570455A0433|0 6|Rabbits
P03571135T0000|13 28|prosodic features
P03572706A0329|10 33|actuarial interpretations
P03575656A0120|0 2|Due
P03577670A0102|28 34|atrophy
P03577670A0236|14 40|metachromatic leukodystrophy
P03578948A0448|0 20|Artificial ventilation
P03581160A0583|13 36|lower heart rate reactivity
P03582149T0001|2 22|epidemiological survey
P03582184A0448|0 4|Drugs
P03582982A0000|8 17|human genes
P03583001A0111|8 27|balloon-gas procedure
P03584426A0706|0 26|Heat-labile-like enterotoxin
P03586925T0001|0 10|Development
P03590911T0001|0 31|Persistent acantholytic dermatosis
P03591464A0840a|6 17|negative test
P03591464A0840b|6 17|negative test
P03592297A0138|0 14|Dorsal foot TcpO2
P03592297A0679|2 9|subjects
P03595418A0688|3 21|nucleotide sequences
P03597218A0901|3 24|absolute concentrations
P03597269A0409|3 12|other model
P03600633A1069|0 3|Cell
P03600705T0000|0 5|Timing
P03601275A0601|5 20|dopamine infusion
P03601533T0001|0 19|Diagnostic importance
P03602261A0238|12 16|basal
P03605895A0888|4 11|patients
P03607109A0370|8 16|processes
P03607961T0001|0 17|Hypoglycemic action
P03608916A0790|2 6|cases
P03608989A0668|14 23|amino acids
P03610663A0201|22 28|sources
P03610674T0000|11 31|dietary zinc deficiency
P03612316A0102|6 9|rats
P03612648A0085|22 39|lupus anticoagulant
P03615550A0000|3 9|effects
P03615550A1094|3 24|rate-decreasing effects
P03615763A0170|0 3|Data
P03616174A1069|2 17|intralobar change
P03616237T0001|0 26|Convulsive status epilepticus
P03618039A0126|13 24|such patients
P03619249A0428|12 18|markers
P03622423A0000|0 5|Groups
P03622571A0208|0 16|Radionuclide study
P03625688A0372|0 13|Immobilization
P03625762A0308|0 9|Comparison
P03626129T0001|0 6|Effects
P03627720A0196|0 6|Typical
P03628532A0000|9 14|saliva
P03628596A0000|0 6|Samples
P03628713A0961|0 18|Separate experiments
P03628794A0648|3 10|patients
P03629973A0240|0 1|W.
P03629974A1468|0 9|Comparison
P03632739T0000|0 20|Cyclosporine treatment
P03635597A0377|16 21|Cohler
P03637037T0000|1 27|preoperative teaching booklet
P03645733T0001|0 14|Hyperthyroidism
P03649340A1119|17 39|mono-intronic precursors
P03651330T0000|0 28|UVA-induced melanocytic lesions
P03651840A0266|6 22|MAO inhibition data
P03652083A0720|21 38|vessel pyridinoline
P03653226A0833|9 45|radiolabelled tissue-distribution study
P03658866A0081|0 25|Systemic lupus erythematosus
P03659603A0797|16 24|amplitude
P03659805A0404|3 25|statistical significance
P03659994A0150|5 11|changes
P03663789A0568|5 11|results
P03664038A0000|44 55|parallel form
P03666957A0219|0 8|Organisms
P03668003T0000|21 30|microscopy
P03668396A0171|5 24|equilibrium solutions
P03668736A0177|3 19|average deviations
P03672532A1111|13 30|significant effects
P03673640A0533|0 13|Low MAO subjects
P03673881A0000|13 28|relative accuracy
P03676054A0865|9 11|Paw
P03676174A0730|2 7|calves
P03678269A0633|0 4|Today
P03678372A0170|11 22|fecal pellets
P03679407A0556|5 11|results
P03679756A0830|0 26|Epithelial nerve fiber defects
P03680791A0230|3 17|histologic grade
P03682805A0375|0 10|Serum levels
P03684378A0653|3 15|colostral milk
P03684517A0462|0 16|Endurance training
P03685073A0200|1 19|rate-decreasing dose
P03687078T0001|0 9|References
P03687148T0187|0 7|Salzburg
P03687313A0000|3 26|new glucosidase inhibitors
P03688202A0377|3 8|models
P03688301A0129|13 17|cases
P03688676A0487|8 18|conversions
P03690262A0428|3 18|maximum amplitude
P03691316A0560|17 30|contact allergy
P03692331A0000|12 38|beta-adrenoceptor antagonist
P03693543A0405|3 52|less-polar mycolic acid-containing Rhodococcus species
P03694102A0000|17 24|data base
P03696899T0001|0 28|Blood serum erythropoietin level
P03697587T0000|3 24|XXXXY chromosome anomaly
P03697798T0001|0 10|Contraction
P03697971A0311|3 15|selenium level
P03698251T0000|0 13|Oxygen delivery
P03700952A0273|0 6|Infants
P03701640A1178|5 11|results
P03703493A0654|11 29|crystalline deposits
P03704087A0394|5 12|subjects
P03709191A0125|17 35|primary visual cortex
P03709627A0247|3 10|subjects
P03710973A0817|0 26|Mean weighted skin temperature
P03712050T0000|0 25|Indium-111 leukocyte imaging
P03712106A0000|11 37|L-methionine supplementation
P03712153T0000|0 47|Primary invasive Haemophilus influenzae type b disease
P03713187A0691|8 14|lesions
P03714348A0833|0 6|Factors
P03714473A0496|0 8|Induction
P03717475A0208|0 2|New
P03717936A0252|0 7|Amikacin
P03720615A0434|21 32|secular trend
P03720966A1043|9 30|nucleic acid N absorption
P03721594A0000|0 7|Adhesion
P03721666A0000|0 5|Nickel
P03722016A0797|3 11|FFA levels
P03728230A0104|27 43|solitary renal cyst
P03732252A0556|8 22|further analyses
P03733563A0716|1 33|significant herd X period interaction
P03733563A0820|0 6|Liver TG
P03734641A0203|3 9|results
P03736081A0465|7 27|coronary sinus pressure
P03738919A0000|0 13|Calcifications
P03743683A0000|14 33|consecutive autopsies
P03743702A0158|15 15|%
P03744168T0001|0 20|Pharmacological action
P03745833A0258|22 31|low voltage
P03746053A0670|0 7|Findings
P03746107A0192|23 26|cent
P03746508A0390|0 7|Failures
P03746601A0299|17 24|problems
P03746896A0890|22 28|results
P03746906A0000|3 9|studies
P03747493A0000|0 21|Splenectomized patients
P03749226A0506|4 16|phencyclidine
P03750700T0001|0 12|Possibilities
P03751308T0001|0 4|Study
P03753022A0000|0 16|Malignant lymphoma
P03755623A1233|0 20|Further investigations
P03755673A0054|12 16|cases
P03757294A0414|5 9|cases
P03758250A0000|0 34|Fast goal-directed voluntary movements
P03759330A0713|16 17|F1
P03759731A0992|0 13|Renal clearance
P03761122T0000|3 11|relations
P03761523A0000|3 6|rats
P03763241A0446|10 23|slight weakness
P03763836T0001|0 6|Results
P03765552A0582|68 92|reticuloendothelial system
P03765731A0918|0 9|Incidences
P03766370A0546|0 16|High radial r values
P03768208A0879|5 11|results
P03769224A0000|20 27|patients
P03770143A1209|17 34|hereditary disorder
P03771670T0058|0 9|Prevention
P03771703A0000|0 36|N-Substituted trimethylsilylcarbamates
P03771749A0465|0 3|MICs
P03772471A1054|11 18|patients
P03774111T0000|0 7|Evidence
P03776080A0400|0 36|Parasitological post-mortem examination
P03776438A0000|0 13|Glucocorticoid
P03776779A0238|34 49|systemic steroids
P03777398A0156|0 7|Examples
P03779182A0370|10 20|drug problem
P03779205A0459|9 16|patients
P03780248A0274|8 18|differences
P03780371A0792|0 18|Repetitive sequences
P03780704A0573|1 13|large increase
P03781000A0101|31 40|variations
P03781948T0000|0 20|Respiratory adaptation
P03783160A0285|0 7|Compound
P03785212A0091|0 4|Human
P03785212A1128|0 11|RPS14 introns
P03788231A0802|12 26|relevant aspects
P03789052A0527|2 34|exaggerated tissue response adjacent
P03791645A1124|5 12|findings
P03795488A0487|7 24|superficial lesions
P03799323A0501|8 21|same hematocrit
P03799790A0146|8 15|examiner
P03802195A0481|5 18|fusion proteins
P03805090A0645|4 21|life-table analyses
P03806696A0000|3 16|lethal toxicity
P03810361A0576|18 52|13h00-16h00 plasma cortisol estimation
P03810867A0305|0 3|Most
P03811852A0109|15 27|complications
P03814493T0000|0 11|Chlorambucil
P03818467A0180|0 7|Selenium
P03818866A0116|0 13|Framingham Type
P03820222A0203|10 29|antibacterial potency
P03824908A0116|3 15|M reading frame
P03826871A0000|2 25|ion chromatographic method
P03827071T0040|0 1|II
P03828209T0000|0 20|Laryngographic changes
P03828500T0001|0 14|Intensification
P03829848T0001|0 18|Autotransplantation
P03830147A0000|3 15|relationships
P03830255A0074|37 66|multivariate normal distribution
P03835413A0616|16 26|late effects
P03836777T0001|0 11|Practical use
P03836853A0204|12 28|year survival rates
P03836854T0000|0 9|Inhibition
P03837609T0000|0 24|Five-year prospective study
P03838797A0903|0 15|Northern blotting
P03840480T0000|0 21|Novel multigene families
P03841627T0001|0 11|Chemotherapy
P03843496A0919|2 12|recent years
P03843676A0381|0 18|Linear extrapolation
P03848527T0020|0 11|Hisako Minowa
P03857577A0413|0 21|Deletion mapping studies
P03860162A0000|0 12|Incorporation
P03861687A0000|14 30|normotensive males
P03862898A0563|0 7|Serum IgM
P03863231A0530|3 12|M-3 subtype
P03863561A0405|9 13|Strep
P03865743A0859|5 11|results
P03866085A0795|20 47|unique suppository formulation
P03869442A0223|11 28|marked hypertension
P03871298A0217|0 41|Single photon emission computerized tomography
P03871445T0000|0 7|Computer
P03873141A0304|4 19|patients vagotomy
P03874921A0862|0 12|Documentation
P03875231A0627|0 2|MRI
P03877298A0718|3 9|results
P03878585A0507|3 24|percentage RFR reduction
P03880838T0000|0 8|Diagnosis
P03881260A0000|1 16|yeast DNA fragment
P03882029A0000|1 18|retrospective study
P03883052T0001|10 27|Magdelaine Comtesse
P03883541A0200|3 23|H2 receptor antagonists
P03885983A0254|5 11|results
P03887085A0000|1 12|high efficacy
P03887769A0093|3 6|Mean
P03887769A0584|21 51|mixed industrial-rural population
P03888621A0185|3 16|structural gene
P03890486A0000|0 38|Pancreaticoduodenal lymph node enlargement
P03891766A1473|0 11|Interference
P03894482A0549|3 10|patients
P03896991T0000|0 12|New techniques
P03898382A0000|0 33|Dual radionuclide subtraction imaging
P03904004A1577|0 3|Such
P03904952T0000|0 15|Nursing education
P03908196T0000|0 16|Shear bond strength
P03908493A0246|2 20|additional advantage
P03910310A0666|44 52|pathology
P03911052A0909|14 19|DIL-CP
P03911702A0530|6 12|earlier
P03911965A0513|10 32|statistical significance
P03912247A0282|21 24|flap
P03913522A0000|4 8|aging
P03914875T0001|0 14|Oral candidiasis
P03915540A0863|14 29|gcd1-101 mutation
P03920700A0491|16 26|alaproclate
P03921727A0523|3 16|concentrations
P03922116A0197|17 24|patients
P03923828A1031|17 31|cryoprecipitate
P03923976T0001|0 15|Thrombophlebitis
P03925712A0229|0 7|Biopsies
P03928357A0340|0 18|Laboratory pyrolyses
P03928442A0463|1 17|significant degree
P03928678T0000|21 46|hormone-induced contraction
P03929486A0309|3 22|blind controlled trial
P03929610A0268|0 20|Mild orbital discomfort
P03930549A0209|32 57|centrifugation valproic acid
P03930894T0000|0 6|Changes
P03931293A0437|14 29|other stabilizers
P03931797A0134|3 19|overall prevalence
P03933232T0000|0 14|Greek classicism
P03933784A0420|3 16|possible origin
P03934667A0124|5 28|chromosomal crsA mutations
P03935117T0000|0 14|Selective effect
P03935375A0414|49 58|morphology
P03935797A0183|60 85|sry messenger RNAs detectable
P03936828T0000|0 17|Chronic thyroiditis
P03937294A0404|0 19|Plasma secretin levels
P03937481T0001|0 30|Spectrophotometric microanalysis
P03939317A0352|21 35|flanking regions
P03940426A0618|0 6|Results
P03940733A0755|26 35|absorption
P03940818T0000|0 18|Fulminant hepatitis A
P03944212A0166|0 13|Tissue pressure
P03944239A0780|18 25|patients
P03946125T0000|0 3|Drug
P03952387A0336|6 16|compartment
P03953361A0000|13 19|effects
P03956647A1063|0 10|Dissolution
P03956695A0617|0 16|Cortisol excretion
P03959045A0000|3 9|studies
P03963860A0137|10 17|patients
P03964489A1195|7 15|% decrease
P03964855A0254|0 10|Angiography
P03965012A0163|3 9|results
P03966687A0000|3 17|financial impact
P03967144T0001|0 12|Hypersplenism
P03970191A0275|0 17|Electrical activity
P03972038A0000|3 12|topography
P03972185A0137|3 15|diabetic state
P03974790A0053|3 19|primary CT findings
P03976323A0821|2 22|consistent correlation
P03977577T0000|0 21|Shoulder forearm support
P03977603A0326|0 8|Piroxicam
P03978045A0857|5 12|findings
P03978132A0108|2 14|MCCP functions
P03979084A1019|8 14|kidneys
P03980386A0000|11 17|effects
P03981421A0246|1 8|flow rate
P03981640A0168|9 15|located
P03981952T0000|3 10|efficacy
P03982288T0000|0 13|Doctor Berglund
P03984683A0000|0 14|Acute appearance
P03985849A0221|0 27|Recurrent acute rhinosinusitis
P03987818A0440|20 23|AP-A
P03987857A0733|3 16|various muscles
P03988001A0227|21 44|rat blood chloroform levels
P03989827T0000|14 30|lactase phenotypes
P03992022A0330|0 9|Activities
P03995513T0000|0 10|Doxorubicin
P03997467A0000|14 37|opiate antagonist naloxone
P03998071T0000|0 23|Electrochemical detection
P03998813A0406|5 22|present experiments
P03999219A0463|0 13|Ultrastructure
P04000347A0442|56 62|persons
P04001413A0093|16 46|simple respiration-control device
P04001490T0001|3 15|POEMS syndrome
P04002131A0506|7 22|disease remission
P04002667A0181|2 24|metastasis-free patients
P04004168A0000|3 10|siblings
P04005190A1288|3 9|extract
P04011338A0620|7 14|patients
P04011466T0000|0 14|Aortic diameters
P04013576A0981|3 22|present investigation
P04013604A0412|23 49|potassium-induced ulceration
P04014833A0400|0 13|Hydrocortisone
P04014861A0000|9 19|feasibility
P04015988T0000|0 17|Marrow cell necrosis
P04017295A0139|3 31|comparison conventional heparin
P04018444A0000|0 19|Chenodeoxycholic acid
P04019066A0000|0 6|Sensory
P04021281T0001|0 13|Ultrastructure
P04021305A0530|0 30|Pharmacological desympathization
P04021431A0000|0 3|OODG
P04021437A0000|0 14|Viral infections
P04024685A0650|7 7|%
P04025178A0126|0 20|Retrospective analyses
P04025179A0955|8 13|adults
P04026903A0512|0 10|Polysorbate
P04026972T0000|0 32|Individual alcohol reaction profiles
P04027182T0000|0 7|Vitiligo
P04028871A0133|3 18|pharmacokinetics
P04031488A1091|1 10|high degree
P04032268A0358|7 16|UV detector
P04032349A0000|2 9|patients
P04032716A0299|3 20|mean transfer ratios
P04033402A1112|14 31|androgenic hormones
P04034220A0205|12 23|wide spectrum
P04034666T0000|0 26|Lower extremity weight bearing
P04036838A0918|29 43|hemodynamic data
P04037809A0964|15 35|low toxic dose schedules
P04038454A0984|15 39|initial plasma retinol level
P04038702A0768|3 9|results
P04039109A0139|17 31|sufficient power
P04039307A0613|2 2|d
P04039439A0000|0 16|Male Japanese quail
P04039439A0842|25 37|Japanese quail
P04039525A0475|0 5|Plasma
P04039667T0000|0 25|Scintigraphic visualisation
P04039744A0141|5 11|results
P04040083A0000|0 9|Rabbit eyes
P04040307A0145|22 52|few perivascular adrenergic nerves
P04040339T0001|0 16|Monitoring changes
P04040858A0000|5 13|September
P04041307A0614|3 9|results
P04041346T0000|0 26|Supraventricular arrhythmias
P04043489A0648|0 6|Visidex
P04048245A0331|0 8|Treatment
P04050771A0474|3 29|Cox proportional hazards model
P04050821A0531|16 30|mechanisms other
P04051521T0001|0 7|Duration
P04052919A0205|20 40|progesterone secretion
P04055593A0523|3 32|fast real-time digital processing
P04056218A0463|19 24|higher
P04056256A0416|0 18|Histamine reactivity
P04058985A0000|0 17|Pharmacologic doses
P04061342A0512|23 38|similar elevation
P04062128T0028|0 17|National Institutes
P04063732A0509|2 9|controls
P04066194A0163|0 17|Greater attenuation
P04066274A0265|11 18|patients
P04067540A0413|3 13|comparisons
P04068663A0452|0 15|Germ-free rabbits
P04068774A1292|3 19|weak relationships
P04068969A0300|0 19|L3-L4 compressive load
P04069756T0025|0 8|Diagnosis
P04070725A0442|0 12|Component P100
P04071063A0863|10 20|differences
P04073848T0000|0 6|Failure
P04074214A0000|0 6|Factors
P04075021T0000|1 3|14C
P04075061A0355|3 9|runners
P04079738A0677|3 7|rates
P04081425T0016|0 14|Clinical aspects
P04082267A0720|14 17|days
P04082592T0000|0 15|Blood eosinophils
P04084607A0663|3 13|imino proton
P04084896A0569|27 44|specific sub-groups
P04085589A0264a|28 41|secretor status
P04085589A0264b|28 41|secretor status
P04086403A1016|0 4|Gains
P04086657T0000|0 29|Postnatal volumetric development
P04086993T0000|0 4|Daily
P04088233A0309|3 13|transit time
P04088396A0145|8 26|patients grades 1-2-3
P04088733T0001|0 7|Activity
P04088936T0001|0 17|Comparative studies
P04093211A0560|21 37|predictive ability
P04101003T0001|0 8|Relations
P04102280T0000|0 8|Treatment
P04103248T0000|0 10|Improvement
P04113011T0000|2 16|desensitization
P04114211T0000|0 13|Renal excretion
P04115870T0000|0 10|Experiences
P04123217T0000|0 8|Formation
P04123662T0000|0 9|Evaluation
P04138224T0095|12 25|tissue emulsion
P04139081T0001|0 13|HL-A antibodies
P04139943T0001|0 12|Demonstration
P04140567T0001|0 18|Histamine metabolism
P04143528A0394|26 37|nomenclature
P04145244T0000|0 9|Relaxation
P04152725T0001|0 6|Studies
P04160980T0000|0 18|Hypothalamic control
P04164595T0020|0 7|Evidence
P04164669T0000|0 37|Ultraviolet light-induced kinin formation
P04172166T0000|0 12|Poliomyelitis
P04175007T0001|17 27|stimulation
P04176249T0001|0 9|Assessment
P04176268T0000|0 13|Aluminium resin
P04176625T0000|0 4|Value
P04179445T0036|0 1|D.
P04189158T0000|0 9|Prevention
P04194466T0000|0 14|Serotonin levels
P04196986T0000|0 28|Cerebrospinal fluid transferrin
P04213917T0001|0 10|High dosages
P04214345T0000|0 14|Inverse relation
P04226360T0001|0 8|Disorders
P04239041T0045|11 25|anticonvulsants
P04246054T0028|0 5|Effect
P04247472T0001|0 10|Estral cycle
P04247966T0000|0 8|Lactation
P04262268T0001|0 6|Studies
P04263748T0042|1 26|medical-geographical review
P04281856T0001|0 2|Age
P04282315T0001|0 12|Sensitization
P04284435T0000|0 8|Vitamin D3
P04289156T0000|3 11|incidence
P04291759T0048|0 16|Laboratory aspects
P04295031T0062|16 24|guinea pig
P04305850T0000|0 8|Androgens
P04308979T0000|0 5|Effect
P04311951T0001|0 16|Therapeutic action
P04315233T0128|0 30|Clinico-physiological experiment
P04316696T0001|0 26|Enzyme histochemical findings
P04321861T0001|0 37|Familial glutathione reductase deficiency
P04323641T0000|0 6|Studies
P04325736T0001|0 12|Serodiagnosis
P04328746T0073|0 15|Ultrasound effect
P04335965T0000|0 9|Metastasis
P04350410T0000|0 6|Genesis
P04364369T0000|0 20|Pre-beta-1 lipoprotein
P04369884T0000|0 9|Conditions
P04371279T0000|0 6|Absence
P04377003A0000|23 42|quantitative analysis
P04377328T0027|0 1|I.
P04385060T0000|0 9|Disulfiram
P04387103T0000|0 8|Particles
P04392584T0000|0 6|Natural
P04394290T0000|14 32|adrenergic receptors
P04407649T0000|0 24|Intracranial arachnoid cyst
P04418687T0000|0 6|Effects
P04423347T0001|0 5|Copper
P04428800T0001|0 5|Effect
P04428981T0000|0 7|Kinetics
P04429269T0000|16 20|mucus
P04437406T0000|1 23|hydrodynamic description
P04445874T0001|0 8|Pathology
P04446923T0001|0 22|Abnormal characteristics
P04460692T0000|8 13|topics
P04468264T0053|0 13|Problems common
P04482661T0001|0 13|Clinical course
P04487835T0001|2 8|parents
P04487920T0001|7 33|Icelandic Red Cross activities
P04488232T0001|0 6|Effects
P04488271T0001|0 8|Treatment
P04495034T0000|12 24|methylbenzene
P04506738T0000|0 8|Junctions
P04510102T0000|0 17|Electrocardiograms
P04511139T0001|0 9|Composites
P04512496T0000|0 6|Hodgkin
P04515631T0000|0 4|Value
P04518624T0000|0 20|Glutathione peroxidase
P04524081T0000|0 22|Histopathologic response
P04533208T0083|0 6|Changes
P04536964T0000|0 14|Intracellular pH
P04539552T0001|0 19|Teratological studies
P04543036T0001|0 9|Directives
P04544430T0001|0 10|Proceedings
P04544704T0001|0 5|Method
P04546974T0000|0 9|Variations
P04547933T0000|0 27|Extracellular fibril formation
P04548483T0001|0 13|Blood platelets
P04551650T0001|0 12|Cell viability
P04552263T0000|0 20|State-approved schools
P04562038T0001|0 19|Further investigation
P04563045T0000|0 6|1,3-bis
P04578686T0000|0 11|Pneumothorax
P04579436T0000|13 36|significant colour changes
P04580044T0047|0 20|Temporal relationships
P04583791T0000|1 12|short history
P04598670T0000|0 20|Local graft irradiation
P04600603T0001|0 5|Letter
P04613073T0001|0 3|Role
P04615525T0001|11 28|antilymphocyte sera
P04615828T0001|0 11|60th birthday
P04621188T0000|0 9|Morphology
P04622430T0000|0 16|Cortical afferents
P04624863T0001|0 8|Mechanism
P04627477T0001|0 16|Resistance pattern
P04632967T0000|0 24|Pulmonary arterial pressure
P04638365T0001|0 5|Effect
P04640155T0045|0 7|Sex ratio
P04645078T0001|0 20|Pathological processes
P04646045T0001|0 21|Benign intramural tumors
P04653144T0000|0 14|General formulae
P04654249T0000|0 10|Measurement
P04656185T0000|0 23|Glucose disappearance rate
P04661961T0001|0 11|Normal values
P04676734T0000|17 38|human umbilical arterial
P04679438T0001|0 15|Antibiotic effect
P04679807T0000|0 24|Sulfuric acid concentration
P04704137T0001|0 3|Role
P04704186T0000|0 12|Range behavior
P04712626T0000|0 19|Chemical constituents
P04718233T0000|0 24|Methyl mercury intoxication
P04727344T0000|0 17|Microdetermination
P04729063T0000|0 18|Compensative justice
P04730467T0000|0 6|Effects
P04733391T0000|0 25|Metal coordination compounds
P04746559T0053|0 9|Estimation
P04752455T0000|0 18|Disability insurance
P04753073T0000|0 5|Choice
P04753286T0000|0 10|Suppression
P04757217T0000|0 6|Studies
P04758799T0000|0 11|Pneumothorax
P04759722T0000|0 16|Polycythemia-1973
P04760826T0000|0 14|Manifest anxiety
P04764049T0001|0 31|Familial juvenile nephronophthisis
P04766888T0000|5 18|heparin therapy
P04778129T0000|0 16|9,11-Seco steroids
P04782788T0001|0 24|Psychological examinations
P04784432T0001|0 12|Possibilities
P04787472T0001|0 5|Change
P04787716T0000|0 11|Observations
P04788701T0001|0 10|Combination
P04789916T0001|0 7|Analysis
P04791420T0000|0 10|Proceedings
P04794218T0001|0 17|Antivitamin K agents
P04796997T0000|0 17|Canine reproduction
P04801663T0049|0 11|Hypoglycemic
P04803629T0001|0 18|Hematopoietic system
P04810131T0000|0 5|Letter
P04813394T0000|0 9|Evaluation
P04820791T0001|0 23|Delta-aminolevulinic acid
P04824747T0000|0 16|Nonteratogenicity
P04826272T0074|0 2|VII
P04828587T0000|0 8|Isolation
P04837183T0000|0 11|Observations
P04839176T0001|0 5|Effect
P04843031T0000|3 8|levels
P04852635T0000|0 3|Lack
P04863895T0000|0 11|Relationship
P04871589T0001|0 14|Plastic solution
P04878680T0000|0 6|Effects
P04884060T0000|3 22|Twentieth Anniversary
P04890336T0001|0 26|Immunelectrophoretic pattern
P04909355T0000|0 29|Motile nocardoid Actinomycetales
P04911925T0001|0 31|Electrocardiographic QRS complexes
P04919613T0001|0 4|Study
P04921762T0000|0 18|Cardiac preservation
P04925617T0000|0 8|Labial bar
P04941419T0000|0 24|Yusuf Dawood Docrat L.R.C.P.
P04941951T0000|0 2|Dr.
P04942414T0000|3 12|metabolism
P04947347T0000|0 11|Spleen weight
P04948325T0000|0 8|Isolation
P04959816T0000|0 17|Human synovial fluid
P04967824T0000|0 6|Effects
P04970131T0001|4 20|reflexions apropos
P04970918T0069|0 9|LA-3848-MS
P04973523T0000|0 20|Immunochemical studies
P04975676T0000|0 12|Morphological
P04976988T0000|0 12|Heterogeneity
P04989251T0000|0 7|Analysis
P04990556T0000|0 11|Reactivities
P04992478T0000|0 16|Plasma histaminase
P04999086T0001|1 16|comparative study
P05000171T0000|11 21|osmotic flow
P05005311T0000|0 13|Immunogenicity
P05012220T0000|0 17|Ten-year experience
P05015678T0000|0 27|Nitrogen-hydrogen tautomerism
P05020660T0000|0 6|Factors
P05021912T0000|0 26|Photopic spectral sensitivity
P05025918T0000|0 10|Angiography
P05027295T0034|0 13|Cholinesterase
P05027799T0000|0 16|Sodium restriction
P05028628T0001|0 7|Clinical
P05031074T0001|0 16|Serum lipid changes
P05031659T0000|0 18|Successful treatment
P05034373T0000|1 12|possible role
P05045351T0000|0 16|Periodic breathing
P05049711T0000|7 19|session report
P05060388T0000|0 23|Clinicopathologic studies
P05065548T0075|5 16|constituents
P05066316T0001|0 7|Relation
P05068271T0000|0 8|Influence
P05075857T0000|0 28|Oscilloscope triggering circuit
P05081814T0000|0 10|Derivatives
P05083872T0000|23 38|training programs
P05087496T0000|0 15|Coronary arteries
P05091970T0000|0 14|Antiviral agents
P05093030T0001|0 9|Separation
P05095988T0001|0 20|Conservative treatment
P05101762T0000|0 12|Spasmus nutans
P05110049T0001|0 6|1st data
P05114515T0000|6 27|lysosomal enzyme release
P05119546T0001|0 8|Treatment
P05120197T0000|0 23|Experimental pancreatitis
P05123884T0000|0 18|Bacterial metabolism
P05124707T0001|0 7|Dynamics
P05124972T0042|0 1|I.
P05128149T0001|0 16|Surgical treatment
P05132558T0000|16 23|caffeine
P05133723T0000|0 5|Effect
P05135168T0000|0 11|New alkaloids
P05138738T0001|7 21|M hemoglobinosis
P05145925T0000|0 19|Radiosensitive nature
P05152314T0001|0 21|Sinusoidal oscillations
P05154132T0000|10 25|different sources
P05162342T0001|0 14|Abdominal tumors
P05170106T0034|0 6|Results
P05172320T0001|0 6|Studies
P05172970T0001|12 25|disablement due
P05174753T0001|0 22|Cleidocranial dysostosis
P05177935T0001|0 8|Proposals
P05203499T0001|0 31|Successive abdominal scintillation
P05210791T0001|0 8|Pneumonia
P05253274T0001|0 11|Osteosarcoma
P05274128T0001|12 22|glucosamine
P05274526T0000|0 6|Relapse
P05276380T0000|0 8|Influence
P05284310T0000|3 10|non-role
P05285978T0076|0 11|Second report
P05299993T0000|0 11|Modification
P05303700T0066|0 11|SAM-TR-68-54
P05305671T0000|1 15|brief discussion
P05308271T0000|0 2|BIM
P05309471T0000|0 7|Problems
P05316745T0000|0 11|Aedes aegypti
P05322558T0000|0 16|Homograft response
P05322747T0034|0 15|Comparative study
P05340801T0000|0 9|Mycotoxins
P05344097T0000|0 6|Factors
P05353667T0000|0 23|Spinal cord representation
P05356107T0001|0 15|Biological action
P05357390T0001|0 3|Auto
P05359464T0000|0 7|Pitfalls
P05362866T0000|0 13|Renin secretion
P05363816T0001|19 42|forensic medical expertise
P05364951T0001|0 13|Histopathology
P05368978T0000|0 9|CNS effects
P05372511T0105|0 16|Diethylene benzene
P05379901T0000|0 11|Midge control
P05388567T0000|3 9|effects
P05389125T0000|3 22|exploratory behaviour
P05394352T0000|0 11|Genitography
P05394461T0001|0 12|Tolerance test
P05410590T0000|9 20|ascorbic acid
P05410641T0000|6 12|percent
P05412122T0000|3 8|Methyl
P05412687T0000|0 17|Antidromic invasion
P05413428T0000|17 26|body fluids
P05414186T0001|8 24|Hong Kong influenza
P05417431T0001|5 14|disagnosis
P05421537T0001|0 11|Difficulties
P05424220T0001|0 17|Lipid concentration
P05425195T0001|0 7|Behavior
P05437405T0000|10 41|forearm arteriolar dilator capacity
P05441564T0001|0 6|Studies
P05445187T0000|0 26|Counter-current heat exchange
P05451324T0000|0 10|Calibration
P05456002T0000|0 6|Mae West
P05460466T0001|0 10|Elimination
P05463837T0023|3 23|absolute configuration
P05466177T0001|0 17|Teratogenic effects
P05471866T0000|3 34|plasma growth hormone concentration
P05472485T0000|0 28|Bimodal cochlear response curves
P05474466T0001|1 23|new hemagglutination test
P05488121T0000|0 14|CO2 assimilation
P05492285T0000|12 30|Hyostrongylus ruidus
P05496619T0000|0 14|Foreign profiles
P05497793T0000|0 6|Effects
P05500957T0001|16 24|clopamide
P05501347T0001|11 28|low dosage radiation
P05502054T0000|0 7|Leukemia
P05525652T0064|0 16|Preliminary report
P05529283T0000|0 11|Quantitation
P05532854T0001|0 29|Gastrointestinal manifestations
P05533214T0001|0 15|Iodine metabolism
P05536803T0001|0 13|Total body water
P05544291T0031|0 1|V.
P05552149T0000|0 2|18F
P05552642T0000|0 10|Propagation
P05553261T0000|0 5|Health
P05555149T0001|0 26|Sensitive fluorometric method
P05556977T0001|0 12|Morphogenesis
P05560428T0001|0 9|Behavioral
P05567721T0000|0 12|Sensitivities
P05572662T0000|0 20|Central venous catheter
P05574818T0000|3 5|Lab
P05593469T0001|4 21|head-brain injuries
P05594277T0051|3 14|modification
P05595036T0001|0 7|Students
P05621339T0001|21 25|doses
P05627251T0000|0 13|Positive shifts
P05642051T0000|10 36|dietary department management
P05671267T0000|3 21|Dimethylaminopropyl
P05672903T0001|0 21|Osteogenesis imperfecta
P05683363T0001|0 12|Investigation
P05683809T0000|0 5|Effect
P05684081T0001|0 11|Measurements
P05689427T0052|3 36|N-Alkyl-N-2-chloroethylaminomethyl
P05692759T0001|0 10|Nephrectomy
P05693602T0001|0 9|Evaluation
P05693605T0001|0 12|Determination
P05715613T0000|0 6|Sterols
P05718386T0001|0 10|Dermoid cyst
P05718500T0001|0 23|Histological observations
P05718994T0000|0 25|Endocardial fibro-elastosis
P05719031T0000|0 6|Studies
P05719746T0001|0 7|Children
P05722341T0000|0 13|Identification
P05725509T0000|0 7|Steroids
P05727222T0000|3 9|effects
P05732641T0001|0 5|Trials
P05733952T0001|17 35|structural integrity
P05733953T0001|12 32|constant magnetic field
P05734847T0000|0 6|Studies
P05740389T0001|0 8|Relations
P05742879T0000|0 14|Transformations
P05749438T0001|0 22|Dissociative anesthetics
P05750950T0001|0 5|Estrus
P05751819T0000|3 9|bearing
P05758469T0001|0 18|Hemodynamics changes
P05760665T0000|0 15|Caries prevention
P05763287T0063|0 1|I.
P05763347T0000|0 19|Clinical applications
P05769307T0000|0 15|Automatic view box
P05774062T0000|0 10|Measurement
P05779953T0000|0 5|Effect
P05781385T0000|20 48|phenolphthalein sulphatase test
P05782943T0001|0 11|Relationship
P05787318T0000|0 15|Long-term effects
P05789870T0001|0 38|Phosphate glucose dehydrogenase deficiency
P05792868T0000|0 33|Evidence forthe electroosmosis theory
P05792911T0000|0 6|Effects
P05794247T0000|0 5|Effect
P05796272T0000|0 34|Experimental chlorpromazine cataracts
P05797287T0069|0 1|I.
P05798063T0000|0 9|Specialist
P05799686T0001|16 36|selective chemotherapy
P05805644T0001|0 8|Variation
P05806615T0001|0 19|Oxidative degradation
P05806936T0000|0 9|Absorption
P05807222T0052|0 11|Ion injection
P05810259T0001|0 15|Polyvinyl alcohol
P05819249T0000|0 5|Mining
P05822499T0034|14 25|digiprogenin
P05823624T0031|12 24|small hospital
P05826818T0098|0 1|I.
P05833022T0001|16 22|changes
P05836483T0000|1 21|malignant true teratoma
P05837169T0001|0 13|Methoxyflurane
P05839844T0000|0 13|Histochemistry
P05847772T0001|0 18|Functional disorders
P05850652T0001|0 4|Study
P05857301T0000|0 17|Chemical histologic
P05858571T0000|0 13|Clinical trials
P05859016T0000|0 24|Hydroxypropyl methacrylate
P05879595T0094|0 9|Statistics
P05881833T0001|16 29|bovine leucosis
P05884183T0001|0 9|Experience
P05890093T0000|0 4|Study
P05890351T0001|0 20|Human antitetanus serum
P05893495T0001|0 6|Studies
P05896996T0001|2 11|catabolism
P05901778T0000|18 25|patterns
P05902458T0001|0 10|Naphthalene
P05909034T0000|0 6|Studies
P05917315T0026|1 10|case report
P05919308T0001|0 11|Interactions
P05930797T0000|0 13|Further studies
P05933228T0000|0 16|Pigmentary rhythms
P05938720T0000|0 4|Story
P05939748T0000|7 22|cervical Pap smear
P05942953T0049|0 1|I.
P05947377T0001|3 18|3-hour test iodine
P05949971T0000|0 10|Persistence
P05959588T0000|0 6|Studies
P05960999T0001|0 4|Value
P05967610T0000|0 22|Adrenergic nerve function
P05969185T0001|0 9|Concussion
P05982700T0000|0 4|Study
P05985275T0000|0 21|Antimicrobial substance
P05992157T0001|3 15|pathogenicity
P05994421T0045|0 12|Consanguinity
P05995140T0001|31 51|effective glucose level
P05999607T0001|0 6|Studies
P06012827T0000|0 21|Pharmacodynamic studies
P06027841T0000|0 10|Nuclear spin
P06035001T0000|0 18|Further observations
P06048505T0000|0 10|Derivatives
P06051644T0000|6 9|Slot
P06054411T0000|0 16|Retention behavior
P06065507T0000|0 27|Compensatory renal hypertrophy
P06070204T0025|0 2|XXI
P06072512T0000|22 36|mucolytic action
P06073427T0001|0 30|Electrophoretic characteriaztion
P06074093T0001|0 3|Iron
P06074640T0001|0 8|Symposium
P06084279A0218|17 24|patients
P06084810A0169|3 21|immuno-purified mRNA
P06084864T0001|0 32|Elevated maternal alpha fetoproteins
P06085839A0721|32 46|combined genetic
P06088722A0171|0 6|Courses
P06089575A0464|0 10|Stimulation
P06090369A0000|21 28|patients
P06090458A0407|3 23|PEPCK promoter fragment
P06091914A0000|0 16|Many mammary tumors
P06092048A1111|7 11|cases
P06092588T0000|0 14|Hepatitis B virus
P06093354A0000|5 24|recombinant DNA clones
P06093363A0612|0 2|USA
P06094591A0000|3 23|envelope glycoproteins
P06095372A0435|18 30|daily oral dose
P06095774T0001|0 18|Histogenetic aspects
P06096246T0000|0 5|Effect
P06096380A0662|0 9|Mature mRNA
P06096863T0000|0 22|Upstream activation sites
P06097027A0000|2 21|intact 5.7-kb provirus
P06097285A1077|17 27|haloperidol
P06098719A0369|7 16|side effect
P06098828A0352|3 9|results
P06099656T0000|0 11|Construction
P06101359T0000|0 8|Diagnosis
P06108610A0518|0 7|Theories
P06109017A0000|3 9|effects
P06110026T0000|0 9|Endorphins
P06111283T0032|0 13|Trial treatment
P06113084T0000|0 19|Cardiac taurine levels
P06113443T0000|0 9|Separation
P06119262T0000|3 15|roll-over test
P06120429T0000|3 20|thyroglobulin assay
P06121577A0280|1 21|Significant reductions
P06130348T0000|0 8|Isolation
P06131038A0000|0 5|Plasma
P06131378A0818|8 11|mRNA
P06136374A0151|6 22|water temperatures
P06137028A0624|0 10|Propranolol
P06138015T0114|0 10|Brief report
P06138313A0948|3 19|distribution phase
P06141764A0339|0 26|Hybrid-selection experiments
P06142279T0000|0 3|Risk
P06143734T0000|7 16|metabolism
P06147504A0086|3 10|patients
P06150069A0422|3 10|patients
P06151518A0000|0 11|Glutamic acid
P06151942A0235|0 16|Serum ascorbic acid
P06152670T0000|0 13|Plasma secretin
P06152844T0000|0 5|Effect
P06153936A0784|2 13|several cases
P06155967A1132|3 14|radiologists
P06158844A0000|0 10|Thalamotomy
P06161823A0129|1 16|Silastic capsules
P06162419A0118|55 59|doses
P06163433T0000|0 5|Effect
P06165068A0547|5 23|pure pancreatic juice
P06165132A0000|34 38|fowls
P06165551A0793|6 22|inappropriateness
P06167806A0000|12 24|chronic UM-272
P06173032T0000|11 23|echothiophate
P06173860A0000|2 10|most cases
P06175691T0000|0 28|Bacillus cereus cross-infection
P06181216A0070|16 40|phenytoin-treated patients
P06182979A0807|5 36|latter category particular emphasis
P06184276T0001|0 12|Unusual course
P06184487A1485|4 7|mRNA
P06185014A0642|19 37|complement factor C3c
P06185493A0468|1 16|polypeptide chain
P06189698A0246|3 15|P165 component
P06191243T0000|0 22|Differential drawing size
P06193351A1010|3 29|intracoronary administration
P06198241A0209|5 11|fusions
P06198532A0982|28 45|thrombotic tendency
P06199132A0179|0 7|Toxicity
P06200300A0409|0 17|Subdural electrodes
P06203843A0757|0 7|Products
P06204120T0001|0 2|Use
P06208024A0168|14 22|resistant
P06208477A0000|18 29|small library
P06209403A0562|2 14|direct repeats
P06209499A0682|3 15|direct effects
P06212776A0000|2 7|Cabras
P06214605A0123|11 18|elements
P06216125A0470|14 26|overall chance
P06217859T0000|0 9|Experience
P06218005A0948|9 16|patients
P06223586A0000|0 17|Immunochemotherapy
P06223586A0460|24 33|mitomycin C
P06224974A0833|0 3|Data
P06225279A0498|3 18|abluminal surface
P06227570A0523|13 22|LL patients
P06229542T0045|0 25|Functional characterization
P06230499A0128|24 46|preoperative irradiation
P06233924T0000|0 9|Fibrin gels
P06234369T0000|0 21|Hepatitis-B vaccination
P06234786A0606|0 18|Radiogallium imaging
P06237518A0117|3 40|customary coupling reagent sulfanilic acid
P06238540A0798|0 25|Ventricular volume stiffness
P06238704T0001|0 8|Synthesis
P06239545A0649|0 9|Weight loss
P06240448A0652|43 52|main phases
P06241900A0000|33 39|effects
P06241980A0855|0 13|Oxygen profiles
P06242113T0001|0 18|Cultivation technics
P06244732T0000|0 15|Radioimmunoassay
P06245672T0000|0 28|Selective macrophage inhibition
P06246254A0676|0 16|Restriction enzyme
P06251469A0830|8 31|different library isolates
P06252520T0000|0 13|Catecholamines
P06252883A0100|1 31|haemolytic enterotoxigenic strain
P06254403A0000|3 15|antibody titer
P06254973A1757|0 3|Poly
P06258699T0000|1 17|double-blind trial
P06258806A0963|17 25|insertion
P06259220A0000|4 14|experiments
P06259220A0464|0 9|Experiment
P06259389A0000|19 21|May
P06270347A0740|1 14|22K polypeptide
P06272844A0000|11 21|simian virus
P06278424A0145|21 32|requirements
P06278544T0027|0 9|Physiology
P06279309A0000|3 8|genome
P06281759A1086|7 11|RNase
P06281786A1222|10 14|clone
P06281891A0399|4 9|neural
P06286191T0000|0 10|Restoration
P06286443A0498|0 27|Postoperative serum ACTH levels
P06286549A0000|0 6|WR-2721
P06287212A1352|7 14|families
P06287231A0914|11 25|TRP1 RI Circle DNA
P06287737A0477|14 32|previous transfusion
P06290859A0426|5 22|hepatitis B patients
P06290899T0000|0 5|Survey
P06291369A0000|4 11|patients
P06295429A0412|16 19|MISO
P06296833A0000|3 11|mutations
P06298014A0647|3 11|ensembles
P06298720A0893|3 20|strong conservation
P06300662T0000|1 17|cDNA cloning vector
P06300836A0285|0 12|Hybridization
P06304771A1284|16 23|GGGXGGAG
P06306342A1156|18 24|studies
P06307099A1005|0 10|Lung density
P06308536T0001|3 25|hepatitis A virus antibody
P06308607A0375|3 11|junctions
P06309020A0473|0 7|Naloxone
P06309855T0000|0 18|Gel route preparation
P06309969T0055|0 1|I.
P06310159A0000|0 7|Viral RNA
P06310457A0000|0 22|Intracellular recordings
P06310553T0000|0 17|Molecular structure
P06310608A0749|3 9|mutants
P06314276T0000|0 7|Plasmids
P06314312A0359|14 27|soybean protein
P06316347A0852|3 11|dnaQ-lacZ
P06316623A0188|0 17|Overall prevalences
P06318078T0000|0 9|Expression
P06318091A0395|3 20|splice acceptor site
P06318322A0350|39 41|SSV
P06319040A1627|19 54|autonomic nervous system activity intact
P06319071A0173|0 13|Female subjects
P06319072A0711|18 27|morning dip
P06319421A0937|11 21|desipramine
P06319740A1331|17 34|gp54 structural gene
P06320380T0001|0 16|Surgical treatment
P06321505A0401|1 16|promoter sequence
P06321634A0123|18 22|mRNAs
P06321770A1353|15 46|chloramphenicol acetyltransferase
P06322183A1070|0 13|NPT II synthesis
P06323556A0126|1 19|computed tomographic
P06324089A0453|3 18|primary structure
P06324121A0256|9 10|MW
P06325415A0757|3 20|greatest difference
P06327039A0743|2 23|significant correlation
P06327292A0846|14 36|Shine-Dalgarno sequences
P06327638A0155|3 12|gene cat-86
P06328002A0000|3 32|myeloproliferative sarcoma virus
P06328012A0549|3 23|same-sized EBNA protein
P06328485A0277|23 40|nucleotide sequence
P06328504A0161|0 2|USA
P06330082A0329|0 1|A.
P06330478A0304|3 10|patients
P06331684A0607|2 16|immunologic test
P06333433A0000|6 13|isolates
P06333878T0000|0 22|Tiaprofenic acid overdose
P06336045A0261a|0 7|Frog type
P06336045A0261b|0 7|Frog type
P06340643A0598|0 3|DMCM
P06340703A0324|0 8|Grimelius
P06341139A0213|0 11|Blood glucose
P06341661T0001|0 10|Clinical use
P06342141A0226|24 46|sufficient understanding
P06345840A0348|2 9|patients
P06346427A0000|15 35|reactive insulin levels
P06349364A1051|5 11|results
P06350092A0916|5 21|posthospital phase
P06354594A0114|0 11|Sweet oranges
P06355483A0134|3 7|genes
P06360426A0501|3 19|enzymic hydrolysis
P06361318A0440|3 23|clinical efficacy rates
P06361318A1127|0 9|Side effect
P06362143A0565|0 18|Plasma renin activity
P06362239T0001|0 11|Martin Luther
P06362602T0001|0 10|Enhancement
P06364265T0062|7 27|gamma-ray spectroscopy
P06367414A0000|0 7|Bepridil
P06369355A0834|0 7|Analysis
P06369954T0000|0 6|Effects
P06370553A0444|7 26|plasma norepinephrine
P06372563T0000|0 12|Renal response
P06373409A1163|0 8|Lauciello
P06373855A0000|6 20|biopsy specimens
P06374369A1112|21 29|major part
P06374418A0877|3 10|aspirate
P06376227A0217|0 2|EGV
P06379363A0415|3 15|numerous tests
P06381438A1280|0 25|Lung prostacyclin production
P06382374A0206|13 15|min
P06384983T0000|0 9|Management
P06385474T0001|0 16|Climatic treatment
P06388189T0001|0 14|Transplantation
P06388818A0000|3 10|patients
P06391496T0000|0 5|Effect
P06394228T0073|0 6|Results
P06394347A1024|0 11|Hydrallazine
P06395804A0382|0 13|Urease activity
P06397009A0204|21 29|short life
P06401749T0000|11 17|lithium
P06402480A0373|3 16|susceptibility
P06402859A0000|0 14|Antithrombin III
P06404842A0127|8 15|patients
P06406060A0000|0 22|195mPt-labeled cisplatin
P06407348A0516|0 20|New beta-blocking drugs
P06411659A0264|2 11|facilities
P06411659A0793|20 31|energy intake
P06412385A0356|7 14|patients
P06413492A0990|0 5|Commun
P06414990A0057|3 21|statistical analysis
P06415299A0233|0 19|Total cumulative doses
P06419251T0000|0 18|Movement programming
P06426493A0331|11 13|min
P06428116T0000|0 20|Transitory subclinical
P06429992T0000|0 17|Gonadotropin levels
P06433442T0000|0 7|Freezing
P06434572A0157|5 12|children
P06434587A0551|14 25|measurable LH
P06435565A0648|5 11|changes
P06437579A0727|0 9|Cimetidine
P06439114A0677|0 10|Ceftazidime
P06439135A0250|0 10|Regional CBF
P06441624A0263|3 9|results
P06443639T0001|0 4|Study
P06443714T0001|9 28|Rhodnius prolixus Stal
P06444119A0340|4 20|causative organism
P06446048A0356|17 38|axillo-axillary by-pass
P06451557A0777|0 10|Deformities
P06452461A0930|8 29|significant correlation
P06452827T0001|0 25|Statokinesimetric recording
P06453290A0000|17 43|histostructural organization
P06454625A0000|18 33|animal experiment
P06459831T0001|0 13|Cardiovascular
P06460889A0111|0 20|Intravenous injections
P06460889A0512|2 6|doses
P06463429A0414|7 8|VE
P06466804A0686|0 7|Exposure
P06467241A0000|0 18|Modern cancer therapy
P06467797A0233|9 24|close correlation
P06468565A0000|3 20|response properties
P06468632A0135|0 10|Endothelium
P06468673A0358|7 38|supraphysiologic E2 concentrations
P06468694A0441|0 10|Stimulation
P06473219T0000|0 4|Value
P06473252A1073|47 65|actual egg production
P06479362A0680|0 13|Hydrocortisone
P06479976A0386|0 29|Significant clinical differences
P06480542A0000|1 20|pharmacokinetic study
P06482179A0497|0 13|Catch-up growth
P06482318A0117|0 18|Thrombocyte function
P06482665A0735|3 10|findings
P06483863A0000|5 15|experiments
P06486932A0000|11 16|deaths
P06487290A0000|0 16|Salivary estradiol
P06492188A0615|0 4|Other
P06493655A0415|0 23|Variable FHR decelerations
P06494215A0248|3 15|response chain
P06494297A0939|3 9|results
P06494766A0241|3 27|persistent fetal dispersion
P06495195A0536|14 29|biochemical tests
P06497671T0001|0 6|Changes
P06501086A0165|0 21|Significant alterations
P06503132A0784|0 2|SFP
P06503329A0588|3 18|average birth mass
P06503885A0342|4 15|machine drift
P06505014A1192|0 17|Other uncertainties
P06506074A0456|0 30|E2 treatments elevated hen plasma TG
P06507629A0717|11 17|kidneys
P06508393T0000|0 12|Serodiagnosis
P06513456T0001|0 20|Adenyl cyclase activity
P06516369T0001|0 10|Proteinuria
P06516847A0393|34 44|pneumococci
P06516977T0000|0 7|Reaction
P06517816A0388|0 1|HA
P06520418A0325|3 9|results
P06521802A0251|0 20|Scientific cooperation
P06521999A0677|23 29|results
P06524202A0167|1 10|new variant
P06524727A0601|0 10|Lymphocytes
P06524761A0596|41 48|immunity
P06527379T0044|11 33|proline/alanine sequence
P06527872T0000|3 11|segmental
P06531286A0382|0 6|Removal
P06535384A1115|5 21|Arithmetic subtest
P06539738T0000|3 25|toxicological evaluation
P06541019A0555|3 10|patients
P06541932A0000|0 6|Methods
P06542372A0159|3 14|present paper
P06542918A1131|16 38|ambiguous discrimination
P06545651A0346|0 19|Ammonia concentration
P06546392A0542|6 42|respect C reactive protein concentrations
P06548953T0001|0 21|Human thyroid stimulator
P06555107A1227|33 58|calcium antagonist Verapamil
P06568939A0000|0 16|Brainstem auditory
P06571587T0000|0 6|Effects
P06579147A0060|3 25|salient clinical features
P06579152A1061|30 32|NPF
P06582285A0222|13 29|comparative safety
P06584416A0157|5 16|radiologists
P06585277A0000|10 31|myelomonocytic leukemia
P06588306A0076|17 37|prophylactic treatment
P06588501T0059|2 27|experimental long-term study
P06591992A0569|2 13|anisotropism
P06593862T0001|0 16|Hepatitis B vaccine
P06594105A0560|3 18|calculated values
P06597709A0596|2 8|pleural
P06599282T0001|3 17|invasive pattern
P06600533T0000|0 9|Azygos vein
P06602580A0664|20 43|acute severe complications
P06602600A0582|3 27|Sarns 51F cavoatrial cannula
P06606043A0598|3 14|other changes
P06607427A0000|5 15|experiments
P06607714T0000|0 13|Limb allografts
P06609166A0209|31 37|samples
P06610347A0581|0 16|Refractory periods
P06612373A0000|50 56|sources
P06615053A0202|7 14|patients
P06615403A0718|7 24|single LAD occlusion
P06625058A0666|48 55|unstable
P06627123A0000|0 15|Female Wistar rats
P06627569T0001|0 1|HL
P06629370A0252|4 11|patients
P06630319A0244|0 6|Brain pH
P06634712A0557|3 9|results
P06643612A0000|0 31|Thin-layer chromatographic methods
P06648156T0034|0 18|Introductory remarks
P06652293A0353|13 24|cut-off point
P06653755A0192|5 26|clofelin administration
P06654047A0694|30 36|variant
P06654686T0001|0 10|Combination
P06655634A0195|1 14|combined series
P06656249T0000|0 20|Nursing home discharges
P06657559A0489|0 4|Trial
P06658029A0086|3 20|carcinogen bioassay
P06658445A0140|0 13|Harmful effects
P06658586T0001|0 22|Angionephroscintigraphy
P06659982A0231|30 40|sleep period
P06662623A0124|1 4|82Br
P06667015A0832|10 17|findings
P06667868T0001|0 21|Morphofunctional status
P06668316A0178|6 37|MOS-Hypersil reversed-phase column
P06670732A0000|23 30|patients
P06671047A1124|5 11|results
P06671065A0000|0 10|Serum lipids
P06671385A0856|0 4|Low NA
P06671925T0000|0 21|Amikacin concentrations
P06672094A0390|3 10|subgroup
P06674374T0000|0 28|Hepatitis B vaccination strategy
P06674516A0350|2 24|intravenous drip infusion
P06674977A1181|10 17|families
P06675047A0000|3 9|authors
P06683807A0160|0 19|Parkinsonian patients
P06683876A0244|5 9|cells
P06684624A0298|0 5|Female
P06684624A0736|0 37|Urinary N-acetylglucosaminidase activity
P06685004A0000|3 14|associations
P06685177T0000|0 11|Dipetalonema
P06685536A0502|8 12|years
P06685643A0179|3 16|concentrations
P06686454A0585|4 24|antibacterial activity
P06687953T0000|3 24|mucosal defence capacity
P06689413A0174|3 11|apparatus
P06689513T0001|0 21|Ultrastructural studies
P06691304A0284|10 28|serum concentrations
P06692517T0000|3 9|effects
P06692631A0129|1 15|stable interface
P06694380A1483|0 7|Plasma NE
P06694778A0000|2 30|long-term hemodialysis patients
P06698047A0445|3 17|Prolactin levels
P06700231A0259|7 25|total tumor resection
P06700469T0000|0 27|Private hospital accreditation
P06702257T0001|0 14|Antithrombin III
P06702643A0000|8 19|infant hearts
P06704467A0539|26 36|photoperiod
P06705456A0346|0 9|Absorption
P06707357A0180|13 24|observations
P06709310A0000|7 29|manifest latent nystagmus
P06709700A0230|9 19|compartment
P06711642A0093|0 28|Significant immunoglobulinuria
P06712314A0148|1 11|total number
P06713200A0630|0 19|Epileptiform activity
P06713204A0867|3 14|AD components
P06714298X0000|2 19|nisoldipine capable
P06714354A0194|0 6|Monkeys
P06715792A0295|0 15|HBB concentration
P06716977A0136|3 9|samples
P06718064T0001|0 16|Plasma lactoferrin
P06719057A0181|15 44|selective renal vein phlebography
P06720371T0000|0 9|Pilot study
P06721188A0200|3 21|statistical analysis
P06723849A0197|3 16|pyramidal tract
P06726257A1179|22 40|5-hydroxytryptophan
P06726257T0000|0 6|Effects
P06728580A0291|3 23|recent measles epidemic
P06731302A0930|13 27|bradyarrhythmia
P06732946A0281|19 23|areas
P06734713T0000|0 38|Diclofenac sodium-chlormezanone poisoning
P06735247A0803|0 44|Postprandial plasma enteroglucagon concentration
P06738410T0000|0 12|Blood pressure
P06740373A0891|28 34|captive
P06740697A0318|3 9|results
P06740919A0162|0 20|Adult Amblyomma lepidum
P06743061A0239|10 16|percent
P06744024A0000|0 7|Morphine
P06748227A0423|3 6|maps
P06749072A0116|0 20|Urinary urate excretion
P06750608A1442|0 8|Mutations
P06751455A0117|26 35|gallstones
P06753902A0437|5 12|patients
P06754662T0001|0 30|Bullous angiolymphoid hyperplasia
P06755468A0180|0 6|Regions
P06755986A0382|0 20|Multiresistant strains
P06760394T0001|0 21|Single tooth replacement
P06762025A0171|3 35|13,14-dihydro-15-keto-metabolites
P06762321T0000|0 17|Nucleotide sequence
P06763897A0216|3 14|hypertension
P06764669T0001|0 24|Colorimetric determination
P06767648A0734|0 11|Measurements
P06772370A0342|0 5|Volume
P06772612A0000|0 6|Effects
P06775834A0000|0 4|HLA-A
P06776918T0000|0 15|Trypanosoma cruzi
P06777229A0243|3 10|subjects
P06781339A0501|36 53|long-term follow-up
P06781728A0690|3 13|alterations
P06782612A0142|1 17|convenient measure
P06782869A0263|0 14|Nitrogen balance
P06784123A0286|0 9|Production
P06784123A0771|3 14|1.9-kb C mu RNA
P06784123T0000|0 10|Transcripts
P06785113A0337|0 49|Non-complement-dependent sperm-immobilizing activity
P06786756T0000|9 24|DNA rearrangement
P06788388A0000|30 37|ICRF-159
P06790572A0330|5 12|isolates
P06791500A0622|15 37|amniotic fluid delta OD450
P06793764T0001|0 9|Host lipids
P06794480A0785|11 33|significative difference
P06794666A0208|3 35|sympathetic neuroeffector influence
P06795119T0000|0 18|Lens aldose reductase
P06795654A0434|0 11|Fenfluramine
P06795832A0148|13 22|Hepatitis A
P06795900A0000|14 58|fatty acid cyclo-oxygenase inhibitor indomethacin
P06795971A0000|3 12|rat incisor
P06796300A0759|10 32|elevated prolactin levels
P06797063A0000|0 5|Factor
P06798609A0000|0 17|Morphine-dependent
P06801778T0001|0 11|Significance
P06802500T0001|0 16|Thyreoliberin VUFB
P06803634A0810|2 10|silicosis
P06805504A0629|12 25|urinary N values
P06805537T0001|0 7|Advances
P06807149A0222|55 68|different forms
P06807149T0000|0 9|Comparison
P06807192A0312|0 3|LCBF
P06807659T0001|0 11|Phagocytosis
P06808287T0001|0 8|Detection
P06808529A0167|14 31|isoniazid solutions
P06809474A1156|0 12|Bile bilirubin
P06809586T0000|0 51|Autoimmune manipulation aids juvenile diabetes management
P06810070A0502|0 14|Other properties
P06810694A0328|13 27|HDL-cholesterol
P06810694A1000|0 10|Apo A-I level
P06812389A0658|0 4|TEMTU
P06815368A0203|3 25|osmotic diuretic mannitol
P06816053A0849|5 12|patients
P06816123A0526|0 7|Selenium
P06816442T0001|0 14|Diagnostic value
P06816609A0639|4 26|% blood pressure reduction
P06817410A0982|14 19|months
P06818113A0384|0 16|Asthmatic patients
P06821147A0468|0 16|Sulphur amino acids
P06822645T0039|0 3|Time
P06823837A0562|16 41|right ventricular wavefronts
P06825641A0076|0 3|Many
P06826813A0264|0 7|Vesicles
P06828396A0095|10 22|contamination
P06829082A0187|17 31|deep hypothermia
P06830033A0661|0 18|Similar observations
P06830351A0397|11 17|Sugiura
P06833047A0000|48 68|respiratory inhibition
P06833422T0000|0 12|Determination
P06835516A0000|8 26|dense epidermoid cyst
P06835914A0192|0 15|Copper treatments
P06837312A0000|0 19|Fibromuscular intimal
P06838388A0896|10 25|rapid development
P06840803A0397|0 16|Histological signs
P06842629A0446|0 24|Significant GMBF reductions
P06848729A0000|5 12|children
P06849842T0000|0 30|Penicillin-G degradation products
P06851280A0144|0 15|Plasma fibrinogen
P06851327A0000|4 11|patients
P06853042A0282|0 25|Distal tubular acidification
P06854957T0066|0 8|Detection
P06856306T0000|3 18|Tullio phenomenon
P06856669A1004|5 11|results
P06858449A0335|0 11|Disturbances
P06858640A0262|12 36|histopathological findings
P06858805A0314|4 9|groups
P06858967A0167|0 24|Serum lactate dehydrogenase
P06863087A0664|0 8|Low-dose D
P06864837T0000|0 7|Efficacy
P06864955T0000|12 15|MMWR
P06868345A0000|13 23|visna-maedi
P06869215A0347|0 9|High levels
P06869986A0000|11 19|platelets
P06872800T0000|0 8|Acute type
P06873504T0000|0 24|Pathogenetic relationships
P06875478A0542|1 19|microU/l thyrotropin
P06876006A0930|0 14|Echosismography
P06876317T0033|0 12|Relationships
P06880563A0516|3 12|prevalence
P06880604A0167|1 12|reassessment
P06880650A0316|3 9|results
P06882578A0464|5 23|ultramarathon runner
P06883385A0509|2 9|patients
P06884450A0234|2 15|visible tumours
P06886031A0898|0 13|Total PGE levels
P06886948A0750|0 10|Normal rates
P06890622A0067|3 14|vasodilatory
P06890935T0001|0 5|Behcet
P06891051A0587|0 7|Survival
P06891270A0000|11 33|emotional-painful stress
P06895559A0000|0 10|Terbutaline
P06895663A0810|51 53|RBT
P06897114A0240|4 17|two-helix motif
P06902722T0000|3 17|hyperacute phase
P06911559T0000|0 9|Statistics
P06916588A0304|3 15|infection rate
P06919347T0001|25 44|Laboratory Assistants
P06928974T0000|3 19|electrocardiogram
P06931124A0109|24 39|complex formation
P06935514A0000|3 9|Authors
P06938948T0001|0 11|Secretory IgA
P06946314T0000|0 13|Serum IgE levels
P06946693T0000|0 2|Use
P06948398A0523|58 72|great importance
P06948493T0026|0 4|Range
P06948868A0082|3 8|scores
P06950004T0047|0 4|Study
P06953957A0503|7 28|creatine kinase activity
P06957125T0000|0 23|Utero-placental blood flow
P06957633T0001|0 10|Development
P06959130A0996|3 21|arginyl peptide bonds
P06962492A0612|0 13|Alveolar growth
P06962634A0190|0 18|Fluorometric methods
P06963337T0000|0 4|Renal
P06966678A0523|3 21|monoexponential rate
P06969638A0180|4 15|examinations
P06972179A0556|0 16|Specific IgE levels
P06972443A0375|0 24|Similar clinical evaluation
P06972501A0615|0 10|Correlation
P06973664A0000|7 30|anterior cleavage syndrome
P06975206A0279|3 21|daily administration
P06977605T0000|0 9|Endorphins
P06978566A0197|2 9|necropsy
P06981991A0756|0 13|Aneurysmectomy
P06984225A0367|0 3|REV I
P06986168A0304|0 16|Complete sequences
P06992600A0405|3 24|extraction measurements
P06993660A0000|0 19|Contractile responses
P06994035T0001|2 16|line calculation
P06994049T0001|0 8|Detection
P06997203A0325|2 16|rubella patients
P07004236A0741|3 9|results
P07007181T0000|11 25|sodium saccharin
P07007591A0324|3 18|residue functions
P07015018A0395|0 18|Synchronous extracts
P07015262A0396|3 6|days
P07016141A0238|11 19|blood flow
P07018810A0002|0 23|Plasma renin concentration
P07021505A0510|5 15|acclimation
P07026328A0369|5 13|diabetics
P07034479A1050|11 13|RMI
P07037479T0000|4 16|cracked-tooth
P07038189A2301|3 18|foregoing results
P07038684A1050|7 28|peptide map similarities
P07040659A0212|3 10|patients
P07044389T0000|0 4|Facts
P07044562T0000|4 6|Pap
P07044842A2062|25 41|rare complications
P07045156A0204|7 36|opsonophagocytic bacterial assay
P07049690T0000|0 16|Glomerular lesions
P07053251A0666|16 35|systemic toxic effects
P07061263A0293|4 19|vascular pressure
P07061350A0042|7 13|Science
P07062036A0072|0 3|Rats
P07062269A0798|7 27|l-methadone-sensitive
P07063606T0000|0 57|Microwave hyperthermia-induced blood-brain barrier alterations
P07064662A0222|0 4|Large
P07064923T0000|0 8|Diagnosis
P07065206A0398|4 15|control sheep
P07068493A0414|3 17|respiratory rate
P07068493A0636|10 24|further increase
P07068496A0000|24 45|pulmonary extravascular
P07068887A0000|38 51|dimensionality
P07072635A0000|1 12|simple method
P07073520A0153|6 31|conventional hemofiltration
P07075024A0540|3 20|uncomplicated cases
P07075438T0000|0 31|Transvenous serial xeroradiography
P07076222A0543|0 14|Recommendations
P07078263T0000|0 2|Use
P07079595A0848|9 30|significant correlation
P07080496A0097|3 27|differential investigation
P07081327A0546|8 25|noninhibitory fluid
P07084198T0000|0 13|Selenium status
P07084617A0204|8 20|8-wk follow-up
P07084814T0000|0 10|Preparation
P07088195T0019|11 22|consequences
P07090151A0165|6 12|turnout
P07094856A0115|3 19|longitudinal study
P07094905A0644|8 40|intracerebroventricular injections
P07096587A0267|16 23|patients
P07097182A0480|3 10|duration
P07105635A0412|0 6|Samples
P07106323A0560|5 11|results
P07106534A0160|34 47|growth function
P07107287A1083|3 14|highest doses
P07107462A0202|3 11|steepness
P07107773A0000|13 40|unconjugated phenylacetic acid
P07109788A0333|13 20|patients
P07110999A0160|15 34|behavioural disorders
P07112320A0086|0 28|CSF adenosine deaminase activity
P07112471A0639|0 18|Histamine reactivity
P07112654A0388|27 47|significant difference
P07113365A0737|0 4|Ficat
P07113897A0285|11 32|significant differences
P07114083A0153|5 15|MOPP therapy
P07116298A1079|24 38|adjuvant therapy
P07116962A0299|3 18|COP-PAWP gradient
P07119890T0000|0 1|Re
P07124743A1223|1 12|limited study
P07125064T0000|0 14|Parasitological
P07125238T0000|3 10|pia mater
P07126067T0000|0 23|Experimental reproduction
P07126413A0000|2 22|colonic delivery system
P07130335A1081|0 13|Administration
P07132408A0387|30 50|magnesium cardioplegia
P07134924A0640|7 17|common types
P07135112T0000|0 5|Repair
P07136524A0180|25 56|second malignant epithelial tumours
P07136569A0000|2 6|Malmo
P07137927A0000|10 19|immunology
P07140060T0000|0 25|Intra-articular dislocation
P07140493A1045|21 29|secretion
P07141130A0615|0 21|Histological evaluation
P07143347T0000|0 5|Cramps
P07147622T0000|10 26|new storage disease
P07149047A0260|3 19|various dog vessels
P07149303T0000|3 19|tetraphasic action
P07154928T0001|0 11|Modification
P07155579T0001|0 26|Asymptomatic bacteriospermia
P07158726T0001|0 6|Triumph
P07160491A0547|3 18|favourable effect
P07162146A0000|16 30|ultrafiltration
P07165767T0000|0 11|Mastocytosis
P07168531T0001|1 20|new Onchocerca species
P07169630A0983|30 50|pronounced differences
P07172690A0547|19 30|disturbances
P07173729A0000|7 22|penetration tests
P07174046T0000|0 14|Vibrio fluvialis
P07174122A0000|0 18|Serum creatine kinase
P07174437A0181|0 8|Organisms
P07175474A0102|42 53|pathological
P07179412A1131|3 19|average annual cost
P07180901A0539|18 33|altered blood flow
P07181985A0107|8 37|mg mitomycin/20 ml distilled water
P07182523A0462|4 9|groups
P07183576A0157|31 44|flucloxacillin
P07184375T0001|1 16|preliminary study
P07184598T0001|0 16|Lacrimal secretion
P07184774T0000|0 13|Re-examination
P07184795A0517|10 23|determinations
P07190627T0000|1 12|further study
P07190869A0316|0 3|CDDP
P07191183A0505|0 8|Treatment
P07191804A0000|3 18|hormonal response
P07191972A0391|4 21|ambient temperature
P07192369T0000|21 48|cumulative behavioral toxicity
P07192722A0682|5 39|successful subtotal parathyroidectomy
P07194905A0332|0 2|TCZ
P07195615A0087|11 23|muricidal rats
P07195880A0621|28 41|practical means
P07202224A0452|3 13|preferences
P07202525A0200|28 33|buzzer
P07202919A0142|0 4|Ulcer
P07203410T0000|0 11|Family visits
P07205120T0000|1 18|transparent overlay
P07205967T0000|0 14|Adverse reaction
P07208984A0000|0 4|Brain
P07214230T0000|0 9|Inhibition
P07214665A0000|3 22|five-drug combination
P07217329A0000|24 48|simultaneous determination
P07217523A0364|0 6|Results
P07218008T0000|0 23|Visual response properties
P07219297T0000|1 15|unified approach
P07219821T0028|0 7|Clinical
P07221179A0156|1 18|dose-dependent fall
P07221354T0000|0 5|Theory
P07225300A0968|5 11|results
P07225540A0193|13 60|gas chromatographic electron capture detection method
P07226440T0000|3 14|hemodynamics
P07228955A0000|0 13|Several authors
P07234308A0121|0 16|Multi drug regimens
P07234755A0838|3 11|monocytes
P07234974T0000|0 20|Morphological features
P07235317T0000|0 15|Clinical accuracy
P07235355A0462|4 18|control subjects
P07236351A0812|9 38|extended recovery hippocampal EEG
P07237123T0000|18 36|single unit responses
P07237560A1038|8 16|deletions
P07237817T0000|0 14|Cross reactivity
P07240343A0000|0 11|Strontium-90
P07242929T0001|0 8|Recording
P07243380A0327|5 6|hr
P07247059A0775|0 14|Catheter transit
P07249497A0688|5 9|women
P07249544A0343|3 17|oral temperature
P07249660T0000|0 12|Determination
P07249895A0177|18 31|prostaglandins
P07251564A0569|11 11|%
P07252346A0223|1 17|surgical technique
P07253335T0000|0 6|Effects
P07256543A0814|15 37|general clinical criteria
P07259325A0394|0 7|Survival
P07260389A0221|0 11|Methisergide
P07260987A0336|3 17|plasma half-life
P07262239T0000|0 6|Effects
P07262625A0000|0 20|Corticosteroid therapy
P07263374T0000|0 17|Static lung function
P07263421A0351|4 7|Sair
P07263745T0000|0 28|Bilateral Charnley arthroplasty
P07264787A0351|8 15|patients
P07266969A0246|22 41|estrogenic properties
P07267675A0000|3 36|new semi-synthetic oral cephalosporin
P07268828A0000|1 17|fluoroimmunoassay
P07270163A0684|3 34|syncytial microvillous projections
P07270991A0149|4 17|pollen allergen
P07274042A0249|0 2|DMI
P07274428A0000|16 26|experiments
P07274482A0000|9 15|neurons
P07274505A0660|2 9|controls
P07276210T0000|0 4|Assay
P07277222A1391|0 11|Similar waves
P07278104T0001|0 22|Leukocyte enzyme activity
P07278578T0001|0 12|Current status
P07280654A0000|16 18|HBE
P07282444A0075|10 14|cases
P07282552A0990|2 7|Group V
P07282943A0097|0 35|Progressive 100-mmHg stepwise decreases
P07283110A0000|3 9|known B1
P07286057A0159|7 25|AUC infinity analyses
P07293100T0001|0 15|Gastrin secretion
P07293327T0001|0 22|Fibrinogen determination
P07295033A0513|15 18|days
P07295417A0092|30 36|regions
P07296303A0418|0 8|Responses
P07296997A0125|8 15|patients
P07297576A0454|13 39|fresh drinking water ad libitum
P07297978A0570|0 13|Anamnestic data
P07298209A0291|18 44|physical performance capacity
P07298259T0000|0 12|Determination
P07298523T0000|0 5|Effect
P07299857A0294|0 9|LD50 values
P07304905A0336|0 14|Autotransfusion
P07306839T0001|0 25|Electron microscopic picture
P07308849A0817|12 22|differences
P07309562T0000|11 48|thin-layer chromatographic determination
P07310206A0154|17 32|microvasculature
P07311881T0000|0 10|MSMS Council
P07312707T0000|0 7|Chordoma
P07320153T0000|0 47|Micro high-performance liquid chromatographic system
P07323063A0000|10 20|age-matched
P07323573A0644|1 10|narrow zone
P07326596A0061|3 15|IgA deficiency
P07327097A0647|2 7|PB mice
P07328000T0000|0 19|Nutritional cataracts
P07330073T0000|0 9|Prevention
P07337609A0531|3 56|geometric mean hemagglutination-inhibition antibody titers
P07340196T0001|3 27|quantitative determination
P07341346A0174|2 27|numerous narrow shunt vessels
P07345217A0000|0 22|Urological complications
P07347728T0000|0 12|Arachnoid cyst
P07349416A0337|16 25|summer coat
P07354367A0162|0 10|Hypotension
P07355527A0467|23 34|Lich-Gregoir
P07356273T0022|0 13|Mucoepidermoid
P07365183A0000|6 17|patients aged
P07369183T0000|3 14|new artifacts
P07369458A0606|58 78|deep muscle temperature
P07372433A0000|0 36|Longitudinal force-length relationships
P07372928A0105|0 4|Tests
P07375836T0000|0 18|Angiographic work-up
P07375864A0431|3 9|authors
P07376165T0001|0 6|Ecthyma
P07377378A0143|0 18|Estrogen replacement
P07377954A0117|12 18|aspects
P07379334A0503|0 6|Changes
P07380615A0478|57 70|blue collar jobs
P07385543T0001|0 9|Importance
P07385920A0189|3 9|results
P07385933A0085|9 19|iv injection
P07386500A0174|0 27|Specific clotting factor assays
P07386864T0000|0 27|Charcoal-facilitated dialysis
P07387242A0236|0 13|Blood variables
P07392519T0001|0 13|Retinal changes
P07393856A0314|10 19|beta-apo-8
P07393976A0000|12 30|sodium phenobarbital
P07394364A0738|16 45|pulmonary gas exchange parenchyma
P07395750A0294|0 15|Underestimations
P07396545A0217|0 11|Chemotherapy
P07397066T0000|0 13|Drug inhibition
P07401318A0823|10 25|lower temperature
P07405701T0000|0 5|Visual
P07406527A0212|26 50|urinary porphyrin excretion
P07408970A0706|3 7|hours
P07410037A0752|8 20|stone-formers
P07413144T0018|0 7|Analysis
P07413242A0000|1 21|16-year follow-up study
P07413441T0070|0 27|Autoradiographic localisation
P07413781A0169|0 21|Hippocampal stimulation
P07413806T0000|3 22|centromedial amygdala
P07414817T0001|0 17|Cataract extraction
P07415340A0280|0 5|Number
P07416204A0437|5 16|intact animal
P07418498A0217|16 33|other complications
P07418829A0191|0 11|Implications
P07419485A0158|34 43|short waves
P07423803T0001|0 8|Treatment
P07425838A0182|15 30|pheochromocytoma
P07426101A0124|7 12|plasma
P07426604A0397|3 7|C18:1
P07426745A0177|1 17|progressive growth
P07428037A0989|11 18|terminal
P07429009T0121|0 17|Microscopic anatomy
P07431059A0000|6 18|cadaver brains
P07432288A0218|0 17|Serum antibody titre
P07434431A0203|13 21|refeeding
P07434456A0286|16 20|units
P07435185A0074|3 10|symptoms
P07436187A0147|19 33|previous studies
P07436459A0245|24 68|hydroxykynurenine/hydroxyanthranilic acid ratio
P07436702A0156|3 16|control persons
P07436794A0148|3 14|control group
P07438346A0381|2 3|pH
P07438482A0145|0 16|Simultaneous right
P07440085T0061|0 15|Arm function tests
P07440430A1074|3 7|lambs
P07445971A0241|3 14|same response
P07449221A0086|25 32|excision
P07449253A0411|5 34|unclipped group arterial pressure
P07450031A0691|0 21|Marked sedative activity
P07450388A0406|2 9|patients
P07453919A0000|4 11|patients
P07455042A0457|2 11|high-speed
P07455521A0414|3 6|ESEG
P07456774A0448|14 30|SLE-inducing drugs
P07457931A0655|1 11|third series
P07458171A0086|8 23|different species
P07461226A0958|2 14|symptoms other
P07461848A0230|3 12|mean values
P07462481A0422|3 31|average backscatter coefficient
P07463294A1216|3 4|wk
P07463465A0297|34 45|control women
P07466831A0714|0 16|Pentachlorophenol
P07467975A0316|0 13|Family planning
P07469692A0000|3 23|term osteomesopycnosis
P07471210A0384|3 12|87K protein
P07472582A0993|19 34|viable myocardium
P07472736A0278|3 19|temporal component
P07473169A0133|0 4|EUK-8
P07473742A0187|3 14|protein ELT-1
P07474078A0838|37 63|cell-free integration studies
P07474085A0932|12 19|R protein
P07474124A1360|5 11|results
P07474140A1036|2 25|site-specific mutagenesis
P07474451A0000|0 23|Magnetic resonance imaging
P07474617A1035|0 7|Patients
P07474772A0274|3 29|Laser Scanning Ophthalmoscope
P07475733T0000|0 6|Malaria
P07475793T0000|0 2|BSE
P07476164A1602|11 56|two-dimensional nuclear magnetic resonance studies
P07476701A0654|12 21|high levels
P07476963A0000|0 40|Peroxisome proliferator-activated receptors
P07476971A0381|18 27|intriguing
P07476975A0492|11 21|lactotropes
P07477245A0625|4 10|strains
P07478514A0237|19 44|larger rat B-myc genomic clone
P07478523A0551|24 45|terminal amino acid forms
P07478525A1177|4 10|classes
P07479004A0421|2 35|electrophoretic mobility shift assays
P07482069A0606|19 21|MTX
P07483276A0139|0 7|Analysis
P07483285A0322|5 19|HPV16 E6/E7 cDNAs
P07483857A0350|0 22|Correlation coefficients
P07487067A0592|3 21|translation products
P07487363A0447|3 13|serum levels
P07487811A0000|3 13|experiments
P07487908A0230|31 43|transcription
P07488247T0000|0 17|Functional analysis
P07488291A0934|0 26|Histopathologic observations
P07488959T0000|13 32|biomathematical model
P07489502A0000|3 26|influenza virus NS1 protein
P07490079A0825|11 17|regions
P07490079T0000|0 15|Molecular cloning
P07490083A0000|0 17|Carbonic anhydrase V
P07490156A0647|0 8|Vitamin D3
P07490278A0799|3 14|latter domain
P07490742A0636|43 61|dsRNA binding domains
P07490766T0000|0 52|Preferential heterodimeric parallel coiled-coil formation
P07490770A0267|0 9|Comparison
P07491111A0221|12 13|GR
P07491305A0102|27 38|localization
P07491791A0263|3 18|promoter mutation
P07493327A0507|16 29|trans-splicing
P07493627A0882|0 8|Treatment
P07494244A0335|14 19|E1A243
P07494274A1015|0 20|Shift-down experiments
P07494293A0585|5 11|results
P07494303A0000|0 29|Human immunodeficiency virus type
P07494306A0240|28 66|VP16 protein-protein interactions specific
P07494314A1287|5 29|transcriptional regulation
P07495059T0078|0 6|Results
P07495120A0260|11 26|prospective Phase
P07495726A1189|5 10|motifs
P07496184T0001|0 12|Common history
P07496400A0525|35 43|HMGR1 mRNA
P07498727A0724|24 27|rev3
P07498791A0680|3 23|second mutation present
P07499242A0898|2 13|adult tissues
P07499252A0150|2 16|hGM-CSF receptor
P07499394A0187|0 1|J.
P07499401A0444|18 24|hnRNPs H
P07499409A0367|0 3|TPBF
P07499421A0237|5 16|present study
P07499848A0409|10 20|stimulation
P07500386A0870|12 32|GapIII protein activity
P07500597A0212|16 25|latest BPVs
P07500950A0000|1 16|tobacco homologue
P07500953A0305|0 17|High ADR1 gene dosage
P07501016T0000|1 22|water-vapour giga-maser
P07501458A0578|15 35|C/EBP family inhibitors
P07501700A0000|3 9|effects
P07501992A0125|5 12|incisors
P07504171A0715|1 36|platelet-derived growth factor receptor
P07504171A1214|16 28|Src SH2 mutants
P07504712A0843|5 16|observations
P07505349A0702|3 16|early lethality
P07505798A0000|11 26|immunogenic sites
P07506253A0742|4 11|enhancer
P07507187T0000|0 8|Mechanism
P07507207A0991|17 30|IRF binding site
P07507458A0250|25 45|coagulopathic patients
P07508082A0821|3 17|highest decrease
P07508140A0448|0 23|Hepatitis B surface antigen
P07508250A0537|19 40|significant correlation
P07508441A0487|0 26|Antibodies affinity-purified
P07508954A0000|3 32|avidin-biotin complex peroxidase
P07509053A0139|14 22|processes
P07509449A0000|24 44|avian sarcoma virus CT10
P07509450A0705|4 29|specific methylation pattern
P07509472A1320|0 9|CONCLUSION
P07509624T0000|0 16|Long-range mapping
P07509811A1357|0 3|GTRE
P07510461A0731|20 36|test abnormalities
P07510635A0479|3 10|antibody
P07510724A1208|3 12|lymph nodes
P07511444A0728|0 11|HCV infection
P07511444T0000|0 23|Hepatitis C virus infection
P07511496A1511|0 23|High plasma concentrations
P07511818A0485|5 44|human IFN-beta-transformed cell populations
P07512159A0992|0 10|Improvement
P07512258A0441|0 19|Liver transplantation
P07512552A0270|0 3|Joys
P07513703T0000|0 9|Activation
P07514295A0000|0 22|Tyrosine phosphorylation
P07514301A0000|3 46|interferon-induced RNA-dependent protein kinase
P07516337A1119|9 11|Lck
P07516466A1054|11 19|injection
P07516469A1025|0 28|Several Src SH3-binding proteins
P07516597A1017|25 45|proteolytic processing
P07516866A0000|1 22|full-length PRL receptor
P07517544A0515|6 9|days
P07517869A0411|14 30|dephosphorylation
P07518257A0351|3 11|promoters
P07518426A0000|0 12|Interleukin-8
P07518460A0771|5 13|other hand
P07518561A0496|22 48|p72syk protein tyrosine kinase
P07518578A0000|24 39|Rous sarcoma virus
P07519447T0000|0 11|Organization
P07519463A0000|19 50|regional myocardial work efficiency
P07519481A1275|2 9|female Sl
P07519606A1269|0 12|Anti-NPROSP-C
P07520098A0211|5 33|B6-derived Db mutant B6.CH-2bm13
P07521009A0377|5 11|mutants
P07521285A1109|3 10|findings
P07521601A0000|0 25|Hematopoietic growth factors
P07521916T0000|0 6|Effects
P07522163T0000|0 11|Presentation
P07523363A0440|13 43|striking HpaII tiny fragment island
P07523710T0000|0 8|Diagnosis
P07524265T0000|9 43|granulocyte-colony stimulating factor
P07525548A1380|3 9|results
P07525596A0584|50 64|full-length Fpr3
P07525843A0859|0 8|Dilutions
P07526609A0736|20 24|sigma
P07527168A0524|0 11|Microvessels
P07528028A1192|23 31|cell lines
P07528325A0165|0 12|Recent studies
P07528531A0904|2 16|viral infections
P07528667A0834|0 19|Minor initiation sites
P07528746A1049|0 23|Phosphoamino acid analysis
P07528772A0616|18 39|structural requirements
P07528772A1539|13 45|tyrosine phosphorylated TAM peptides
P07529124A0119|3 28|three-dimensional structure
P07529504A0000|0 14|Pharmacological
P07529516A0474|3 20|subsequent patients
P07530128A0578|3 22|median post-treatment
P07530502A0974|0 7|Addition
P07530502T0000|0 24|Membrane-bound Steel factor
P07530549A0956|0 7|Analysis
P07531321A0369|0 7|Patients
P07532278A0833|0 6|Horvath
P07533527A0128|0 8|Cell lines
P07533758A1038|3 20|amino acid sequences
P07533858A1503|8 35|multiple alanine substitutions
P07533880T0000|3 13|FinO protein
P07534285A0155|23 35|ligand binding
P07534286A0842|1 19|chicken paxillin cDNA
P07534297A0141|9 42|4.1-kilobase pair HindIII DNA fragment
P07534306A0444|3 41|overexpressed His6-tagged GrsA derivatives
P07535593A0714|0 2|CD7
P07535768A1076|0 7|HVH2 mRNA
P07537267A2094|25 40|sequences located
P07537362A1112|24 49|Shb-SH3 domain proteins v-Src
P07537736A0453|3 9|results
P07537851A0000|0 12|Transcription
P07537851A0891|0 10|Experiments
P07538068A1094|12 18|results
P07538122A0800|37 47|Fab fragment
P07538173A0307|0 45|MBP-Rep68 delta-mediated DNA-RNA helicase activity
P07538818A0197|10 24|critical regions
P07539119A0291|37 45|mutations
P07539119A0985|4 12|mutations
P07539314T0000|0 6|Changes
P07540607A0709|0 10|Retreatment
P07540773A0576|3 8|levels
P07540866A1069|14 26|insulin effect
P07541589A0652|0 19|Morphologic variables
P07541912A0485|0 15|Sequence analysis
P07542577A0438|3 16|fusion proteins
P07542616A0313|0 4|GCD10
P07542616A0486|0 4|GCD10
P07542698A0137|0 6|Sources
P07543592A0624|1 30|transformation-competent mutant
P07543684A1027|14 17|cAMP
P07543868A0414|0 26|Appropriate restriction sites
P07544357A0808|4 8|PPC-1
P07545510A0735|3 13|gene product
P07545920A1336|3 11|such genes
P07546256A0000|1 33|retrospective epidemiological study
P07546293A0968|3 9|results
P07546294A0000|3 15|RAD6/UBC2 gene
P07546794A0100|0 15|Echocardiography
P07547220A0229|2 28|on-going screening programmes
P07547500A0066|23 35|fusion protein
P07547510A0261|42 46|sites
P07548425A0000|13 16|cats
P07548858A0000|3 10|flow rate
P07549005A0530|8 27|parallax measurements
P07550216A0195|14 25|normal limits
P07551787A0917|15 26|optimization
P07552974A0217|0 19|Specific requirements
P07553942A0810|3 16|pea rps10 intron
P07554541A0587|3 13|optimal care
P07555373A0000|0 13|Serum magnesium
P07557091A0314|0 6|METHODS
P07557276A0526|0 22|Alanine aminotransferase
P07557387A0241|38 46|C/EBP beta
P07557424A0124|0 3|XYL1
P07557446T0000|0 17|Various transcripts
P07557717A0184|21 36|chest wall muscles
P07558263T0000|0 6|Closure
P07558583A0562|25 33|synthesis
P07559233A0534|0 22|Citrate synthase activity
P07559347A0000|18 36|putative operon bglPH
P07559355A0066|13 36|contiguous genes necessary
P07559356T0000|3 16|hypBFCDE operon
P07559402A0622|18 19|VT
P07559430A0909|0 1|R.
P07559478A0389|13 19|O'Neill
P07559488A0440|0 17|Control experiments
P07559510A0000|8 38|Micrococcus luteus UV endonuclease
P07559524A0000|0 24|Several different oncogenes
P07559524A0741|0 23|Cyclin D1 promoter activity
P07559555A0557|7 9|ERM
P07559563A0282|1 6|mutant
P07559639A0996|14 33|R206S HSF substitution
P07559640A1230|6 10|bases
P07559650A0558|5 11|results
P07560137T0000|0 22|Differential sensitivity
P07560662A0496|15 39|hypertonic saline challenge
P07562775A0596|10 20|eosinophils
P07563072A0773|0 10|Comparisons
P07563076A0766|5 18|intron chimeras
P07563090A0124|32 54|plus-strand DNA synthesis
P07563090A0624|0 15|Characterization
P07563994A0488|3 10|patients
P07564004A0292|5 11|minutes
P07564210A0557|4 40|combined intravenous anaesthetic regimen
P07565031A0454|6 17|food products
P07565049A1032|29 43|clinical outline
P07565104A0084|18 26|pilin gene
P07565113A0000|3 44|chloramphenicol-resistance transposon Tn4451
P07565669T0000|0 8|Ras p21Val
P07565672A0798|2 6|cells
P07565685A0420|3 18|peptide sequences
P07565688A0797|0 27|Immunofluorescence microscopy
P07565688T0000|0 9|Expression
P07565709A0000|0 15|T-cell hybridomas
P07565712A0286|0 8|Deletions
P07565713A0634|0 13|Overexpression
P07565720A0256|3 18|DNA binding domain
P07565723A0200|3 8|kinase
P07565731A1629|1 12|general model
P07565736A2134|25 34|C/EBP alpha
P07565740T0000|0 10|Endocytosis
P07565775A1265|0 18|Individual mutations
P07565775T0000|0 17|Mutational analysis
P07565776A0612|0 9|Disruption
P07565797A0116|0 7|Deletion
P07567079A0014|26 43|Cryptosporidium spp
P07567300T0000|0 24|Staphylococcal enterotoxin
P07567830A0072|0 6|METHODS
P07567979A1266|3 10|findings
P07567980T0000|4 31|p53 DNA-binding domain peptides
P07568026A0622|3 12|Stat5b mRNA
P07568116A0902|3 16|hydropathy plot
P07568118A1267|5 11|results
P07568576A0074|41 53|Type A behavior
P07568865A0305|3 11|carcasses
P07569075A0585|16 33|lung cancer patients
P07569532T0001|0 26|Pediatric medical emergencies
P07569640A0539|0 21|Protein electrophoresis
P07569770A0298|0 6|METHODS
P07571766A0122|12 25|high percentage
P07571953T0000|0 16|Negative-staining
P07572582A0000|0 9|Mibefradil
P07574064A1416|9 46|minimum alveolar concentration anesthesia
P07574682T0000|0 3|cDNA
P07575416A0000|0 13|Protein kinase C
P07575416A1970|48 60|careful choice
P07575438A1409|23 45|helix-loop-helix factors
P07575947T0000|13 21|electives
P07576178A0000|0 23|Polypeptide growth factors
P07576179A0781|37 52|CpG dinucleotides
P07576307A0144|29 54|proximal regulatory cassette
P07576307A1654|16 33|ENK-specific motifs
P07577904A0141|0 9|Infant aged
P07579023A0214|9 20|dose-finding
P07579164A0409|14 17|cDNA
P07579328A0653|0 4|MZF-1
P07579328A1345|9 36|heterologous DNA binding domain
P07579683A0660|0 7|Analyses
P07579695A0336|20 38|synthetic phenotypes
P07579695A0693|37 47|Mif2 protein
P07579704A0085|17 27|actin cables
P07580058A0000|3 9|effects
P07580330A0331|9 20|daily intakes
P07580782T0000|0 14|Imaging features
P07581364A0500|5 16|further cases
P07582316A0696|18 22|pairs
P07582592A0545|0 3|HRES
P07583190A0306|5 28|early structural processes
P07583562A1826|2 4|men
P07585246T0000|0 16|SL1 trans-splicing
P07585559A0000|1 26|pyrazolo-quinoline compound
P07586403A0765|17 25|relations
P07588240A0000|3 46|Caenorhabditis elegans death susceptibility gene
P07588245T0000|0 9|Repression
P07588603A1054|3 9|results
P07588608A1687|0 10|Obstruction
P07588628A0318|0 13|Overexpression
P07588633A0362|10 14|c-Fos
P07588750T0061|0 6|Cloning
P07588777A1524|5 16|observations
P07589069A1245|37 41|forms
P07590264A0373|26 40|such differences
P07590268A0350|38 39|Dm
P07590268A0740|1 22|2.4-kb MAPKAPK-2 message
P07590283A0820|17 27|chimeric TdT
P07590525A0811|3 15|average values
P07590657A0624|0 14|Cholangiography
P07590744A0829|17 28|cDNA sequence
P07592072A0217|2 6|Trial
P07592220A0846|0 11|End-tidal PO2
P07592337A0891|5 11|results
P07592439A0000|0 3|A511
P07592467A0000|14 36|peroxisome proliferation
P07592485A0734|2 28|NCR-sensitive gene expression
P07592647A0797|3 46|single-stranded DNA Pur alpha recognition element
P07592647T0000|0 10|Association
P07592658A0309|3 35|insulin-induced DNA-binding complex
P07592676A0466|12 21|conditions
P07592706A1465|0 7|Exchange
P07592710T0000|3 38|interferon-inducible protein kinase PKR
P07592711T0000|0 13|Truncated forms
P07592721A0827|7 20|common mutation
P07592723A0814|0 12|Phorbol esters
P07592730A0204|0 5|Levels
P07592771A0258|3 27|mouse beta 2-syntrophin gene
P07592790A1457|29 32|PEDF
P07592946A0261|15 21|cloning
P07592946A0997|15 31|putative TATA boxes
P07593266A1174|26 50|adenine-uridine rich region
P07593896A1053|18 40|new measurement technique
P07594047T0000|0 6|Effects
P07594592A0755|0 7|Deletion
P07595221A0733|5 9|cells
P07595374A1215|3 9|domains
P07595857A0521|3 16|peak velocities
P07596283A0396|16 21|enzyme
P07596287A0183|3 20|nucleotide sequence
P07596287A1724|3 11|ORF3 probe
P07596558A0824|5 11|results
P07596697A0971|14 34|pancreatic polypeptide
P07597030A0260|15 21|cloning
P07597488T0000|0 19|Hemolytic jaundice due
P07597804A1007|3 13|transcripts
P07598106A0709|0 16|Mean growth changes
P07598303A1728|11 20|few studies
P07599449A0445|3 16|fracture groups
P07599653A0898|18 28|differences
P07600111A0000|3 12|prevalence
P07600986A0605|9 28|immunoprecipitations
P07601078A1003|0 7|Subjects
P07601121A0153|0 7|Analysis
P07601445A0207|16 37|BAT1 translation product
P07601827A0778|7 17|lacZ fusions
P07601828A0095|26 41|characterization
P07603726T0000|0 28|Vestibular adaptation exercises
P07603956A0115|3 20|experimental design
P07604047A0704|1 9|cDNA clone
P07604783A0952|11 28|significant changes
P07604794A0958|0 15|Total cholesterol
P07605990A1110|8 21|further studies
P07606548T0000|0 7|Benefits
P07606587A0266|0 22|Piperacillin-tazobactam
P07607197A1048|0 23|Basal plasma renin activity
P07607213A0140|14 52|anomalous structure/activity relationship
P07607233A0186|3 16|structural gene
P07607342A0703|22 41|experimental evidence
P07607537A0954|13 22|phenotypes
P07607607T0000|0 7|Increase
P07607669A1112|5 18|flanking region
P07608268A0194|21 29|disorders
P07608649A1429|9 21|blood pressure
P07608968A0836|0 7|Analysis
P07609037A0775|11 19|depletion
P07609079A0387|0 14|Transactivation
P07609372A0261|0 5|M.M.C.
P07610052A1064|18 33|complexes similar
P07610324A0319|0 10|Oncological
P07610716A0117|16 31|prevalence values
P07610735A1471|0 8|Diltiazem
P07612174A1064|0 15|Subhuman primates
P07612557A0635|13 20|children
P07614762A0224|3 25|cryptococcal antigen test
P07615541T0000|0 17|Functional analysis
P07615634A0535|5 15|transcripts
P07616056A0278|4 5|mu
P07616563A0532|8 11|CarP
P07616569A0168|11 15|genes
P07616802A0315|11 29|significant increase
P07618280A0550|6 22|nucleocapsid-like
P07618548T0000|3 23|Babcock Surgical Clinic
P07620491T0000|0 8|Resources
P07622058A0411|3 20|PEBP2 alpha proteins
P07622060A0967|2 24|human proliferative cells
P07622521A0418|7 21|previous mapping
P07622932T0000|0 24|Histopathological features
P07623807A0162|14 23|mechanisms
P07623814A1040|2 10|CV-1 cells
P07623821A0649|10 16|factors
P07623821T0000|0 9|Regulation
P07623825T0000|3 40|carboxyl-terminal transactivation domain
P07623838A1112|0 1|D.
P07623840A0352|20 46|synthetase-related sequences
P07623844A0639|14 18|Bcl-2
P07624119A0528|12 15|PAX3
P07624581A0312|3 10|subjects
P07624615A0267|0 12|Acute decrease
P07626378T0000|0 16|Hepatitis B vaccine
P07626469A1341|0 20|Basal promoter activity
P07626806A1098|3 10|RAT3 gene
P07627317A1502|3 4|Al
P07628389A0145|0 24|Tumor necrosis factor-alpha
P07628438T0000|13 34|insulin receptor homolog
P07628451A0114|14 15|RA
P07628456A0000|3 33|double-stranded RNA binding domain
P07629103T0000|0 40|CCAAT/enhancer-binding protein isoforms beta
P07629113A0726|0 2|SCA
P07629122A0323|0 17|Mutational analysis
P07629123A0885|9 23|similar mutation
P07629150A0155|0 9|Expression
P07629163A0770|0 2|NH2
P07629196A0274|30 52|GTPase-deficient mutants
P07630687A0010|46 63|clinical conditions
P07630934A0343|0 4|Harel
P07631267T0001|0 11|Radiotherapy
P07633444T0000|0 21|Structural organization
P07633756A0690|3 21|ARX2 procedure models
P07635140A0172|33 38|enzyme
P07635312A0692|5 15|mutagenesis
P07635572A1153|0 8|CIITA mRNA
P07636179A0000|3 17|normal cell cycle
P07636187A0585|0 9|Consistent
P07636337A0687|5 11|results
P07636408T0000|0 9|Comparison
P07636648A1229|16 37|DTaP booster vaccination
P07636962A1288|18 42|amino-terminal determinant
P07636962A1883b|16 22|fusions
P07636984A1349|16 28|potential role
P07637718A0218|14 26|messenger RNAs
P07638517A0000|4 6|May
P07639106A0678|34 40|best fit
P07639703A1703|2 13|retinoic acid
P07640309A0000|3 28|C-terminal peptide sequences
P07640422A0649|0 12|Thromboxane B2
P07642490A0318|1 9|new vector
P07642538A0138|23 35|RSK activation
P07642538A0744|15 19|C-Lys
P07642544A0868|22 78|human protein-tyrosine phosphatase alpha-overexpressing cells
P07642633T0000|1 17|TATA-less promoter
P07644127A0000|5 25|electrical stimulation
P07644466A0578|23 27|assay
P07644503A0729|11 25|over-expression
P07646439A0535|14 21|proteins
P07647303T0000|3 18|homeobox gene ATK1
P07647570A0713|7 23|likely explanation
P07648338A0815|5 11|results
P07649098A0676|27 47|principal observations
P07650958A0123|3 9|changes
P07651131A1407|0 15|Band-shift assays
P07651141A0265|6 13|terminus
P07651340A0286|0 15|Retransformation
P07651386A0925|30 41|p53 induction
P07651398A0257|2 6|flies
P07651398A0803|1 20|potential binding site
P07651398T0000|14 24|gene product
P07651400A0335|4 13|inhibition
P07651424A0487|0 18|Biochemical analysis
P07651424A0743|2 15|wild-type cells
P07651734A0961|0 19|Northern blot analysis
P07651835A0652|11 33|relative binding affinity
P07652066A0677|16 30|anatomic concept
P07652575A0435|12 25|microinjection
P07652582A0000|0 15|INF-alpha therapy
P07653094A0169|9 36|amino terminal deletion mutants
P07653812T0000|0 40|Intrathecal acetyl cholinesterase inhibitors
P07653892A0306|16 28|isoflurane MAC
P07654239A0698|0 2|Max
P07654712A0774|3 13|yeast enzyme
P07654740A0563|0 7|Key areas
P07655184A0852|36 63|chimeric transmembrane protein
P07655505A0527|6 11|shoots
P07655509T0000|1 48|polymorphic bipartite motif signals nuclear targeting
P07656588A0101|0 29|Comparative DNA sequence analysis
P07657162A1412|14 36|transcription activation
P07657668A0642|0 12|TH-SH3 binding
P07657705A1181|5 11|results
P07658262A0944|0 13|Protein S levels
P07658471A0000|3 19|plant hormone auxin
P07658777A0400|28 35|patients
P07659085A1520|3 50|ubiquitous transcription factor Oct-1 forms complexes
P07659515T0000|1 25|new non-LTR retrotransposon
P07659529A0135|6 21|deletion analysis
P07659746A1464|3 30|CVA16.4 proteolipid transcript
P07659757A0191|0 9|Incubation
P07660712A0118|14 35|specific immune response
P07663138A0835|5 11|nadolol
P07663160A0287|3 22|synthetic DNA sequence
P07663963A1588|0 25|Adrenergic system activation
P07663998T0000|0 19|Transabdominal repair
P07664278A0135|0 1|A.
P07665172A0000|0 19|Transcription factors
P07665187A0208|0 14|Primer extension
P07665187A0824|0 14|Primer extension
P07665477A0901|0 3|EsaR
P07665567A0495|0 15|Sequence analysis
P07665605A1127|3 18|plasmin-derived D
P07665633A0284|3 18|clinical isolates
P07665948A0591|0 8|IgE levels
P07666414A0614|0 24|Tissue-specific expression
P07666415A0000|3 20|nucleotide sequence
P07666523T0000|0 12|Investigation
P07666538A0000|0 9|Initiation
P07666966A0207|0 24|Mean longitudinal extension
P07667097A0267|16 19|p255
P07667195A0146|0 4|L-735
P07667621T0001|0 23|Doppler ultrasound studies
P07668009A0172|5 21|endemic cumlations
P07669351A1278|3 12|properties
P07670504A0834|34 54|diffuse banding pattern
P07670943A0308|21 34|female patients
P07672821A0763|3 17|physical linkage
P07672822T0000|0 15|Genomic structure
P07673128A0989|3 13|third domain
P07673154A0688|3 30|tyrosine-phosphorylated state
P07673178A0982|3 9|results
P07674649A0508|1 49|single-case experimental ABAB multiple baseline design
P07675445A0463|5 10|clones
P07675449A0848|5 24|glioblastoma cell line
P07676492A1000|29 35|reports
P07676587T0000|0 22|Veterinary certification
P07676655A0214|3 20|serum concentration
P07677573A0000|1 22|significant correlation
P07677715A1076|3 11|TAF factor
P07677836A1356|0 23|Diffuse white matter injury
P07678006A0472|0 22|RNase protection analyses
P07678006A0901|0 5|Little
P07678051A1303|3 14|PDGFR mutants
P07678242A0473|8 24|direct correlation
P07678593A0708|14 18|clone
P07678602A0153|22 42|B lymphoblast cell lines
P07678695A0604|3 19|ectopic expression
P07679390A0721|0 14|RNase protection
P07679836A0387|5 11|results
P07680035A0221|3 7|roles
P07680120A1008|0 5|RT-PCR
P07680629T0000|0 15|Molecular cloning
P07681147A1420|0 36|Two-dimensional phosphotryptic analyses
P07681513A0000|0 9|Piroximone
P07681539A0000|0 17|Cytogenetic studies
P07682842A0294|18 43|different fMLF-R transcripts
P07682842A0771|3 11|first exon
P07683131A0885|3 18|genomic structure
P07683375A0000|19 25|effects
P07685263A0503|8 30|polymerase chain reaction
P07685823A1234|0 12|RNA polymerase
P07685874A0258|0 13|Salivary sodium
P07686619A0704|0 3|Chem
P07687320A0526|0 23|Recombinant plasmid pFV100
P07687541A0200|22 60|temperature-sensitive fission yeast mutant
P07687541A0992|5 9|RCC1p
P07687745T0000|3 24|immunosuppressant FK506
P07688112A0274|0 22|Prostate specific antigen
P07689154A0168|0 21|Protein phosphorylation
P07689501A0420|7 14|carriers
P07691837A1359|7 8|bp
P07691885T0000|0 13|Identification
P07692366A0000|0 9|BACKGROUND
P07692668A0326|2 44|abundant 1.1-kb virion-sense polyadenylated RNA
P07692754T0000|0 10|Risk factors
P07693132A0100|7 13|cloning
P07693372A0115|25 30|fungus
P07693672A0259|0 4|DNase
P07693699A0831|25 49|nucleotide binding function
P07693708A0000|0 40|Insulin-like growth factor-binding protein-2
P07693967A0905|16 17|RV
P07693975A1418|14 21|proteins
P07693975T0000|0 19|Reverse transcriptase
P07695629A0489|13 40|mck1 mds1 mrk1 triple disruptant
P07696183A0567|21 30|properties
P07696450A0271|0 7|PATIENTS
P07696878A0222|3 16|leader sequence
P07697294A0329|1 11|small amount
P07698219A0551|0 11|Cell adhesion
P07698727A0386|2 17|local destruction
P07699632A0522|8 23|mixed race persons
P07699632A0715|3 28|data complement other studies
P07699845A0537|0 20|Clinical studies SY5555
P07700361A0125|8 31|most SH2-pTyr interactions
P07701266A0808|0 6|RESULTS
P07702327T0000|0 30|Experimental adhesion prophylaxis
P07702378A0668|23 30|children
P07702752A0545|16 24|sequences
P07702808A0427|0 26|Within-subject BP differences
P07704040A0000|27 39|mouse NMO1 cDNA
P07704273A0000|15 20|JRG582
P07704456A1014|22 33|acceleration
P07704689T0000|0 20|Solitary thyroid nodule
P07704730T0000|0 16|Male contraception
P07705476A0292|5 19|daily food intake
P07705627A1107|13 15|Mad
P07706273T0000|0 24|Transcriptional regulation
P07706287A0698|11 19|inability
P07706291T0000|2 12|E box element
P07706299A0563|0 15|Inhibition assays
P07706307A0914|3 19|amino acid sequence
P07706396T0000|0 8|Mutations
P07707523A0704|5 9|cells
P07707531A0550|4 21|experimental design
P07707544T0000|0 27|Immediate-early transcription
P07708058A0178|3 5|GRE
P07708488A0151|16 22|results
P07708497A0000|0 24|Transcriptional activation
P07711667A0766|1 20|multivariate analysis
P07711730A0000|0 28|Carnitine palmitoyltransferase
P07713421A1435a|20 42|gain-of-function mutants
P07713421A1435b|20 42|gain-of-function mutants
P07713936A0393|0 6|Binding
P07714608A1252|2 23|significant differences
P07714758A1193|0 12|Blood pressure
P07715200A0000|0 16|Anesthesiologists
P07715602A1088|17 32|gene cluster codes
P07715922A0188|49 71|corneal endothelial cells
P07717823A0328|0 23|Standard reference sources
P07719527T0000|0 16|Weak allergenicity
P07720572A0701|15 26|myoD promoter
P07720572A1584|9 23|clear difference
P07720709A0755|5 30|Ki-ras-transformed 3T3 cells
P07720710A0861|3 5|Oct
P07721074A0766|0 15|Atopic dermatitis
P07721422A0241|0 25|Primer extension experiments
P07721878A1163|3 13|beta subunit
P07723247A0187|10 19|mechanisms
P07723247A1161|7 20|hour incubation
P07724452A0344|4 19|dietary treatment
P07728201A0660|11 24|recent evidence
P07729427A0942|0 15|Deletion analysis
P07730273A1309|3 6|NarX
P07730328A0000|0 23|Vascular endothelial cells
P07730336A0606|7 11|ATF-1
P07730337A1439|3 8|Ng/RC3
P07730337T0000|0 8|Structure
P07730795A0104|3 20|amino acid sequences
P07731686A0000|3 11|TTG-2 gene
P07731898A0823|7 13|studies
P07733075A1200|0 11|Short therapy
P07735590A0990|18 29|mite allergen
P07735833A1078|0 10|CONCLUSIONS
P07737024A1003|0 19|Whole bowel irrigation
P07737118A0317|3 22|MPS1 open reading frame
P07737508A0649|4 5|Tb
P07737944A0000|0 25|Hematopoietic growth factors
P07738026A0216|56 60|forms
P07738839A0173|6 14|IC breaths
P07739382A0457|0 19|Phylogenetic analyses
P07739520A1250|2 9|homologs
P07739542A1419|20 26|cyclin E
P07739544A0364|12 28|amino acid sequence
P07739566A1076|10 33|Pax-6-BSAP fusion proteins
P07740487A0167|12 30|possible association
P07740490T0000|10 18|estrogens
P07741255A0194|8 16|districts
P07742024A0121|11 18|symptoms
P07742363A0135|3 18|mammalian enzymes
P07742363A0941|1 9|triple Ser
P07742550A0407|3 7|cases
P07742917T0001|0 6|Icterus
P07743472A0181|0 13|Female patients
P07743515A0223|17 34|tissue distribution
P07743697A0703|0 3|Data
P07744763A0514|0 14|Binding activity
P07744776A0617|0 17|Transcript analysis
P07744846A1006|0 7|Analysis
P07744954A0418|23 49|central alpha-helical portion
P07745008A0892|0 17|Radioligand binding
P07745311A0264|0 8|Diagnosis
P07745684T0000|0 22|Human papillomavirus type
P07745685A1442|14 20|virions
P07745693A0914|0 6|Studies
P07745696A0932|0 25|Restriction mapping analysis
P07745726A0960|3 31|replication reporter constructs
P07745726A1496|36 50|18-bp palindrome
P07746397A0233|0 6|METHODS
P07746794A0000|17 47|available intravenous formulation
P07746937A0100|0 16|Lung function tests
P07747462A0332|0 18|Sequence comparisons
P07748451A0343|3 25|mean marginal discrepancy
P07748493A1045|16 29|Aplysia Afurin2
P07748502A0794|0 3|Rats
P07748848A0263|3 38|term endovascular papillary haemangioma
P07748952A0462|14 30|internal promoters
P07748952A1329|5 11|results
P07749088A0119|0 9|Coronary T1
P07749461A0632|4 5|kb
P07749461A1022|0 17|Functional analysis
P07750217T0000|0 23|Indium-111 OncoScint CR/OV
P07751848A0222|3 31|carnitine palmitoyltransferase
P07752223A0960|3 7|Myc LZ
P07752454A0341|23 25|CNS
P07752644A1031|5 15|VF resistant
P07752886A0595|3 30|smallest active FecR derivative
P07753027A0240|3 20|gene pairs psbB-psbT
P07753030A0173|0 19|Hybridization signals
P07753796A0625|12 28|amino acid sequence
P07753796A0743|0 9|Expression
P07753837A0724|4 6|RNA
P07754713A0227|10 13|NUC1
P07755884A0000|0 18|Intrastriatal grafts
P07755914A0000|0 8|OBJECTIVE
P07757315A1227|14 24|aggregation
P07758167A1488|0 11|Growth curves
P07758246A0469|28 30|bps
P07758459A1277|3 5|UAS
P07758837A1118|28 43|regulatory region
P07759094A0634|1 23|polymorphic dinucleotide
P07759525A0417|3 10|proteins
P07759529A0288|9 18|approaches
P07760790A0327|0 13|Serum induction
P07760819A0731|10 19|activation
P07760841A0221|0 3|UAS1
P07760841A0647|17 44|ADH2 upstream regulatory region
P07760844A0413|0 8|Induction
P07761091A0294|0 11|Inactivation
P07761216T0000|0 31|Short-course amphotericin B therapy
P07761420A0909|12 29|45Ca-binding assays
P07761434A1084|5 8|AP-1
P07761467A0666|3 15|second complex
P07762431A0356|32 35|cDNA
P07762504A0648|40 53|oral amiodarone
P07763727A1035|0 13|Plasmids pAMS12
P07765118A0967|3 18|maximum induction
P07766885A0405|11 26|polypeptide chain
P07767011A0689|0 5|Repair
P07768824A0167|11 27|fla gene expression
P07768836A1126|0 25|Primer extension experiments
P07768848A1880|0 11|Polypeptides
P07768898A0492|19 24|values
P07768953T0039|0 3|EEA1
P07770033A0978|0 18|Nucleotide sequences
P07771671T0000|44 59|carbon electrodes
P07771745A0442|0 8|Elevation
P07772036A1000|18 41|ubiquitous nuclear factors
P07774137A0000|3 17|potential impact
P07774807A0405|3 14|bHLH proteins
P07774925A0084|0 2|YAC
P07775428A0172|11 16|clones
P07776685A0000|20 30|feasibility
P07776711A0295|0 7|MATERIAL
P07776882A0000|3 14|present study
P07776979A0702|11 17|COUP-TF
P07777518A0483|0 12|DNA sequencing
P07779558T0000|0 19|Muscle GSH-Px activity
P07779811A0901|0 7|Mutation
P07779812A0000|3 11|c-myc gene
P07780148A1153|11 13|PML
P07780525A0495|0 8|Schooling
P07780719A0477|16 31|diastolic driving
P07780738A0091|8 11|Cdks
P07782087A0559|14 46|minor transcription initiation sites
P07782113A0726|3 20|roxithromycin doses
P07782302A0479|25 38|DEDDDL sequence
P07782775A0889|11 14|ORFs
P07783064A0452|0 25|Serial followup strength data
P07783641A0591|0 3|CodY
P07783822A0000|0 8|OBJECTIVE
P07784061A0894|6 28|most other small G proteins
P07784078A1064|34 47|gene expression
P07784079A1018|0 11|Transfection
P07784197A0827|0 16|Cytosolic extracts
P07784199A0000|3 18|ribosomal protein
P07784870A0119|3 20|provisional reports
P07784942T0001|11 24|thrombomodulin
P07786820A0284|0 5|CPT-11
P07786821A2292|0 9|CONCLUSION
P07787179A0312|3 12|bp fragment
P07789275A0325|20 20|s
P07789342A1352|11 29|extracellular domain
P07789396A0504|0 7|Lipiodol
P07789809A1246|9 20|Western blots
P07789971A0758|12 23|other regions
P07790271A1185|11 18|lens dose
P07790377A0561|0 9|Antibodies
P07790719A0098|8 21|national effort
P07791760A0424|0 12|GnRH treatment
P07791763T0000|0 15|Molecular cloning
P07791764A0357|26 37|Jurkat T cells
P07791768A0930|16 34|cell cycle regulators
P07791769A0826|0 3|ICP4
P07791771A0183|0 3|Otte
P07791776T0000|0 15|Characterization
P07791783A0000|0 14|SRY-related cDNA
P07793783A0189|0 9|Scalp flaps
P07794556A0000|5 10|Center
P07795104T0000|0 4|Risks
P07795576A0126|0 10|Examination
P07796935A0284|13 28|inhibitory effect
P07797077A0842|3 33|amino-terminal DNA-binding domain
P07797346T0000|2 9|outbreak
P07797476A1001|3 14|RAP74 subunit
P07797583A0222|15 38|various base substitutions
P07798134T0000|3 17|hsp70 gene family
P07798207A0759|10 27|amino acid sequences
P07798217T0000|1 24|secondary phosphorylation
P07798217T0095|8 31|glycogen synthase kinase-3
P07798271A0330|4 13|last region
P07799437A0656|0 10|Other assays
P07799925A0526|0 13|Reconstitution
P07799931A0287|36 57|transcriptional control
P07799931A1232|12 29|Maf-related protein
P07799939A0628|3 16|27-base element
P07799948A0777|11 18|deletion
P07799950A0282|2 8|studies
P07800479A0201|3 11|first gene
P07800505T0000|0 15|Characterization
P07801180A0197|21 30|advantages
P07802355T0000|0 15|Comparative study
P07802655T0000|0 15|Characterization
P07803809A1852|0 13|Further studies
P07806492A1162|15 23|cucumisin
P07806507A0121|0 18|Molecular dissection
P07806532A0659|0 11|Protein cHMGI
P07806651A0097|37 50|racial identity
P07806820A0091|9 16|elevated
P07807002A0500|9 16|segments
P07808210A1510|3 25|negative predictive value
P07809128T0000|0 16|Oncogenic capacity
P07809410A0606|11 15|cases
P07811639A0222|0 16|Endo16 transcripts
P07811964A1252|1 34|unique leucine-proline repeat element
P07812450A0849|7 13|full ORF
P07813466A0074|3 10|U14 genes
P07813786A0641|3 14|related cDNAs
P07814321A0850|0 7|Deletion
P07814323A0313|0 8|Inclusion
P07814388A0662|2 22|broken L-cell membranes
P07814403A0433|0 3|Chem
P07814405A1170|6 14|first time
P07814717A0669|0 7|Increase
P07815546A0411|0 4|Virol
P07815811A1487b|0 23|Coronary vasoconstriction
P07816025A0196|0 9|Comparison
P07816049A0686|0 5|Atcys1
P07816049A1157|0 35|Southern blot hybridization experiments
P07816617A0763|5 11|results
P07816619A0000|20 48|Arabidopsis thaliana cDNA clones
P07816619A0872|32 46|Dr1-like protein
P07816630A1333|25 26|bp
P07816808A1102|27 35|STR family
P07818416A0895|3 5|pre
P07819225A1094|19 31|acidic residue
P07820057A0000|0 23|Tumor necrosis factor alpha
P07821790A1084|12 16|UCRBP
P07822161A1172|13 23|monkey opsin
P07822329A0773|21 30|ubiquitous
P07822333A0376|0 3|Chem
P07823919A1422|11 20|activation
P07823951A1100|5 11|results
P07823953A0777|15 33|I kappa B alpha mutants
P07823964A0922|3 28|negative regulatory activity
P07824325A0714|2 15|different times
P07824464A0169|0 23|On-line angioscopic images
P07824657A1456|11 27|cysteine formation
P07824726A0454|25 33|subgroups
P07825888A0715|10 18|subgroups
P07826412T0112|1 13|new hypothesis
P07826625X0000|0 14|Basal components
P07828584A0681|0 10|Mutagenesis
P07828600A0095|0 6|Binding
P07828811A0556|20 38|regulated G1/S arrest
P07828824A0307|0 8|Mutations
P07828852A0153|19 27|telomeres
P07829057A1097|3 14|marker orders
P07829057T0000|0 24|Integrated mapping analysis
P07829097A0000|16 20|DXS52
P07829102T0000|0 15|Haplotype mapping
P07829519A1251|4 14|utilization
P07829554A0257|29 63|systemic humoral immune system response
P07830112A0532|27 29|PFR
P07831310A0000|1 28|genetic complementation system
P07831799T0000|0 17|Nucleotide sequence
P07831829A1324|0 9|Comparison
P07832086A1023|3 17|drug sensitivity
P07832779A0719|0 14|Deglycosylation
P07834582A0115|0 16|Dietary supplement
P07835088A0238|3 8|HSD3B1
P07835214A0603|12 22|prevalences
P07835273A0000|0 33|Insulin-stimulated glucose transport
P07835273A0411|29 38|adipocytes
P07835710T0000|0 19|Intron-exon structure
P07835826A0195|0 7|Fraction
P07835886A0894|3 17|kallistatin gene
P07835888A0402|3 7|locus
P07836218A0128|4 10|studies
P07836228A1052|2 25|interatrial communication
P07836364A0000|0 3|Self
P07836390A1152|3 17|characteristics
P07836406A0884|0 10|Isoelectric
P07836471A0375|10 24|protein sequence
P07838156A0789|8 28|cotransfection studies
P07840643A1006|16 49|Flavobacterium glycosylasparaginase
P07841230T0000|0 11|Dissociation
P07841663A0685|0 18|Superoxide dismutase
P07841663A0845|5 11|studies
P07844142A0640|0 15|Molecular cloning
P07844155A0327|25 59|receptor-linked tyrosine phosphatases
P07844201T0000|0 11|Sex selection
P07844425A0289|3 10|students
P07844555A0406|20 41|E mu pim-1 transgenic mice
P07845672A0368|0 9|Comparison
P07846153A0403|0 9|Chrispeels
P07846163A0422|3 7|mRNAs
P07846199A0000|11 17|ethanol
P07846942A0717|0 18|Digitalis glycosides
P07846942T0001|0 17|Atrial fibrillation
P07847036A0353|6 10|doses
P07848358A0254|15 47|aspartate aminotransferase activity
P07851643A1365|10 16|studies
P07851758A0330|0 23|Physical analysis maps SAL6
P07852037A0548|15 41|DCT method yields reliable data
P07852361A0868|0 6|Removal
P07852400A0519|0 26|Rho GDP/GTP exchange inhibitor
P07853448A0601|1 9|major task
P07853476A0159|0 6|Schnell
P07853488T0000|0 12|Encapsidation
P07853524A1944|0 6|Removal
P07854130A1387|16 19|PilE
P07854130T0000|3 17|pilE gene product
P07854324A0281|12 33|functional conservation
P07854324A0742|19 23|clone
P07856102A1616|21 35|phosphorylation
P07857086A0949|15 15|%
P07857163A0551|13 30|6-fluoroquinolones
P07857344A0591|5 13|half-life
P07857762A0611|3 18|MAP kinase cascade
P07858986A0310|1 16|comparative study
P07859238A1150|2 19|serious side effects
P07859301A0325|24 40|DNA-binding domain
P07859371A1246|0 14|Specific binding
P07859665A0498|3 12|mean jitter
P07859739T0000|0 3|Lack
P07859777A0000|0 27|Recombinant human serum albumin
P07860208A0000|26 42|interleukin-1 beta
P07860646A1363|25 39|considerable use
P07862092A0302|17 21|clone
P07862108A0987|0 25|UV cross-linking experiments
P07862129A1391|2 18|acute-phase livers
P07862141A0317|14 36|loss-of-function alleles
P07862141A1412|22 25|RFX1
P07862150A0429|4 9|mutant
P07862154A0340|0 6|Cloning
P07862162A0408|15 22|inositol
P07862165A0184|10 23|monkey COS cells
P07862168A0000|3 13|interleukin
P07862533A0000|3 7|Wilms
P07863047A0229|0 9|OBJECTIVES
P07863619A0098|23 29|contour
P07863992A0908|12 19|patients
P07864652A0753|0 9|Constructs
P07864652A1901|19 40|lipoyl domain constructs
P07864709A0324|0 6|METHODS
P07865129A0293|16 22|ATF/CRE
P07865786A0457|0 13|Gene expression
P07865787A1086|3 9|results
P07865876A1292|3 27|tissue-specific expression
P07865888A1309|12 30|mammalian cells PBP74
P07865895A0896|3 18|second experiment
P07865917A0191|0 8|Treatment
P07867604A1777|3 9|results
P07867622X0000|0 13|Promoter region
P07867944A0365|0 7|Upstream
P07869721A0000|40 51|closing phase
P07869913A1076|6 19|ISO+AT infusion
P07869937A1142|16 33|kilogram body weight
P07870305A1015|2 72|nucleus ventralis anterior thalami-nucleus ventralis lateralis thalami neurons
P07871718A1132|8 16|inclusion
P07871721A0000|3 23|first open reading frame
P07871721A0392|4 21|sequence alignments
P07871754A0857|37 54|important mechanism
P07871755A0521|16 19|VLPs
P07871757A0846|0 7|Analysis
P07871891A0227|0 4|SUP46
P07872673A0332|12 33|functional relationship
P07872788A1717|3 12|high degree
P07873631A0114|3 9|regions
P07873831T0000|0 29|Secondary pancreatic involvement
P07873876A1035|3 11|NR2 hybrid
P07874060A0810|0 4|TDEYA
P07875595A0910|4 9|humans
P07876134A0348|16 31|characterization
P07876191A0808|0 9|Expression
P07876192A0443|2 9|ICE gamma
P07876194T0000|0 10|Endocytosis
P07876210A0275|35 44|eukaryotic
P07876210A0751|0 7|Mutation
P07876300A0994|3 20|p97-depleted nuclei
P07876562A1646|1 16|potential outcome
P07877308A1175|3 14|full protocol
P07877619A1284|22 45|cell-specific suppression
P07878029A0721|10 14|CBF-A
P07878040A0505|11 29|homologous sequences
P07879204T0000|0 14|OKT3 prophylaxis
P07880442A0236|3 41|major PKC beta transcription initiation site
P07880449A0091|21 40|low dose X-rays effects
P07880650A0493|1 20|quantitative analysis
P07881077A0195|0 29|Supplementary Phase Contraste RSE
P07883167A0157|2 6|yeast
P07883168A0090|0 8|Mutations
P07883193A0000|1 11|DNA fragment
P07883754A0993|5 24|gel retardation assays
P07885999A0000|0 20|Several nuclear factors
P07886610A0000|46 53|patients
P07887226A0858|16 28|serum ferritin
P07887859A0315|10 28|consecutive patients
P07887859A0998|0 15|TcPO2 measurement
P07888156A0169|12 29|University Hospital
P07888156T0000|0 12|Current status
P07888306A1659|0 9|Expression
P07888623A0721|0 12|PMEK1 displays
P07888629A0344|0 10|Translation
P07888788A1010|18 33|hypersensitivity
P07888828A0765|43 54|RH-like genes
P07890485A0827|4 21|steady illumination
P07890599A0132|17 32|mouse cDNA library
P07890674A0916|3 10|catenins
P07890680A1193|18 34|core DNA polymerase
P07890740A0997|3 10|PSD2 gene
P07891638T0000|0 20|Computerized detection
P07891685A1051|5 11|results
P07891708A0690|4 6|Epo
P07891708A1192|12 36|hypoxia-induced expression
P07891709A1542|5 16|observations
P07891713T0000|0 15|Small Maf proteins
P07891720A0818|17 23|binding
P07892076A0578|0 7|Survival
P07892353A0667|4 10|factors
P07894021A1130|36 38|DS2
P07894359T0000|0 21|Glomerular hemodynamics
P07894761A0000|12 29|retrospective study
P07896088A0720|16 29|C-terminal tail
P07896291A0693|42 55|cytogenetic map
P07896615A0554|17 24|skin flow
P07896817A0204|0 7|Proteins
P07896846T0000|22 29|isoforms
P07896852T0000|0 10|Involvement
P07897359A0354|3 11|wild-type
P07897696A0000|0 45|Erythrocyte delta-aminolevulinic acid dehydratase
P07898178A0849|3 14|relative risk
P07898275A0254|5 11|classes
P07898589T0000|4 15|tobacco issue
P07898840X0000|0 17|Pregnancy screening
P07899581A0000|14 39|Ca entry blocker nitrendipine
P07899634A0000|0 6|PURPOSE
P07900915A0000|38 58|gastrointestinal tract
P07901121T0000|0 22|Cooperative dimerization
P07901125A0416|20 29|high degree
P07902532A0312|29 34|BOX DNA
P07902532A1655|0 15|Deletion analyses
P07902583A0545|0 7|Analysis
P07903099A0918|15 31|unusual transcript
P07903670A1202|3 14|mutant allele
P07905413A0585|6 21|chronic treatment
P07905453A0281|0 6|Results
P07906265A0897|0 21|Preliminary experiments
P07906616A0191|6 30|electromyographic response
P07907846A0623|0 4|Group
P07908012A0678|27 41|LNNB performance
P07908187T0000|0 3|ISIS
P07908827A1200|8 25|specific antibodies
P07909936A0672|3 26|present treatment strategy
P07910716A0359|3 14|study cohorts
P07910946A0323|0 7|Analysis
P07911736A1715|5 7|MTD
P07912123A0711|0 37|Mitogen-induced lymphocyte proliferation
P07913080A0564|1 40|decanucleotide promoter sequence homologous
P07913891A0174|11 17|targets
P07913926A0878|0 15|Northern analysis
P07914192A0211|0 22|HER2 overexpressing cells
P07914192A0844|0 14|Gel-shift assays
P07914507A1029|0 9|Comparison
P07914700A0000|13 48|RNA-dependent eIF-2 alpha protein kinase
P07915144A0000|0 34|High-frequency electrical stimulation
P07916003A0688|0 6|Similar
P07916326A0000|0 28|Detailed molecular organization
P07916327A0250|15 21|cloning
P07916577A0190|15 37|potential candidate genes
P07916588A0471|21 38|South African strain
P07916685A0455|23 44|arogenate dehydrogenase
P07916689A0312|11 20|POT1 clones
P07916689A1407|3 29|Y. lipolytica genomic POT1 gene
P07916729T0000|1 19|leucine zipper domain
P07916983A0623|17 18|CT
P07917016A0581|12 22|DNA-binding
P07917540A0000|2 9|patients
P07918097T0000|3 31|novel Notch homologue mouse Notch
P07918128A0000|0 9|BACKGROUND
P07918494A1163|39 49|thioredoxin
P07919540A0240|5 22|genetic alterations
P07919540A1119|18 21|exon
P07922709T0000|0 19|Biological activities
P07925022A0285|0 9|Expression
P07925097A1205|0 22|Immunoreactive AR content
P07925282A0705|0 9|Disruption
P07926729A0000|0 17|Genetic alterations
P07926739A0766|3 19|expression pattern
P07926748A0383|0 3|NOT4
P07926749A0471|7 19|site selection
P07926774A0652|3 25|p73pct1/p85cdc10 complex
P07926775A0895|15 21|stripes
P07926789A0960|3 21|DNA sequence adjacent
P07927130A0625|0 30|CMV hyperimmunoglobulin treatment
P07927267T0000|0 22|Internal biliary drainage
P07927711A0698|0 2|ORF
P07927838A0000|7 12|groups
P07928954A0545|0 18|DNA sequence analysis
P07929165T0000|0 10|DNA sequence
P07929238A0734|6 13|Genomics
P07929411A0087|25 43|polypeptide sequence
P07929431A0949|0 7|Plasmids
P07929559A0000|0 16|Cytoplasmic dynein
P07929560T0000|0 13|Identification
P07931490A0237|0 7|PATIENTS
P07932095A0000|4 33|new naphthalene related compounds
P07932943A0113|52 68|awareness strategy
P07933066T0000|8 27|exclusive interaction
P07933076A0211|18 22|EBNA2
P07933095A0000|22 26|v-Rel
P07933101A0131|0 14|Previous studies
P07933107A0991|16 33|nucleotide sequence
P07933116A0412|3 9|p55 mRNA
P07934331T0037|1 18|simple registration
P07934666A0158|3 25|transverse magnetization
P07935094A0516|0 6|RESULTS
P07935370A0000|26 28|CD4
P07935375A1197|0 9|Expression
P07935379A0347|8 27|tTG-transfected cells
P07935383A0108|7 37|RNase H-mediated mapping technique
P07935395A0094|22 24|kDa
P07935415T0000|0 24|Tissue-specific expression
P07935418A0447|6 16|v-erbA probe
P07935426A0714|12 19|isoforms
P07935447A0972|17 30|direct evidence
P07935451T0000|0 27|Human T-cell leukemia virus type
P07935468T0000|0 9|Activation
P07935471A0613|7 38|endogenous HSF DNA-binding activity
P07935472A0276|0 8|Enhancers
P07935472A0790|3 28|predominant binding activity
P07935491A0495|5 15|RZR subtypes
P07935491A1182|19 34|response elements
P07935577A0305|0 8|Treatment
P07935626A1249|3 20|unexpected presence
P07935997A0000|3 12|parameters
P07936635A1134|0 7|Mutation
P07936640A0900|12 18|binding
P07936650A0656|15 23|subdomain
P07936650A1752|17 24|new model
P07937106A0100|3 15|v-ets oncogene
P07937108A0325|12 26|functional mRNAs
P07937112A0220|3 20|individual subunits
P07937127A0645|34 69|strong enhancer-type activation domains
P07937132A0819|11 13|U21
P07937147A0205|1 13|genetic system
P07937656A0182|0 28|Univariate statistical analysis
P07937841A0790|5 11|results
P07937954A0612|0 2|HBx
P07937965T0000|0 3|Role
P07938137A0384|3 8|groups
P07941174T0001|0 11|Laser therapy
P07941739A0000|5 14|kb fragment
P07941750A0344|11 20|homologous
P07942076A0497|14 36|estradiol concentrations
P07942448A1227|10 17|patients
P07942722T0000|0 11|Constipation
P07943556A0694|5 11|persons
P07944461A0321|0 5|TG-day
P07944542T0000|0 17|Vibrio cholerae O139
P07945134A0079|3 12|volunteers
P07945330A0103|4 18|differentiation
P07945937A0358|0 15|Sequence analysis
P07947930A0499|3 12|fibrinogen
P07948129A0297|7 13|vectors
P07948921A0051|0 5|Optima
P07949137A0000|11 36|acute leukemia adult patients
P07949137A0532|3 22|pretransplant regimen
P07949164A0799|3 23|site-directed mutation
P07949205A0286|10 23|testololactone
P07949551A0000|0 2|Use
P07949770T0000|8 29|hepatic portal blood flow
P07951410A0647|3 6|HeLa
P07951410A1332|0 16|E1A autoactivation
P07951874A0320|0 14|Cestode invasion
P07953785A0648|6 17|heat exposure
P07954475A0714|0 7|Analyses
P07954891T0000|0 3|ERV1
P07956578A0851|0 14|Lesion diameters
P07956869A0000|37 54|breast cancer tissue
P07957085A0207|0 3|Cbf3
P07957106A0471|38 57|GST-POU fusion protein
P07957106A0875|5 13|mutations
P07957158A1532|13 26|filtration rate
P07957243A1316|13 20|residues
P07957559A1557|8 16|rapamycin
P07957632A0000|0 24|Intraventricular injection
P07958446A0000|3 27|hepatocyte nuclear factor-3
P07958865A1152|0 20|Homozygous null embryos
P07958898A1050|14 23|dTFIIA-L/S
P07958911A0500|1 26|strong trithorax binding site
P07958915A1507|13 19|changes
P07958920A1157|0 9|Antibodies
P07959011A0379a|0 9|C/EBP alpha
P07959011A0379b|0 9|C/EBP alpha
P07959015A0478|3 9|results
P07959734A0194|2 11|human brain
P07959760A0763|3 22|centromeric YAC contig
P07959952A1446|1 4|cDNA
P07959953A0423|0 4|IFI16
P07960608A0228|0 6|Courses
P07960796A0154|0 9|Peter Elfer
P07961545A1314|0 17|Other adverse events
P07961755A0474|0 7|Homology
P07961957A1565|44 48|TEF-1
P07961958T0000|0 24|Rat kidney carboxylesterase
P07963540A0795|0 23|Recombinant I-kappa B alpha
P07963782A0000|14 30|chemical stability
P07964162A0941|10 19|mechanisms
P07964458A0179|1 13|candidate gene
P07964459A0845|4 8|motif
P07964624A0491|3 9|P131 ORF
P07964770A0172|15 22|patients
P07964814T0000|0 29|Elementary visual hallucinations
P07964918A0000|14 35|patient-related factors
P07965152A0764|0 7|Segments
P07966565A0901|21 24|mRNA
P07966583A1268|0 21|Transient transfections
P07966602A0130|0 6|Roizman
P07966873A0693|0 7|Articles
P07967360A1048|3 13|present data
P07967725A0262|3 18|nuclear receptors
P07968409A0123|23 43|HIV-infected-patients
P07969115A0000|7 32|organello footprint analysis
P07969116A0196|3 14|Nur77 protein
P07969132A0268|10 17|plasmids
P07969135A0913|21 34|Cln2 PEST domain
P07969136A0273|0 33|Electrophoretic mobility shift assays
P07969152A0721|9 59|carboxyl-terminal HSF transcriptional activation domain
P07969181A0313|22 31|high levels
P07969954T0000|0 29|Distal lower motor neuron syndrome
P07971282A0000|0 20|Regulators responsible
P07971709A0907|1 22|normal systemic response
P07972012A0956|1 20|full-length cDNA clone
P07972237A0665|1 29|high-resolution restriction map
P07972831A0563|0 10|PAI-1 levels
P07973364A0325|5 18|present article
P07973397T0001|0 12|Determination
P07973825A0445|3 15|recovery value
P07975763A0000|15 29|hepatitis C virus
P07975882T0000|0 18|Human adenovirus type
P07977239A1283|0 17|Outflow obstruction
P07977648A0880|0 9|Sequencing
P07978229T0000|2 20|unusual complication
P07978406A0998|5 12|ISO group
P07979810A0340|17 26|parameters
P07979827A0722|0 6|KRN2391
P07980440A0138|2 22|H4IIE rat hepatoma cells
P07980468A0298|0 3|Acta
P07980669A0373|0 19|Basal plasma AVP levels
P07981143A0633|12 22|nucleotides
P07981246A0112|3 15|previous study
P07982964A1017|0 2|ATX
P07982995A0000|11 32|site-specific mutations
P07983011A0617|0 15|Sequence analysis
P07983704A0330|0 3|Type
P07983712A0914|45 55|same plasmid
P07983715A0996|0 13|Point mutations
P07983716A1082|13 20|Northern
P07983744A0920|13 24|nuclear forms
P07984088A0592|0 12|Transcription
P07984105A1509|11 25|complementation
P07984261A0536|3 6|ICBF
P07985305T0001|14 27|hydronephrosis
P07987924A0670|3 14|inflation hub
P07988559A0836|3 14|other element
P07988730A0220|3 23|basal promoter strength
P07988731A0002|58 75|inducible promoters
P07988731A1301|27 30|GF14
P07988945T0000|0 22|New diagnostic strategies
P07990136A1124|21 47|selectivity arrest elongation
P07991437A1032|0 10|Propafenone
P07991582A1023b|0 17|Mutational analysis
P07992027A0485|1 8|patients
P07993559A0233|1 11|recent index
P07994021A1223|0 18|Alternative splicing
P07995173A0585|0 7|Transfer
P07995910A0119|32 42|specificity
P07997174A0936|27 41|phosphorylation
P07999066A0238|9 14|HIV tat
P07999363A0000|6 15|variations
P07999604A0139|16 27|such patients
P07999982A0086|0 24|Cumulated maximum lod scores
P07999995A0000|1 26|receptor-like protein kinase
P08000074A0162|28 28|%
P08000112T0000|0 10|Goodpasture
P08000427A0000|1 13|cDNA clone pCZ1
P08000497A0179|0 6|METHODS
P08001136T0000|0 11|Relationship
P08001792A0284|3 6|git1
P08001966A0563|5 15|same regions
P08002564A0249|0 18|DNA sequence analysis
P08002857A1070|0 10|CONCLUSIONS
P08003700T0000|0 20|Differential screening
P08004442A0265|3 9|effects
P08005230A0222|9 26|reporter gene system
P08005412A0608|16 34|white gene expression
P08005438A1185|0 4|SPP41
P08006101A1142|0 35|Standard curve correlation coefficients
P08006772A0000|8 20|pulse oximeter
P08006773A0836|22 41|plasma concentrations
P08007835A0538|1 14|causal analysis
P08007954A0374|0 14|Deletion studies
P08007975A0000|3 10|IPL1 gene
P08011017A0169|8 23|oxygen saturation
P08011166A0207|3 26|complete gene organization
P08012448T0000|0 3|INO2
P08012566A0254|3 29|pentafluorobenzyl derivative
P08013348A0143|0 12|Mammalian ABPs
P08013457A0342|0 10|Src homology
P08014228A0278|0 14|Sample treatment
P08014377A1277|12 21|conditions
P08014919A0530|4 17|proprioceptive
P08015672A1282|2 16|control patients
P08015850A1076|1 20|more complete analysis
P08016102A1238|13 31|regulatory sequences
P08016189A0741|0 10|Granisetron
P08017290A1347|3 39|femoroarterial coronary sinus difference
P08018361A0636|22 42|thermal neutron fluency
P08020702A0000|0 10|Endotoxemia
P08020702A0137|32 57|lipid A monoclonal antibodies
P08020806A0187|44 51|patients
P08020962A1226|24 33|V beta locus
P08020965A0465|12 24|genomic region
P08021175A0486|3 20|pexB upstream region
P08021177A0000|3 11|fepA-entD
P08021225A0000|0 15|Sequence analysis
P08022212A0071|25 37|two-frequency
P08023662T0000|0 24|Intraoperative measurement
P08024139A0393|47 58|equal volumes
P08025074A0000|21 25|nylon
P08025669A0724|3 10|proteins
P08028671A0687|16 29|microinjection
P08029001A1020|5 11|results
P08029334T0000|0 6|Cloning
P08030239A0833|20 32|truncated form
P08030243A1011|12 39|NS35-specific RNA capture assay
P08030704A1503|0 9|CONCLUSION
P08031424T0000|0 7|Ketamine
P08033490A0875|16 26|disposition
P08034318A0724|29 43|multiple species
P08034486A0579|3 11|incidence
P08034680A0180|19 25|zeta PKC
P08034682T0000|0 15|Stable expression
P08034708A0000|3 16|molecular basis
P08034741A0000|28 43|characterization
P08034742A0307|0 1|M.
P08035498A0833|11 26|computer analysis
P08035499A0941|45 49|kinds
P08035505A0586|0 9|Processing
P08035517A0753|12 19|promoter
P08035796A0890|0 11|32Pi labeling
P08035833A1556|5 8|YMIP
P08036004A0292|3 10|R2 region
P08037338A0000|0 6|PURPOSE
P08039422A0000|3 27|nerve growth factor beta gene
P08040336A0435|14 28|upstream element
P08040391T0000|0 5|Number
P08040468A0303|15 35|mast cell degranulation
P08041362T0000|0 15|Molecular cloning
P08041793A0242|2 15|earlier studies
P08043523A0000|8 26|elevated serum levels
P08044794A0000|3 17|tumor suppressor
P08044800A0550|4 32|DNA containing promoter activity
P08044802A0462|8 19|Southern blot
P08045431A0894|0 3|HupI
P08045834A0783|3 20|PCr resynthesis rate
P08046923A0000|29 36|patients
P08048582A0821|8 19|regional MVO2
P08048916A0000|0 3|IGF I
P08049401A0428|0 15|Immunodepression
P08049444A0351|0 14|Tryptic cleavage
P08049521T0000|0 29|Aberrant protein phosphorylation
P08049885T0000|0 16|Acute pancreatitis
P08051019A0365|0 19|Alginate biosynthesis
P08051059A1000|3 18|sequence upstream
P08051074A0000|23 34|footprinting
P08051102A0532|0 6|Heparin
P08051151A0347|3 19|relative abundance
P08053697A0000|0 9|BACKGROUND
P08054281A0731|3 16|retention index
P08055939A0159|3 23|central globular domain
P08055939A0707|14 30|approximate length
P08055941A1264|3 10|topology
P08056474A0438|1 10|single NMSC
P08057356A0531|1 22|constitutive mutant form
P08057356A1824|0 10|Comparisons
P08057421A1583|0 12|Direct binding
P08057762A0878|12 38|satisfactory reproducibility
P08057833A0573|6 17|ParA proteins
P08058326A0463|5 19|further insights
P08058948A0810|0 9|CONCLUSION
P08062824A0626|28 34|FKBP-33
P08062833A0000|10 11|nt
P08063108A0109|3 10|acfD gene
P08063766A0595|10 13|beta
P08063775T0000|0 9|Regulation
P08063791A1370|5 11|results
P08063836A0904|14 18|c-Abl
P08064351A1020|0 11|Long-latency
P08065310A1144|18 28|ninth heptad
P08065324A0458|29 38|snRNA genes
P08065327A0000|0 24|Extensive DNA rearrangement
P08065331A0279|16 37|site selection procedure
P08065338T0000|3 21|Oct-2 glutamine-rich
P08065365A0000|0 6|Binding
P08065366A0918|32 36|Dbf8p
P08065368A0839|0 4|Ariga
P08065901A0997|3 9|results
P08066094T0000|0 9|Marine oils
P08067013T0001|3 24|diagnostic significance
P08067123A0248|14 20|results
P08067546A0000|30 55|coronary vasomotor responses
P08067607A0568|0 21|Significant alterations
P08069298A0492|5 29|alternative splice variants
P08069427T0000|0 25|Roux-en-Y gastroenterostomy
P08069481A0736|0 22|Surface-coil experiments
P08070004A0782|0 25|Large interpatient variation
P08070393A0631|3 15|maximal effect
P08070654A0000|0 3|KAR1
P08070654A0574|0 4|CDC31
P08071356A0232|6 25|transcript elongation
P08071982T0000|18 39|skeletogenital syndrome
P08072352A0567|6 13|patients
P08072547A0690|0 2|Ras
P08072547A1009|1 13|short sequence
P08072547T0000|0 27|c-Fos transcriptional activity
P08073505T0000|1 13|new generation
P08075070A1632|0 16|Essential features
P08075421A0621a|3 12|partial ORF
P08075421A0621b|3 12|partial ORF
P08076631A0000|3 9|binding
P08076937A0851|0 13|Rapid detection
P08077236A0243|0 7|Wild type
P08078167A0000|0 8|OBJECTIVE
P08078416A0581|3 20|bactericidal effect
P08078473A1107|0 9|Expression
P08079268T0028|0 2|Use
P08082215A0230|3 16|immune response
P08082286A0748|0 16|Acupuncture effect
P08082292T0000|7 16|NK activity
P08082360A0411|0 13|Smoking history
P08082440A0339a|1 3|LH P
P08083011A0584|3 11|relative R
P08083220A0988|10 32|ternary complex formation
P08083963A0795|3 23|LTR-binding activities
P08083998A1723a|5 11|results
P08083998A1723b|5 11|results
P08083999A0501|0 22|Vaccinia virus-expressed
P08084339A0907|24 33|transcript
P08084592A0145|2 5|HeLa
P08085228A0000|0 25|Demographic characteristics
P08085609A0384|0 6|Results
P08085782A0164|12 16|cases
P08086450A0467|0 9|Comparison
P08086453T0000|0 8|Structure
P08087887A1067|3 19|polyubiquitin gene
P08088022A1417|7 37|stress-induced arrhythmic disease
P08088513A0419|14 28|genetic evidence
P08088777A0754|3 20|consensus gene order
P08088818A1053|3 11|high level
P08089184A0825|14 27|megabase region
P08089834A0561|5 11|mutants
P08089887A0742|0 22|SECONDARY OUTCOME MEASURE
P08090571T0001|0 10|Elimination
P08090746A1288|2 13|8-bp sequence
P08090767A0000|21 38|DNA polymerase delta
P08091655A0000|19 23|Marek
P08091665T0000|0 10|Cowpox virus
P08091669A0828|18 20|P35
P08093450A0688|0 10|Mutagenesis
P08093616A1214|0 4|DNase
P08093616T0000|0 22|Novel 8-base pair sequence
P08093642A0600|12 43|microsatellite repeat polymorphism
P08094464A0869|8 11|tyrA
P08094464A2014|9 12|span
P08094498A0614|0 3|Most
P08094927A0311|0 14|Previous studies
P08095698T0000|0 9|Metabolism
P08095872A1672|44 51|inotropy
P08095875T0000|0 6|Effects
P08096066A0623|3 14|RFLP patterns
P08096944A0951|15 32|ovarian stimulation
P08097666A1135|0 5|A23187
P08097732A0000|0 9|Activation
P08098228A0625|1 10|transcript
P08098842A0660|0 8|Mutations
P08098882T0001|0 26|Salazopyrine desensitization
P08098914A0400|18 32|Pes-Ves relation
P08099443A0359|10 12|HRI
P08100057A0577|0 14|Double-staining
P08100765A0361|25 51|transgene expression patterns
P08100843A0134|0 15|Southern analysis
P08101134A0376|3 16|concentrations
P08101171A0924|11 17|results
P08101839A0000|43 55|human mdr1 gene
P08101843A0151|3 25|tyrosine hydroxylase gene
P08102364A0000|0 33|Tobacco mosaic virus-infected tobacco
P08103379A0577|19 28|amino acids
P08103935T0000|0 8|Isolation
P08104189A1168|24 38|proSRIF cleavage
P08105727A0099|0 9|Fenoldopam
P08105994T0000|0 14|Clinical aspects
P08106087A0139|7 20|flanking region
P08106245A0325|3 26|indoor radon concentration
P08106313A1492|3 9|results
P08106325A0000|0 3|DtxR
P08106369A0000|0 10|Vasopressin
P08106398A1003|5 11|results
P08106512A0522|7 20|promoter region
P08107167A0222|0 5|Anti-B
P08107208A0673|57 68|recombinants
P08108099T0000|0 9|Evaluation
P08108343A0000|0 18|Comparative analysis
P08108413A0964|3 13|other normal
P08111035A0098|3 32|cis-acting regulatory properties
P08111974A1034|36 37|CX
P08112341A1128|0 1|L.
P08112526A0443|13 45|extracellular calcium concentration
P08112601T0000|0 21|Structural organization
P08112611A0404|15 37|1092-bp open reading frame
P08112870A0484|0 14|Western blotting
P08113736A0309|3 18|gene organization
P08114702A0000|0 6|Members
P08114710A0137|25 29|LBP-1
P08114745A0953|5 11|results
P08115744A0462|3 7|films
P08115744A0846|3 18|GafChromic method
P08116245A0174|0 14|Viral genomic RNA
P08118044A0318|0 9|GATA-1 mRNA
P08119149A0000|0 24|Tumor necrosis factor-alpha
P08119907A0000|27 47|cellular p21ras protein
P08119958A0273|12 19|C2 domain
P08119995A0814|36 54|T3R-RXR heterodimers
P08120019A1500|13 22|Hm1 mutants
P08120029A0864|19 39|decay reaction mixtures
P08122364A0954|0 15|Deletion analyses
P08122370A0331|15 26|counterparts
P08123787A0554|11 27|amino acid sequence
P08124785A0445|0 6|METHODS
P08124912A0456|38 45|SF levels
P08124956T0000|0 54|Sodium-taurocholate-induced acute necrotizing pancreatitis
P08125258A0142|8 15|inactive
P08125319A1085|3 11|ipiO genes
P08125337A0940|0 13|Sterol analysis
P08125949A1162|43 56|spinach L12 mRNA
P08126096A0478|7 17|experiments
P08126096A1071|3 16|alpha 7A form RNA
P08127950A0000|33 62|hypothalamic-pituitary-thyroid
P08128629A1164|0 10|CRS function
P08129955A0572|0 11|Serial levels
P08130942A0051|0 14|Regionalization
P08131545A0158|31 46|community members
P08131746A0140|0 2|MEK
P08132541A0000|0 15|Genomic DNA clones
P08132574A0831|0 6|Members
P08132667T0000|0 9|Expression
P08133502T0105|0 26|European Community Huntington
P08134108A0277|3 7|c-myc
P08134115A1161|0 5|MSSP-1
P08136383A0359|8 12|hours
P08138180A0593|0 29|Certain spt10 spontaneous alleles
P08138364T0000|0 8|Varieties
P08139001A1235|3 9|results
P08139004A0278|5 7|UTR
P08139017A1465|12 20|major site
P08139031A1168|15 62|oligonucleotide-directed site-specific mutagenesis
P08139539A0446|2 11|Rat 1a cells
P08139542A1229|3 11|mutations
P08139542T0000|10 13|mRNA
P08139543A0427|11 15|genes
P08139543A1520|0 6|Genetic
P08139562A0404|25 29|lines
P08139577T0000|0 18|Identical components
P08139914A0554|30 44|dnHLH protein Id1
P08139928T0000|0 3|RNP1
P08140847X0001|0 4|Crohn
P08142875A0877|9 26|complete dissection
P08143198T0001|0 10|Restoration
P08143236A1055|7 50|ethanol regimen impaired spontaneous alternation
P08143667A0222|11 12|sd
P08144035A0387|0 6|Several
P08144037A0000|0 10|Thioredoxin
P08144470A0711|3 10|mutation
P08144497T0000|3 21|cysteine-rich region
P08144504T0064|0 14|Kinetic coupling
P08144572A0786|0 2|ATP
P08144615A0533|0 8|Digestion
P08144631A0000|0 8|Signaling
P08144668A0802|25 29|exon V
P08144852A0000|3 11|responses
P08145646T0000|0 8|Structure
P08145770A1078|7 18|observations
P08148463A0000|3 27|colony-stimulating factors
P08148756A0358|11 25|lung destruction
P08149484A0151|0 17|Expression plasmids
P08149484A1551|5 11|results
P08150970A0434|5 15|cutoff level
P08151787A0355|0 8|Insertion
P08151787T0000|0 6|Mapping
P08151790A0354|3 20|revertant TATA boxes
P08151980T0001|0 18|Panlobular emphysema
P08152800A0357|8 16|ETS domain
P08152800A0709|0 15|Gel shift analysis
P08153130T0000|0 6|Effects
P08153146A0327|0 9|Dotarizine
P08154171A0649|5 10|issues
P08154182A0955|3 12|usefulness
P08156332T0000|0 35|Endoscopic transthoracic sympathectomy
P08157009A0264|0 18|Sequence comparisons
P08157009T0000|26 33|APS1 gene
P08157663A0882|5 11|results
P08157674T0000|0 26|Biochemical characterization
P08159174A0581|16 26|foreign gene
P08160054A0224|3 10|patients
P08160387T0000|0 29|Functional postnatal development
P08160905A0217|6 13|patients
P08163183T0000|3 30|xylose isomerase-encoding gene
P08163498A0789|3 17|phosphopeptides
P08163528T0000|0 38|Mitochondrial Mas70p signal anchor sequence
P08163546A1230|31 36|Ypt51p
P08164302A0547|8 24|basal TPN solutions
P08164661A0414|13 23|TFIIIC alpha
P08164679A0809|0 20|Transactivation domain
P08164680A1086|17 32|protease activity
P08164684A1266|3 8|ligand
P08166402A0631|0 17|Cerebral125 albumin
P08167396A0154|20 26|neurons
P08167555A0972|0 7|Response
P08169201A0291|13 34|amino-terminal sequence
P08169709T0000|0 17|Aneurysmal bone cyst
P08170400T0000|0 7|Location
P08172416A0860|0 9|Moxidectin
P08172598A0237|0 20|Northern-blot analysis
P08172653A1589|3 17|variable regions
P08172905A0000|25 45|alanine tRNA synthetase
P08173532A0000|0 17|Simple reaction time
P08173693A0390|1 16|second study group
P08173814A0132|5 11|viruses
P08175031A0566|0 8|Treatment
P08175188A0685|20 25|ppm SO2
P08176742A0190|23 37|assay conditions
P08177143T0000|0 17|Renal cell carcinoma
P08178446A1160|18 22|ICP10
P08178490A0879|23 36|signal function
P08178572A1118|4 30|concensus poly A addition sites
P08179827T0000|0 6|Factors
P08180129A1256|0 7|Exposure
P08181755A0989|0 15|Northern analysis
P08182041A1067|3 9|results
P08182056A0695|3 12|high degree
P08182171A0000|3 10|efficacy
P08183552T0000|3 16|human eps15 gene
P08183915A0000|18 31|105-kDa protein
P08183915T0000|0 18|Alternative splicing
P08184923A0829|0 11|Topical L-NNA
P08185288A0106|30 50|female healthy subjects
P08187085A0086|5 18|rearrangements
P08187088A0530|0 11|Frequent loss
P08187177A0405|1 21|single amino acid change
P08188258A0000|0 22|Glutamyl-tRNA synthetase
P08188290A0544|8 19|sequence data
P08188603A0230|22 31|intact gene
P08188606A1034|0 18|Restriction analysis
P08188978A0822|3 19|baroreflex latency
P08189174A0148|0 5|DESIGN
P08189498T0000|0 13|Identification
P08189503A0000|11 30|full-length cDNA clone
P08189533A0203|10 27|structure-function
P08189533A0919|0 17|Gel electrophoresis
P08190633A0000|3 25|transcription factor AP-2
P08190633A0273|3 16|mature AP-2 mRNA
P08191910A0228|0 8|San Martin
P08192140A0209|3 14|participants
P08192451A0885|3 16|7-day treatment
P08192795T0000|0 32|Thrombotic thrombocytopenic purpura
P08193147A0831|0 9|Comparison
P08194139A0498|0 10|CONCLUSIONS
P08194549A0000|18 29|male kayakers
P08194753A0157|30 34|rhp51
P08194970A0000|0 4|Women
P08195186A0000|1 19|partial cDNA sequence
P08195216A1022|28 31|HIS3
P08195217A0799|46 81|reticulocyte lysate translation product
P08195233A0147|15 20|kinase
P08196607A0280|0 15|Deletion analysis
P08196616A1112|30 35|ZAP-70
P08196618A0473|0 4|PRL-1
P08196624A0593|2 25|Mv1Lu lung epithelial cells
P08198524A1134|2 4|kDa
P08199204A0746|0 2|H-7
P08199878T0000|3 9|effects
P08200528A0970|33 44|Tn903 neo gene
P08201352A0239|11 38|congenital protein C deficiency
P08201758A0125|0 19|A-69-year-old patient
P08201932A0355|2 20|physical examination
P08202546A1206|27 50|hUBF-promoter interaction
P08203260A1204|17 20|SIMV
P08204348T0000|0 4|VP-16
P08204403A0000|11 15|males
P08204426T0001|0 11|Simultaneous
P08204824A0000|1 12|genomic clone
P08205827A0940|0 10|CONCLUSIONS
P08206848A0296|3 6|pyrR
P08206867A0874|0 23|Southern blotting analysis
P08206991A0466|0 8|Acylation
P08207022T0000|0 17|Subunit composition
P08207232A0503|0 35|Electrophoretic mobility shift analysis
P08207405A0372|0 2|BYV
P08207795A0409|13 27|precise location
P08207805A0000|3 31|p53 tumor suppressor gene product
P08208247T0030|0 17|Mutational analysis
P08208540A0000|0 13|Rearrangements
P08208540A0417|0 6|Cloning
P08208540A1114|0 29|Transient co-transfection assays
P08208618A1334|5 10|HR21ap
P08209051T0000|0 27|Intravenous antibiotic therapy
P08209423T0000|11 16|frames
P08209772A0167|3 9|ns2 gene
P08212571A0597|0 14|Co-transfection
P08212571A0971|0 7|Analysis
P08212897A0404|3 23|hydrophobicity profile
P08213235A1024|0 10|Measurement
P08213747A0000|21 36|excess prevalence
P08216115A0158|3 10|patients
P08217862A1336|25 47|rat conditioning paradigm
P08218056A0000|3 16|ultrastructure
P08218230A1505|3 18|regulatory region
P08218230A1920|22 34|GRE sufficient
P08219072A0287|0 3|Acad
P08219081A0000|3 12|PRB-1b gene
P08219227A0830|0 10|Replacement
P08220494A0231|3 15|T-cyt promoter
P08220621T0000|9 19|manuscripts
P08221251A0239|13 14|CT
P08222384A0455|0 4|SIN-1
P08222556T0000|0 5|Effect
P08222618A0000|3 23|BASIC computer programs
P08223425T0000|3 15|yeast SSS1 gene
P08223554A0574|3 9|lengths
P08223576A1261|12 20|H4PteGlun
P08223592A0424|0 3|TATA
P08223613A0105|0 3|GGS1
P08223613A0519|38 55|homologous products
P08223823T0000|0 17|Stroop interference
P08223875A0711|0 10|Stimulation
P08224260A1248|0 9|CONCLUSION
P08224907A0000|0 26|Genomic Southern blot analysis
P08225657A0000|11 19|ibopamine
P08226616A0000|3 11|nit-3 gene
P08226776A0990|26 41|two-state process
P08226777A0936|1 25|Dictyostelium transformant
P08226780A0160|4 8|motif
P08226794A0501|1 5|Ala85
P08226798A1124|15 24|CaM binding
P08226956A1397|10 23|apparent effect
P08227129T0000|3 27|major myosin-binding domain
P08228805A0540|1 23|second important molecule
P08228997A0866|3 9|results
P08229102A0768|17 33|QLMI questionnaire
P08229330A0000|0 10|Most smokers
P08229826A1145|3 20|inhibitory response
P08230418A0812|11 13|nef
P08230445A0000|15 33|vpr open reading frame
P08230452A0551|3 56|recombinant vaccinia virus-expressed mutant P1 polyproteins
P08230452A1489|11 24|capsid proteins
P08231398A0802|0 6|RESULTS
P08231577A1027|0 3|Acid
P08231816A1473|7 27|total-protein extracts
P08232304A1166|12 20|deletions
P08232412A1342|3 12|lemdr1 gene
P08234166A0425|3 17|bioavailability
P08234276A0556|0 27|Similar synergistic activation
P08234308T0000|0 5|Notice
P08237112A0553|2 9|homology
P08237171A0000|10 16|odd case
P08237578A0253|9 23|lipid metabolism
P08238626A0248|3 7|PaCO2
P08239164A0551|0 3|CPAP
P08239586T0000|0 6|Effects
P08240170A0000|4 8|forms
P08241139A0378|7 7|%
P08241656A0189|23 31|first case
P08242861A0368|4 14|4,8-DiMeIQx
P08243476A1177|5 12|cysteine
P08244034T0000|0 43|Recombinant Leishmania surface glycoprotein GP63
P08245013A0000|14 27|molecular basis
P08245125A0822|0 7|Addition
P08245456A0501|5 9|cells
P08245461A0700|0 21|Hu-Met-1 mRNA expression
P08245933A0617|0 17|Partial engorgement
P08246984A0512|0 7|Northern
P08246984A0923|5 11|results
P08246987A0260|15 42|protein-tyrosine kinase domain
P08247005A0584|0 6|Strains
P08247043T0000|0 9|Hepatitis B
P08248246A0838|29 31|Sp1
P08248253A1785|5 24|combined observations
P08248688A0726|9 26|enzymic stimulation
P08249319A0578|0 7|Clipping
P08249390A0111|3 10|duration
P08251506A0503|3 16|247-kDa complex
P08251622A0000|3 10|promoter
P08252067A0917|8 25|limited comparisons
P08252976A0467|0 4|Rinit
P08253386A0800|39 65|fibronectin splicing enhancer
P08253387A0801|0 9|Inspection
P08253387A1291|14 22|sequences
P08253777A0301|1 19|cAMP response element
P08253958A0000|9 24|serological tests
P08254738A0428|14 28|mutant T antigens
P08255022A0827|11 23|hypoperfusion
P08255341A0554|3 10|patients
P08255758A0000|23 40|untranslated region
P08257666A0662|5 16|present study
P08257754A0711|3 12|fourth dose
P08258025A1131|0 10|CONCLUSIONS
P08259650A0640|0 25|Nucleotide sequence analysis
P08260635A0926|4 9|intron
P08261398A0392|3 35|drug-resistant cell lines P388/ADR/3
P08261398A0838|9 26|rapid amplification
P08262041A0727|3 14|phi AP3 factor
P08262054A0565|13 39|N-terminal cytoplasmic domain
P08262067A1608|3 20|functional homology
P08263933T0000|0 15|Molecular cloning
P08264579A1209|3 9|cloning
P08264582A0750|10 37|full-length cytoplasmic domain
P08264583A0520|12 27|biochemical basis
P08264591A1190|24 37|largest subunit
P08264617A0000|0 20|Recombinant expression
P08264628A0418|0 25|Oligonucleotide competitors
P08264631A0746|3 18|227-to-239 region
P08264650A0925|0 7|Analysis
P08264664A0128|0 6|TGF beta
P08265602T0000|0 2|Val
P08265955T0000|0 14|Strategic change
P08267658A0391|9 25|expensive solution
P08267667A0748|0 21|Repeated administration
P08268718A0676|0 15|Human bcl3 protein
P08268833T0000|3 19|therapeutic action
P08268912A0657|7 28|translation experiments
P08269424A0339|5 28|peripheral administration
P08269439X0000|0 19|Pentazocine analgesia
P08270257A0551|1 24|sequence homology analysis
P08270580A0155|1 18|favourable response
P08270985A0590|0 16|Response durations
P08273122A0708|0 6|RESULTS
P08274774A0958|11 21|REP21 plants
P08275618A0457|0 9|Drug effect
P08276234A0119|21 23|YY1
P08276336A0371|3 23|retrospective analysis
P08276732A0799|9 17|decrement
P08276762T0000|0 5|Effect
P08276851A0347|12 24|Pay4p sequence
P08276854A1894|3 9|results
P08276865A1188|3 30|kinase inhibitor staurosporine
P08276871A1001|26 40|overall identity
P08276900A0543|0 1|S.
P08277632A0997|3 14|survival rate
P08278423A0147|0 6|Mothers
P08278480T0002|0 1|G.
P08278548A0597|3 6|psaD
P08278929A0866|4 24|Hy-Vac SPF type V embryos
P08279098T0001|0 39|Peripheral vitreochorioretinal dystrophies
P08280476A0602|5 11|studies
P08280925A0261|30 46|antibody responses
P08281153A0543|21 30|high degree
P08281536A0626|0 12|Interleukin-6
P08281634A1801|0 14|Other parameters
P08281740A0000|0 8|Responses
P08282501A0358|12 22|small number
P08282576A0297|0 6|Tumours
P08282749A1474|0 5|Thomas
P08283292A0779|0 5|Plasma
P08283531A0700|3 26|Stryker frame modification
P08284227A0336|0 23|Glomerular mesangial cells
P08284337A0825|0 27|Routine psychometric screening
P08285710A0634|1 26|single 1.8-kb transcript mRNA
P08286035A0587|13 31|sequence information
P08288240A0304|3 20|sequence similarity
P08288240A1343|40 63|neuron-specific SCG10 gene
P08288554A0295|10 26|amino acid sequence
P08288596A0663|11 12|T3
P08288606A0240|6 42|polymerase chain reaction-based approach
P08288622A0725|3 20|structural analysis
P08288633A0144|1 16|complementary DNA
P08289339A0527|0 20|Additional exonuclease
P08289341A1202|0 9|Repression
P08289342A0931|1 6|mutant
P08289357A0724|3 9|results
P08289593A1404|30 33|rats
P08289783A0000|3 7|Oct-3
P08289783A1476|5 28|site-directed mutagenesis
P08289784A0381|17 18|M.
P08289793A1226|15 43|negative transcriptional effect
P08289831A0290|0 7|Analysis
P08289834A0341|20 28|test cells
P08290278A0374|10 13|Mxi1
P08290421A0165|21 40|renal tubular acidosis
P08291233A0000|1 9|cDNA clone
P08291620A0372|3 15|basic patterns
P08291761A0416|0 8|Animal age
P08291886T0024|0 22|Fast continuous expansion
P08293412T0000|12 27|multicenter study
P08293992A0432|22 23|nt
P08293993A0948|0 2|ENV
P08294386A0000|0 9|BACKGROUND
P08294429A0153|0 7|Analysis
P08294459A0446|12 28|amino acid sequence
P08294511A0639|36 47|69-kD protein
P08294865A0236|0 14|Several features
P08294906A1315|34 59|neurotransmitters glutamate
P08296434A1141|3 18|Harleco apparatus
P08297376A0236|0 14|Co-transfection
P08298129A0274|34 58|tissue-specific expression
P08298129T0000|0 8|Isolation
P08299181A1148|0 14|Subretinal fluid
P08299568A1401|21 30|activation
P08299725A0724|35 40|intron
P08299896A0626|0 10|Concordance
P08299896A0880|0 19|Regression line slopes
P08300463A0581|0 11|Praziquantel
P08300527T0000|0 9|Inhibition
P08300601A0745|23 32|activation
P08300605A0432|0 22|Transcriptional analysis
P08300605A0671|10 17|elements
P08300611A0341|0 23|Site-directed mutagenesis
P08300611T0000|0 14|Concerted action
P08300625A1352|3 15|COOH-terminal
P08301702A1083|0 21|Monospecific antibodies
P08301841A0000|9 28|GSH-Px enzyme activity
P08302589A1132|3 25|HGF-induced cell motility
P08303233A0313|11 24|lexical priming
P08304301A0331|0 6|METHODS
P08304342A0605|5 17|present report
P08305058T0000|0 11|Pneumothorax
P08306356A0000|0 29|Different cortical malformations
P08306834A0866|0 8|T2 cancers
P08306959A0278|0 7|IFN alpha
P08307338A0227|0 8|Mutations
P08307564A0233|12 31|sequence-tagged sites
P08308008A0201|29 35|binding
P08309726A0000|6 19|further insight
P08309912A0306|0 9|Amiodarone
P08309953A0776|5 11|results
P08309957A0000|3 13|experiments
P08309975A0662|0 8|Depletion
P08312243A0177|32 36|NaFe3
P08314163T0000|0 7|Recovery
P08314922A0941|39 61|dynamic perfusion changes
P08316100A0586|3 9|neglect
P08316209A0000|3 46|positive-acting global sulfur regulatory protein
P08316240A1068|0 7|Analysis
P08317092A0304|3 18|C-terminal region
P08317094A0778|5 8|ends
P08319396A0448|2 17|T2 weighted images
P08319907A0754|8 19|rap1t alleles
P08320120A0361|0 24|Pronounced microangiopathy
P08321199T0000|0 18|Epigenetic switching
P08321203A0840|0 11|NF-kappa B p65
P08321227A0854|33 45|culture medium
P08321741A0396|3 12|first group
P08322117A1019|6 12|methods
P08322823A0839|10 25|clear correlation
P08323294T0000|0 49|Chicken sterol carrier protein 2/sterol carrier protein x
P08324107A0000|3 31|plasmatic albumin concentration
P08324280A0098|5 11|lesions
P08324792T0000|11 22|minute period
P08325504A0226|7 10|RD19
P08325639A0129|0 14|Previous studies
P08325720A0840|27 38|blood lactate
P08325883A0368|16 34|putative RBP1 protein
P08327488A0839|3 14|defective RNA
P08331064A0440|0 6|Release
P08331067T0000|0 25|Complete nucleotide sequence
P08331728A0686|0 6|Binding
P08332033T0000|0 27|Morphometrical quantification
P08332492A0145|15 29|multigene family
P08332495A0408|7 22|significant level
P08333643A0000|0 12|Pneumoscrotum
P08334158A0660|3 16|first gene codes
P08334304A0473|0 20|Triton-disrupted cells
P08334989A0070|68 77|cell-cycle
P08335710A0338|15 31|high ionic strength
P08336012A0632|29 52|peripheral white blood cell
P08336543A0243|2 5|mice
P08336698T0000|0 3|TFEC
P08336738A1273|18 28|third ligand
P08337828A0895|0 13|Similar results
P08337841A0612|2 23|infected mammalian cells
P08340400T0000|0 15|Molecular cloning
P08342703A0966|3 11|mean power
P08343041A0000|8 26|antisperm antibodies
P08343216A0883|0 31|PPD-specific IgG subclass responses
P08343961A0000|0 18|Anterior body pattern
P08344248A0910|0 4|GAP-N
P08345191A1140|3 17|peptide sequence
P08347677A0308|3 27|phosphorylation efficiency
P08348919T0000|0 13|Botulinum toxin
P08349104A0000|26 29|GAL1
P08349104A0450|16 22|results
P08349499A1169|0 2|Sex
P08349632A0679|0 17|Sequence comparison
P08350061A0209|3 12|mechanisms
P08350398A1616|16 38|ER lumenal variable domain
P08352066A0000|21 34|beta-estradiol
P08352268A0000|0 29|Recombinant human erythropoietin
P08355062A0000|0 20|Single-photon emission
P08355063A0456|3 11|rCBF ratio
P08355539A0133|0 6|METHODS
P08355680A0824|0 3|2-AP
P08355696A0236|3 13|UV induction
P08355697A0000|0 26|Protein tyrosine phosphatases
P08355857A1293|0 10|ST elevation
P08356792A1275|13 23|p21X protein
P08356792T0000|0 19|HTLV-1 gene expression
P08356944A0589|26 50|sodium lauryl sulfate method
P08357834A0285|25 42|amino acid sequences
P08360112T0036|0 2|XII
P08360180A1041|16 26|barley PSI-K
P08361754A0733|5 13|other hand
P08361755A0734|10 19|conditions
P08361761A0174|14 18|v-Rel
P08363332A0365|3 23|simultaneous recording
P08365944A1537|0 9|CONCLUSION
P08366034A0637|23 38|cysteine residues
P08367388T0035|0 34|Cerebro-oculo-facioskeletal syndrome
P08367487A1014|37 47|17S U2 snRNPs
P08369887A0781|0 10|Differences
P08370119A0642|13 29|single 1977-bp exon
P08370119A1521|0 7|Deletion
P08370275A0290|3 12|chimpanzee
P08371650T0000|0 10|Dissipation
P08371713T0000|0 20|Alternative transcript
P08371936T0000|3 31|Functional Independence Measure
P08373274A0546|0 9|Polymyxin B
P08373972A0335|0 3|SvO2
P08374753A0335|3 26|transverse relaxation time
P08375651T0000|21 34|heavy chain gene
P08376397A0788|3 20|binding specificity
P08376796A0172|12 20|VH regions
P08377199A1432|37 54|proper conformation
P08378082A1031|5 12|findings
P08380736A0895|3 10|7-kb mRNA
P08380896A0938|0 7|Kinetics
P08381121A0773|3 27|other transmembrane regions
P08382296A0766|0 8|McCann III
P08382300A0341|5 13|cell lines
P08382303A0507|3 25|E1 nuclear transport motif
P08382303T0000|3 22|E1 replication protein
P08382359A0469|64 77|tumor induction
P08382769A0924|31 41|nucleotides
P08382778A0891|19 48|protein shares extensive homology
P08383129A0776|3 36|low molecular mass polypeptide complex
P08383214A0389|0 16|Secondary cleavage
P08383217A0357|3 12|C-terminal
P08383287A0611|37 44|estrogen
P08383323A0000|0 16|Optimal activation
P08383492A1205|37 64|interrupted aromatic aa stretch
P08383526A0591|12 16|genes
P08383622T0000|0 7|Identity
P08383850A0206|5 16|present study
P08384309A0000|3 43|intracellular basic region/helix-loop-helix
P08385131A0000|3 28|alpha 2A-adrenergic receptor
P08385337A0282|1 18|sequence comparison
P08385581A0126|10 14|genes
P08386279A1621|3 25|transactivation function
P08386280T0000|0 7|Mutation
P08386317T0000|0 26|Nuclear protein phosphatase 2A
P08386318A1102|10 13|IL-6
P08386319A1229|0 7|Mutation
P08386592A0089|0 22|Growth factor stimulation
P08386637A1220|26 39|mammalian cells
P08387155A1248|4 20|stimulatory effect
P08387507A1015|15 19|Myf-5
P08387519A0000|28 57|high level human desmin expression
P08387662A0302|13 24|patients self
P08387743A0624|0 10|Replacement
P08387994A0980|3 18|orf61 gene product
P08388496A1117|0 9|Expression
P08388510A0891|0 7|Analysis
P08388543A1263|13 26|mutant receptor
P08388600A0000|0 16|Estrogen treatment
P08389074A1227|0 8|Mutations
P08389365A1344|30 56|methyl-directed repair system
P08389453A0193|0 19|Uracil DNA glycosylase
P08390120A0785|0 20|Current clinical trials
P08390665A0000|0 20|Lithium phthalocyanine
P08390747A0586|25 32|genetics
P08390831A0143|0 9|Recipients
P08391534A0828|0 6|Elledge
P08391748A0452|0 4|Drugs
P08392221A0449|0 5|Losses
P08392623A1374|0 18|IE2-IE2 interactions
P08393143A1281|3 11|Sp1 region
P08394019A0695|0 12|Precipitation
P08394255A0000|1 26|sheep testicular cDNA library
P08394464A1080|3 21|putative Rev proteins
P08394862A0565|11 18|patients
P08395004A0141|12 24|spt2 mutations
P08395004A0558|0 18|Nuclear localization
P08395010T0000|12 32|ninth C-terminal heptad
P08395014A1364|0 18|Genetic interactions
P08395654T0000|0 18|Steroidogenic factor
P08395681A0388|10 30|functional differences
P08396120A0690|3 28|rhaB transcription start site
P08396261A0388|0 11|Several lines
P08396657A0452|0 2|Liu
P08396667T0000|0 6|BCR-ABL
P08396713A0305|5 15|experiments
P08396749A1112a|0 13|LDL cholesterol
P08396749A1112b|0 13|LDL cholesterol
P08396913A1379|4 18|negative element
P08397123T0000|22 47|distal promoter-like element
P08399970T0000|1 29|new bioencapsulation technology
P08400240A0166|8 27|hypersensitivity site
P08400928A0318|0 12|INTERVENTIONS
P08401570A0828|15 34|putative binding sites
P08401614A0187|0 9|French bean
P08403245A1234|0 24|Plasma thromboxane B2 levels
P08403804A0754|2 41|stepwise linear multiple regression analysis
P08405433A0000|3 31|human insulin-like growth factor
P08406004A0691|11 37|transient transfection assays
P08406352A0172|0 11|Army veterans
P08406419A0155|17 28|seropositive
P08406497A0000|0 6|Defects
P08407784A0850|18 21|recJ
P08408194T0000|14 18|roles
P08408825A0000|0 25|Neonatal lupus erythematosus
P08408841A0281|0 19|Genetic abnormalities
P08408963A0048|8 9|L.
P08409284A0262|9 18|absorption
P08409593A0357|2 5|CFDN
P08410042T0000|0 23|Creutzfeldt-Jakob disease
P08410097A0356|1 17|high mean intensity
P08411024T0000|4 14|young people
P08411276A0302|16 25|PIC patient
P08412120A0839|0 3|Skin
P08412620A0688|23 24|bp
P08412662A0333|15 20|cosmid
P08412665A0000|3 12|scr regulon
P08413186A0077|11 29|molecular mechanisms
P08413186A1199|3 10|Ntl1 gene
P08413205A0733|0 31|Transient transfection experiments
P08413209A0159|3 21|amino-terminal third
P08413215A0327|26 49|various NF-kappa B subunits
P08413223A0847|4 17|multiple copies
P08413239A0490|17 38|end-adjacent sequence CA
P08413260A1437|5 11|results
P08413274A0452|0 3|MDBP
P08413291A1473|0 13|Transgenic mice
P08414410A0270|0 6|METHODS
P08414502A0244|0 9|Consistent
P08415637A0000|3 24|ADP-ribosylation factor
P08415643A0555|3 8|E1 gene
P08415712A1153|0 26|Genomic Southern blot analysis
P08416952A0956|0 23|Metabolic labeling studies
P08416977A0892|5 14|CTD kinases
P08417117A0592|8 11|mRNA
P08417330A0149|24 44|51-bp promoter fragment
P08417331A0745|16 23|HIR1 gene
P08417349A1633|25 35|replication
P08418183A0000|10 16|factors
P08419318A1695|0 3|Biol
P08419333A0126|33 47|DNA repair enzyme
P08419338A0273|0 1|L.
P08419376A0357|3 20|nucleotide sequence
P08420230A0544|0 4|SAECG
P08420571A1880|14 18|PACE4
P08421295A0365|4 17|fusion proteins
P08421687A0397|3 24|selenocysteine residues
P08421823A1041|0 10|CONCLUSIONS
P08421897A0000|9 18|past decade
P08421910A0599|5 14|components
P08422975A1205|3 28|obvious functional necessity
P08423831A0523|53 69|significant issues
P08425050A0898|2 24|extensive inverted repeat
P08425221A0000|11 40|novel cytoplasmic tyrosine kinase
P08427501A0221|0 15|Large differences
P08428722A1123|5 24|multivariate analysis
P08428750T0000|0 11|Localization
P08428907A0653|11 21|stage larvae
P08428940A1763|3 12|such mutant
P08428952A0399|8 16|L-plastin
P08428952A1957|29 35|fimbrin
P08428953A1718|4 11|promoter
P08428965A1868|3 11|half-life
P08429019A0735|3 7|DNase
P08429019A2022|35 54|YY1 consensus sequence
P08429020A0495|20 24|exons
P08429568A0000|0 36|Rhizobium meliloti large plasmid pRmeGR4b
P08430087A0467|20 34|recombinant beta
P08430095A0161|45 59|related function
P08430095A0913|18 22|Smd1p
P08431100A0108|28 47|fine motor performance
P08432137A0000|13 47|parameters pleural adenosine deaminase
P08432526A0580|5 9|exons
P08432696A1117|0 7|Deletion
P08435755A0938|2 11|Experiment
P08435755A1078|0 2|PNT
P08435794A0658|0 10|CONCLUSIONS
P08435885A0787|9 27|positive correlation
P08437521A0000|0 18|Mutations truncating
P08437737A0100|0 13|Naval personnel
P08438584A0524|0 19|Weak promoter activity
P08438584T0000|16 34|coat protein promoter
P08439564A0883|3 28|amino acid sequence alignment
P08439597A0000|4 21|short communication
P08439597A0176|31 54|retrospective study design
P08440238T0000|12 21|C-terminus
P08440688A1509|5 11|studies
P08440720A1404|0 9|Constructs
P08441379A0912|16 48|proIL-1 beta cap site-proximal region
P08441394A1297|10 15|PC-PLC
P08441411A1260|2 30|mitogen-stimulated splenocytes
P08441423A0145|33 36|GCD6
P08441869A0334|3 17|plateau MO2 value
P08442384A0430|41 50|amino acids
P08442384T0000|3 23|SCH9 protein kinase mRNA
P08443122A0657|12 17|T cells
P08443339A1374|0 24|Histochemical localization
P08443340A0522|28 45|expression patterns
P08443341A0384|0 19|Southern blot analysis
P08444184A0245|0 8|Sudomoina
P08444344A0000|0 10|Zinc fingers
P08444345A0403|10 19|bovine EFIA
P08445299T0000|0 5|Effect
P08445655A1009|0 11|Localization
P08445729A0657|0 10|Replacement
P08445792A0469|0 3|Type
P08446579A0784|10 34|transcription factor Gal-ER
P08446579A1210|3 18|exogenous fos gene
P08447005T0001|0 10|Elimination
P08449133A0578|0 13|Endosonography
P08449943A0225|5 16|present study
P08449978A0000|0 7|Analysis
P08449986A0455|0 16|Overlapping clones
P08450015A0175|17 36|preliminary isolation
P08451187A0267|17 34|several differences
P08451331T0000|0 7|Pathways
P08453101A0128|0 14|Pokeweed mitogen
P08453950A0498|9 24|seizure induction
P08454077A0956|11 14|rats
P08454591A0692|0 9|Sequencing
P08454591A1322|20 31|inducibility
P08454858A0285|0 7|Ig-alpha
P08455598A0000|0 13|Sterile mutants
P08455611A0000|12 32|functional interaction
P08455611A0154|12 35|transient expression assay
P08455623A0630|0 13|Initial results
P08455629A0335|0 8|Breitbart
P08456378A0134|21 31|feasibility
P08456879A0000|0 8|OBJECTIVE
P08457205A0240|0 24|Internal amino acid sequence
P08457291A0170|0 8|Estradiol
P08458660A0855|0 6|Air lead
P08458849A0364|25 41|flaN transcription
P08458906A0827|1 12|micrograms/l
P08459012T0000|0 13|Fibular dimelia
P08459465A0257|4 19|prospective study
P08460270A0205|21 30|infections
P08460346A0350|19 31|double blinded
P08460918A0252|0 4|Group
P08461946A0386|39 57|renographic findings
P08461981A0882|21 32|animals older
P08463284A1531|0 10|Nuclear beta
P08463320A1219|6 38|copper-phenanthroline footprinting
P08463485T0000|0 6|Effects
P08464056A0000|0 5|Finger
P08464056A0510|0 14|Further evidence
P08464924A0243|1 7|rat cDNA
P08466864A0878|0 17|Mutational analyses
P08468320A0941|6 7|J.
P08468475A1280|2 37|F42A-stimulated internalization assays
P08469831T0001|3 26|microcirculatory dynamics
P08470021A0195|13 22|prevalence
P08470895A1617|0 10|Examination
P08471241T0000|3 21|short-term synthesis
P08471629A0816|0 14|Pseudosubstrate
P08471796A1654|12 18|results
P08472750A0999|0 20|Nitric oxide inhalation
P08473731A0149|0 17|B cell-specific mb-1
P08473967T0000|0 9|Bipolarity
P08474438A0000|10 34|nuclear ribonucleoproteins
P08474439A0877|0 8|Mutations
P08474456A1041|0 28|Transient transfection analysis
P08474464A0348|35 36|TR
P08475104A0341|17 36|25-bp promoter element
P08476087A0814|5 24|protective influences
P08476854A0097|0 4|DNase
P08479742A0985|44 54|excess wt p53
P08481004A0321|7 11|clone
P08482539A0913|0 19|Northern blot analysis
P08483412A0000|3 6|nifJ
P08483479A1056|17 19|PTH
P08484514A1536|24 33|isoflurane
P08484689T0000|0 9|Prevalence
P08484891A0000|8 39|olfactory associative conditioning
P08485317A0000|3 18|fission yeast dsk1
P08486035T0000|0 6|Closure
P08486276A0419|0 17|Sequence comparison
P08486705A0181|3 11|yeast gene
P08488700A0283|3 12|strategies
P08490002A0620|0 5|Xylose
P08491124A0517|3 23|technical construction
P08491383A0154|3 15|alpha-subunit
P08491383A1291|17 29|alpha-subunit
P08491683A0651|5 12|patients
P08492164T0000|0 21|Spontaneous burst firing
P08492290A0306|13 32|potentiometric method
P08495786A0085|0 21|Cryopreservation straws
P08496157A0000|3 11|bcl-2 gene
P08496184A0772|3 24|active open reading frame
P08496185A0484|0 16|Subsequent cloning
P08496475T0000|0 12|Calcification
P08496599A0310|11 29|alternative splicing
P08496601A1153|16 24|promoters
P08496848A0692|8 35|essential contrast differences
P08497190T0079|0 15|Sequence analysis
P08497248A0000|18 25|receptor
P08497259A0452|13 32|SUP4A53T61 transcript
P08497269A0999|4 21|sequence similarity
P08497273T0000|0 4|NF-HB
P08497280A0266|20 23|SWI4
P08497280A1397|32 38|pathway
P08497280T0000|0 39|Multiple SWI6-dependent cis-acting elements
P08498570A1118|13 19|changes
P08499376A0000|0 11|Multizone PRK
P08499903A0883|4 11|patients
P08499916A0000|3 12|COL7A1 gene
P08500524A0424|18 36|productive gamma gene
P08500938A0408|22 25|BGCT
P08501030A0456|7 22|nitrate induction
P08501678A0498|4 15|new knowledge
P08503348A0226|3 27|HMG CoA reductase inhibitors
P08504707A0376|3 10|etiology
P08504928T0000|10 27|230-kD TFIID subunit
P08504932A0123|3 17|enigmatic aspect
P08504933A0000|0 4|Pit-1
P08505075A0236|0 12|Maximum number
P08505312A0285|0 3|Biol
P08505340T0000|0 15|Characterization
P08505495A0253|3 11|retention
P08505605A0461|0 21|Patient characteristics
P08506317A0000|0 6|Members
P08506384A0146|2 15|mammalian cells
P08507921A1021|18 29|observations
P08508774A0242|0 7|Analysis
P08508778A0112|0 11|Yeast mutants
P08508861A0294|3 10|patients
P08509051A0316|12 19|patients
P08509333A0843|1 13|36-kDa protein
P08509335T0000|0 3|SSG1
P08509419A0785|0 9|Expression
P08509430A0372|3 30|first involved complementation
P08510320A0000|10 16|strains
P08510320A1249|36 40|MRSAs
P08510647A1347|0 3|Beg2
P08510924A0490|34 48|transactivation
P08511994A0000|18 34|one-year-old carps
P08512728A0991|0 6|RESULTS
P08513025A0000|20 36|skinfold thickness
P08514757A1100|4 16|immunophilins
P08514766A0732|3 16|GTPase activity
P08515619A0184|0 16|Tl-201 uptake ratio
P08515776A0971|1 23|second hydrophobic domain
P08516301A0080|15 16|kb
P08516308A0669|12 14|RAD
P08516324A0000|8 31|chromosomal translocation
P08517737A0889|5 12|findings
P08518797T0000|0 24|X-linked liver glycogenosis
P08519621A0150|26 37|observations
P08519862T0001|0 10|Measurement
P08520646A0000|0 20|Embryo coculture system
P08521414A1384|5 13|cell lines
P08521717A0126|2 25|immunoperoxidase reaction
P08521780A0485|0 9|Umweltchem
P08522175A0306|0 4|Egd1p
P08522511A1250|8 10|PLB
P08522511A1578|5 19|flanking regions
P08522530A1342|4 11|nifA mRNA
P08523031A0737|54 58|onset
P08523545T0000|3 25|human papillomavirus type
P08523566A1106|1 19|chaotropic detergent
P08524036A0747|0 7|Contrary
P08524229T0000|0 10|Degradation
P08524235A0695|0 6|Cloning
P08524241A0212|15 23|induction
P08524260A0835|3 17|domain structure
P08524267A1022|45 73|wild-type prothymosin alpha gene
P08524272T0000|0 21|Differential regulation
P08524284A0309|38 42|cDNAs
P08524292A1022|0 6|Results
P08524294A0652|3 6|skp1
P08524314A0216|3 6|TEA1
P08525186A0288|0 7|Refugees
P08526620A1344|34 64|terminal SC5b-9 complement complex
P08528479A0000|0 17|Videonystagmoscopy
P08528796A1470|3 5|MCA
P08529098A0549|8 27|sequence similarities
P08529630A0840|26 37|P protein mRNA
P08529654A0589|3 47|B. germanica cyclophilin amino acid sequence shares
P08529662A0507|29 39|soluble form
P08530105A0308|3 15|minimal region
P08530107A1003|0 9|Consistent
P08530149A0689|0 9|Comparison
P08530342T0000|3 19|human gp39 promoter
P08530345A0880|0 19|Transfection analyses
P08530369A0099|9 27|autophosphorylation
P08530384A0559|4 29|protein-protein interaction
P08530418A1182|30 46|TR2 orphan receptor
P08530432A0093|14 27|mutant proteins
P08530503A1004|6 8|ARF
P08531373A0470|21 44|recurrent annular erythema
P08531669A0950|0 10|Competition
P08532516A0000|21 30|properties
P08532536A0925|0 13|TIEG expression
P08532967A0364|2 17|infectious origin
P08533472A0777|12 26|protein products
P08533473A0375|31 38|ADH1 gene
P08533757A0204|4 11|families
P08534217A0402|3 10|subjects
P08534367A0984|0 5|PTP-S3
P08534848A0188a|8 17|NR isoforms
P08534848A0188b|8 17|NR isoforms
P08534855A0000|3 21|Arabidopsis FAD7 gene
P08535138A0857|18 37|G0-arrested leaf cells
P08535537A0000|19 44|pharmacological backgrounds
P08536694A0000|0 13|Protein kinases
P08537388A0825|27 35|deletions
P08537403A0336|3 22|protein kinase domains
P08538052A0000|1 25|human recombinant cDNA clone
P08538382A1012|0 12|Erythrocyte AA
P08538483A0207|10 28|consideration weight
P08538702A0214|10 20|polypeptide
P08541499A0306|0 24|Certain transcript patterns
P08541793A0796|0 18|Spontaneous recovery
P08542026A0792|0 2|DAF
P08542027A1471|3 9|XS2 gene
P08542746T0000|0 11|Diabetes care
P08543173A0314|9 15|TATA box
P08543275A0130|31 41|recent burst
P08543595A1093|13 22|efficacies
P08543810A0000|19 23|genes
P08544820T0000|0 15|Characterization
P08545502A0914|5 9|SPECT
P08546707T0000|0 24|Transcriptional activation
P08547205A1060|3 9|results
P08548291A1059|7 25|selective activation
P08549706T0000|12 35|hepatitis B virus infection
P08549859A1604|42 53|chromosome 3p
P08550425A1401|12 19|subunits
P08550460A0374|3 28|transposon-inactivated gene
P08550461A0284|0 5|Cheung
P08550462A0815|0 7|Upstream
P08550467A0863|0 25|Sucrose-specific regulation
P08550470A1021|9 12|CheW
P08550476A0610|3 10|promoter
P08550564T0000|0 12|CXC chemokines
P08551572A0155|0 29|Oligodeoxynucleotides antisense
P08551577A0000|0 20|Retroviral replication
P08552042A1497|21 39|promoter methylation
P08552045A0973|8 25|consensus sequences
P08552082A0480|19 36|proline-rich region
P08552086A0150|33 55|vitamin D response element
P08552092A1678|12 25|protein binding
P08552093A0657|0 14|Differentiation
P08552095A0686|0 9|Consistent
P08552095A0758|14 23|abundances
P08552095A1115|0 4|Paf1p
P08552096A0151|6 33|high-copy suppression strategy
P08552387A0000|0 24|Molecular characterization
P08552643A0261|0 5|Clones
P08552670A0665|0 3|Abp1
P08552670T0000|0 13|Identification
P08553580A0102|1 21|short open reading frame
P08554069A0743|13 22|homozygous
P08554540A1480|5 11|regions
P08554723A0187|10 13|rats
P08555076A0333|0 22|Liposomal Amphotericin-B
P08555168A0390|0 2|Mg2
P08555289A0207|0 22|Magnetic storm indicators
P08555446A0000|0 22|Transgenic tobacco plants
P08555498A0427|0 9|Human LAF-4
P08555597A0808|0 7|Hb levels
P08555753A0591|0 2|CBT
P08556707A1390|29 34|218leu
P08558187A0403|0 5|Cycles
P08561607A1443|19 28|infections
P08561893A0100|9 17|great deal
P08561897A0604|0 7|Mobility
P08562688A0968|0 7|Upstream
P08563483A0094|7 11|cases
P08564488A1359|0 19|High fibrinogen levels
P08564588A1318|0 18|Strontium chloride Sr
P08565330A1783|13 30|epigenetic features
P08565548A0196|22 43|arthritogenic potential
P08566747A0756|0 2|SBF
P08566751A0455|19 30|open question
P08566751A0788|18 24|gHoxb-1
P08566754A0783|6 23|splice site sequence
P08566756A0752|24 26|SAP
P08566773A1023|13 16|CTS1
P08567556A0000|24 38|myoglobin-bound
P08567683A0401|3 15|human purH cDNA
P08567717T0000|26 59|spindle pole body duplication gene MPS1
P08567847A1005|16 27|SM-CMA system
P08569443A0123|55 65|differences
P08569680A0636|1 17|mutant areA product
P08569684A0000|0 15|Oligonucleotides
P08570615T0000|0 9|Disruption
P08572616A0000|0 11|Apparent loss
P08573083A0645|19 23|motif
P08573637A0434|57 67|paracetamol
P08574414A1037|5 11|primers
P08574583A0658|3 12|Clb5 kinase
P08575609A0526|3 10|C/D ratio
P08575614A0264|0 10|Rad6 mutants
P08575618A1138|0 20|RNase protection assays
P08575754T0000|0 15|Molecular cloning
P08576042A0765|0 13|Overproduction
P08576131A0151|11 26|molecular cloning
P08576131A0685|3 32|preferential heterodimerization
P08576179A0126|9 11|PKR
P08576245A0000|0 4|GRP78
P08576262A0160|3 14|IL-8 receptor
P08576546A0975|3 14|second series
P08580083A0259|14 35|functional significance
P08580671A0137|12 22|prospective
P08581174A0472|11 27|molecular analysis
P08582143A0614|5 11|studies
P08582633T0000|0 10|Suppressors
P08583783A0870|8 10|ANP
P08583846A0121|0 15|Recent literature
P08583846A0807|4 38|current methodology beta-2 transferrin
P08584026A0115|3 12|hIGF-I gene
P08584035A0740|0 21|Gel mobility shift assays
P08584074A0000|10 17|patients
P08584530A0545|0 22|Significant correlations
P08585324A0467|28 35|SSC1 gene
P08585324A0823|38 54|Leu-tRNA precursor
P08585639T0000|0 19|Occupational exposure
P08585883A0381|0 15|Hybrid female mice
P08585957A0101|16 42|putative transcription factor
P08585994A0567|5 19|reference probes
P08586643A0951|11 27|recombinant enzyme
P08586874T0000|0 6|Studies
P08587075T0000|10 23|microaneurysms
P08588852A0236|9 49|following pregnancy ultrasonographic studies
P08589315A1029|9 27|overall survival rate
P08589358A0235|10 17|units/kg
P08589358A0841|1 13|3-week regimen
P08589735A0577|7 16|constructs
P08590465A0773|43 44|S.
P08591700A0972|3 19|mean body mass index
P08592590A0822|5 12|findings
P08592713T0001|0 19|Synthetic enantiomers
P08593813A0967|0 15|Polysome analysis
P08595012A0817|2 13|nondiabetics
P08595184A0407|19 27|estimator
P08595414A0000|13 25|sequence ready
P08595627A1513|13 16|KATP
P08595658A0961|3 22|DNA sequences upstream
P08595836T0000|6 14|shrinkage
P08595878A0201|6 27|present genetic evidence
P08597108A0642|0 4|QBMDs
P08597177T0000|0 6|Effects
P08597596A0135|16 34|ATP-binding cassette
P08597636A0000|3 12|T-box motif
P08598051T0000|0 16|Molecular analysis
P08598359X0000|2 21|overall treatment time
P08598449A0784|15 23|signaling
P08599945T0000|0 8|Mutations
P08599946A0999|39 48|p40 complex
P08600028A1129|18 33|trans-activation
P08600048T0000|0 29|Pseudomembranous conjunctivitis
P08601283A0875|21 33|SECIS elements
P08601284A0000|24 29|spacer
P08601490A0659|5 11|animals
P08601616A0726|4 16|spindle defect
P08601806A0875|20 24|RPF-1
P08602169A0484|5 15|point mutant
P08602608A1056|14 27|evaluable cases
P08603921A1346|0 33|Carboxy-terminal Spc110p truncations
P08604338A0198|4 12|EWS-FLI-1
P08604338A0885|2 27|electromobility shift assays
P08604708A1086|0 16|Additional studies
P08605302A1770|0 13|DNA methylation
P08605324A0434|3 10|viral LTR
P08605326A0772|0 20|Overlapping cDNA clones
P08605705A0676|13 23|IgM class CIC
P08605931A0777|0 13|Epitope mapping
P08606267A0740|0 8|Variables
P08608126A0811|16 24|fatty acid
P08608222T0000|3 34|membrane-distal cytoplasmic region
P08608447A0806|20 43|nonsense codon recognition
P08608448A0353|12 19|residues
P08610272A0265|0 6|Ongoing
P08610328A0228|0 6|SUMMARY
P08610582A0150|10 17|patients
P08611280A0820|4 16|atrial volumes
P08612852A0553|0 6|RESULTS
P08614403A0557|10 23|abundant levels
P08614403A0989|24 49|GAL4-REV-erbA alpha chimeras
P08614410A0000|3 19|alpha T3-1 cell line
P08615012A0627|0 13|Cotransfection
P08615025A1214|11 23|glycosylation
P08615183T0000|0 6|Effects
P08616743T0000|12 14|Dr.
P08617216A0584|12 23|complete DnaJ
P08617237A0489|6 26|different phosphoforms
P08617238A0334|0 11|TNF Treatment
P08617243A0336|15 26|novel protein
P08617311A0979|16 33|sequence similarity
P08617800A0150|0 6|Control
P08617800A0675|0 4|DNase
P08617802A0993|5 11|results
P08618433A0000|3 42|novel hematopoietic growth factor FLT3 ligand
P08618433A1720|15 33|selective expression
P08618864A0754|0 14|Further analysis
P08618882A0343|0 7|Analysis
P08619866A0000|10 36|serum hepatocyte growth factor
P08619910A0000|3 17|neural mechanism
P08620003T0000|0 14|Protein splicing
P08620856A1172|25 46|western blot experiments
P08620889A0771|17 19|G+C
P08621017A1186|0 7|LY290181
P08621384A0935|0 8|Treatment
P08621420A1166|14 18|bands
P08621448A0862|11 26|complementary DNA
P08621451A0552|0 3|Biol
P08621453A0815|11 40|anti-phosphotyrosine antibodies
P08621542A0535|3 21|novel protein kinases
P08621628A1233|5 11|hGRbeta
P08621659A0189|0 3|Gas6
P08621661A1035|4 18|P5CDh cDNA clones
P08621664A1430|0 13|Polymerization
P08621714A0361|31 44|disulfide bonds
P08621719A0000|34 59|c-cbl proto-oncogene product
P08621719A0568|1 19|substantial fraction
P08621730T0000|2 20|AP-1 binding sequence
P08622030A0667|2 23|significant differences
P08622070A0889|7 14|patients
P08622596A0189|3 5|men
P08622645A1026|15 17|VDR
P08622668A1155|5 11|results
P08622675A0587|0 8|Inclusion
P08622698T0000|9 23|mammalian Notch1
P08622887A1026|0 33|Electrophoretic mobility shift assays
P08622893A0000|3 16|large subfamily
P08623554A1058|3 15|17-kDa protein
P08624445A0257|14 46|detailed genomic sequencing analysis
P08625806A0263|0 6|Krox-20
P08625900T0000|0 46|Pituitary adenylate cyclase-activating polypeptide
P08625924A0411|0 8|Clones 33F
P08625987A1086|8 32|bone marrow cells expression
P08626065A0000|25 47|3574-bp Bacillus subtilis
P08626290T0000|0 19|Aeromonas salmonicida
P08626313A1037|0 9|Expression
P08626325A0543|50 53|UmuD
P08626437A0332|0 8|Lyn kinase
P08626493A1468|0 8|Mutations
P08626529A0000|5 18|autoantibodies
P08626529A0799|12 30|proline-rich regions
P08626539T0000|0 17|Binding specificity
P08626540A1007|26 48|nanomolar concentrations
P08626596A0000|26 60|mammalian AMP-activated protein kinase
P08626610A0931|0 25|Sterol-mediated suppression
P08626612A1040|0 1|Am
P08626667A1372|0 25|EMSA competition experiments
P08626667A1517|0 12|Transcription
P08626698A0989|10 24|10-fold increase
P08626777A0537|0 15|Sequence analysis
P08626785A0674|0 27|Retinoid-dependent activation
P08626809A0729|14 17|pPKR
P08627354A0000|0 18|Vertebrate synapsins
P08627649A0734|0 33|Electrophoretic mobility shift assays
P08627667A0132|0 4|ZEBRA
P08627688A1520|23 32|mutant I299
P08627719A0784|0 25|UV cross-linking experiments
P08628251A1455|0 6|CM-ACO3
P08628254A0665|19 33|Jun/eb1 chimeras
P08628255A0932|14 22|HeLa cells
P08628260A0895|9 36|transient transfection studies
P08628284A0181|14 32|yeast reporter strain
P08628302A0683|2 7|hnRNP K
P08628681A0364|28 33|kb mRNA
P08628681A0821|0 19|Sequence conservation
P08629348A0237|10 33|favourable natural history
P08630542A1421|5 12|findings
P08630548A0000|0 15|Several cytokines
P08630583A1056|2 3|pH
P08630599A0534|14 40|elastin peptide concentration
P08631667A0851|0 13|Identification
P08631685A0000|3 16|structural gene
P08631760A0609|30 38|SH2 domain
P08631797A0982|0 9|Consistent
P08631817T0000|0 13|Identification
P08631820A0755|3 6|cDNA
P08631822A0677|11 26|plasmin fragments
P08631908A0224|0 6|VDR/RXR
P08631934A0000|3 9|members
P08631944A0663|18 24|isoform
P08631958T0000|0 51|Human cytomegalovirus immediate-early protein IE2 tethers
P08632009A1067|3 13|specificity
P08632015A0879|3 12|antibodies
P08632015A1226|0 25|Immunocytochemical analysis
P08632018A0587|1 11|DNA fragment
P08632463A1508|36 39|beta
P08632779A0351|3 12|XPG regions
P08633855A1064|3 10|lacS gene
P08634290A0000|3 8|genome
P08634357A0527|3 20|extraction recovery
P08634420A1784|0 8|HuEpo-R Ab
P08634423A0498|14 25|integrations
P08634697A1155|22 26|cDNAs
P08635771A0000|30 35|ONLINE
P08636031A1413|0 10|Interaction
P08636124A0410|24 27|cDNA
P08636149A0220|4 18|mutant receptors
P08636211A0983|0 5|EMBO J.
P08636428A1363|17 23|results
P08637006A0000|0 12|Transcription
P08637711A1121|27 30|IL-6
P08637717A0817|1 13|second peptide
P08637717A1231|1 10|p21 peptide
P08638435A0522|0 6|Results
P08639310A0548|0 2|OND
P08639521A1032|3 19|dynamic properties
P08639561T0000|0 8|Adduction
P08639742T0000|0 8|Isolation
P08639837A0268|19 44|several trans-acting factors
P08640866A0473|0 7|Exposure
P08641705A0986|5 25|different observations
P08642282A1009|9 24|first description
P08642285A1548|0 16|DNA-STAT complexes
P08642313A0770|21 39|appropriate cell line
P08642313T0000|0 72|T cell leukemia-associated human Notch/translocation-associated Notch homologue
P08642693T0000|0 20|Polyprotein processing
P08643111A0855|12 14|LL2
P08643382A0752|2 33|apparent N-terminal transit peptide
P08643513A0361|0 15|Deletion analysis
P08643557A0259|6 21|critical question
P08643578A0000|0 8|RAS2val19
P08643578A0532|12 32|Rho family protein Cdc42
P08643633A1187|4 20|immunoprecipitate
P08643646A0479|18 21|verA
P08643682A0268|0 23|Subcellular localizations
P08643759A0338|0 19|Menstrual-cycle phase
P08644734A0404|22 41|human cDNAs homologous
P08645214A1052|15 18|BL21
P08645219A1377|0 2|Ca2
P08647086A0622|0 3|Cdk2
P08647086A0720|3 23|Cdk2-cyclin-D1 complex
P08647086T0000|0 23|Cyclin-dependent kinase-2
P08647091A0592|14 19|clones
P08647264T0000|0 7|Ligation
P08647434A1124|0 12|Large T antigen
P08647451A0663|0 24|Northern blot hybridization
P08647802A0000|1 32|human cytoplasmic signaling protein
P08647822T0000|1 10|direct role
P08647884A0547|18 37|endoplasmic reticulum
P08648408A0792|7 9|PHT
P08648665A0956|8 19|LE6 deletions
P08648665A1320|0 12|ORF E8 colinear
P08648726A0713|0 6|Cloning
P08649372A0501|0 15|Clb2/Cdc28 kinase
P08649372A0755|3 17|carboxy terminus
P08649373T0000|0 33|Multiple single-stranded cis elements
P08649386A1032|1 24|new UASH consensus sequence
P08649389A0000|25 43|human CTCF cDNA clones
P08649389A0692|0 17|Mutational analysis
P08649393A0000|1 30|chromosome transmission fidelity
P08649403A0963|3 14|growth defect
P08649405T0000|0 2|Sp1
P08649424A0000|0 9|Expression
P08649425A0373|14 15|bp
P08649425T0000|25 42|chromatin structure
P08649427A0689|32 35|cDNA
P08649428A1227|51 59|synthesis
P08649440T0000|3 15|heterogeneity
P08649773A1374|12 16|BCL-6
P08649841A0956|15 18|uORF
P08650818A0000|1 15|secondary spread
P08651853A0607|0 22|Mesial temporal sclerosis
P08651853T0000|0 22|Mesial temporal sclerosis
P08652081A1953|4 24|specific adverse events
P08654200A0274|10 33|magnetic resonance imaging
P08654375A0544|1 18|mutational analysis
P08654390A0000|0 12|Heme oxygenase
P08654435A0540|2 15|inactive analog
P08654946A0475|3 4|aa
P08654946A0986|3 25|transcription start point
P08654972A0000|0 6|Defects
P08654983A0000|14 38|signal recognition particle
P08655497A0000|1 9|novel gene
P08655555A0772|13 21|deletions
P08655555A1368|3 13|DNA sequence
P08656672A0678|2 30|apparent ufo mRNA overexpression
P08657135A1444|19 25|studies
P08657150A1049|9 30|negative regulators such
P08657157A0000|0 24|Transcriptional regulators
P08657183A0145|7 27|strand selective repair
P08657918A0360|0 8|MATERIALS
P08659545A0000|27 39|transcript map
P08660733X0000|11 21|populations
P08660748X0000|28 48|predator-prey dynamics
P08660866A0504|2 19|cuticular positions
P08660892A1044|0 22|Transcriptional blockade
P08660998A0851|3 16|mMIWC1 promoter
P08661007T0000|0 14|Human MN/CA9 gene
P08661100A0285|3 25|exon-intron distribution
P08661101A0396|0 18|DNA sequence analysis
P08661104A0687|36 45|1.5-kb mRNA
P08661114A0564|11 17|domains
P08661116A0963|0 15|Promoter activity
P08661119A0085|17 44|human EP4 receptor gene sequence
P08661613A0691|4 8|users
P08662193A0404|5 32|separate activation subdomains
P08662499A0484|9 9|F
P08662617A2051|34 36|HIP
P08662789A0673|3 19|corresponding gene
P08662852A1297|13 24|multiple GRK2
P08662928A1153|65 76|STAT proteins
P08662928T0000|0 8|Receptors
P08662936A0428|23 44|FR-19 amino acid sequence
P08662980A0762|27 36|DNA binding
P08663000A0000|3 10|receptor
P08663120T0000|0 13|Oncogenic Raf-1
P08663127A0697|0 17|Hydropathy analysis
P08663141T0000|1 27|cis-acting DNA element located
P08663172A0311|16 39|hydrophobic amino terminus
P08663219A0246|3 10|promoter
P08663310A0157|8 10|SRF
P08663326A0000|3 37|final sigma54-dependent DmpR activator
P08663392A0215|27 39|human DSG3 gene
P08664229T0000|0 17|Clinical evaluation
P08664347A0923|0 3|None
P08664462A1404|5 11|changes
P08664667A0093|9 13|Delhi
P08665853A0228|7 34|interleukin-3-dependent cells
P08666102A0820|0 3|ZIOS
P08666238T0000|0 29|Selective translation initiation
P08666241A0930|29 39|43-bp region
P08666383A1252|5 12|findings
P08666398T0000|0 2|YAC
P08666404A0311|0 8|Isolation
P08666913A0000|0 4|Ly-49
P08668124A0744|3 11|Dox-A2 ORF
P08668142A1048|17 21|hARF4
P08668158A0765|30 34|Rpm1r
P08668158A1252|12 18|strains
P08668190A1364|0 23|Vacuolar membrane vesicles
P08668201A1059|0 18|Detailed mutagenesis
P08668203A1230|0 2|FTF
P08668209A0406|0 5|Merlie
P08668210A0000|0 18|Substantial evidence
P08669274T0000|0 26|Stylohyoid chain ossification
P08669676A1644|3 11|incidence
P08670556A0425|4 13|micromol/1
P08670853A0000|0 15|Cluster formation
P08670910A0156|0 13|DNA polymerase E
P08672242A0517|7 28|reporter gene constructs
P08673026T0000|3 17|factor structure
P08675026A0420|26 35|homologous
P08675395A0751|0 6|RESULTS
P08675608T0000|0 6|Outcome
P08675763A0788|0 11|Mean increase
P08675769A0158|0 13|Nonreturn rates
P08675821A0657|10 13|EMPD
P08676266A0838|3 12|mean values
P08676383A0518|4 15|half molecule
P08676454A0731|18 20|Pra
P08676456A0879|1 25|chimeric VP16-Tat construct
P08676495A0129|13 22|splice site
P08676858A0309|8 14|cloning
P08676858A1084|1 16|phylogenetic tree
P08677443A0238|3 22|Hoosier Oncology Group
P08677678A0258|30 55|immunomodulator neurotropin
P08678959A0640|0 20|Sestamibi scintigraphy
P08679131T0000|0 12|Atopic allergy
P08680702A0548|7 26|significant lethality
P08680706A0889|6 6|h
P08682155A0902|3 25|euglobulin clot lysis time
P08682317A0900|0 13|HS inducibility
P08682868A0738|11 24|DSK2-1 mutation
P08683106A0374|8 11|IL-2
P08683108A0965|0 9|Consistent
P08683108A1501|18 24|results
P08683983A0785|23 30|D protein
P08683983A1163|3 9|results
P08684522A0415|0 27|Immunofluorescence microscopy
P08684742A0000|0 8|OBJECTIVE
P08686381A0527|5 8|ORFs
P08688190A0000|3 22|new flavone glucosides
P08688556A0242|56 75|multicopy suppressors
P08689520T0000|0 17|Reproductive period
P08690118A0845|3 28|logistic regression analysis
P08690198A0346|0 6|METHODS
P08691106A0733|8 16|D8 binding
P08691962T0000|0 10|Limited role
P08692885A0663|12 14|A20
P08692892A0330|3 9|Pro-258
P08692924A0328|8 18|DNA sequence
P08697728A1199|3 17|predictive value
P08698756A1240|0 10|CONCLUSIONS
P08700531A1420|7 17|chromosome X
P08702517A0000|12 16|genes
P08702543A0000|0 3|Gap1
P08702556A0000|24 35|purification
P08702633A0164|20 54|Gbetagamma subunit-mediated increases
P08702644A0499|1 4|cDNA
P08702728A1325|26 37|wild-type Shc
P08702756A0000|3 16|small GTPase Rho
P08702807A0964|11 20|activation
P08702826A0870|12 28|upstream insertion
P08702845A0000|18 33|structural motifs
P08702936A0168|2 18|expression library
P08702936A0984|12 26|recombinant TARC
P08703005A0645|3 20|cis-acting elements
P08703010A0905|27 43|cis-acting element
P08703908A1814|16 23|findings
P08703959A0659|28 43|proton resonances
P08704124A0420|16 24|fragments
P08704240A1111|10 18|TF-1 cells
P08705056T0000|0 16|Workplace violence
P08706368A1024|0 6|RESULTS
P08706662A1125|3 9|results
P08706731A1303|10 48|considerable spatio-temporal similarities
P08707424A0709|15 25|ERV3 env mRNA
P08707516A0194|0 15|Initial estimates
P08707825A0063|25 41|smooth muscle cells
P08707840A0753|5 32|immunogold electron microscopy
P08707846A2308|0 9|Concurrent
P08707922A0334|0 27|Transcription initiation sites
P08708984T0000|27 38|indomethacin
P08709224T0000|0 30|Epstein-Barr virus nuclear protein
P08709245A1521|3 9|studies
P08709251A0000|0 22|Homologous recombination
P08709637A1471|29 44|IL-7R alpha chains
P08709831A0599|15 21|potency
P08710151A0782|21 29|mean value
P08710371A0000|37 64|oncogenic human polyomavirus BK
P08710371A0499|0 7|Site S-II
P08710377A0577|0 2|Cbl
P08710504A0995|0 9|Activation
P08711631A0989|0 8|Treatment
P08712799A0123|0 14|Unaided attempts
P08713933A0606|0 19|Laboratory evaluation
P08716757T0001|0 22|Microcomputer management
P08717391A0466|5 10|fusion
P08717559A0223|3 16|standard dosage
P08719155A0105|15 30|molecular cloning
P08719156A0953|10 16|introns
P08719697A0221|0 6|METHODS
P08719832A0397|18 41|lateral rhinotomy approach
P08720407A1386|0 9|CONCLUSION
P08721526A0000|3 13|predominant
P08721989A1012|3 9|results
P08721999A0432|22 35|common features
P08721999A0727|0 2|U24
P08722011A0103|25 36|GTPase domain
P08722568A1001|0 18|Chromatin repression
P08723352A0084|37 70|G1-specific cyclin-dependent kinases
P08723365T0000|0 19|Possible relationship
P08723883A0823|0 18|Blood GSH-Px activity
P08723883A1684|3 16|concentrations
P08726024A0244|5 8|cats
P08726024A0532|22 24|PCR
P08726247A0175|8 39|quantitative concentration changes
P08727192A0000|0 10|STUDY DESIGN
P08727992A0570|12 20|injection
P08728040T0000|0 21|Differential activation
P08730470A0000|7 22|general agreement
P08731155A0499|3 7|weeks
P08731222A0000|32 42|projections
P08731511A0625|3 8|levels
P08732665A0000|0 12|Amplification
P08733123A0000|0 35|Facioscapulohumeral muscular dystrophy
P08733123A0951|3 18|mature chromosome
P08733874A0000|0 7|Patients
P08733881A0343|0 25|Full thyroid function testing
P08734538A0613|3 17|third experiment
P08738510A0254|3 25|relative tumor FDG-uptake
P08739209A0700|0 10|Zatebradine
P08739260T0000|0 4|Catha
P08740416A0239|20 24|Seb1p
P08740416A0919|3 15|SEB1 homologue
P08741206A1551|16 35|ventricular afferents
P08741280A0374|0 8|Large ones
P08742135A0000|0 8|Fragments
P08742385A0211|7 20|frequent causes
P08745669A0000|9 16|patients
P08746605A0377|22 34|ACE inhibitors
P08746981A0154|3 12|treatments
P08747078T0000|0 14|Low-dose aspirin
P08747343A0790|0 11|Protein films
P08748033A0874|12 15|cpxA
P08749393A0783|3 14|PI3K_68D cDNA
P08749394A0874|7 24|interaction studies
P08750173A0000|0 11|AIMS/METHODS
P08750190A0000|31 49|alternative splicing
P08750702A0183|0 10|Study groups
P08751635A0135|10 29|severe cortical damage
P08752714A0000|3 12|occurrence
P08754777A1214|3 7|upTRE
P08754802T0000|0 21|Transcriptional control
P08754827A0231|0 5|Hoeben
P08754834A1097|6 21|genomic fragments
P08754840A0793|9 30|glucan synthase activity
P08754852A0960|2 21|gel retardation assays
P08755898A0339|3 9|classes
P08756332A0000|0 6|Members
P08756433A0282|8 23|characterization
P08756556A0406|3 6|cDNA
P08756597A0854|0 6|Mutants
P08756609A0498|10 26|amino acid sequence
P08756617A1204|0 3|Biol
P08756636T0000|0 20|Semidominant mutations
P08756642A0230|0 10|Alterations
P08756712A0227|0 14|Previous studies
P08757265A0466|0 6|Neurons
P08757943A0876|15 29|negative element
P08759870A1128|14 33|fbpA operator sequence
P08760286A0696|3 22|structural similarity
P08760776A1559|0 9|CONCLUSION
P08760872A0696|3 9|results
P08760889A0170|3 11|cDNA clone
P08760889A0531|0 9|Comparison
P08761169T0000|0 25|Cognitive visual dysfunction
P08761480A0331|0 10|Interaction
P08762021A0156|11 34|load-insensitive measures
P08762172A0178|0 21|Large strain differences
P08762472A0000|11 35|ligustrazine hydrochloride
P08763207A0402|7 19|oxidation peak
P08763311A0189|0 12|Phenylephrine
P08763925A0588|26 37|genes located
P08763953A0805|14 17|traA
P08764015A0284|0 1|A.
P08764136A0000|19 23|genes
P08766049A0000|0 9|CASE REPORT
P08766781A0322|5 14|same period
P08768374A0765|3 6|P-wr
P08768377A1387|10 20|hcf109 locus
P08769132A0000|3 23|human MSH-2 gene product
P08769409A0114|26 50|tissue-specific expression
P08769566A0000|25 28|cDNA
P08769568A0949|19 23|genes
P08770021T0000|9 23|PTHRP production
P08770896A1121|0 9|Subsequent
P08770920A1220|14 25|coexpression
P08770981A0328|3 10|patients
P08771781A0103|34 49|intergenic region
P08771781A1103|3 18|ORFII gene product
P08771787T0000|0 15|Characterization
P08774732A0271|13 15|Sp1
P08775674A0000|0 9|OBJECTIVES
P08776735A0000|17 27|human kidney
P08776748T0000|3 19|low P300 amplitudes
P08776792A0626|0 4|Sleep
P08776793A0811|3 10|patients
P08776901A0000|0 17|Chloroplast mutator
P08777374A1471|0 19|Indoor concentrations
P08778265A0422|1 29|neuropsychological test battery
P08778700A0476|29 34|rarity
P08780339A0142|13 24|single-blind
P08781119A0723|5 18|flanking region
P08781144A1520|4 6|18F
P08783180A0000|8 14|methods
P08783666A0957|20 30|engraftment
P08784787A0383|11 26|thrombin receptor
P08787110A0981|14 17|CPET
P08789441A0339|5 16|fluorescence
P08790288A0068|33 37|cDNAs
P08790291A1022|38 41|thi1
P08790387A0299|5 16|rat rnu allele
P08792217A1407|19 55|steady-state testicular TIMP-2 mRNA level
P08793029A0246|0 16|Control intact rats
P08793693A0237|0 5|DESIGN
P08794254A2957|5 7|SPK
P08794326A0405|17 43|strong Tas-responsive element
P08794339A1162|11 17|binding
P08794348A1067|1 30|transgenic complementation assay
P08794363A0259|15 36|bZIP structural homology
P08794547A0648|3 6|rCBF
P08794547A1403|8 19|basal vessels
P08794601A0000|3 19|triple combination
P08794869A0274|0 11|Several lines
P08795304T0000|0 19|Plasma thrombomodulin
P08797362T0037|0 5|Update
P08798420A0207|3 18|characterization
P08798443A0660|0 5|Serine
P08798443A1218|3 12|DNA binding
P08798512A1197|16 22|factors
P08798610A0843|0 3|PIP2
P08798635A0870|8 16|spleen GAP
P08798641A0400|0 3|Biol
P08798643T0000|1 34|novel phosphotyrosine-binding domain
P08798648A1816|0 6|Cys-757
P08798700A0134|3 15|transcription
P08798762A1279|14 20|results
P08798782A0976|0 2|Lck
P08798893A0611|12 19|freezing
P08801403T0001|0 25|Myelomatous pleural effusion
P08803710A0701|0 17|Five-year survivals
P08803845A0665|13 35|unidentified macroscopic
P08804012A0662|3 19|partial categories
P08804389A0893|0 19|Northern blot analysis
P08805338A1061|8 17|disruption
P08805824A1155|20 28|zero-loss
P08806491A0542|0 10|Transcripts
P08806693A0584|23 31|sequences
P08806817A0244|0 15|Sequence analysis
P08806817A0716|0 22|Genomic DNA hybridization
P08807245A0843|1 23|3-yr retrospective review
P08807288T0000|0 8|Isolation
P08807408A0524|0 6|METHODS
P08808120A0774|0 7|Patients
P08808275A1193|11 26|RAD23 equivalents
P08808707A0631|0 8|Ha-RasV12
P08808756A0587|0 15|Sequence analysis
P08808924A0326|3 19|hydropathy profile
P08808927A0417|1 28|1.5-kb HindIII genomic fragment
P08808939A0000|0 25|Carbon catabolite repression
P08809680T0000|0 8|Melatonin
P08810040A0955|1 16|subsequent screen
P08810278A0682|28 42|cellular protein
P08810323A0735|12 30|polyglutamine motifs
P08812012T0000|3 9|effects
P08812020A0597|3 17|third experiment
P08812106T0000|0 7|PCNA mRNA
P08812490A0000|1 15|1.8-kb cDNA clone
P08812490A0542|0 23|PCR/Southern blot analysis
P08812490A1509|3 22|high sequence homology
P08813766A0605|3 10|third ORF
P08813900A1088|6 12|phytase
P08814651A0000|15 29|temporal factors
P08816052A0238|0 3|Data
P08816438A0316|0 19|Quantitative analysis
P08816443A1674|8 28|multidomained ROK alpha
P08816452A0936|5 12|findings
P08816453A0000|3 11|elevation
P08816459A0090|2 18|interaction screen
P08816460A1769|5 11|results
P08816461A0892|23 27|Upf1p
P08816472T0000|0 13|Identification
P08816482A0234|10 24|related variants
P08816483A0869|0 8|Mutations
P08816498A0000|3 29|serine/threonine kinase Raf-1
P08816504T0000|0 47|Platelet-derived growth factor-dependent activation
P08816507A1125|2 28|transient cotransfections E1A
P08816759A0000|3 23|retinoid Z receptor beta
P08816792A0000|0 25|DNA-dependent protein kinase
P08817323A0714|6 29|complete sequence identity
P08817324A1070|0 9|Sequencing
P08818436A0557|11 30|multivariate analysis
P08818718A1229|19 44|single intravenous injection
P08820324A1699|3 8|limits
P08820642A0173|3 25|harpin-encoding hrpZ gene
P08820648A0123|23 55|additional ribonucleotide reductase
P08822208A1364|14 20|results
P08822399A0518|0 18|Motivational factors
P08823163T0000|0 23|High-resolution structure
P08823187A1020|0 8|Titration
P08823260A1161|0 3|FEV1
P08823646A1012|0 13|Administration
P08823709A0220|0 6|Therapy
P08824201A0270|0 7|Chernoff
P08824585A0260|13 30|novel protein kinase
P08824798A0761|0 20|Human ESP1/CRP2 protein
P08824800A0808|3 11|fragments
P08824805A0832|0 6|Several
P08824881A0133|0 13|Linkage studies
P08824884A0000|3 23|cytogenetic expression
P08825087A0213|0 18|DNA sequence analysis
P08825178A0071|3 28|initial inpatient experience
P08825554A0000|0 14|Tristetraprolin
P08825556A0522|18 24|CREsp-a
P08825633A0304|0 7|Analysis
P08825636T0000|3 30|complete exon-intron structure
P08825639A0827|2 25|inverted Alu repeat element
P08827783A0499|3 6|ewes
P08828142A0000|0 20|Feline leukemia viruses
P08828152A1238|0 9|Comparison
P08828152A1825|3 6|RPO1
P08828857A2423|8 21|primary GE cells
P08829393A0083|11 26|dipole estimation
P08831364A1252|4 12|verapamil
P08832146A0959|0 10|Proximal CBD
P08833153A0628|27 44|hCHLR gene sequences
P08833653A0304|17 45|LIM domain homeobox protein isl-1
P08833653A0783|8 12|isl-1
P08835393A2829|14 26|other pathways
P08835895A1292|3 10|CD4 count
P08835969A0000|8 28|diagnostic laparoscopy
P08836032T0000|0 14|Bifunctionality
P08836172A1382|0 2|RVR
P08836740A1025|7 10|CES1
P08837503A0392|8 19|repeat motifs
P08837746A0951|26 38|BrAAP activity
P08838144A0107|12 33|functional significance
P08838148A1218|1 26|stable heterologous cell line
P08838314A0129|50 53|V1aR
P08838585A0968|31 54|overall backbone deviation
P08838805T0000|0 18|Genomic organization
P08839498A0507|23 42|regional distribution
P08839832A0729|17 28|CD30v protein
P08839832A1220|0 26|Constitutive phosphorylation
P08839911A0716|4 4|%
P08840501A0345|27 46|new actin-related gene
P08840506A0544|8 11|ORFs
P08840997A0765|0 8|MVR typing
P08842143A0000|0 12|Plasmid pAL618
P08843411A0801|3 9|classes
P08843412A0543|15 44|transferable 40-amino acid region
P08843419A1290|0 2|OKA
P08844448A0000|2 11|open-label
P08844577A0000|0 9|Tilmicosin
P08844712A0000|0 5|Effect
P08845378A0368|0 23|Restriction enzyme mapping
P08846775A0110|14 17|Swi4
P08847138A0609|3 16|detection ratio
P08847403T0000|3 13|many embryos
P08847723A2351|0 11|IMPLICATIONS
P08848013A1469|3 21|nonconsensus TATA box
P08848052A0733|5 14|properties
P08849208A1022|0 7|Demispan
P08849569A0615|3 12|techniques
P08849778A0226|15 33|toeprinting analyses
P08849778A0598|0 11|Previous work
P08849834A0000|28 41|volume flow rate
P08850585A0602|3 18|enzyme activities
P08851337A1092|0 12|Tonsillectomy
P08851434A0383|2 9|lean mice
P08853303A0431|0 24|Pharmacokinetic parameters
P08853893A0158|28 54|distinct E2F complexes present
P08854459A0000|16 23|overview
P08854844A0637|21 37|non-visualization
P08855804A1528|5 11|results
P08856077T0000|0 20|Alternative processing
P08856132T0000|0 7|Evidence
P08858211A0694|4 14|GAP activity
P08858268A1307|0 9|CONCLUSION
P08858463A0853|17 28|AIDS patients
P08861955A0927|12 38|second RCC1-like motif located
P08861963A0375b|3 29|reconstituted RNA polymerases
P08861963T0000|0 36|Transcription factor recognition surface
P08862522A0690|0 9|Consistent
P08862743A0603|11 23|erythrocyte Mn
P08863824A0509|0 6|Cloning
P08864061A0000|0 9|Expression
P08864219A0178|3 33|minimum inhibitory concentrations
P08866485A0125|23 43|export proteins capable
P08867519A0557|3 12|elevations
P08868473A1287|13 15|p28
P08868660A0087|3 9|main aim
P08868954A0648|27 33|effects
P08869358A0121|0 15|Many human viruses
P08869763A0378|28 44|clinical phenomena
P08869825A0000|0 14|Previous studies
P08870266A0651|19 30|observations
P08871542A1352|27 52|common regulatory mechanisms
P08871567A0000|0 11|MSSP proteins
P08871567A0629|0 3|Gene
P08871635A0000|0 19|B cell antigen receptor
P08872162A0884|4 10|alleles
P08872671A0573|24 45|blood flow shunt fraction
P08873063A0493|10 26|amino acid sequence
P08873063A0875|0 12|ECM disruption
P08873159A0791|16 23|patients
P08874399A0277|5 8|days
P08874631A1133|0 13|Discrimination
P08876167A0322|10 36|intrinsic DNA-binding subunit
P08876167A0717|3 8|HiNF-D
P08876701A0177|19 37|related UmuC-homolog
P08877103A0081|22 35|mdr2 expression
P08877818A0184|3 15|amplification
P08878019A0357|3 28|intranodal mesothelial cells
P08878037A0000|3 10|gene ccpA
P08878044A1390|2 19|InlC deletion mutant
P08878045A0606|8 19|N-Nus complex
P08878573A1370|0 13|Administration
P08879080A0265|10 14|ACOAs
P08879237A0744|10 24|initiation sites
P08880405A1170|0 8|Selection
P08881036A0351|13 15|PCR
P08881542T0000|0 34|Sodium polystyrene sulfonate treatment
P08882492A0000|3 30|mammalian homeodomain proteins
P08882710A0000|0 9|Interferon
P08884273A1413|3 17|TYAC/P1 resource
P08884757A0653|0 21|Confirmatory statistics
P08885270A0428|5 11|mutants
P08886845A1274|28 43|myogenin promoter
P08887643A1167|14 34|common upstream signals
P08887647T0000|0 15|Fission yeast mal2
P08887652A0341|0 8|Selection
P08887659A0753|0 8|Mutations
P08887661A0138|0 4|IRF-1
P08887661A1061|11 24|cotransfection
P08887667A0992|16 38|Tyr-19 dephosphorylation
P08887674A0630|1 6|subset
P08887674A0920|6 13|settings
P08887678A0000|0 9|Expression
P08890537A0355|28 35|patients
P08891131A0000|0 25|Enterococcus faecium strains
P08891337A0614|3 22|amino-terminal region
P08891341A0724|0 26|Transient transfection assays
P08891345A0684|15 31|UTR characteristic
P08891346A1217|12 27|biological effect
P08891474A0667|5 12|findings
P08892755A0186|11 18|carp JAK1
P08892755A0981|8 18|DNA fragment
P08892757T0000|0 15|Molecular cloning
P08892859A0563|21 59|MDV-transformed T-lymphoblastoid cell line
P08893779A0229|13 52|extensor digitorum longus muscle tendon units
P08893822A0560|0 15|Northern analysis
P08894144A0330|11 46|10-12-week-old male Sprague-Dawley rats
P08894144A1173|0 2|CsA
P08894826A0228|0 10|Individuals
P08895522T0000|0 18|Oncogenic activation
P08895579A0583|0 15|Northern blotting
P08895997A0336|0 6|Physiol
P08896272A0000|3 20|nucleotide sequence
P08896280A0860|24 41|steady-state levels
P08896402A0587|0 15|Natural FL protein
P08896473A0282|49 52|HHCA
P08896590T0000|7 11|exons
P08896795A0166|5 9|Spurr
P08896804A0000|3 14|present study
P08897663T0000|9 13|Tower
P08897721A0000|0 8|Infection
P08898336A0268|0 22|RNase protection analysis
P08898365A0274|0 4|Rss1p
P08898866A0458|9 43|regulatory serine phosphorylation site
P08898893A0202|3 11|PAI-2 gene
P08899719A0318|8 14|contigs
P08900164A0188|0 1|T.
P08900190A0430|0 12|Growth factors
P08900296A0000|3 15|up-regulation
P08901135A1132|3 13|NIT2 protein
P08901635A0000|9 18|much effort
P08901658A0498|0 16|Vascular responses
P08902214A1486|33 54|additional exogenous PRL
P08902548A0144|0 28|Intraperitoneal administration
P08902641A0930|5 14|VA-SMV mode
P08902847A1946|54 61|affinity
P08902988A0258|0 12|Factor V Leiden
P08903339A0264|9 26|first determination
P08905819A0531|16 20|cases
P08906056A1290|5 12|patients
P08906139A2935|23 39|careful monitoring
P08909546A0810|15 18|PEA2
P08910292T0000|0 8|Signaling
P08910373A0315|0 16|Percent identities
P08910550A0501|18 36|previous observation
P08910567A2269|3 19|human gene fragment
P08912232A0260|15 16|ML
P08912807A0411|20 31|deer receptor
P08913186A0431|18 32|further evidence
P08913387A1010|0 8|Rifabutin
P08913974A0533|11 17|percent
P08914388A1645|19 19|H
P08914522A0118|3 11|STE20 gene
P08914532A0598|4 9|enzyme
P08915051T0000|0 23|Magnetic resonance imaging
P08915508A0000|0 25|Moloney murine leukemia virus
P08915559A0366|0 18|REM sleep deprivation
P08916928A0950|3 13|same ligands
P08916960A0350|10 30|serial biopsy specimens
P08916960A1331|10 14|cases
P08917270A0229|0 9|BACKGROUND
P08917435A0481|2 14|essential role
P08917449A0000|0 24|Leukemia-inhibitory factor
P08917696A0485|23 39|fos/jun activation
P08918456A0455|3 17|optimal sequence
P08918464A0225|0 32|STK/RON-expressing Ba/F3 pro-B cells
P08918810A0967|7 11|DNase
P08918885A0811|0 3|Kss1
P08918885A1087|11 23|dig1 dig2 cells
P08918918T0000|0 18|Paracrine activation
P08918934A0424|0 9|Comparison
P08919289A0402|9 19|first report
P08919907A0763|0 18|Transient expression
P08919986A1262|16 27|limited range
P08920499A0164|0 22|Blood sampling procedures
P08921387A1182|0 7|Analysis
P08921667A0294|1 26|given standard input function
P08921865A1293|33 34|ss
P08922344A1539|22 41|normotensive subjects
P08922384A0466|0 13|Immunoblotting
P08922385A0622|14 39|dominant negative inhibition
P08922390A0361|3 14|current study
P08922390A0793|34 50|single binding site
P08922390A2076|24 31|paxillin
P08922391A0304|1 33|single protease-resistant structure
P08922488A0187|0 12|Several agents
P08923258A0353|0 6|Jerseys
P08923460A0565|0 9|RUSH-1 beta
P08923469A1391|5 11|results
P08923470A0458|0 18|PPAR gamma mRNA levels
P08924211A0941|0 4|Exons
P08924381T0000|0 11|Growth factor
P08925545T0001|0 24|Recombinant erythropoietin
P08927169A0178|29 36|body lice
P08927612T0000|0 5|Ki-ras
P08927841A0053|0 18|Epidemiological data
P08929089A0231|11 19|ratio M/Pc
P08929563T0000|0 15|Rat liver catalase
P08931388A0806|3 20|mobility shift assay
P08931991A1026|16 29|strong evidence
P08932363A0807|7 19|E1A N-terminus
P08932385T0000|0 15|Small Maf proteins
P08933487A0325|5 22|third occasion water
P08933640A0000|11 27|maternal ingestion
P08934533A0784|12 24|same mutations
P08934540A0673|3 9|nm23-H1
P08935931A0787|0 9|CONCLUSION
P08935991A0844|3 29|nucleotide sequence alignment
P08936128A0611|0 10|Discordance
P08936640A0105|0 10|DATA SOURCES
P08937112A0561|0 6|RESULTS
P08937631A1223|0 18|Histological changes
P08937981A0840|12 24|co-expression
P08937989A1365|3 9|results
P08938418A0099|0 3|Merr
P08938420A0862|3 14|accumulation
P08939891A0285|8 28|yeast one-hybrid screen
P08939966A0816|11 26|protein synthesis
P08940132A1120|5 12|findings
P08940134A0705|2 4|3Y1
P08940298A0962|9 16|residues
P08942999T0000|0 26|Recurrent G-to-A substitution
P08943032A0000|18 30|tet-repressor
P08943354A0295|0 12|Recent studies
P08943928A1137|0 13|Administration
P08943934A0604|6 14|Theriault
P08944755A0211|0 3|Biol
P08945479T0000|0 14|Structural basis
P08945810T0001|0 18|Evolutive morphology
P08946166A0568|9 15|results
P08946668A0077|0 4|FK506
P08947028A0992|5 11|results
P08948440A0628|3 22|ERH expression profile
P08950144A0172|0 6|Waves N1
P08950352A0525|17 23|Chilean
P08951815A0465|0 9|Regulation
P08952483A0207|0 24|Several particular features
P08952796A0743|13 17|years
P08952965A1182|0 9|Comparison
P08953340A0000|3 9|effects
P08954725A1175|19 32|Tbx6 expression
P08955071T0000|0 9|Disruption
P08955111A0989|3 9|results
P08955136A0606|0 10|Recombinant
P08955159A0000|0 18|Human acid ceramidase
P08955189A1198|3 27|0.22-kb NheI/BglII promoter
P08955306A0224|0 7|Northern
P08955402A0288|3 9|classes
P08955928A0390|0 5|Damage
P08958137A0534|0 23|Lipid hydroperoxide levels
P08958720A1204|26 32|maximal
P08959062A0372|15 24|vasculitis
P08959117A0708|18 42|potential endocrine changes
P08959778A0292|11 32|significant differences
P08960827A1169|5 11|results
P08961873T0000|0 34|Abnormal urinary coproporphyrin levels
P08962614A0000|18 32|immunoglobulin E
P08964067A0188|0 9|Thrombosis
P08964172A0221|0 5|Filter
P08967870A0000|9 17|protocols
P08967963A1735|3 17|promoter segment
P08969495A0256|3 12|sequencing
P08969777A0771|3 26|microdensitometric scores
P08970352A0880|29 31|LDD
P08970951A0823|25 30|levels
P08970979A1246|11 18|extracts
P08970984A0765|3 14|SCMV SNE sites
P08970991A0747|4 18|serum withdrawal
P08971009A0860|25 46|simple two-step strategy
P08971721A1314|12 29|serological studies
P08971835A1057|2 6|Group
P08972182A0000|3 13|Fas receptor
P08972182A0527|0 2|Fas
P08972211A0059|3 21|imprinted expression
P08972232A0365|30 34|hGCN5
P08973185T0061|14 30|arginine mutations
P08973527A0000|0 16|Complementary DNAs
P08973630A0923|6 10|cases
P08973917A0632|0 11|Several cDNAs
P08973917T0000|0 8|Isolation
P08974103A0451|0 7|Patterns
P08974135A0052|16 23|thiamine
P08975532T0001|0 12|Liver injuries
P08975713A0454|12 22|cDNA library
P08976253A0637|42 46|serum
P08977013A0788|3 14|implications
P08977235A0134|0 4|G-CSF
P08977235A0588|0 6|Mutants
P08977401A0227|3 13|RI alpha gene
P08978690A0262|15 23|Rad3/Mec1
P08978817A0620|11 23|double mutants
P08978996A0000|22 36|hepatitis C virus
P08979089A1197|0 17|Stable transfection
P08979828A1561|0 27|Such multisensory interactions
P08980413A0500|3 5|P13
P08980522A0280|3 6|cDNA
P08980533A1160|11 26|C-terminal region
P08980536A1196|24 28|G-box
P08980819A0193|0 8|Mortality
P08981371A2049a|11 21|PIP2 content
P08981371A2049b|11 21|PIP2 content
P08985109A1285|24 37|anterior margin
P08985115A1571|3 21|first identification
P08985122A0501|3 16|promoter region
P08985415A1096|3 24|STAT-1 signaling pathway
P08986190A0927|0 10|Reperfusion
P08986214A0000|13 39|hepatic regenerative response
P08986228A0000|0 7|Children
P08986692A0306|0 11|INTERVENTION
P08986770A0268|31 49|I-POU/tI-POU message
P08986812A1214|6 17|wild-type p53
P08987009A0400|31 43|prerequisites
P08987225A0675|7 22|common risk factor
P08988257A1256|0 8|Silencing
P08988913A0821|14 35|previous two-pool models
P08989025A0359|4 22|voltage-operated Ca2
P08989763A0605|0 15|Several artifacts
P08990168A0688|8 23|p48 gene induction
P08990194A0000|25 38|thyroid hormone
P08990397A1437|8 31|nonphotosynthetic mutants
P08992115A0199|3 13|progression
P08993393A0498|12 32|potential implications
P08993393T0000|0 20|Differential signaling
P08993831A0000|6 30|skeletal muscle development
P08993836A0699|14 20|results
P08994825A0000|0 9|BACKGROUND
P08994832A0782|0 16|Ectopic expression
P08994968A0926|2 14|N-terminal arm
P08995054A0618|0 9|Similarity
P08995054A1368|0 1|D.
P08995410A0000|0 25|Eukaryotic initiation factor
P08995410A1109|27 33|Hershey
P08995614T0000|0 13|Identification
P08995652A0812|3 9|results
P08995659A0563|0 5|Fourth
P08995681A0518|4 8|ICP27
P08996730A1146|0 3|Lack
P08997490A1127|0 9|C/EBP beta V
P08997532A0116|0 10|Specific IgG
P08998115A0114|0 20|SUMMARY BACKGROUND DATA
P08999414A0819|3 13|differences
P08999857A0801|11 15|E-box
P08999882T0000|0 9|Expression
P09000049A1341|13 15|Mnt
P09000108A0330|3 22|transcription product
P09000146T0000|0 16|Phenotypic changes
P09000589A0000|3 12|resurgence
P09000632A2341|5 14|p51 subunit
P09001213A1111|13 34|high level transcription
P09001245A0187|0 5|NUP145
P09001313A0000|0 9|Prevalence
P09001667A0312|5 9|cases
P09001828A0222|12 18|men aged
P09002648A0202|0 4|BCL-2
P09002672A0439|23 31|mTRF1 cDNA
P09003001A1593|24 37|E12 bHLH protein
P09003001A1909|3 15|E-box sequence
P09003311A0478|1 17|5.3-kb DNA fragment
P09003312A0740|0 17|Full-length AT-PHH1
P09003410A0000|3 18|human p100 protein
P09003462A0792|12 27|new mutation sites
P09003463A0198|33 48|characterization
P09003617A0000|1 6|cohort
P09004304A0000|31 45|reproducibility
P09004504A0000|3 18|primary structure
P09004987T0001|0 21|Serotonin concentration
P09005273A0322|0 18|MAIN OUTCOME MEASURES
P09005273A1558|0 9|CONCLUSION
P09005609A0299|0 17|Control examination
P09005836A0977|31 36|horses
P09005979A0841|3 9|GHR mRNA
P09006007A0997|3 9|results
P09006010A0527|3 25|linker-peptide insertion
P09006022A0252|17 28|gene products
P09006051A1162|0 3|PrpB
P09006555A0738|0 18|MAIN OUTCOME MEASURES
P09006902A0370|15 18|cDNA
P09006910A0000|16 25|mechanisms
P09006914A0812|0 2|JNK
P09006914A1127|3 9|effects
P09006935A0590|0 2|Sp1
P09006936T0000|0 13|Identification
P09008301A0193|0 16|Mutant enzyme forms
P09009208A0337|3 8|primer
P09010223A0667|30 33|ELK1
P09010223A1850|4 11|R-domain
P09011591A0309|3 13|total number
P09011744A0790|3 28|murine chromosomal locations
P09011745T0000|0 10|CDNA cloning
P09012405A0785|15 19|TTD-A
P09012636A0723|0 9|Adjustment
P09013499A0198|2 11|Experiment
P09013760A0000|0 42|Cholesterol side-chain cleavage cytochrome P450
P09015543A0210|3 18|possible solution
P09015757T0000|0 17|Structural analysis
P09015799T0000|0 17|Serotonin receptors
P09016566A0655|3 23|Y-type structural motif
P09017443A0734|1 25|false positive marker screen
P09018122A1389|3 11|detection
P09018133A0244|0 19|Phylogenetic analysis
P09019302A0600|13 15|PLP
P09020138A0833|4 7|HEF1
P09020169A0552|0 3|SIM1
P09020172A0964|0 8|Complexes
P09020856A0560|27 30|TIS1
P09021684A1418|0 15|Experimental data
P09022040A0263|7 25|L-plastin expression
P09022632T0000|11 21|gynecologic
P09023197T0000|3 12|dnaK operon
P09023378A0959|21 24|CBF1
P09024039A0247|9 25|ASA physical status
P09024097A0000|0 8|OBJECTIVE
P09024793A1325|5 37|electrophoresis mobility shift assay
P09024805A0905b|1 29|heterologous promoter construct
P09025122A0374|0 20|Subsequent experiments
P09025549A0000|41 50|competence
P09027346A1957|8 22|antibody binding
P09027506T0000|0 10|cDNA cloning
P09028089A0183|32 43|hypertension
P09028308A0590|3 17|initial patients
P09028942A0000|0 50|Human granulocyte-macrophage colony-stimulating factor
P09028998A0143|16 35|adequate local control
P09029091A0881|21 55|TCR-mediated tyrosine phosphorylation
P09029104A0226|8 12|IGLL1
P09029159A0000|3 12|interferon
P09029713A1120|27 47|cAMP-dependent control
P09029956T0000|0 14|Object relations
P09030581A0990|15 24|COS-7 cells
P09030688A0435|2 12|rlf2 mutants
P09030781A0734|0 10|Most kinases
P09031639A0474|8 13|kb cDNA
P09032233T0000|0 10|Interaction
P09032248A0239|8 12|Pho85
P09032250A0257|8 28|yeast two-hybrid system
P09032254A0724|0 15|Enhancer activity
P09032258A0395|0 6|Studies
P09032259A0150|0 21|Constitutive activation
P09032259A0972|12 25|Rac1 activation
P09032267A0850|0 13|Overexpression
P09032275A1133|4 19|inhibitory domain
P09032304T0000|0 13|Identification
P09032328A0650|0 12|DNA sequencing
P09034337A0251|0 6|Studies
P09035307A0000|24 37|30-year-old man
P09035612T0000|0 23|Cardiac endothelin release
P09036529A0343|3 8|workup
P09037032T0000|3 39|proliferation potential protein-related
P09037064A0183|0 16|Recent application
P09037163A1652|3 11|relevance
P09038166A0818|0 7|Exons A1a
P09038192A0846|1 21|MEK-specific inhibitor
P09038202A1951|30 47|repression activity
P09039744T0000|8 26|period-peak analysis
P09040011A1316|10 12|p56
P09041123A0195|23 35|cognate ligand
P09042078A0202|17 19|MBF
P09042269A1007|5 12|findings
P09042683A0492|3 18|FBF questionnaire
P09042755T0000|3 30|alternative sigma factor sigmaB
P09042911A0626|0 22|Cognate promoter elements
P09043534A1600|10 31|meaningful decreases due
P09043768A0139|16 26|biokinetics
P09045636A0789|0 15|CD3 cross-linking
P09045805A0945|0 26|Acetoin-dependent expression
P09045842T0000|0 8|Mutations
P09045919A1250|50 58|activator
P09046013A0000|3 25|neuroprotective efficacy
P09046090T0000|3 7|genes
P09046186A0189|3 11|protector
P09046384A0403|0 21|Marinol/marijuana usage
P09047252A0209|0 6|METHODS
P09047344A0000|0 24|Calmodulin-binding peptide
P09048617A0648|23 44|tyrosine kinase receptor
P09049198A0289|20 38|possible involvement
P09049270A0488|0 19|Northern blot analysis
P09049304A1193|2 23|co-transfection studies
P09049306A0830|3 9|HBP gene
P09049313A0116|6 14|instances
P09050689A0685|3 25|best endometrial ablation
P09050847A0180|17 44|III-specific TBP-TAF complexes
P09050849A0000|0 10|Cytohesin-1
P09050849A1459|43 62|BFA-sensitive ARF-GEP
P09050861A0903|32 34|DEK
P09050867A0542|5 12|elements
P09051656A0390|0 12|Tissue samples
P09053309A1103|13 41|impaired floor plate development
P09053494A0612|0 6|RESULTS
P09053835A0865|9 19|p53 activity
P09053973A1252|0 9|CONCLUSION
P09055221A0288|17 21|SSTEs
P09056761A0000|2 16|eukaryotic cells
P09057325A0177|11 21|plasmid pCM2
P09057648A0422|0 22|Transient cotransfection
P09057703A1389|0 13|Snail mortality
P09057840A0946|3 20|recombinant protein
P09057841T0000|0 11|Derepression
P09058002T0000|0 20|Exploratory-motor task
P09058250A0128|7 19|complications
P09058323A1287|3 9|results
P09058373A0670|0 25|RNase protection experiments
P09058373A1620|0 14|Functional tests
P09058378A1134|20 42|glucocorticoid receptors
P09059039A0850|0 10|99mTc-HMPAO
P09060045A0576|4 22|brief review analyses
P09060444A0557|4 18|promoter segment
P09060622A1679|9 19|first report
P09060623A0961|3 17|human coreceptor
P09060676A1634|5 11|changes
P09060971A0982|0 6|RESULTS
P09061697A0629|13 13|%
P09061697T0000|0 20|Myocardial SPET imaging
P09061698A0177|0 12|99Tcm-DMP-HSA
P09062130A0116|0 5|Relief
P09064659A1055|23 43|first mammalian homolog
P09064868T0001|1 11|miracle cure
P09065170A0853|13 22|zidovudine
P09065463A1012|0 16|DNA strand exchange
P09065690A0463|0 4|Ume6p
P09065768A0862|3 13|second class
P09067577A0307|2 10|cell lines
P09067577A0721|2 19|untransformed cells
P09068989T0000|0 5|Effect
P09071308A0376|0 6|RESULTS
P09071407T0000|11 18|oxytocin
P09072361A0357|2 28|cellular supernatant fraction
P09073074T0000|0 21|Antisense transcription
P09073582A0444|1 14|previous report
P09074508A0397|3 15|human CD38 gene
P09075739A0827|0 3|Type
P09076336A0281|0 11|GH deficiency
P09077076A0219|0 14|Positive CRP test
P09077108A0458|9 21|febrile period
P09077437T0000|0 20|Recognition mechanisms
P09077438A0076|13 29|essential subunits
P09079625A0935|0 9|Syndecan-4
P09079638A0883|3 13|3ASubE cells
P09079650A0136|0 6|Members
P09079689A0472|0 3|MOP5
P09079817A0928|10 21|NO production
P09079878A0000|7 8|kb
P09079902A0713|8 10|Pra
P09079904A0995|9 22|iron regulation
P09079915T0000|0 24|Molecular characterization
P09079928A0525|0 11|M. leprae OxyR
P09079928A1319|3 13|binding site
P09080250A0212|5 16|present study
P09080517A0215|11 18|patients
P09081389A1088|0 4|Grade
P09081392A0174|22 45|tolerable salvage regimens
P09082335A0730|0 3|None
P09083291A1378|5 13|TGF-beta1
P09083345A0851|18 23|values
P09083563A0971|3 18|prominent lesions
P09084174A0667|24 33|C-terminal
P09084176A0601|0 22|Transcriptional activity
P09084227A0833|0 9|Hovenitin I
P09084621A0374|0 11|Movement time
P09084621A2567|0 4|Areas
P09085842A0181|0 12|Recent studies
P09085842A1559|8 35|tri-snRNP-specific 27K protein
P09086268A0611|8 9|P7
P09087430A1046|11 24|same U1A peptide
P09088371T0000|0 11|Plasma levels
P09088416A0000|0 57|Idiopathic bilateral recurrent branch retinal arterial occlusion
P09088737T0000|0 9|Epithelial
P09089093A0373|0 8|Sequences
P09089653A0615|0 18|Recombinant plasmids
P09089653A1112|0 7|Analysis
P09090050A0419|8 17|homologous
P09090054A0186|20 23|loci
P09090592A0175|8 14|methods
P09091010A1003|5 9|women
P09091125A0161|0 23|Autorosette-forming cells
P09091403T0001|0 7|Analysis
P09092493A0861|19 25|VIP CyRE
P09092580A1354|5 11|studies
P09092636A0802|3 9|results
P09092675A0283|1 16|P22 R17 derivative
P09093867T0000|12 27|Ac/Ds transposons
P09094093A0578|25 31|TATA box
P09094315A0541|41 53|B-Myb activity
P09094671A1192|0 28|Candidate tumor suppressor genes
P09096229T0000|0 13|Excision repair
P09096234T0000|2 9|aromatic
P09096958A0000|28 47|monoclonal antibodies
P09098066A0119|4 8|locus
P09098899A0000|0 8|Coliphage
P09098899A0435|3 22|UV absorption spectrum
P09099683A0000|0 19|Diacylglycerol kinase
P09099702A0000|26 32|cloning
P09099702A0692|23 29|conRTRE
P09099743A0585|15 26|purification
P09099745A1446|0 14|Active complexes
P09100202A0000|6 10|Class
P09101085A0686|3 13|derivatives
P09101910A0394|3 24|perioperative mortality
P09102113A0739|0 26|Chronic renal failure patients
P09103382T0000|3 19|new FIGO definition
P09104816A0610|11 13|Vpu
P09105042A1497|25 33|phenotype
P09105363A0636|18 49|plasma atomic emission spectroscopy
P09105530A0000|2 11|egg protein
P09106057A0000|13 37|simultaneous determination
P09108029A0399|13 31|DNA-binding activity
P09108038A1128|8 16|LRR domain
P09108207A0306|42 64|oropharyngeal irritation
P09108279A0431|19 24|8-OxoG
P09108451A0160|0 6|Results
P09110176A0890|0 7|Northern
P09111004A0732|3 20|predominant effects
P09111048X0000|7 35|testis-specific mRNA transcript
P09111059A0327|9 25|MAR-binding domain
P09111309A0674|0 13|Cotransfection
P09111314A0970|0 7|Cyclin D1
P09111314A1243|15 41|posttranslational regulation
P09111331A0119|3 13|Rlm1 protein
P09111340A0240|10 27|cis-acting elements
P09111367A1098|12 22|experiments
P09111863A0743|18 29|common region
P09112400A1155|0 18|DNA-binding activity
P09114972A1366|4 12|induction
P09115242A0934|13 19|Western
P09115247A2069|0 24|11-Aminoundecanoyl-SK-NH2
P09115265A1160|3 29|carboxyl-terminal CCCC module
P09115279A0345|0 18|Cdc2 co-precipitates
P09115357A0073|0 5|Little
P09115365A0000|0 9|Expression
P09115395A0478|7 14|proteins
P09115989A0993|30 48|psoralen cross-links
P09117345A0945|0 9|Activation
P09118196A0281|0 10|Performance
P09118664A1734|0 11|L-canavanine
P09118704A0771|0 6|RESULTS
P09119031A1036|3 35|different holoenzyme RNA polymerases
P09119112A1350|39 44|GATA-5
P09119391A0870|3 16|exonic sequence
P09121424A0296|32 42|Swi3 homolog
P09121430A0132|0 2|Shc
P09121430A1075|11 22|Y239/240F Shc
P09121432A0000|3 37|Ras guanine nucleotide-binding protein
P09121433A0463|10 13|Rlm1
P09121435A1183|0 6|Domains
P09121452A0538|0 22|Domain switch experiments
P09121454A1328|3 19|similar phenotypes
P09121476T0000|0 4|PRH75
P09121774A0611|5 14|activities
P09121774T0000|11 24|small GTPase Rac
P09121998A0663|0 18|Time-activity curves
P09122168A1427|18 36|direct demonstration
P09122176A0970|3 9|results
P09122198A0478|0 13|Point mutations
P09122215A0335|11 21|novel method
P09123055T0000|0 19|Hepatocellular injury
P09123787A0486|32 40|responses
P09124054A1164|3 11|prognosis
P09126487A1399|6 8|Hum
P09126622A0466|3 18|pigment intensity
P09128730A0000|0 22|Malonate decarboxylation
P09129147A0644|3 20|Jem peptide sequence
P09130595A0478|15 21|cloning
P09130700A0676|0 13|Further support
P09130718A0497|0 8|Sequences
P09130720A0417|1 13|genetic screen
P09131139T0000|0 10|Implication
P09132011A0298|0 9|Comparison
P09132057A0559|1 11|polypeptide
P09132061A0828|3 5|atp
P09133122A0656|0 20|Additional information
P09135066A0653|30 39|active Mek1
P09135149A0000|43 90|M-phase-inducing Cdc2/Cdc13 cyclin-dependent kinase
P09135772T0000|0 15|Glycemic response
P09135928A0912|11 16|mmol/l
P09136015A0529|3 12|sequencing
P09136080A1469|3 9|results
P09138076A1099|2 23|gel mobility shift assays
P09138492A0806|0 13|Laboratory exam
P09139665A0784|18 30|PhLP complexes
P09139694A0789|0 8|CTF1alpha
P09139721A0183|0 7|Cyclin G2
P09139737A0000|1 24|sterol-regulated protease
P09139892A1150|20 23|orfX
P09139910A0350|0 15|Sequence analysis
P09139910A1572|14 27|Anabaena strain
P09140079A2528|34 36|TRs
P09140474T0000|2 21|leishmaniasis endemic
P09142146A0887|0 6|RESULTS
P09143328A1002|16 27|first example
P09143465A0838|0 5|Pure T1
P09144165A0614|13 26|ternary complex
P09144165A1275|21 27|NFAT RIR
P09144195A1051|21 32|PS1 fragments
P09144770A0906|4 12|conformer
P09144958A0047|32 39|promoter
P09146027A0809|10 15|Group B
P09146071T0001|0 15|Dystonic movement
P09147420A0623|28 38|HCMV IE1/IE2
P09147420T0000|0 2|TAR
P09147788A0458|0 29|Respiratory chain enzyme activity
P09147832A0174|0 7|Children
P09148770A0977|0 10|Cellular Csk
P09148903A1715|8 14|studies
P09148929A0372|3 16|P1 genomic clone
P09148935A0805|0 28|FN-stimulated c-Src PTK activity
P09149825A0151|1 18|promising new cement
P09149929A0750|0 8|Congruent
P09150334A0559|63 65|min
P09150566A0316|21 26|grains
P09150595A0225|7 15|elicitors
P09150595T0000|0 24|Molecular characterization
P09150728A0596|3 6|mRNA
P09150774A0616|0 9|Anesthesia
P09151152A0174|12 36|depressed protein C activity
P09151376A0000|22 45|hyperbetalipoproteinemia
P09151806A1125|31 39|2.0-kb LAT
P09151828A0919|3 26|altered amino acid residues
P09151837A0723|0 24|Rep-Rep protein interaction
P09151925A0479|3 7|C-LIP
P09152656A0149|8 15|patients
P09153010A0499|3 16|main advantages
P09153319A0844|21 38|preformed triplexes
P09153319A1332|0 22|Transfection experiments
P09153348A0647|17 25|plasma TBG
P09153795A0298|2 15|several studies
P09154283A0307|0 10|Latanoprost
P09154621A1475|5 11|results
P09154795A0628|5 21|various techniques
P09154797A0777|0 27|Saturable spermidine transport
P09154819A0501|0 22|Transient overexpression
P09154822T0000|0 9|Inhibition
P09154827A0158|0 14|Previous studies
P09155015A0140|17 34|protein kinase MEKK1
P09155024A0955|0 13|Overexpression
P09156883A0294|8 17|parameters
P09157100A0583|13 19|signing
P09157337A0545|20 33|married couples
P09157760A0000|4 15|quantitative
P09159111A0437|37 53|circular dichroism
P09159160A0000|0 16|Positional cloning
P09159183A0119|0 4|Genes
P09160361A0858|3 17|30-day mortality
P09160881A0491|18 40|co-precipitation studies
P09162084A0956|36 48|Src-SH2 domain
P09162092A0675|0 22|MKK3 autophosphorylation
P09162097A0776|22 36|MAdCAM-1 variant
P09162097A1258|51 67|human MAdCAM-1 cDNA
P09163332A0275|11 42|site-directed mutagenesis approach
P09164543A0219|0 7|MATERIAL
P09164856A0980|26 48|identifiable TATA element
P09165004A1700|0 10|SRE activity
P09165035A0842|0 31|Serum alkaline phosphatase activity
P09165039A0728|3 15|monkey LHR cDNA
P09165039A1372|13 29|marmoset monkey LHR
P09165118A0311|2 13|unc-4 mutants
P09167421A0234|0 23|Intracavitary irradiation
P09168083A0987|26 28|HAT
P09168134A0858|0 17|Sequence comparison
P09168218A0216|0 6|METHODS
P09168511A0640|30 45|developments such
P09168623A0614|1 25|xylE transcriptional fusion
P09168879A0219|2 24|AcMNPV-infected Sf9 cells
P09168892A1016|0 7|Mutation
P09169127A0371|3 16|close proximity
P09169420A0000|3 36|mammalian phosphoinositide 3-kinases
P09169475A0272|5 11|studies
P09169475A0772|0 11|Localization
P09169593T0000|0 16|Insulin regulation
P09169852A0235|0 9|Sequencing
P09169853A0000|0 4|Pax-3
P09170159A0348|21 34|dendritic cells
P09170159A0721|5 13|mutations
P09171038A0219|12 18|Sjogren
P09171081T0000|0 6|Cloning
P09171235A0851|10 23|overexpression
P09171239A1118|8 17|amino acids
P09171239A2146|16 51|RXR-specific ligand 9-cis-retinoic acid
P09171363A0149|2 9|ciliates
P09171389A0549|10 19|occurrence
P09171468T0000|0 24|Diver respiratory responses
P09171969A1165|0 10|Measurement
P09172312T0000|0 15|Characterization
P09172414A0000|1 51|reversed-phase high-performance liquid chromatographic
P09172641A0181|0 16|Mutational studies
P09172812A0660|17 27|fludarabine
P09173733A0404|5 23|different techniques
P09174049A1788|14 43|p34CDC2 histone H1 kinase activity
P09175708A1526|5 9|PRL-R
P09175858A1449|8 16|B-S mutant
P09176340A1194|0 12|Transcription
P09176837A0211|0 15|Computer software
P09177169A0935|1 14|similar chimera
P09177857A0000|3 12|conditions
P09178269A0107|6 10|genes
P09178491A0262|13 19|regions
P09178494A1123|18 24|folding
P09178752A0574|0 2|EGF
P09180687A0096|24 27|SulA
P09181130A1067|17 23|Krox-20
P09181130A1587a|24 39|detailed analysis
P09182281A0197|30 41|Cyclosporin A
P09182527A0443|0 9|Consistent
P09182707A0254|0 2|SPP
P09182990A0245|6 35|conditional-lethal mutant allele
P09183145T0001|0 9|Evaluation
P09183406A0637|1 34|neonatal alloimmune thrombocytopenia
P09185183A0089|17 23|unaided
P09185183T0000|0 41|Merosin positive congenital muscular dystrophy
P09185586A0000|0 18|Most eukaryotic mRNAs
P09185645T0000|0 9|Comparison
P09186056A0514|5 27|transient overexpression
P09186430A0341|15 20|ocular
P09186507A0882|11 24|126-nucleotide
P09187136A0000|0 5|SSeCKS
P09187277A0118|0 3|Type
P09187371A0450|10 26|1.3-kb mRNA species
P09187637A1199|0 16|Taurine deficiency
P09188094A0934|15 18|mcs4
P09188699A1388|3 25|extended rat SP-A isoforms
P09188863A0954|0 18|Alternative splicing
P09189783A0000|57 76|several small feedings
P09189896A0611|3 10|findings
P09190202A0166|4 14|coat protein
P09190821A0707|3 21|second primary mutant
P09190940A0127|0 8|Induction
P09191052A0850|8 10|PCE
P09192732A1384|15 33|NH2-terminal portion
P09192769T0000|0 15|Molecular cloning
P09192786T0000|0 11|Organization
P09192842A0988|5 29|mouse-human somatic hybrids
P09192998A0356|10 22|mutant enzymes
P09193072A0199|0 14|Cytological data
P09193077A0000|0 18|Light regulatory unit
P09193080A0904|0 17|Sequence divergence
P09193671A0347|3 13|active state
P09194250A0708|25 35|World Summit
P09195923A0125|3 14|immunophilin
P09197241A0770|2 20|adherent macrophages
P09197342T0000|0 8|Secretion
P09197408A0126|0 9|Sequencing
P09199167A0942|0 13|Overexpression
P09199286A0086|17 20|mkh1
P09199292A0536|11 35|stoichiometric association
P09199318A1147|12 15|p150
P09199322T0000|0 11|Denaturation
P09199327A1250|29 35|EM motif
P09199328T0000|14 21|residues
P09199348A0156|22 50|other important U14 interactions
P09199353A1924|12 18|results
P09199413A0518|11 22|inoculum size
P09199626A0613|4 8|cases
P09199932A1357|0 28|Promoter recognition algorithms
P09199970A1101|0 21|Recombinant soluble pMCP
P09200029A0211|0 7|Clinical
P09200498T0000|0 11|Spatial zones
P09200530A0411|0 30|Liquid chromatographic separation
P09200811T0000|3 20|linear plasmid pDHL1
P09201946A0000|3 13|RNA-binding
P09201980A0910|3 15|p20-CGGBP gene
P09202147A0866|24 28|yeast
P09202669A0614|3 8|pWP-19
P09202669A1530|16 46|rAAV-mediated gene transfer system
P09202859A0091|3 13|serum levels
P09203585A0660|1 15|striking feature
P09203586A1197|17 27|recruitment
P09203731A0497|9 31|International Commission
P09204566T0000|0 9|Functional
P09204570A0110|19 32|new MADS box gene
P09205113A0587|4 6|E14
P09205677A0577|0 3|Lung
P09205965A1249|3 9|results
P09206230A0000|0 8|OBJECTIVE
P09206968A0000|0 10|Disturbance
P09208214A0572|0 18|Sternocleidomastoid
P09208930T0000|0 13|Identification
P09209031A0350|3 24|C-terminal mature region
P09209312A0968|3 14|RNA construct
P09209372A0345|21 25|AML1a
P09209406A1021|25 41|homologous regions
P09209438A0994|13 33|ATL-16T nuclear extract
P09210012A0000|11 23|social support
P09210478A0000|24 48|hypoxia-inducible factor-1
P09211354A0000|0 12|Stromelysin-1
P09211605A0478|0 5|Tendon
P09211675A0392|0 11|Surveillance
P09211913A0000|0 41|Aryl hydrocarbon receptor nuclear translocator
P09211934A0722|0 4|DNase
P09211981A0526|25 28|gar2
P09212059A1356|21 52|metal affinity chromatography assay
P09212059A1856|3 16|overall results
P09212063A0425|28 34|A-phage
P09214274T0001|0 18|Colorectal carcinoma
P09215525A0581|16 25|Dox effects
P09215891A0000|3 10|products
P09216017A0621|0 9|Vitrectomy
P09216936T0000|7 15|editorial
P09218436A0443|4 12|promoters
P09218459A0000|0 18|Serum response factor
P09218520A0075|15 21|studies
P09218599A0184|30 39|mechanisms
P09218775A0000|21 27|strains
P09218775A1229|0 7|Activity
P09219526A0383|3 29|Man9-mannosidase specificity
P09220158A0537|1 20|soluble 62-kDa protein
P09220177A0564|3 17|CPK-MB isoenzyme
P09222057A0176|0 4|Serum
P09222115A0545|0 6|Results
P09223042A0000|0 23|Liver regional blood volume
P09223122A0774|3 23|gray matter NAA/mI ratio
P09223229A0565|9 14|murine
P09223475A0898|0 37|Chloramphenicol acetyltransferase assays
P09223479A1193|0 4|ORF M1
P09223506T0000|0 40|Transcription factor binding sites downstream
P09223647T0000|0 15|Crystal structure
P09223667A0139|7 27|transient transfection
P09223880A1147|17 30|injection speed
P09224655T0000|0 18|Alternative splicing
P09224811A0000|3 14|current study
P09225151T0000|13 26|different types
P09225506A0462|3 14|control group
P09225682A0579|14 43|positive anti-GM1 antibody titers
P09225686A0683|0 34|Stereotactic radiofrequency lesioning
P09225998A0000|0 32|NF-kappa B/Rel transcription factors
P09226113A0857|22 38|source water sample
P09226345A0436|12 21|food intake
P09227099A0106|31 42|modification
P09227332A1798|10 12|DDC
P09227799A0254|15 28|diagnostic tool
P09228042A0109|16 42|dermatan sulfate proteoglycan
P09228092A1779|5 12|analyses
P09228202A0581|3 45|selective 5-HT3 receptor antagonists ramosetron
P09229420A0158|0 12|Re-evaluation
P09229595A0618|3 16|corneal buttons
P09230129A0039|11 29|apparent homogeneity
P09230216T0000|0 30|Human thymine-DNA glycosylase maps
P09230307A0329|0 2|FOG
P09230384A0725|3 11|mean times
P09230384A1056|9 14|BACTEC
P09230894A0422|18 24|KmMig1p
P09230945A0089|1 24|pre-boutonniere deformity
P09230986A0000|0 20|Autoimmune neutropenia
P09232593A0946|15 45|characteristic expression pattern
P09233487A1386|0 13|Future analysis
P09233772A0136|22 25|p532
P09233801A1180|8 18|L45 sequence
P09233809A0381|6 15|mouse lines
P09233809A0815|7 31|plasmid-derived transgenes
P09233811A0072|25 39|HMG-box proteins
P09234677A0770|36 51|short transcripts
P09234690A0242|0 7|Upstream
P09234696A0238|0 29|Prominent protein kinase cascades
P09234703A0192|0 2|JNK
P09234713A0754|37 56|ligation-mediated PCR
P09234717A0000|0 12|Recent studies
P09234720A1015|38 40|MEK
P09234723A0846|27 36|other cases
P09234725A1892|17 47|ligand-dependent transactivation
P09234727A0770|0 20|Gal4-Eed fusion protein
P09234736A0999|6 26|hybridization analysis
P09234743A0475|14 21|proteins
P09235073A0000|2 6|years
P09235424A1200|10 17|measures
P09235618A0000|11 18|patients
P09235995A0339|1 5|1996a
P09235998A0788|10 27|membrane expression
P09236118A1455|3 9|results
P09236224A0939|0 18|Sustained activation
P09236441A0639|14 21|patients
P09236656A0124|3 25|mean total white cell count
P09237695A0000|1 29|prospective observational study
P09237862A0782|5 20|experimental eyes
P09238467A0763|5 11|lesions
P09238850A0785|12 15|ICER
P09238850A2042|4 23|night-day oscillation
P09238860A0175|16 22|nucleus
P09238860A1974|5 9|cells
P09239635A0477|11 14|dogs
P09241092A1108|0 10|CONCLUSIONS
P09241232A0653|3 13|Ogg1 protein
P09241232A1154|1 17|consensus sequence
P09242375A1313|13 20|findings
P09242499A0505|0 9|Volunteers
P09242506A1033|0 2|E2F
P09242551A0653|0 8|EBER1 mRNA
P09243267A0401|0 6|METHODS
P09243385A1314|15 27|presaturation
P09243505A1194|14 35|DNA-binding experiments
P09243587A0000|0 17|PURPOSE/OBJECTIVES
P09243840A0663|3 16|related studies
P09244100A0194|10 13|rats
P09244282A1371|0 10|Mutagenesis
P09244350A0000|0 4|BRCA1
P09244430A0693|3 24|alternative splice sites
P09246343T0000|0 10|Proteinuria
P09246585T0000|0 13|Neural blockade
P09247645A0000|3 33|new temperature-sensitive alleles
P09248639A0152|4 14|cell strains
P09249039A0124|16 25|key enzymes
P09249070A0989|0 3|Cell
P09249710A0331|10 27|ELISA-positive sera
P09250554A0402|0 7|Patients
P09251843A0189|0 26|Reactive lymphoid hyperplasia
P09252397A0081|23 33|repair rates
P09252406A0511|0 7|Tyrosine
P09252879A0470|16 27|HRCT findings
P09254678A0106|0 6|Gtx mRNA
P09254709T0000|0 7|Contacts
P09255349A0836|20 25|GTPase
P09256973A0455|3 4|E2
P09256973A0673|0 6|RESULTS
P09257651T0000|3 17|human U4/U6 snRNP
P09257887A0457|0 4|G-CSF
P09258439A1001|7 22|expression system
P09258606A0822|0 8|Crosstalk
P09259052A0568|0 15|Supershift assays
P09259313A0950|13 28|PI kinase activity
P09259315A0809|0 7|Mutation
P09259320A0830|5 33|lectin-affinity chromatography
P09259328A0440|0 25|Deletion mapping experiments
P09261155A0833|15 16|PH
P09261178T0000|3 42|mouse extracellular signal-regulated kinase
P09261184A0170|16 39|gel mobility shift analysis
P09261200T0001|0 8|MR imaging
P09261397A0509|0 23|Gag protein sequence motifs
P09263010T0000|0 8|Induction
P09263094A0799|0 11|MEASUREMENTS
P09263856A0563|13 29|theoretical models
P09264466A0947|3 13|Cut9 subunit
P09265534A0455|12 32|Gy/20 fractions/5 weeks
P09265642A0668|10 28|biosynthetic pathway
P09265932A0575|6 10|women
P09267306A0381|48 51|apo B
P09267431A0000|3 19|soybean cDNA clones
P09267439A0000|0 4|Genes
P09267542A0126|0 9|Naltrexone
P09268298T0000|0 18|Ent-kaurene synthase
P09268387A0293|52 71|ELL functional domains
P09268578A0225|12 24|cDNA sequences
P09268631A0316|12 35|transcription orientation
P09268638A0332|15 49|directional chromosome walking studies
P09268652A0116|11 32|novel zinc finger protein
P09268661A1405|3 9|results
P09269879A0266|0 14|Nasal absorption
P09269900A1035|14 20|results
P09271393A1333|38 50|Tax anchors CBP
P09271394A0558|0 4|DNase
P09271397A1596|0 9|Consistent
P09271400A0475|0 12|Various assays
P09271417A0585|5 14|adult mouse
P09271417A1011|3 36|MCAD nuclear receptor response element
P09271496T0000|0 14|Mapping features
P09272108A1295a|0 7|Analysis
P09272108A1295b|0 7|Analysis
P09272138A1153|3 18|complete response
P09275159T0000|0 38|Heterogeneous nuclear ribonucleoprotein A1
P09275164A0000|3 21|m7GpppN cap structure
P09275990A0938|5 13|first part
P09276882A0479|25 26|CC
P09277472A1070|0 26|Myocardial interstitial edema
P09277629A0268|3 13|experiments
P09278441A0163|0 3|Biol
P09278441A1160|21 38|CARP mRNA expression
P09278441A1777|0 13|Overexpression
P09278445T0000|0 19|Substrate specificity
P09278450A1338|0 33|Electrophoretic mobility shift assays
P09278454A1261|0 10|Examination
P09278475A0465|6 10|scs32
P09278494A0762|15 17|Sp1
P09278758A1636|0 9|CONCLUSION
P09279379A0310|19 44|pBR322 deoxyribonucleic acid
P09279889A1124|0 3|Area
P09280747A0195|16 39|hydralazine hydrochloride
P09282329A0527|9 18|mechanisms
P09282911A0277|31 50|neuronal cell cultures
P09282985A0961|9 19|differences
P09283828A0484|5 22|circadian responses
P09285715A1257|8 19|previous data
P09285789A0712|0 7|Human Duo
P09286115T0000|0 2|S2F
P09286981A0147|0 3|ArgR
P09287036A0457|0 25|Plasma leptin concentrations
P09287352A0930|0 9|Consistent
P09287362A0589|26 34|SH3 region
P09288848A0780|12 13|Gy
P09288916T0000|0 18|Polarised expression
P09290207A0731|7 12|mutant
P09290571A0420|7 14|patients
P09290571A0799|3 13|cycle length
P09291077T0000|0 23|Transient hyperammonaemia
P09291098A0452|23 31|kb mRNA V-1
P09291098T0000|1 22|specific distal promoter
P09292499A0887|5 18|repressor sites
P09293006A1412|3 18|higher expression
P09294139A0729|7 30|135-bp core homology region
P09294161A0650|15 30|wild-type protein
P09294161A1103|5 12|findings
P09294262A0885|3 16|promoter region
P09294422A1223|6 28|cysteine residues located
P09294422A1376|3 9|por gene
P09294452A2107|7 24|downstream operator
P09294453A0949|3 12|ORF3 mutant
P09294471A1198|7 15|Cox models
P09296251A0163|20 26|reports
P09297698A0933|5 15|transcripts
P09299696A1074|17 30|cryptosporidia
P09300323A1182|13 54|subendocardial/subepicardial blood flow ratio
P09300697A0000|0 10|Proteasomes
P09300698A1219|46 49|MQ9b
P09301114A0573|0 8|Takahashi
P09301350A0946|3 21|sputum interleukin-8
P09303437A0875|16 23|deletion
P09303635A0000|0 6|Gaucher
P09304123A0079|5 17|discoloration
P09305592A0000|7 44|chromosomal translocation characteristic
P09305631A0770|0 13|Overexpression
P09305755A0540|5 18|flanking region
P09305870A0894|3 24|recognition specificity
P09305944A0621|14 27|RanGAP activity
P09307065A0553|14 21|MHC class
P09307312A0172|0 7|Evidence
P09308234A0225|0 2|Mnt
P09308738A1216|5 26|United States high-MW HES
P09309457A0680|0 5|Assays
P09310836A1019|3 15|tandem repeats
P09311164A0245|14 28|current density J
P09311568A0595|3 20|cleavage dipeptides
P09311796A0218|5 19|previous studies
P09311808A0341|31 40|p4 molecule
P09311810A0814|7 18|accumulation
P09311835A0147|11 48|preliminary biochemical characterization
P09312025A0373|5 11|effects
P09312025T0000|0 19|Protein phosphatase 2A
P09312028A0975|17 49|RXRalphaF318A constitutive activity
P09312032A0165|5 11|introns
P09312087A0000|0 12|Recent studies
P09313755A0816|13 22|clustering
P09314306A0571|0 14|Supplementation
P09314487T0000|0 8|Detection
P09314537A1600|5 12|findings
P09314554A0149|25 46|scanthrough translation
P09314570A0153|12 19|proteins
P09315631A1064|0 7|Deletion
P09315632A1137|15 30|novel observation
P09315633A0333|10 26|amino acid sequence
P09315651T0000|0 10|Involvement
P09315678A0278|8 12|Cbf5p
P09316937A0133|53 65|discrepancies
P09317131A0000|0 25|Ig heavy chain class switching
P09317131A1332|3 15|available data
P09317757T0000|0 7|EXERCISE
P09317830T0000|12 24|SONG FREQUENCY
P09321406T0000|3 26|pheromone response pathway
P09321657A0439|27 35|mutations
P09321930A0567|11 38|multiple tumor suppressor genes
P09322738A0510|3 22|histidine-tagged gene
P09322872A0745|10 17|deletion
P09323366A0000|3 20|malate synthase gene
P09323366A0299|2 17|deletion analysis
P09323612A0374|0 3|Lack
P09324720A0317|7 11|meals
P09324878A0952|13 31|abdominal aortic wall
P09324922T0065|0 18|Fermentation process
P09324988X0000|0 9|Substrates
P09325022A0192|0 6|Ovaries
P09325135A0737|3 21|Trx-CT fusion protein
P09325273A1240|5 11|results
P09325278A0458|1 22|data base homology search
P09325284A0469|12 15|cDNA
P09325322A1293|3 12|inhibition
P09326163A0942|0 6|RESULTS
P09326246A0567|0 15|Sequence analysis
P09326263A0410|7 10|RACE
P09326317A0372|9 18|first study
P09326727T0000|3 15|regurgitation
P09327881T0000|0 37|Positron emission tomography radioligands
P09328341A1449|0 10|Attenuation
P09328343A0181|0 9|Expression
P09328349A1679|8 15|CCAAT box
P09328476A0068|0 9|U4/U6 snRNP
P09328476A0374|0 5|Hprp3p
P09328824A0000|3 28|growth-promoting properties
P09328833A0588|9 20|complete cDNA
P09331119A0659|7 17|common grade
P09331864A0230|0 18|Serum concentrations
P09331864A0848|0 20|Serum E2 concentrations
P09333018A0000|0 25|Interferon Regulatory Factor
P09333026A0397|3 18|genomic structure
P09333026A0851|41 46|tumour
P09333168A0310|0 19|Anti-hepatitis A virus
P09334264A0540|13 26|calf thymus CstF
P09334330A0252|0 12|Null mutations
P09334331A0910|3 9|results
P09334475A0327|0 7|PATIENTS
P09335267A0142|12 26|operon structure
P09335298A0529|24 35|parCBA operon
P09335298A1227|15 23|insertion
P09335298A2129|23 41|apparent differences
P09335608T0000|0 22|Splice-junction elements
P09335619A0583|0 25|Nucleotide sequence analysis
P09336455A0000|17 24|kinetics
P09337861T0000|0 6|Cloning
P09338414A0430|0 6|Ea value
P09339900A0939|0 17|Functional analysis
P09340641T0001|0 5|Effect
P09341139A0690|11 25|resensitization
P09341158A0167|3 14|medium chains
P09341182A0605|61 73|BTB/POZ domain
P09341192T0000|0 11|Osmotic shock
P09341193A0362|16 18|Sp1
P09343208A1405|14 27|segment nesting
P09343210A1112|12 19|deletion
P09343222A0415|3 5|AGM
P09343398A1193|0 11|Processivity
P09343426A0456|0 27|Alanine substitution mutations
P09343432A0209|3 5|Scm
P09343433A0000|28 32|genes
P09343433A0360|9 18|rad6-delta
P09343982A0890|3 11|amplitude
P09344650A0967|14 32|transmembrane domain
P09345037A0886|9 13|roles
P09345495A0000|0 19|PET activation studies
P09346238T0000|0 12|F-box proteins
P09346621A1181|14 35|liver allograft shortage
P09346925A0660|3 12|SH3 domains
P09346935A0459|2 20|far-Western analysis
P09346935A0927|5 24|ZNF74 sublocalization
P09346938A1680|0 30|Ki-ras4BVal-12 transfectant cells
P09346953A0000|3 14|cellular rate
P09348226A0852|14 16|EGF
P09348931T0000|10 16|lottery
P09349501A0196|25 47|N-terminal portion common
P09349967A0653|3 9|results
P09351242A0719|0 8|Induction
P09351823A0414|17 29|MAPK functions
P09352016A1110|6 17|AF G-CSF level
P09352127A0953|1 19|positive correlation
P09353247A0922|15 39|over-replication phenotype
P09353255A0159|0 4|Rip1p
P09353296A0510|3 12|CNXA domain
P09353304A0732|0 8|Deletions
P09353328A0736|18 38|kinase catalytic domain
P09353343A0919|0 12|RNA polymerase
P09353343T0000|0 9|Modulation
P09354349A0338|0 17|Histological slides
P09354644A0124|5 16|biosynthesis
P09354676A1714|5 12|findings
P09354684A1158|11 18|mutation
P09354757A1444|0 16|Amino acid residues
P09356645A0672|26 32|sarcoma
P09358045A0000|3 24|full length cDNA sequence
P09358055A0590|21 28|homology
P09358069T0000|0 16|Codon optimization
P09358837T0000|0 14|Parodoxical rise
P09359844A0674|2 2|%
P09359887A1168|32 44|Rat7p/Nup159p
P09360422A0135|12 19|patients
P09360953A1057|5 12|residues
P09360956A0840|24 38|phosphorylation
P09360993T0000|0 20|Mouse mast cell protease
P09361007A0922|1 25|DNase I-hypersensitive site
P09362105X0422|1 27|Pulmonary vascular resistance
P09362473A1540|12 18|results
P09362480A0452|2 23|unusual cysteine triplet
P09362499A0000|3 12|Fis protein
P09363759A0000|0 18|Protein phosphatases
P09364211A0319|3 43|cell cycle-regulated transcription factor E2F
P09364440A2206|22 37|modular structure
P09364750T0000|0 24|Transcriptional regulation
P09365201A2018|5 11|studies
P09365272T0000|0 24|Xenopus Ran-binding protein
P09365431A0314|29 43|benzodiazepines
P09366456A0234|0 6|METHODS
P09366517A0835|0 2|PKA
P09366517A1828|3 10|findings
P09366628T0000|0 1|Re
P09367288A0115|1 9|second aim
P09367392A0567|15 32|additional sequence
P09367426A1354|14 24|primary role
P09367676A0275|0 23|Restriction enzyme mapping
P09367676A1115|0 19|Transfection analyses
P09368006A1332|3 9|results
P09368014A0740|3 17|lysozyme FEF site
P09368026A0000|0 10|Osteocalcin
P09368026A0435|24 30|effects
P09368057A1083|11 23|other proteins
P09368058A0969|11 52|CAK-phosphorylated phosphopeptide comigrates
P09368100A1354|3 27|mHIF-1 alpha structural gene
P09368190A1053|20 43|upstream IRE-like sequence
P09368419A0000|2 12|Arabidopsis
P09368419A0628|1 4|cDNA
P09368760A0665|0 8|Human PDK1
P09369450A1358|8 25|synergistic effects
P09369451A0693|0 17|Mutational analysis
P09369453A0273|6 21|most other members
P09369482A0690|0 19|Electromobility shift
P09370276A0781|2 17|open reading frame
P09370307A0093|13 21|AACA motif
P09371431A1172|0 11|Strain CFN037
P09371431T0000|0 9|Expression
P09371455A0000|40 51|lipase operon
P09371564A0713|23 26|tRNA
P09371566A1384|26 44|HeLa nuclear extracts
P09371596T0000|0 21|Differential regulation
P09371612A1964|0 3|Acad
P09371622A0779|0 7|Chimeras
P09371626A1345|3 9|results
P09371657A0165|24 46|alanine cluster mutations
P09371698A1254|0 11|Transfection
P09371731A0627|4 10|inserts
P09372287A0296|5 23|monopolar electrodes
P09372451T0000|0 7|Epitopes
P09372908A1068|0 11|Polyhomeotic
P09372924A0758|16 29|rhHR23 proteins
P09372937T0000|3 45|yeast silent information regulator Sir4p anchors
P09372950A1283|5 11|results
P09372960A0456|0 15|Polysome analyses
P09372968A0532|0 15|Sequence analysis
P09372968A0996|14 17|HeLa
P09373140A0000|3 35|mouse M-lysozyme downstream enhancer
P09373155T0000|0 13|Identification
P09373651A0255|0 12|Bitter cassava
P09374082A0504|22 33|effect states
P09374541A0277|9 27|protein binding sites
P09374541T0000|0 21|Constitutive protection
P09376325A0167|0 9|Comparison
P09376626A0737|0 8|Radiation
P09376782A0328|30 52|major MMT general practice
P09377355A0362|17 32|extensive own data
P09377374A0000|12 27|characterization
P09379301A2036|3 9|microns
P09380504A1255|3 11|ZnF20 cDNA
P09380507A0514|0 23|Glutathione S-transferase
P09380697T0000|3 39|sterol regulatory element-like sequences
P09380707A0714|12 29|DNA-bound LAZ3/BCL6
P09381261A0970|0 10|CONCLUSIONS
P09381950A0209|0 8|Ischaemia
P09382498A0618|9 12|MCTs
P09382850A0000|0 9|BACKGROUND
P09382886A1061|0 10|Direct proof
P09382924A0131|37 47|stimulation
P09383156A0691|3 28|major RNase E cleavage product
P09383188A0654|30 39|lower match
P09385169T0000|3 6|AONE
P09386074A0694|3 6|pigs
P09387333T0001|13 33|morphological research
P09387999A1053|3 12|amplitudes
P09388198A1396|30 65|signal transduction pathway independent
P09388199A0948|12 26|separate domains
P09388200A0639|0 9|Inhibition
P09388201A1027|2 3|PU
P09388246A0903|12 58|immunogold electron microscopy immunocytochemistry
P09388271A1243|3 15|mobility shift
P09389137A0763|18 25|apoplexy
P09389198A0363|9 17|aftermath
P09389492A0520|3 16|similar fashion
P09389666A0538|5 17|Hex expression
P09389669A1009|5 7|dpp
P09389982A1383|0 10|CONCLUSIONS
P09390125A0379|0 6|RESULTS
P09390183A1027|0 18|Western blot analysis
P09391173A0811|0 22|Transcription start sites
P09392979T0000|0 11|AIDS-related
P09393706A1171|5 7|Fis
P09393717A1517|5 16|observations
P09393771A1659|0 16|TNF-alpha exposure
P09393875A0873|18 45|human papillomavirus late mRNAs
P09393966A0190|10 38|related IgH constant region genes
P09394650A0121|57 72|normal lymph nodes
P09395456A0424|16 31|heavy chain motifs
P09395470A0294|0 11|CKbeta4GT-II
P09395525A0395|20 48|CCAAT/enhancer-binding protein
P09396402A0264|0 7|PATIENTS
P09396427A1488|17 45|residual infarct-zone viability
P09396437A0878|5 13|BMI cutoff
P09396722A0185|8 12|ApxII
P09396796A1173|31 35|CDF-1
P09396823T0000|38 50|DNA polymerase
P09397261A0940|0 18|Interleukin-1 levels
P09397723T0001|0 20|Responsibility matters
P09398267A0440|0 19|Southern blot analysis
P09398332A0732|0 8|Sequences
P09398598A0256|29 47|Chinese hamster ovary
P09398855A0438|0 4|SCID V
P09400613A0594|0 11|Coexpression
P09400613A1209|5 31|GST-PKR fusion chromatography
P09400738A1046|6 32|greater inflammatory response
P09402029A1632|17 36|avirulent strain H37Ra
P09402088A2250|5 11|defects
P09402139A1121|0 11|Similarities
P09403059A0209|4 15|binary repeat
P09404725A0644|4 7|days
P09405195A0320|0 21|Large genomic constructs
P09405380A0800|22 31|categories
P09405536A0777|9 29|conditioning procedure
P09405685A0113|3 48|sequence-specific DNA binding transcription factor
P09407026A0426|0 11|TSA treatment
P09407031A0557|4 11|UV damage
P09407031A0974|9 30|moderate overexpression
P09407036T0000|0 10|Tcn1p/Crz1p
P09407090T0000|0 8|Structure
P09407642A0305|15 26|gel technique
P09408516T0000|0 8|Stability
P09408796A0648|0 25|Multiple regression analyses
P09409416A0111|0 21|Bilateral basal arteries
P09409774A0214|5 16|genomic level
P09409821T0000|26 34|RAD30 gene
P09411459A0729|11 23|new experiment
P09412079T0001|0 10|Diet therapy
P09413375A1486|2 12|ICU patients
P09414074A0827|0 17|Resistance training
P09414287A0637|0 14|Gel-shift assays
P09414319A1442|0 5|Y15170
P09415711A1348|0 15|Gel mobility shift
P09416467A0959|5 11|results
P09416898A1798|3 12|mean values
P09417082A0127|11 26|signaling cascade
P09417108A0000|3 21|murine Htf9-a/RanBP1
P09417493A0823|2 11|accordance
P09417870A0105|28 36|depletion
P09417928A0980|0 10|Replacement
P09417941A1287|3 19|disulphide bridges
P09418040T0000|0 11|Mg-chelatase
P09418057A0684|3 7|R-EST
P09418861A0623|3 22|multidomain structure
P09418871A0620|21 23|DDB
P09418882A0760|13 22|antibodies
P09418905A1396|5 11|results
P09419415A0236|26 39|STAT activation
P09419421A0385|2 22|serum-stimulated cells
P09419680A1112|0 9|CONCLUSION
P09420219A0284|30 39|parameters
P09420220A0070|0 40|Cell factor-mediated regulatory interactions
P09420234A0654|0 7|MpB GroEL
P09420239A1937|3 19|critical mutations
P09420251A1363|0 1|C.
P09420252A0092|11 28|long terminal repeat
P09420269A0000|13 22|genomic RNA
P09420275A0682|16 27|requirements
P09420275A1111|14 23|affinities
P09420671A1190|0 10|CONCLUSIONS
P09421507A0000|3 17|SR protein family
P09421508A0696|26 30|TCF11
P09421511A0827|8 23|other comparisons
P09421516A1516|0 12|Deadenylation
P09421521T0000|0 24|Holliday junction resolvase
P09422351A0000|0 2|Ca2
P09422727A0196|1 27|cAMP-responsive element-like
P09423123A0000|0 3|IVOX
P09423310A0251|0 18|Histopathologically
P09423856A1098|0 17|Protease activities
P09423968A0039|22 34|such analgesia
P09424012A1774|5 29|large field placement errors
P09425036A0649|25 39|inactive version
P09425038A0752|0 1|A.
P09425676A0000|0 17|Neuronal mechanisms
P09426068A0826|3 21|c-myc/TGF-alpha HCCs
P09426143A1358|35 53|antagonistic effects
P09426183A0000|3 31|well-known Rel/NF-kappaB family
P09426239A0386|3 11|cglIM gene
P09426595T0000|0 28|Lysine-ketoglutarate reductase
P09426907A0391|43 56|new formulation
P09426958A0110|3 12|study goals
P09427544A0000|3 9|pel gene
P09427551A0501|18 22|exons
P09427627A0802|2 15|Xenopus embryos
P09427627A0930|1 16|cytosolic variant
P09427627T0000|0 20|Small-molecule control
P09427844A0739|14 31|inactive dAK subunit
P09428389A1805|0 10|CONCLUSIONS
P09428787A0138|1 12|genomic clone
P09428799A0897|30 36|smaller
P09429913A0528|0 6|RESULTS
P09430461A0742|5 17|clinical study
P09430661A0796|0 22|Transient overexpression
P09430668A0172a|3 10|promoter
P09430730A0374|0 1|S.
P09431812A0576|21 22|Hh
P09431828A1472|14 27|median increase
P09432752A0109|0 7|Patients
P09434160A0767|0 13|Several PTPases
P09434160A2078|0 9|Expression
P09434185A0902|17 25|SPP1 genes
P09434979A0790|3 9|results
P09435056A0128|3 24|functional mature domain
P09435116A0437|0 6|Isomers
P09435789A0961a|8 12|RAD17
P09435806T0001|0 12|Clinical value
P09436657A0303|46 53|pathways
P09436706A0168|22 57|intracytoplasmic sperm injection cycles
P09436795A0350|0 17|Protein C deficiency
P09436989A1011|34 50|essential function
P09437001A0769|11 24|overproduction
P09438165A0405|0 13|Normal baseline
P09438427A0727|22 31|CE2 element
P09438427T0000|2 13|evolutionary
P09440166A0857|0 6|RESULTS
P09440616A0422|20 29|activities
P09441664A0377|27 59|liver-enriched transcription factor
P09441746A0546|1 9|cDNA clone
P09442017A0435|6 12|Science
P09442024A0236|0 1|P.
P09442024A0708|1 14|hybridoma clone
P09442031A0586|28 37|estimation
P09442072A0716|7 11|DNase
P09442080A0856|1 22|reciprocal binding assay
P09442172A0908|14 21|basal FSH
P09443948A0000|1 16|comparative study
P09443972A1145|3 9|results
P09443973A1028|0 3|CES4
P09443978A0262|26 30|cells
P09444316A0388|2 32|apparent clinical signs indicative
P09445056A0215|10 47|mutation-directed chemical cross-linking
P09445488A0230|23 38|USH1C disease gene
P09445488A1169|0 17|PowerBLAST analysis
P09446600A0260|1 13|fusion protein
P09446616A0780|0 13|Reconstitution
P09446815A1021|21 36|regulatory region
P09447917A0000|15 21|Geisler
P09447962A0452|3 18|second transcript
P09447962A1027|0 9|Consistent
P09447963A0223|0 3|Sip1
P09447973A0168|0 9|Consistent
P09447979A1430|0 12|Such mutations
P09447994A0000|0 13|Several studies
P09448268A0186|13 18|kinase
P09448574A0964|3 10|findings
P09449018T0000|0 19|Childhood misbehavior
P09450932A0142|0 14|Genetic analysis
P09451003A0894|5 21|Esigma54 promoters
P09451016A1037|0 5|GlcNAc
P09451857T0001|0 12|Demonstration
P09452421A1042|0 9|Antibodies
P09452444A0000|0 12|Interleukin-6
P09452444A0450|14 28|various deletion
P09453537A0863|28 36|CCAATC box
P09453689A0000|26 39|intact perianal
P09454719A0181|3 20|correct termination
P09454735A1782|0 5|Levels
P09455695A0762|0 8|ALT levels
P09456312A1064|16 34|COOH-terminal domain
P09458021A1373|4 4|%
P09458030A0192|43 45|MMF
P09459241A0707|0 3|Pao2
P09459685T0001|0 20|Typical configurations
P09459835A0297|4 7|cats
P09460171T0000|0 9|Resistance
P09461594A0000|36 53|DT40 lymphoma B cells
P09463174A0670|12 29|preliminary results
P09463380A1050|9 15|xTAK1KN
P09463560A0124|0 7|PATIENTS
P09463964A0243|3 7|assay
P09463991T0000|11 15|audit
P09464248A0289|1 16|canonical TATA box
P09464525T0000|0 9|Expression
P09465035A1032|1 17|putative inhibitor
P09465783A0449|0 18|Platelet aggregation
P09466267A1192|5 15|himA mutants
P09466931T0000|0 12|Cross-talking
P09467044A0973|3 35|ipsilateral breast tumor relapse rate
P09467707T0000|0 17|Sibling aggregation
P09467900A0701|3 15|CAPLC1 protein
P09467955A0468|33 42|occurrence
P09468386A0594|0 4|Pet-1
P09468509A0463|21 29|F2771 cDNA
P09468514A1065|0 15|Northern analysis
P09468515A0621|7 21|further deletion
P09469415A1337|18 23|beta 2m
P09469820A0151|3 7|mRNAs
P09469833A0533|34 48|site specificity
P09469933A1060|5 11|tissues
P09471984A0000|0 9|BACKGROUND
P09472038T0000|0 23|Cytoskeletal polarization
P09472608A0253|33 51|cellular protein YB-1
P09472616A1004|15 24|amino acids
P09473040A1303a|9 16|alcR gene
P09473040A1303b|9 16|alcR gene
P09473317X2131|0 8|Copyright
P09473483A0953|24 37|particular care
P09473755A0318|0 7|PATIENTS
P09474001A0825|14 16|SPs
P09474648A0298|13 19|P-SAECG
P09475378A1449|0 54|Competitive reverse transcription-polymerase chain reaction
P09475724T0000|0 3|TOR2
P09475898T0000|0 25|Transcervical amnioinfusion
P09476399A0141|20 37|large tea plantation
P09476520A1326|0 11|Simple models
P09477316A0140|20 26|pathway
P09478921A0126|0 9|Substrates
P09478971A1896|0 17|Reporter constructs
P09478976A0718|0 18|Transfection studies
P09478976T0000|0 10|Oncostatin M
P09479498A0000|15 37|new human RING-finger gene
P09480831A0272|14 32|regulatory mechanism
P09480843A0848|3 21|COOH-terminal region
P09480929T0000|0 30|Soluble FasR ligand-binding domain
P09481826T0000|0 6|Control
P09482107A0551|3 12|inhibition
P09482902A0423|0 7|C.D2-Chr
P09482902A0942|14 22|wild-type
P09483596A0626|46 55|conditions
P09484463T0000|0 6|Cloning
P09484781A1233|12 28|direct association
P09485308A1165|3 11|FMN moiety
P09485790T0000|0 22|Alison Bell Memorial Award
P09486035A0051|0 6|METHODS
P09486531A0638|6 18|organogenesis
P09486890A0234|8 18|laparoscopy
P09487130A0383|14 27|telomere length
P09487590A0657|3 14|mean duration
P09487841A0132|3 6|ESEM
P09488441A0615|0 2|Sp1
P09488466A0695|35 49|full-length mRNA
P09488486A0000|3 24|TATA box-binding protein
P09488486A0906|1 16|triple-mutant TBP
P09488491A0000|0 10|E2F activity
P09488713A0886|15 32|complete inhibition
P09488725A0904|14 34|true molecular identity
P09488725T0000|0 24|Molecular characterization
P09489670A1157|2 11|C. albicans
P09490676A0800|12 18|binding
P09490727A1041|4 41|structure interconnects specific triplets
P09491074A0104|15 33|regulatory mechanism
P09492038A0352|5 16|current study
P09494078A1362|6 18|5HT5A receptor
P09495283A0000|14 25|reporter gene
P09495771A0379|0 20|Localized fluorescence
P09498553A0702|2 8|TATA box
P09498553T0000|0 9|Structural
P09498769A0095|3 19|expression pattern
P09499031A0000|3 29|intercistronic gene junctions
P09499048A1003|0 27|Infectious mutant virus progeny
P09499061A0000|0 7|Cleavage
P09499254A1309|3 12|DSF regimen
P09501093A0071|0 9|Activation
P09501169A0000|0 23|Histone acetylation levels
P09501982A1178|0 10|CONCLUSIONS
P09502627A0705|0 6|RESULTS
P09502720A0214|0 17|CyIIa transcription
P09502720T0000|0 23|Cis-regulation downstream
P09503017A1021|25 34|human HYAL1
P09503526A0614|2 9|patients
P09504423A0114|26 35|4E-BP1 gene
P09504514T0000|0 19|Randomised comparison
P09504553T0000|0 13|Therapeutic use
P09504906A0099|0 7|Analysis
P09505135A0182|0 22|Peripheral visual stimuli
P09505733A0246|9 15|studies
P09506439A2179|0 8|PKC-gamma
P09506959T0000|0 13|Identification
P09506962A1000|17 36|proteolytic targeting
P09506983A0304|0 6|Primers
P09506990T0000|0 15|Human ZFM1 protein
P09507032A1144|16 31|CSF1R/IRDelta960
P09508119A0498|0 10|CONCLUSIONS
P09508377A0863|5 11|results
P09508511A0588|2 8|ferrets
P09508775A0293|3 32|cAMP-dependent mitogenic pathway
P09509226A1235|0 10|CONCLUSIONS
P09510189A0192|19 41|exon-intron organization
P09510398A1138|3 13|risk factors
P09510582A0157|20 27|patients
P09510925A0389|5 28|haemoglobin concentration
P09511724A0483|5 9|cells
P09511760A0221|7 31|restriction enzyme analysis
P09512416A0460|0 6|RESULTS
P09512550T0000|0 2|E1A
P09512559T0000|0 29|Position-independent expression
P09513759A0716|0 16|Calcitriol therapy
P09514156A1147|0 10|Alterations
P09514159A0562|0 39|Most pituitary hormone-coding gene promoters
P09514260A1083|10 21|small inteins
P09514272A0482|0 11|Purification
P09514962A0841|0 3|M-66
P09515031A1020|5 11|results
P09515032A1230|0 5|RT-PCR
P09515665T0000|0 10|Ganciclovir
P09515858A0000|0 9|BACKGROUND
P09515921A1662|3 21|spontaneous mutation
P09515924A0104|7 7|g
P09515924A0553|3 26|PDH complex-encoding genes
P09516472A0292|19 36|functional elements
P09517646A0149|0 11|Azithromycin
P09517989A0476|19 35|people co-infected
P09518383A0000|0 9|BACKGROUND
P09518808T0000|0 20|National certification
P09519757A0482|3 20|rare novel mutations
P09519828A0809|0 24|Chimaeric VP16-E2 molecules
P09519830A0282|19 31|potential role
P09520398A0124|5 11|changes
P09521907A0190|24 26|otd
P09521909A0081|0 18|APETALA3 transcripts
P09521913A0400|15 23|mutations
P09522297A0744|0 8|Cell lines
P09522979T0000|0 30|Cervicovaginal foetal fibronectin
P09523478A0572|11 13|IgM
P09523551A0367|4 11|variants
P09524122A0336|1 18|constitutive allele
P09524222A0769|3 15|COOH-terminus
P09524222A1113|0 10|PCR analysis
P09524229A0000|3 11|gene lac-1
P09524250A0767|4 19|TRE-like elements
P09524259A0301|3 18|hp55 gamma protein
P09524267A1023|3 14|plant protein
P09524273A0205|21 39|genomic organization
P09524276A0939|0 11|LysR proteins
P09525105A0298|8 34|anti-inflammatory activities
P09525598A0325|0 9|Regulation
P09525888A1482|0 20|Full-length FLAP clones
P09525891T0000|0 6|Members
P09527921A1178|16 35|DNA-protein complexes
P09528758T0000|0 4|Rex-1
P09528766A0915|8 17|inhibition
P09528768A0000|0 4|Cells
P09528770A1379|3 49|RAS-cyclic AMP-dependent protein kinase cAPK pathway
P09528784A0000|3 6|mei4
P09528792A0000|0 18|Alternative splicing
P09528858A0205|6 10|cases
P09528950A0716|3 18|genomic fragments
P09528987A1348|0 21|Cotransfection analyses
P09529156A1238|0 7|Deletion
P09529216A0644|0 11|Flap survival
P09529649A0307|0 7|Jean Klig
P09529721A0000|0 18|Potential indicators
P09530251A0766|0 3|SNAC
P09531538A0983|24 57|enhancer-dependent splicing activity
P09531549A0658|7 20|binding studies
P09531559A1153|7 22|affinity analyses
P09533030T0000|0 10|Cytochrome b
P09533109A0449|1 16|possible decrease
P09535082A0537|14 34|Paf-containing extract
P09535579A1105|16 26|assumptions
P09535833A0228|12 28|amino acid sequence
P09535835A0279|0 5|ROCK-I
P09535851A0591|10 17|isoforms
P09535892A0000|3 13|beta subunit
P09535908A0321|26 36|LNX messages
P09536028A0945|14 30|contractile action
P09536440A0000|0 12|Recent studies
P09536901A0362|3 18|separate occasion
P09537295A0951|13 26|minor start site
P09537295T0000|0 7|Analysis
P09537361A0149|3 16|iron dependence
P09537375A0198|3 20|gntR deletion mutant
P09537378A1227|15 22|deletion
P09537651A0366|7 11|sites
P09538156A0130|0 11|BRCA1 protein
P09538220A0000|3 31|mitochondrial regulatory region
P09538258A0200|48 60|Ras activation
P09539421A0970|5 15|Sir proteins
P09539721A0599|24 27|DnaA
P09539746A0781|0 9|Expression
P09539779A0621|0 10|Whole-mount
P09540062A0755|5 11|mutants
P09541280A0404|9 17|plasma IgE
P09541636T0000|0 20|Creatine kinase release
P09541721A0894|17 55|ischemia/angiotension II-induced AHF model
P09543227A0815|0 5|Group A
P09544987A1583|24 33|RU486-PR-B
P09544991A0483|0 10|PRL receptor
P09544991A0750|3 24|dominant negative mutant
P09545146A0884|0 10|CONCLUSIONS
P09545293A0590|0 4|Sites
P09545312A1197|3 14|observations
P09545323T0000|0 20|ATP-dependent assembly
P09545332A0137|0 7|Mutation
P09545353A1071|22 41|tandem kappaB elements
P09545638A0330a|24 56|single yeast hnRNP methyltransferase
P09545638A0330b|24 56|single yeast hnRNP methyltransferase
P09545638A0836|0 24|Recombinant HRMT1L2 protein
P09545638A1181|3 15|possible roles
P09545638T0000|0 13|Identification
P09546424A1550|26 42|PDGF beta-receptor
P09547311A1394|12 23|interactions
P09547349A0000|3 72|ether phospholipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine
P09548481A0000|36 43|promoter
P09549179A0774|0 10|Serum levels
P09549398A1463|0 15|Overall agreement
P09549632A1189|34 34|%
P09549660A0782|19 26|data sets
P09549783T0000|0 14|Spatial accuracy
P09550591A0454|0 18|Successful treatment
P09550919A0365|24 39|cumulative manner
P09551096A0108|0 3|RNAs
P09551182A0212|7 24|retinoid signalling
P09551938A0318|10 33|nuclear regulatory factors
P09551972A1033|0 11|Fluorescence
P09552469A0225|21 29|piroxicam
P09553040A0651|0 11|Cell survival
P09553134A0596|3 38|N-syndecan-dependent neurite outgrowth
P09553143A0729|8 22|ZAP-70 substrate
P09553686A0000|3 25|pharmacokinetic patterns
P09555046A1617|3 9|results
P09556557A1238|14 27|central regions
P09556561A0671|8 19|H/ACA snoRNAs
P09556566A0174|9 24|vitamin D receptor
P09556573A1062|0 13|Further studies
P09556861A1018|10 26|current literature
P09557678A0140|28 42|acute expression
P09557682A0490|4 19|possible isoforms
P09557708A1426|0 20|Specialized actin tails
P09557912A0699|5 11|mean IOP
P09560221A0282|1 4|cDNA
P09560325A1285|0 34|Post-translational modifications such
P09560390A0771|21 37|checkpoint control
P09560430A0000|0 3|Ime1
P09561560A0579|0 13|Rhesus macaques
P09561616A0142|0 11|Deltamethrin
P09562398A0848|0 16|Trichloroethylene
P09562558T0000|0 16|Solution structure
P09564860A2139|11 35|receptor/G protein coupling
P09564860A2315|24 45|third intracellular loop
P09564917A0900|9 14|levels
P09565576T0000|1 15|catalytic domain
P09565584A0770|10 24|basic amino acids
P09565606A0520|7 15|stem-loop
P09566731A0458|8 12|genes
P09566871A0343|2 12|fus3 mutants
P09566871T0000|0 26|Posttranslational regulation
P09566876A0000|3 31|general transcription factor IIA
P09566882A0693|31 34|Pho2
P09566918A1115|0 11|Substitution
P09568445T0000|0 14|New-onset angina
P09568549A0188|23 41|acute administration
P09570030T0000|0 21|Fetal growth retardation
P09570107A0355|10 25|PCDFs/PCDDs ratio
P09570133A0474|12 34|DNA-protein interactions
P09570944T0000|0 11|Localization
P09570952A0000|3 33|complete exon-intron organization
P09571563A0000|0 6|PURPOSE
P09572428A0526|0 3|Mean
P09572491A1044|16 20|cells
P09572511A0148|3 14|new algorithm
P09572965A1235|1 8|third ORF
P09572990A0630|20 23|hSIE
P09573187T0000|0 24|Transcriptional repression
P09573202A0900|29 34|levels
P09573244A0523|8 18|mRNA species
P09573374A0687|5 24|Southern blot analysis
P09573378A0761|0 2|U73
P09573884A0392|8 25|mandibular position
P09574799A1072|0 14|Echinostomiasis
P09575143A1189|3 14|localization
P09575187A1558|16 24|NF-kappaB
P09575217A0000|0 20|Many cytokine receptors
P09575217A0971|1 26|site-directed R618K mutation
P09576230T0000|11 38|nitric oxide synthase inhibitor
P09576915A0269|13 25|recombination
P09577365A0747|2 15|angiodysplasia
P09577395A0000|12 38|human vestibulo-ocular reflex
P09578042A0363|16 37|seizure-offset patterns
P09578570A0200|36 43|protein Z
P09579602A1720|5 17|modifications
P09579789A0974|3 16|present results
P09579808A0000|0 9|UDP-GlcNAc
P09580062A0100|5 12|patients
P09580563A0331|12 28|amino acid sequence
P09580700A0841|3 22|DNA binding activities
P09581552A1323|0 17|Molecular modelling
P09581775A0185|5 16|present study
P09581834A2578|19 25|results
P09581872A0000|2 17|connective tissue
P09582267A0326|22 41|human SINA-homologous
P09582306T0000|1 13|point mutation
P09582308A1165|44 69|disulfide-linked homodimers
P09582326A0151|0 1|N.
P09582327A0295|25 32|GH3 cells
P09582331A0506|6 19|flanking region
P09582343A0000|16 40|radiosensitive cell line SX9
P09582350A0165|2 9|patients
P09582635A0523|0 6|Results
P09582953A0000|0 9|OBJECTIVES
P09582953A1097|0 6|RESULTS
P09582953A1670|18 28|plasminogen
P09583201A0759|0 3|None
P09583208A0171|0 14|Marked elevation
P09583592A0263|0 5|DESIGN
P09583823A0238|0 6|METHODS
P09584165T0000|0 4|RACK1
P09584179A0673|0 15|Peptide sequences
P09584180A0701|3 32|same IL-4-inducible reporter gene
P09584194A0000|0 3|HEF1
P09584194A1305|21 27|spindle
P09585253A1147|17 26|activation
P09585540A0440|9 27|zinc-depleted enzyme
P09586285A0551|3 10|patients
P09586832A0229|3 7|lines
P09587549T0001|0 16|Convulsive seizure
P09588228A0370|22 36|anticytokeratin
P09590294A0453|0 13|Genetic studies
P09590540A0513|3 10|bZP2 cDNA
P09591221A0137|0 14|Control subjects
P09592125A0000|0 4|Class
P09592168T0000|0 17|Structural features
P09592208A0470|7 20|other qualities
P09592219A0652|3 9|results
P09593302A1165|3 25|mechanistic implications
P09594299A0468|0 6|RESULTS
P09595496A0000|18 27|high levels
P09596536A0219|28 45|knee loading changes
P09596542A0542|13 20|surfaces
P09596638T0000|0 17|Comparative mapping
P09596738T0000|0 4|Roles
P09598205A0430|20 34|monosaccharides
P09598894A0732|2 13|most subjects
P09599102A1191|0 7|Analysis
P09599664A0881|3 15|DNA sequencing
P09599724A0193|1 22|stratified random sample
P09599897A0000|14 31|laboratory features
P09601007A0223|9 30|community metabolic data
P09601510A0215|12 33|other known retroviruses
P09601516A0695|0 11|Substitution
P09601921A0000|0 10|Tributyltin
P09601940A0280|5 18|flanking region
P09602124A0127|0 6|Fregnac
P09603345A1257|0 6|GLRaV-2
P09604052A0166|0 10|Demographic
P09605137A0677|20 24|c-Jun
P09605930A1428|0 15|Identical results
P09605934A0801|4 15|E box sequence
P09606633A0523|0 20|Interferon beta therapy
P09606924T0000|0 26|Liquid chromatographic method
P09609342A0000|19 23|types
P09609705A0895|0 10|Examination
P09609720A0357|3 29|protease-resistant fragments
P09610755A1731|3 24|side-to-side difference
P09611016A0652|0 9|CONCLUSION
P09611229A1664|32 35|FAS1
P09611234A0098|0 17|Rev-erbAalpha/beta
P09611877A0455|13 20|isolates
P09612351A0386|23 43|persistent oscillation
P09612775A0726|3 17|ParaSight-F test
P09613574A0905|11 28|recombinant protein
P09613946A0194|1 25|deproteinization procedure
P09614065A0966|0 10|Elimination
P09614106T0000|5 35|high mobility group-like sequences
P09617765A0174|21 36|open reading frame
P09617807A0929|1 20|phylogenetic analysis
P09618150A0127|2 19|physiological doses
P09618150A1464|11 17|insulin
P09618164A0709|15 15|O
P09618475A0747|1 13|large deletion
P09618481T0000|0 9|Regulation
P09619631A0344|0 6|RESULTS
P09619777A1583|3 22|weak base ketoconazole
P09620273A0189|2 8|mammals
P09620606A0000|15 21|signals
P09620873A1710|33 59|luteal HSP-27 phosphorylation
P09620955A0370|33 42|leader mRNA
P09621062A0810|20 24|sites
P09621372A0369|0 22|Routine blood examination
P09621893A0000|0 14|Previous studies
P09622055A0207|3 9|members
P09622121A0525|0 17|Anti-PTB antibodies
P09622121T0000|8 17|antibodies
P09623830A0000|3 16|therapeutic use
P09625762A0426|3 21|viral oncoprotein E1A
P09625807A0000|16 44|mRNA differential display method
P09626662A1076|0 17|Similar experiments
P09627285A0160|0 6|SETTING
P09627285A0554|0 5|RESULT
P09627598A0384|0 6|RESULTS
P09628375A0700|5 18|ePTFE specimens
P09628419A0812|16 19|Wing
P09628821A1194|18 31|KG1a EST dataset
P09628890A0455|20 36|Specific mutations
P09629449A0540|3 9|results
P09630245A0102|0 11|Yeast U1 snRNP
P09630245A0903|0 11|Yeast U1 snRNP
P09631366A0951|8 17|first cycle
P09632217A0477|3 28|opioid antagonist naltrexone
P09632637A0361|21 49|hepatic stellate cell regulation
P09632709A0464|3 11|cDNA clone
P09632734A0081|20 27|proteins
P09632734A0943|7 19|p82 expression
P09632785A0000|3 28|pre-mRNA splicing factor U2AF
P09633171A0321|3 10|brackets
P09633274A0000|0 15|Exercise training
P09633630A0740|11 13|Aer
P09633879A0246|7 26|continuous compliance
P09635149A1148|0 9|Hematocrit
P09635276A1608|0 9|Regulation
P09636119T0000|0 27|Commutative saccadic generator
P09636358A0000|3 24|virus-associated VAI RNA
P09636670T0000|0 8|Structure
P09636708A0460|3 13|YccA protein
P09637689A0150|3 11|major type
P09638342T0000|17 18|L1
P09638485A0111|0 17|Atmospheric benzene
P09638650A0169|14 28|noncoding region
P09638793A1446|5 36|profound normovolemic hemodilution
P09639074A0707|0 2|Sp1
P09639410A3282|5 9|genes
P09639558A0957|18 40|C1q-dependent haemolysis
P09639565A0225|8 13|distal
P09640162A0242|3 15|second patient
P09640802A0467|28 47|cosmetic consequences
P09641167A1359|0 9|CONCLUSION
P09642042A0646|0 16|Binding affinities
P09642200A0956|16 23|one-half
P09642214A0244|30 61|protein-tyrosine phosphatase SHP-2
P09642227A0000|0 11|Osteoadherin
P09642238A0532|0 5|Intron
P09642238A1285|3 8|intron
P09642276A0881|3 10|cleavage
P09642764A0469|32 42|QCM response
P09643153T0000|1 9|Treatment
P09643546A0436|0 22|Transcription initiation
P09643548A0000|3 7|genes
P09645576A0148|0 2|RNA
P09645942A1164|1 9|major pool
P09645961A1158|3 9|results
P09647233A0336|2 12|macrophages
P09647240A0000|14 16|p53
P09649069A0490|24 49|various laryngeal parameters
P09649265A1575|0 10|CONCLUSIONS
P09649315A0943|0 10|Examination
P09649426A0636|14 24|PKA activity
P09649437A1140|20 37|direct interactions
P09649438A0182|10 49|human transcription elongation factor P-TEFb
P09649501A0358|13 30|hydrophobic repeats
P09649537A0000|0 6|Genomic
P09650180A1130|3 22|general recombination
P09650186A1043|3 11|low number
P09650275T0000|16 42|biological weapons convention
P09650299A0000|0 4|VirD2
P09650299A1334|38 53|VirD2 omega domain
P09650403A0868|3 13|DHEAS levels
P09650789A0185|0 10|Orientation
P09651321A0000|0 8|Cystatin A
P09651367T0000|8 13|RalGDS
P09651375T0000|0 5|GTPase
P09651383A0967|8 16|mutations
P09652736A1205|21 25|E2F-1
P09652737A1244|7 30|shift/supershift analysis
P09652742A0455|24 35|unmutated p53
P09653182A1298|17 37|heterologous virus RNAs
P09653641A0471|0 12|Human isoforms
P09653648A0445|0 9|Comparison
P09653745A0180|0 6|Malaria
P09655248A0000|3 19|gp330/Megalin/LRP
P09655916A0415|5 23|DNA recognition helix
P09656414A0220|0 5|Dosage
P09656485A0351|4 19|additional copies
P09657003T0000|0 24|Evolutionary relationships
P09658104T0000|0 3|Role
P09658122T0000|0 11|Fowlpox virus
P09658403A1207|0 7|Addition
P09658405A0000|3 11|Dax-1 gene
P09658769A0058|17 38|recombinant IFN alpha-2b
P09660823A0934|8 29|Ser/Thr phosphorylation
P09660836A0983|0 21|Quantitative evaluation
P09660838A0920|0 9|Regulation
P09661676T0000|0 18|Clinical implication
P09662339A0744|7 11|cells
P09662443A0402|33 51|genomic organization
P09663062A0175|0 19|Tensile bond strengths
P09664033A1204|30 51|polycistronic precursor
P09665361T0000|0 17|Suppressive therapy
P09665503A0526|8 28|healthy male volunteers
P09665720A0325|14 16|Mg2
P09665720A1145|5 20|high-affinity Mg2
P09666103A0496|3 16|missense allele
P09666114A0389|0 17|Structural analysis
P09667482A0978|22 41|possible contribution
P09667795A0000|0 16|Acute pancreatitis
P09668063A0274|27 37|Ets proteins
P09668096A0806|61 68|partners
P09668098A0868|13 31|human FGF-BP promoter
P09668108A1017|0 11|Manipulation
P09668119A0496|0 33|Electrophoretic mobility shift assays
P09669641A0425|3 20|diagnostic accuracy
P09670034A0340|17 21|Ddc1p
P09670912T0000|1 14|Complex partial
P09670943T0000|0 19|B cell antigen receptor
P09671313A0334|0 4|Chem.
P09671464A0316|8 11|SNF1
P09671496A0557|26 30|c-Cbl
P09671576A0900|19 34|visceral endoderm
P09671579A1168|13 20|noi/pax2
P09671791T0000|0 27|Ligand-independent activation
P09673037A0358|0 6|METHODS
P09673436A0898|2 23|canrenoate-treated rats
P09675154A0690|17 41|unrelated Japanese families
P09675896A0959|0 6|Removal
P09676349A0000|2 7|Level A
P09676419A0158|0 5|METHOD
P09677330A0584|3 41|PDE4A-subfamily-specific linker region LR1
P09677405A0856|0 16|Pol32Delta strains
P09677410A1059|5 12|same time
P09678579A0768|35 43|AtCP1 gene
P09678837A0736|33 46|responsiveness
P09679066A1352|5 11|results
P09679750A0304|28 56|prostate cancer chemoprevention
P09680994A0169|31 43|P. hybrida gene
P09681822A0520|0 26|Identical c-erbB3 transcripts
P09682897A0218|14 18|years
P09683576A0542|9 46|potential cleavage site located N-terminal
P09685021A0127|0 6|METHODS
P09685226A0000|9 18|calcitonin
P09685346A0419|16 20|Pitx2
P09686344T0000|3 13|biochemical
P09686603A0124|28 45|cis-acting elements
P09687498A1173|3 9|results
P09687511A1091|0 13|Downregulation
P09687514A0521|23 59|mammalian cell-free transcription system
P09688264A1029|4 12|repressor
P09689047A0253|1 12|prerequisite
P09689919A1192|8 21|bovine PEDF cDNA
P09691031A1050|22 33|Sro7 function
P09691037A0355|7 15|sequences
P09692965A0904|4 11|cysteine
P09693035T0000|0 8|Human ULK1
P09693134A0782|17 32|molecular markers
P09693306T0000|0 28|Cochlear microphonic potentials
P09694034A0713|5 11|results
P09694514A0000|3 36|complement C3a anaphylatoxin receptor
P09694599A1355|0 10|CONCLUSIONS
P09694725A0500|0 15|Band-shift assays
P09694860A0498|3 18|C-terminal region
P09694869A0932|41 45|STATs
P09694897T0000|3 55|heterogeneous nuclear ribonucleoprotein C protein tetramer
P09695194T0000|27 37|proportions
P09696164A0000|8 19|simple system
P09696819A0450|12 18|mutants
P09698457A0778|0 19|Homozygous mutant mice
P09698457A0976|3 15|mutant protein
P09698512A0296|0 6|METHODS
P09700644T0000|13 44|age-associated brain abnormalities
P09701609A0116|37 64|phosducin-like orphan proteins
P09701616A0108|0 43|Reverse transcriptase-polymerase chain reaction
P09701821A1108|11 23|transcription
P09701895A0119|19 30|children aged
P09703021A0000|2 8|insects
P09703213A0280|2 12|experiments
P09703276A2346|5 11|results
P09703816A0139|0 4|IA-CT
P09704006A0224|0 8|Arnt3 mRNA
P09704296T0000|0 37|Acute idiopathic thrombocytopenic purpura
P09704569T0000|3 18|genomic structure
P09704857T0000|0 10|Correlation
P09704927A0479|5 29|shares significant homology
P09705258A0837|3 16|IE13.1 cell line
P09705324A0213|0 4|DNase
P09705324A1602|10 16|studies
P09705352A0879|8 11|Hsk1
P09705497A0227|3 15|yeast MMS2 gene
P09705564T0000|0 9|Expression
P09706565A1072|0 9|Anesthesia
P09707498A0262|0 19|MK-801 administration
P09707577A1047|28 43|endocytic markers
P09708450A0648|0 7|Toxicity
P09708565A0000|37 43|factors
P09710131A0374|4 10|methods
P09710582A0535|11 13|Rho
P09710589A1111|0 23|Site-directed mutagenesis
P09710591A0981|0 8|Mutations
P09710599A0310|5 15|former cells
P09710599T0000|0 19|Persistent activation
P09710614T0000|0 13|Identification
P09710615T0000|0 4|Vam7p
P09710621A0598|42 58|consecutive series
P09710641A0000|35 39|Pax-6
P09712037A0470|0 13|Tctex-1 binding
P09712297T0000|3 32|prothrombin gene G20210A mutation
P09712644T0000|0 24|Transcriptional regulation
P09712859A1110|3 9|binding
P09712898A0911|5 9|TRAF2
P09712898T0000|0 27|Tumor necrosis factor signaling
P09712915A0672|16 30|minimal promoter
P09712919A0307|5 11|studies
P09713584A1193|0 10|Respondents
P09713990T0000|0 8|Isolation
P09713996A0262|0 13|Overexpression
P09713996T0000|0 10|Cytogenetic
P09714109A0000|0 9|BACKGROUND
P09714109A0785|7 27|blood pressure increase
P09714835A0345|16 32|carboxypeptidase D
P09715278A1079|0 11|RA-treatment
P09715278A1526|3 16|histopathology
P09715384A0235|3 16|smaller vessels
P09716095T0000|0 13|Pressure ulcers
P09716179A0974|0 18|RXR-gamma expression
P09716183A1036|0 2|TBP
P09716435A1004|9 17|CR/PP diet
P09717246A0526|9 11|ILC
P09717835A0941|5 20|sequence analyses
P09717887A0239|3 14|present study
P09718372T0000|0 7|Evidence
P09718671A0000|3 24|Abbreviated Injury Scale
P09719636A1134|36 44|mutations
P09721207A0637|5 21|backcross analysis
P09721798A1734|12 18|percent
P09722043A2070|12 20|TPN groups
P09722161A3065|0 9|Regulation
P09722508A0953|30 42|Galpha11 Q209L
P09722766A0706|3 21|micturition pressure
P09723896A0000|0 40|Peroxisome proliferator-activated receptors
P09724654A0761|21 38|late-firing origins
P09724654A1120|20 31|active S-CDKs
P09724754A0173|0 7|Tyrosine
P09724763T0000|0 24|Nonsynonymous substitution
P09724772A0840|0 19|Gel retardation assays
P09725292A1473|0 9|CONCLUSION
P09725651A0077|3 14|PC-based RTPS
P09725854A1060|29 52|apparent regulatory action
P09726201T0000|0 4|JCAHO
P09726979T0000|0 15|Molecular cloning
P09726987T0000|1 48|human SPT3-TAFII31-GCN5-L acetylase complex distinct
P09726988A0275|0 5|Oleate
P09726991T0000|0 6|Mapping
P09727045A0817|1 16|further mechanism
P09727046A0000|27 44|DNA-binding protein
P09727046A0784|3 10|CBF1 site
P09729481A0000|3 43|rat branched-chain-2-oxo-acid dehydrogenase
P09729481A1177|0 14|Co-transfection
P09730413A0642|5 22|such investigations
P09731354A0963|14 21|degrees C
P09731513A1090|19 25|results
P09731704A0000|20 37|cooperative effects
P09731704A1472|0 11|Transfection
P09731705A2126|0 6|Studies
P09733493A0493|3 9|results
P09733647A1960|13 47|Thr-Gly-X-X-Gly-Asp-Gly-Lys-Ile-Phe
P09733794A1323|18 24|changes
P09733815T0000|0 7|Tyrosine
P09733854A0198|3 29|only abundant viral transcript
P09734808A0000|9 22|test efficiency
P09735286A0599|3 8|defect
P09735366A1180|5 29|homology cloning techniques
P09735368A0636|10 20|wild-type m8
P09735371A0227|13 18|unc-86
P09736239A0436|9 29|2h resuscitation period
P09736697A0783|0 9|Expression
P09736697A1107|0 3|MEKs
P09736715A0729|12 31|phosphatidylinositol
P09736770A0351|0 11|Transfection
P09737453A0557|0 5|Plasma
P09737921T0000|0 15|Genome plasticity
P09738010A0305|3 13|FAS promoter
P09738087A0583|11 31|independent predictors
P09738693T0000|0 6|Effects
P09739401A0000|0 8|OBJECTIVE
P09739913A0194|0 9|CASE REPORT
P09741391A0581|13 35|single-chambered body box
P09741783A0000|0 10|Anastrozole
P09742129A0491|0 1|W.
P09743128A0969|0 6|Moritta
P09743233A0526|0 7|Mutation
P09743720A0268|0 6|ANIMALS
P09744095A1016|13 25|double mutants
P09745797A0943|21 36|underpredictions
P09747651A0000|0 12|Laser ablation
P09747873T0000|3 35|SH2-containing adapter protein GRB10
P09748261A0000|35 58|known acyl-CoA synthetases
P09748286A0000|19 43|placenta-specific enhancer
P09748513X1360|0 8|Copyright
P09748669A0414|26 34|dichotomy
P09749533A0764|0 4|Clone
P09749988A0000|0 6|Badcock
P09750325A0000|3 9|effects
P09750540A0000|0 26|Multiple chemical sensitivity
P09751061A0000|0 17|POU-domain proteins
P09751114A0967|0 8|Wild-type
P09751114A1987|5 11|results
P09751166A1460|7 21|previous results
P09751458A0845|0 19|desmethyltrimebutine
P09753241A0524|0 21|Endoscopic examinations
P09753730A0881|0 14|T7 transcription
P09753769A0362|3 9|primers
P09753774A1642|0 5|Plants
P09753774A2246|34 51|amino acid sequences
P09753775A0734|8 11|ICK1
P09754571A0169|1 16|5.0-kb transcript
P09754571A1257|3 11|hBRAG gene
P09755191A0553|17 22|swa5-1
P09755199A0373|19 34|molecular lesions
P09755199A0559|18 40|hypomorphic Scm mutations
P09755478A0366|0 15|Northern analysis
P09756687A0981|10 25|characterization
P09756895A0322|0 11|Genomic locus
P09757012A0942|13 15|PDZ
P09759180A0000|0 9|BACKGROUND
P09759691A1051|2 9|analyses
P09759865A0673|13 20|IL-1beta
P09760243A0970|0 14|Cotransfections
P09760341T0000|0 24|Phosphocreatine hydrolysis
P09761711A0000|0 18|Pseudocontact shifts
P09761723A0226|0 5|GETS-1
P09761791A0489|16 21|U1-70K
P09763421A1199|3 17|major phenotypes
P09763446A0000|0 11|Small GTPases
P09763446A1234|3 5|GEF
P09763470A0000|0 23|Dopamine beta-hydroxylase
P09763470A1756|33 44|critical role
P09763522A2545|16 23|antibody
P09763607A0521|11 28|virulent Ngo strains
P09764741A0092|7 11|beams
P09765261A0000|3 38|human T cell lymphotropic retrovirus type
P09765271A1108|30 52|insulin response sequence
P09765277A0000|3 45|murine facilitative glucose transporter isoform
P09765285A0998|19 27|half-site
P09765285A1763|3 8|levels
P09765372A0669|3 13|high density
P09765388T0000|0 11|Inactivation
P09765394A0000|3 36|Epstein-Barr virus transactivator Zta
P09765394A1590|0 13|Cotransfection
P09765411A0991|0 18|Sequence comparisons
P09765466A0231|0 1|J.
P09765754A1727|19 25|studies
P09767504A1371|1 16|single rectal dose
P09767575A0657|19 26|adjacent
P09767593A0130|8 11|YopH
P09767687T0000|0 19|Phylogenetic position
P09769209A0100|0 21|Previous genetic studies
P09769910A1700|3 12|activation
P09770241A0000|13 26|thermal imaging
P09770378A0641|0 9|EGFR levels
P09770415A0139|21 26|THOV NP
P09770493A0499|2 5|PP2A
P09770686A0484|7 24|frequent risk factor
P09771555A0499|3 9|results
P09771967A1052|12 18|LB1 gene
P09771985A0238|2 9|subjects
P09773975A1873|0 21|Wild-type AT1A receptors
P09773981A0415b|12 33|glucocorticoid receptor
P09774403A0107|0 1|T.
P09774444A0351|3 26|carboxyl-terminal portion
P09774450A0000|25 35|mouse enzyme
P09774484T0000|0 15|UGA codon position
P09774641A0824|0 8|Forskolin
P09774662A0958|3 13|ARF promoter
P09776293A0777|0 6|RESULTS
P09776360A0620|0 1|CM
P09776360A1781|0 8|NF-kappaB
P09777477A0000|0 8|Observers
P09777600A0000|1 22|simple analytical method
P09777999A0796|0 6|RESULTS
P09778006A0718|14 25|baseline Vmca
P09778068A1129|0 30|Multivariate Cox survival analysis
P09778191A0000|16 24|new method
P09778197A0415|0 25|Cost-effectiveness analysis
P09780002A0996|8 13|E2FBP1
P09780228A0122|0 9|Sequencing
P09780228A0613|12 27|domain structures
P09780336A0771|0 7|Analysis
P09781761A0384|3 15|Ho Chi Minh City
P09781871A0404|0 16|Glycogen synthesis
P09781874A1061|3 16|cwg2-1 mutation
P09784063A0621|0 15|Deletion analysis
P09784192A1027|9 15|peptide
P09784245T0000|0 28|Cardiac myosin-binding protein C
P09785114A1026|10 12|PND
P09786197A0322|0 7|Analysis
P09786404A0541|9 21|aggregates/ml
P09786926A0095|34 59|fatty-acid synthase promoter
P09786926A1372|20 33|binding studies
P09786932A1042|5 9|IRF-7
P09786949A0114|0 1|J.
P09787323A0000|0 6|PURPOSE
P09788739A1096|7 33|CD44-associated serine kinase
P09789025A0149|0 6|Galphaq
P09789795A0607|19 36|subjects adrenaline
P09790499A0545|0 19|Northern blot analyses
P09790767A0372|31 47|sequence tag clones
P09790768A0621|0 10|Htra2-beta3
P09790771A0956|0 16|Gng3lg transcripts
P09790771A1032|7 33|interspecific backcross panel
P09790986A0689|13 30|polyclonal antibody
P09792439T0000|0 9|Inhibition
P09792627A0441|0 4|SRC-1
P09792630A1127|32 57|transcription start site CTCA
P09792682A0713|5 11|results
P09792702A0754|0 9|Expression
P09792714A1408|16 19|AF-1
P09794414T0000|9 31|protein kinase C signaling
P09794795A0183|0 12|Ligand binding
P09795130A0742|50 66|deleterious effect
P09795170A0774|16 49|polyadenylation site 504bp downstream
P09795213A0129|0 11|RBP56 protein
P09795341A0806|2 34|electrophoretic mobility shift assay
P09797189A0559|0 24|Gel-mobility shift analysis
P09797456A0000|0 9|BACKGROUND
P09797456A0883|0 4|AMY-1
P09798068A0290|0 6|RESULTS
P09798100A0705|2 4|Day
P09798263T0000|0 28|Antidepressant-like properties
P09799086A0725|7 30|tentative hotspot mutation
P09799237A0624|0 19|SRF-deficient embryos
P09799362A0507|5 36|characteristic structural features
P09799362A1463|0 14|Over-expression
P09799634A0161|16 28|computer model
P09799793T0000|0 20|Large-scale sequencing
P09800187A0100|7 11|Trp53
P09801156A0220|10 18|fragments
P09801333A0174|3 18|full-length N gene
P09802206A1058|7 22|sequence homology
P09802902A0225|25 28|ARNO
P09803081T0000|0 13|Renal pathology
P09804779A0000|0 19|Transcription factors
P09804779A1163|16 23|pathways
P09804836A0000|15 38|37-kDa cytoplasmic protein
P09805052A0119|0 3|Dose
P09805977A0143|3 22|various available data
P09806516A1212|45 52|patients
P09806516A1689|0 9|CONCLUSION
P09806546A1270|18 21|RFX5
P09806826A0244|25 30|defect
P09806826A1773|24 35|localization
P09806830X1174|0 8|Copyright
P09806857A0854|2 17|open reading frame
P09806858T0000|0 13|Identification
P09806919A0447|7 9|usp
P09807755A0146|2 26|intact neurovascular supply
P09808155A0813|0 10|Examination
P09808216A0000|0 9|BACKGROUND
P09808366A0828|0 12|Fatal apneusis
P09808441A0320|1 19|comparative analysis
P09810087A0379|0 6|RESULTS
P09811695A1146|5 11|results
P09811718A0979a|5 11|results
P09811730A1396|0 14|Competition EMSA
P09811730T0000|0 8|Mechanism
P09813041A1122|0 1|GH
P09813063T0000|0 9|Expression
P09813093A0624|28 34|YCL024W
P09813098A0521|0 9|Paralemmin
P09813110A0982|10 26|amino acid sequence
P09813203T0000|11 40|low-profile serine substitutions
P09813207A0434|0 28|Transcription start site mapping
P09813254A0000|14 27|oligoadenylate
P09813259A1097|3 10|findings
P09813635A0678|5 14|striations
P09814637A1214|0 15|Low PbrO2 readings
P09814905A0598|3 14|consequences
P09815578A1245|25 34|alteration
P09815948A1065|3 27|pharmacokinetic parameters
P09817131A0296|9 10|HK
P09817190A0074|16 27|cyclosporin A
P09817373A0000|0 6|PURPOSE
P09817601T0000|0 15|Characterization
P09819038A0448|0 15|Recombinant FVIIa
P09819110A0703|0 12|CD4 lymphocyte
P09819216A0220|6 17|Biochemistry
P09819288A0578|0 5|Levels
P09819377A1209|1 8|mutation
P09819391A1123|29 32|Arfs
P09819411A0897|2 6|DNase
P09819414A1103|12 17|nexins
P09819421A0000|0 11|Cyclophilins
P09819422A0768|7 33|protein retention experiments
P09819430A0000|3 20|Ras-related GTPases
P09819440A0000|10 22|transcription
P09819440A0783|0 12|Endogenous RMP
P09819507A0000|12 18|rabbits
P09820163A0565|3 9|mapping
P09820205A0000|3 15|zona pellucida
P09820611T0000|0 13|Therapeutic use
P09820621A0067|8 34|pathological thyroid function
P09821978A1255|5 21|cognitive deficits
P09822602A0237|35 44|activation
P09822602A1172|5 34|hypoxia-inducible nuclear import
P09822647A0000|3 18|rat aldolase C gene
P09822652A1118|1 17|synergistic effect
P09822661T0073|0 20|Quinone-binding domain
P09822685A0596|0 14|Western analyses
P09822690A0000|0 21|Mammalian sperm motility
P09822825A0141|27 30|BAP2
P09823014T0000|0 5|Effect
P09823561T0001|0 27|Low-grade gastric MALT lymphoma
P09823775A1122|5 11|studies
P09824001A1665|12 22|hemodynamic
P09824021A1263|0 9|CONCLUSION
P09824158A1336|10 32|BCL-6 POZ domain mutations
P09826434T0000|0 22|Partial characterization
P09826658A0691|4 15|core sequence
P09826778A0943|0 14|Over-expression
P09827446T0001|0 26|Familial autoimmune hepatitis
P09827724A1362|2 10|mutations
P09827878A0091|5 25|glutathione peroxidase
P09827993A0000|0 29|Retroviral nucleocapsid proteins
P09828137A0000|27 30|rad1
P09829836A0000|26 36|progression
P09829836A0815|0 24|Positive genetic selections
P09829843A0119|3 40|hematopoietic colony-stimulating factors
P09829843A0819|3 12|injections
P09829916T0000|0 9|Expression
P09832099A0000|11 44|regional right ventricular wall motion
P09832436A0738|0 13|RT-PCR analysis
P09832436T0000|0 15|Molecular cloning
P09832504A0596|45 47|Tat
P09832505A0903|23 38|activation target
P09832511A0269|6 22|early neurogenesis
P09832518A0615|3 18|repression domain
P09833610A0626|3 11|exodomain
P09833740A1112|0 25|Pyrrolidine dithiocarbamate
P09834070A0793|12 32|synergistic activation
P09834521A0000|3 25|retrovesical hydatid cyst
P09835615A0574|0 18|Biochemical analysis
P09836881A0441|11 18|BCH group
P09837714A1068|3 9|results
P09837715A0581|21 34|constant amount
P09837824A0419|12 26|telSMN mutations
P09837907A0857|13 24|TNF receptors
P09837913A0000|0 3|Type
P09837913A0419|39 55|sequence tag clones
P09837914A0844|0 3|Biol
P09837920A0222|25 46|structural requirements
P09837933T0000|0 5|P-CIP1
P09837945A0820|0 17|Immunolocalization
P09837978T0093|0 18|Resultant activation
P09838122A0489|15 43|full-length coding cDNA sequence
P09840822A0462|23 29|tagging
P09840928A0884|0 9|Consistent
P09840932A0365|32 36|B-Myb
P09840934A0435|7 12|Ha-Ras
P09840943A0144|15 30|novel human cyclin
P09842517A0497|0 16|Initial experience
P09843378A0187|3 20|dopamine D4 receptor
P09843412A0130|9 35|amyloidogenic 42-residue form
P09843572A0944|22 32|experiments
P09843577A0000|24 28|cells
P09843944A0976|0 7|A-tracts
P09844106A0835|0 18|Pyk2 phosphorylation
P09844921A0000|0 2|Raf
P09845043A0000|3 21|US National Institute
P09845662A0085|0 7|Collagen
P09845856A0560|0 6|RESULTS
P09846033A0488|0 6|RESULTS
P09846482A0441|39 57|enzymatic activation
P09846927A0227|24 34|perforation
P09847371A0000|0 19|Jembrana disease virus
P09847397A0935|15 15|%
P09848653A0597|0 4|Nhp2p
P09849421A0332|38 47|Norwegians
P09849722A0797|20 41|happy facial expressions
P09849961A0387|0 14|Down-regulation
P09849965A0000|20 44|mammalian two-hybrid system
P09851614A0109|8 21|unique features
P09851700A0000|15 50|human tissue-type plasminogen activator
P09851988A0085|17 24|arginine
P09852005A1287|0 10|Competition
P09852068A0150b|3 27|human SHBG proximal promoter
P09852109A1475|35 49|profile analysis
P09852136A0174|17 24|mutation
P09852136A0507|0 14|Wild type HA-p190
P09852752A0950|15 39|ANCA-associated vasculitis
P09854034A0536|3 12|downstream
P09855111A0905|23 36|overexpression
P09856397A0099|0 14|Dry matter intake
P09856732A0114|10 16|studies
P09857038A1374|0 1|E.
P09857197A0289|0 4|Yap1p
P09857265A0669|0 9|Mean intake
P09858094A0583|8 16|amplitude
P09858531A1017|12 30|RING1 overexpression
P09858571T0000|3 15|yeast RER2 gene
P09858572A0000|3 25|yeast retrotransposon Ty5
P09858577A1186|9 12|SKO1
P09858581A0183|0 17|Elevated expression
P09858588A1046|3 37|slower-electrophoretic-mobility form
P09858593A0334|16 33|amino acid sequences
P09858599A0392|4 22|NUP98-HOXA9 chimeras
P09858619A0356|0 12|Recent studies
P09858713A1174|0 6|Genetic
P09858714A1171|7 9|ORF
P09858745A1350|16 18|IBS
P09858745A2033|7 25|transcription assays
P09858883A1106|0 14|BIAcore analysis
P09860979A0521|0 9|Expression
P09861099A1011|0 19|Positive correlations
P09861365A0000|3 38|Og4C3 enzyme-linked immunosorbent assay
P09862343A0225|13 29|gp200-MR6 ligation
P09862481A0000|3 15|Mig1 repressor
P09862496A0187|0 7|Ethylene
P09863624A0629|3 12|divergence
P09863624A2301|0 37|Agonist-induced receptor internalization
P09863720T0000|0 33|Recurrent arterial thrombotic disease
P09864141A0528|12 16|Stat3
P09864335A1226|17 23|results
P09864689A1408|5 12|findings
P09865775A0162|35 42|couplers
P09866068A1058|0 10|CONCLUSIONS
P09867159A1444|15 36|optimal threshold values
P09867253A0229|4 16|c-Jun activity
P09867855T0000|0 47|Dorsal root ganglia neuron-specific promoter activity
P09868412A1628|0 9|CONCLUSION
P09869297A1807|12 16|roles
P09869356A0926|0 6|CAL gain
P09869400A0203|0 10|Comparisons
P09869528T0000|0 11|Lead fixation
P09871353A0174|36 58|A. salmonicida infections
P09872326A0566|22 42|EIA-inducible CBF/cdc2
P09872337A0000|3 24|percutaneous absorption
P09872832A1262|3 19|BAL concentrations
P09873060A0901|0 22|Phosphorylation analyses
P09873291A0620|0 14|Two-way analysis
P09874803A0000|3 45|human pathogenic bacterium group A Streptococcus
P09875541A0210|3 15|orbitofrontal
P09876794T0000|0 8|Improving
P09877417A0704|0 14|Plasma CCK levels
P09878256A0000|3 31|peroxisome biogenesis disorders
P09878437A0967|3 12|active site
P09878542A1151|0 9|Consistent
P09879766A0402|2 6|PAV-3
P09880029A0703|3 27|putative MDV genome products
P09880103A0387|0 2|MPO
P09880327A0322|23 55|mammalian Golgi-associated proteins
P09880512A1251|19 22|Bmp2
P09880513A1013|4 11|proteins
P09880543A0570|0 3|HEED
P09880544A0693|0 32|Fas-resistant DT-40 lymphoma B-cells
P09881666A0535|1 5|motif
P09881692A0094|19 42|nominal allotypic variants
P09881692A1109|31 41|latent genes
P09882303A1413|0 4|TRAF2
P09882303A1984|30 34|TRADD
P09882303T0000|0 45|Epstein-Barr virus-encoded latent membrane protein
P09882321A0948|33 37|cells
P09882334A0822|8 21|serial passages
P09882337A0000|0 20|Varicella-zoster virus
P09882348A0611|23 43|phosphorylation status
P09882451A0195|5 9|genes
P09882489A0451|57 78|specific mef2 expression
P09882499A0231|17 41|transgenic mouse technology
P09882593A0996|5 20|second experiment
P09882638A0235|15 35|crimped collagen fibers
P09883639A0000|0 5|Number
P09884232A0286|0 9|Comparison
P09884275T0000|0 24|Interferon-alpha treatment
P09884747A0477|0 19|Immunological testing
P09885431A0000|0 8|OBJECTIVE
P09886602A0000|0 9|OBJECTIVES
P09886843A0339|20 28|human gene
P09886850A0145|3 25|transcriptional activity
P09887544A0000|0 9|BACKGROUND
P09888711A0781|0 20|Bioplastique granuloma
P09888994A0858|4 21|Tbx6-subfamily gene
P09889202T0000|0 25|Structure-function analysis
P09889306A0321|26 45|Glvr-1 gene expression
P09890778T0000|0 12|Carbohydrates
P09891009T0000|0 15|Molecular cloning
P09891046A0269|23 25|PKR
P09891046A0554|11 29|ribosomal protein L18
P09891049A0761|0 9|Processing
P09891061A0373|11 35|transcriptional regulators
P09891061A1240|14 49|positive SpHE transcriptional regulator
P09891065A1493|12 37|rhoA-mediated SRE activation
P09891085A0815|0 18|Nip7p-depleted cells
P09891092A1000|13 26|Sm-binding site
P09891707A0000|4 20|different subtypes
P09892017A2151|0 17|Further experiments
P09892021A0712|0 13|Overexpression
P09892422A1096|3 38|perifascicular connective tissue sheath
P09892642A0172|0 1|E1
P09892662A0334|15 32|mutant alpha subunit
P09892736A0343|1 12|gapped search
P09893060A0767|0 19|Northern blot analysis
P09893262A1272|23 39|regulatory schemes
P09893913A0656|0 8|Induction
P09894962T0000|16 30|clinical profile
P09895323T0000|12 24|distinct roles
P09897032T0000|19 37|optical self-pulsing
P09900679T0000|0 14|Wave cybernetics
P09903722T0000|0 18|Autoionization rates
P09904139T0000|0 20|Unitary-group approach
P09911328T0000|0 15|Nonlocal approach
P09913308T0000|0 15|Soft-x-ray lasing
P09914156A1496|15 21|regions
P09914500A0000|0 18|Nuclear factor kappa B
P09914518A1217|13 23|enhancement
P09914525A0890|0 13|Recombinant Ffh
P09915118T0000|0 23|Unilateral naris occlusion
P09915798A1077|12 16|hsp90
P09915860A0000|3 10|promoter
P09915860A0119|0 2|Sp1
P09916786A0811|0 11|Measurements
P09916809A0405|0 7|Human MGP
P09917064T0000|0 8|Dual roles
P09917387T0000|3 41|RNA polymerase III-recruiting factor TFIIIB
P09917389A1239|12 26|RNase E digestion
P09917391A0380|0 23|Transcription readthrough
P09917555T0001|0 7|Analysis
P09918096A0520|5 14|second case
P09918715A0304|0 3|MotA
P09918715A1158|13 16|MotA
P09918720A0998|3 14|S229A variant
P09918842A0184|3 18|high conservation
P09920539A0272|3 14|stimulations
P09920775A0075|19 28|bp relative
P09920882A0287|0 3|Chem
P09920896A1230|2 23|significant differences
P09920903A1045|5 11|results
P09920930A0521|0 6|C3 toxin
P09920930A0959|8 14|C3 toxin
P09920982A0253|11 22|present study
P09921179T0001|9 38|intraoperative echocardiography
P09922230A1482|17 23|results
P09922856A0459|0 9|Trinipatch
P09923245A0482|3 6|RMRI
P09924675A0412|41 51|conceptions
P09924987A0000|0 23|Pokeweed antiviral protein
P09925120A0074|0 8|OBJECTIVE
P09925372A0458|13 16|ZFPs
P09925372A1063|11 26|higher expression
P09925777A1195|7 25|high affinity hnRNP A1
P09927193A0107|10 21|such proteins
P09927449A0421|0 13|Overexpression
P09927570A0507|13 25|RNU2 fragility
P09927585A0796|0 30|Competitionsupershift EMSA assays
P09927589T0000|0 9|Similarity
P09929088A0000|0 6|CONTEXT
P09929811A0000|0 10|Experiments
P09931118A1072|10 15|p42/44
P09931191A0434|17 33|different subjects
P09931216A0566|0 6|Airflow
P09931252A1055|4 12|mutations
P09931391A0944|0 15|Complete recovery
P09931435A0357|12 22|transcripts
P09932288A0378|0 9|Expression
P09933428A0351|0 8|IFN-gamma
P09933641A0241|12 20|sequences
P09933848A1008|4 17|alloantibodies
P09934611A1054|4 13|dependence
P09935377T0108|0 4|Genoa
P09936001T0000|0 18|Electronic structure
P09938097T0000|0 20|Bound-exciton transfer
P09940132T0000|0 12|Unified theory
P09943651T0000|0 12|Internal modes
P09944066T0073|0 1|II
P09945838T0000|0 34|Envelope-function matching conditions
P09947191T0000|0 28|Neutron scattering measurements
P09949160A0600|3 23|Erythroid 32D Epo1 cells
P09949178A0264|33 45|interleukin-6
P09949312A0524|0 6|Airflow
P09950213A1660|7 43|normal intestinal epithelial goblet cells
P09950394A0336|23 45|carboxyhemoglobin levels
P09952378A0529|3 11|odds ratio
P09952425A0893|14 17|HIPP
P09959737T0000|10 18|neutrinos
P09961326T0000|9 20|fluctuations
P09961682T0000|0 4|Model
P09964171T0000|0 2|NMR
P09964770T0000|0 13|Microstructure
P09965234T0000|0 23|Anisotropic heat transport
P09965909T0000|0 13|Direct approach
P09971776A0838|0 8|Mutations
P09971790A0856|0 15|Several mutations
P09971806A1585|3 12|lytic cycle
P09971815A2094|33 60|several candidate latency genes
P09971822A1542|18 31|functional role
P09973351A1522|19 33|DcuS-DcuR system
P09973607A0254|34 49|characterization
P09974642T0000|0 8|Crossover
P09976626T0000|0 6|Erratum
P09980944T0000|0 17|Interplane coupling
P09982923T0000|0 18|Electronic structure
P09983871T0000|0 17|Raman investigation
P09984526T0000|0 6|Effects
P09985302T0000|0 22|Chaotic electron dynamics
P09986796A1761|8 16|deletions
P09987176A0260|5 10|months
P09987634A1265|13 15|PRK
P09987961A0093|3 14|early lesions
P09988682T0033|0 15|Molecular cloning
P09988767A1496|0 35|Interspecific mouse back-cross analysis
P09988850A0000|3 8|Scales
P09989334A0964|24 40|processing signals
P09989339A0968|33 43|brain weight
P09990057T0000|0 12|Recombination
P09990060A0803|10 15|motifs
P09990060A0937|16 49|coactivator CREB binding protein/p300
P09990315A0205|0 2|TPO
P09990507A0000|0 9|BACKGROUND
P09990507A0763|0 10|CONCLUSIONS
P09994942T0000|3 12|NMR studies
P09995847T0000|0 24|Optical-absorption spectra
P09995897T0000|0 10|Observation
P09999256T0000|0 24|Quantum-statistical theory
P09999742T0000|0 2|NH3
P10000253T0000|0 14|Chirality-glass
P10001333T0038|0 13|Echo modulation
P10001541T0000|0 9|Mechanisms
P10002245T0000|0 11|Far-infrared
P10006319T0000|0 15|Surface spin waves
P10007469T0000|17 23|librons
P10007564T0000|0 28|Multilayer-relaxation geometry
P10008261T0000|0 20|Temperature dependence
P10009565T0000|0 19|GW Gamma approximation
P10013227T0000|0 19|Precision measurement
P10019841T0000|16 40|second post-Newtonian order
P10021333A0674|0 17|Genetic experiments
P10021350A0093|5 16|current model
P10022032A0000|11 36|clinical antianginal studies
P10022210A0620|0 6|Factors
P10022850A0929|13 34|amino-terminal fragment
P10022858A0985|12 41|potent splicing enhancer sequence
P10022867A1069a|0 10|Elimination
P10022867A1069b|0 10|Elimination
P10022875A1265|20 36|other Ras effectors
P10022880A0000|0 35|Mammalian Ras GTPase-activating protein
P10022905A0446|5 16|mog-1 alleles
P10022921A0608|17 24|SIN3 gene
P10022925A0870|3 21|Nmd3 protein sequence
P10022978A1261|20 33|various repeats
P10024383T0000|0 9|Calcitonin
P10024498A0783|0 34|Electrophoretic mobility-shift assays
P10024882A0541|25 28|cdk7
P10025050A1052|15 35|H2-receptor antagonist
P10025506A0079|2 7|humans
P10025506A1078|2 5|TATA
P10026146A0680|3 12|inhibition
P10026211A0136|0 7|Proteins
P10026211A0543|20 33|pDeltaCREC/EBP
P10026229A0950|18 28|mutagenesis
P10026275A0549|0 32|Several secondary structure elements
P10026784A0331|22 43|developmental functions
P10026784A0929|0 35|High-affinity site-specific DNA binding
P10026784A2166|5 16|Oct-1 crystal
P10026824A0309|0 27|Systematic functional analysis
P10027498A0536|0 17|Most other end points
P10029337A0406|3 17|fatigue exercise
P10029860A0605|5 23|radiological aspects
P10029917A0366|0 6|Results
P10031854T0000|0 19|New Langevin equations
P10032519T0000|0 19|Radiative corrections
P10032581T0000|0 43|Depth-controlled grazing-incidence diffraction
P10033973T0000|0 18|Oscillatory exchange
P10034615T0000|0 21|Structure determination
P10035841T0000|0 15|Magnetic trapping
P10036181A0603|0 11|Northern blot
P10036191A0000|3 20|microphthalmia-TFE
P10037004A0000|11 22|patients aged
P10037378A0176|3 14|dorsal nerves
P10037460A0221|11 29|muscarinic receptors
P10037576T0000|0 25|Early-onset scleral necrosis
P10037681A0494|0 20|Successful interaction
P10037774A0366|29 54|signal transduction pathways
P10041728T0000|0 18|Vacuum Rabi splitting
P10043466T0000|0 19|High-pressure effects
P10044519T0000|15 28|turbulent flows
P10046849T0000|0 40|Large scale electronic structure calculations
P10047970T0013|0 21|Current world literature
P10049357A0608|5 11|results
P10049359A1073|0 13|Recombinant unr
P10049742T0000|0 7|Analysis
P10049775T0000|0 6|Mapping
P10049912T0000|0 13|Identification
P10050883A0967|0 9|Inhibition
P10051030A1080|26 30|males
P10051400A0000|3 15|Lp mouse mutant
P10051488A1293|0 14|Further analysis
P10051488A1610|0 8|Mutations
P10052371A0171|0 10|STUDY DESIGN
P10052878A0135|10 27|high set-up accuracy
P10053852T0000|0 3|Role
P10054976T0000|0 11|Spectroscopy
P10055173T0000|0 19|Band structure effects
P10059496T0000|0 26|Acoustic transmission spectra
P10063122T0000|0 22|Two-Channel Kondo Lattice
P10063739A0601|0 49|Basal midexpiratory lower esophageal sphincter pressure
P10064604A0824|0 3|CPDs
P10065176A0657|25 45|hormone receptor status
P10065684A0916|5 13|other hand
P10066790A0497|0 12|Gel filtration
P10066798A0391|0 32|Cyclin D1-associated kinase activity
P10066815T0000|3 30|SH2 domain-containing inositol
P10068040A0136|13 23|mouse genome
P10068418A1194|12 29|bone mineral density
P10068446A0124|15 24|studies due
P10068637A1320|14 21|Csx/Nkx2
P10068674A0644|42 47|Lyp RNA
P10068834A0713|3 7|costs
P10069815A0285|34 54|functional interaction
P10070158A0573|0 24|Independent splicing events
P10071205A0833|11 15|genes
P10071212A0399|18 32|O. australiensis
P10071761A2374|11 17|mapping
P10071806A0377|9 21|resectability
P10072205A0167|44 45|ML
P10072774A0537|0 5|RT-PCR
P10073899A0740|3 26|lowest culture failure rate
P10073940A0335|0 16|Ectopic expression
P10073947A1110|3 26|corresponding differences
P10074135T0000|0 6|Primary
P10074282A0236|5 13|other side
P10074425A0729|13 24|inactivation
P10074520T0000|0 13|Identification
P10074903A0915|19 25|results
P10074921A1169|0 13|Similar results
P10075415A1178|0 16|Partial sequencing
P10076007A0656|3 6|MSY2
P10077188A1172|16 33|helicase-like genes
P10077533A0976|19 32|molecular tools
P10078734A0480|3 23|H-reflex recovery curve
P10078876A0000|3 9|origins
P10079173A0000|0 29|Human neuronal Elav-like proteins
P10080436T0000|0 9|Comparison
P10080875A0772|3 9|results
P10080901A0271|6 13|peptides
P10082137A0262|3 9|results
P10082554T0000|0 16|Functional domains
P10082570A0440|25 33|gene UBP43
P10082573A1015|5 11|results
P10082585A0512|10 33|additional non-Sir factors
P10084294A0219|14 22|great need
P10085088A0918|5 11|results
P10085120A0000|23 39|signaling pathways
P10085140A1004|5 11|results
P10085383A1367|0 7|KEY WORDS
P10085505A1184|3 14|systolic peak
P10085605A0239|0 8|Specimens
P10085697T0000|0 39|FASEB Federal Funding Consensus Conference FY
P10086544A0504|42 58|intensive care unit
P10086725A0000|0 8|MDS1/EVI1
P10087213A0878|0 7|Analysis
P10087549A0720|3 10|JTc delta
P10087993A0782|11 18|deletion
P10087993A1352|0 23|Site-directed mutagenesis
P10090125A0750|15 38|alpha1 antagonist prazosin
P10090146T0000|0 21|Differential expression
P10090535A1194|3 11|algorithm
P10090943A1426|3 11|mean value
P10090943A1976|2 13|normal B cells
P10091594A0284|0 20|Conformational studies
P10091619A0104|0 5|Schwab
P10092132A0285|0 14|High-level gains
P10092847A0455|30 39|active MREs
P10092856A0798|3 6|cDNA
P10094314A0935|17 28|RNA sequences
P10094396A0000|0 14|Topoisomerase II
P10094701A0000|0 9|Recent work
P10095059A1003|3 9|numbers
P10095061A0592|0 15|Sequence analysis
P10095062A0558|16 32|complete structure
P10096469T0000|0 21|Dopaminergic modulation
P10096573A0207|0 14|Previous studies
P10097120T0000|2 5|exon
P10097932A0915|4 22|CsA-treated patients
P10098601A1320|0 17|Mutational analysis
P10098744A0630|35 43|phenotype
P10099247A1051|1 13|high reactor pH
P10099576A0666|12 17|valves
P10100605A0392|10 25|respiratory burst
P10101159A0742|1 8|mutation
P10101198A0632|1 24|deletion mutation analysis
P10101198A0946|1 14|database search
P10101744A0917|5 10|trials
P10102000A1206|10 17|patients
P10102136A0220|11 18|total PSA
P10102136A0646|0 3|Type
P10102627A0217|11 28|DNA binding activity
P10103002A0705|1 32|single N-glycosylation site present
P10103057A0251|17 28|optimization
P10119827T0000|0 11|Judge OKs docs
P10120952T0000|0 4|HANYS
P10125354T0000|0 11|Groups dicker
P10132730T0000|0 18|Troubled CareNetwork
P10134977T0000|0 4|JCAHO
P10146207A0223|0 14|Ultrasonography
P10153759A0360|0 3|UPMC
P10171173A0955|9 16|concerns
P10181397A0641|12 17|trends
P10184191T0045|0 5|Holger
P10187317T0000|0 7|Hospital
P10187798A1098|0 13|Overexpression
P10187842A1155|18 27|PPARgamma2
P10187864A1372|5 11|results
P10190324A0000|17 27|elastin gene
P10191090A0000|0 23|Spatiotemporal expression
P10192134A1088|0 7|25-OH-D3
P10192432A0214|9 13|names
P10192638T0000|0 22|Methanesulfonyl fluoride
P10193950A0478|0 6|METHODS
P10194225A1132|0 13|Voluntary wheel
P10194230A0817|24 36|dialysate PGE2
P10194451A0000|12 37|probable causal relationship
P10194762A0648|7 19|precipitation
P10194769A0146|3 13|such element
P10195425T0000|0 15|Characterization
P10195690A0000|3 43|peroxisome proliferator-activated receptors
P10195697A0456|8 20|F-SRC-1 mutant
P10196127A1059|3 15|catalytic site
P10196248A0482|3 27|complete circular TTV genome
P10196266A0000|3 24|Asian mouse Mus castaneus
P10196316A0715|24 28|VZV gK
P10196318T0000|0 23|CCAAT displacement protein
P10196597A0510|9 16|findings
P10197763A0580|5 35|different site-directed mutations
P10197985A0145|7 27|RNase H protection assay
P10198003A1505|0 7|Analysis
P10198056A0000|0 32|Many eukaryotic cell surface proteins
P10198061A0339|5 24|cell-free import assay
P10199539A1353|2 9|ischemic
P10200473A0171|2 29|endogenous mammalian regulator
P10201468A0297|0 12|Plasma glucose
P10202006A0546|4 21|recombinant product
P10202006A1266|0 13|Polypyrimidine
P10203611T0000|0 52|Technetium-99m methylene diphosphonate scintimammography
P10205099A0377|0 12|INTERVENTIONS
P10205176A0000|0 15|Nuclear receptors
P10205176A0704|4 11|tethered
P10205588A0000|0 8|OBJECTIVE
P10205933A0699|0 7|Bacteria
P10206152A1024|48 54|mitosis
P10206698A2041|5 12|findings
P10206959A0368|0 5|Pathol
P10207041A0065|3 21|eukaryotic cell cycle
P10207049A0693|3 10|GAC1 gene
P10207049A1001|3 9|results
P10207087A0956|0 2|MEF
P10207090A0801|32 34|GRR
P10207092A0924|4 18|phosphorylation
P10207115A0389|17 34|total cellular level
P10208865A1246|23 40|osteoclast cultures
P10208893A0839|11 17|results
P10209021A0212|3 20|molecular mechanism
P10209031A0832|3 16|Fyn NH2 terminus
P10209119A0076|9 13|yeast
P10209119A0594|40 61|functional similarities
P10209759T0000|0 14|Antithrombin III
P10210952A0261|2 11|retrospect
P10211329A0457|5 16|observations
P10211422T0000|0 16|Acute pancreatitis
P10211919A0846|13 30|greater improvement
P10212278A0387|0 36|Stress-inducible protein kinases capable
P10212284A0000|12 23|growth factor
P10212332T0000|0 17|Chronotherapeutics
P10212426A1067|0 25|Group psychometric functions
P10212969A0470|0 11|Uroflowmetry
P10214610A0900|0 20|Marked racial variation
P10215485A0837|0 22|Significant correlations
P10215594A1728|0 7|Glucagon
P10215608A0161|35 50|characterization
P10215803T0000|24 42|intravenous infusion
P10215811A0635|0 13|Initial control
P10215850A0754|23 41|genomic organization
P10216052A0105|3 6|aims
P10216052A1682|29 37|new subset
P10216161A1530|0 17|Sequence comparison
P10217683A0509|0 20|Canalith repositioning
P10218109T0000|0 16|Solution structure
P10218200A0534|4 7|eyes
P10218357A0486|0 6|RESULTS
P10219091A0246|28 35|gene CTL1
P10220275A0694|3 9|binding
P10220364A0087|5 14|afterglows
P10221467T0000|0 23|Constrictive pericarditis
P10221820A0902|2 14|undilated type
P10223338A1601|40 60|chimeric fusion protein
P10223338A2186|3 9|results
P10223498A0479|0 7|Efficacy
P10224244T0000|0 7|Evidence
P10224257A0079|2 8|XO males
P10224289T0000|0 8|Induction
P10224293A0000|0 34|Receptor protein tyrosine phosphatases
P10224293A2021|5 34|well-characterized brain regions
P10224513A0240|12 20|stressors
P10224758A0202|3 14|control group
P10225279A0450|35 42|MDV2 UL54
P10225945A0436|20 31|MAD2 staining
P10226029A0905|2 16|epithelial cells
P10226074A0637|5 16|untranslated
P10226838A1011|3 10|motility
P10228009A0600|0 8|Induction
P10228155A1293|0 6|SCFFWD1
P10228157T0000|1 39|Bub2p-dependent spindle checkpoint pathway
P10228561A0539|13 31|modular organization
P10228795A0842|0 6|RESULTS
P10229084A0000|0 32|Two-dimensional gel electrophoresis
P10229668A0190|10 26|other cdc33 mutants
P10229668A0560|1 13|cdc33-1 strain
P10229682A1151|0 15|Regulatory motifs
P10231026A0253|3 15|gene structure
P10231454A0731|0 16|Total serum calcium
P10231485A0342|0 15|Sequence analysis
P10231513T0000|0 23|Cranio-caudal differences
P10231581A1125|0 23|Site-directed mutagenesis
P10231862A1117|0 23|Breast-fed newborn infants
P10232078A0552|0 7|Ischemia
P10232600T0000|0 23|Prostate-specific antigen
P10232872A0081|13 23|subclinical
P10233147A0218|0 4|Ras2p
P10233885A0899|0 9|Consistent
P10233946A0000|0 11|Previous work
P10234698A0728|18 35|detrimental effects
P10235265A0197|27 62|ubiquitin-dependent proteolytic system
P10236651T0000|0 9|Predictors
P10240361T0000|0 13|Canadian survey
P10243927A0000|13 31|full-scale fire tests
P10271171A0458|0 10|Online LATCH
P10281637A0000|0 8|Reporting
P10304090T0000|0 18|Medicare SNF benefits
P10308312A0203|15 27|current status
P10318806A0000|0 6|Members
P10318806A0476|5 16|present study
P10318806A0918|0 7|Analyses
P10318859A0535|14 22|calpeptin
P10318900A0637|0 33|Three-dimensional structural studies
P10318918A0824|8 25|mutational analysis
P10319320A1022|19 26|findings
P10319327A1237|0 7|Analysis
P10319955A0941|12 22|differences
P10320177A0487|0 27|Baseline electrocorticography
P10320480A0451|11 23|genetic system
P10320579A1831|13 16|FlgN
P10321158T0000|0 3|Post
P10322022A0263|0 5|Rep63A
P10322629A0198|15 21|cloning
P10323225A0244|0 7|Km values
P10323463T0000a|0 15|Interferon-alpha
P10323463T0000b|0 15|Interferon-alpha
P10323863A0852|43 69|active recombinant telomerase
P10325413A1211|11 17|binding
P10326221A0531|0 17|Homozygous mutation
P10326654A0351|11 26|pilot experiments
P10326856T0000|2 33|end-to-end pancreaticojejunostomy
P10327051A0688|27 57|Stress-Activated-Protein-Kinase
P10328351A0443|0 11|Blood samples
P10329135A1326|5 11|results
P10329566A0610|5 12|terminus
P10329574A1733|0 15|O. novo-ulmi RNA-7
P10329586A0414|12 22|fibronectin
P10329625A0715|18 31|cell surface CD4
P10329736A0681|23 43|yeast two-hybrid system
P10329736A1106|0 17|Insulin stimulation
P10330134A0765|3 16|mRNA expression
P10330146A0730|14 31|unspliceable intron
P10330159A1258|5 7|VDR
P10330168A0135|26 32|kinases
P10330396A0387|3 22|RanQ69L preincubation
P10331276A0298|8 15|elements
P10331646A0595|21 37|amino acid sequence
P10331730A0504|0 6|RESULTS
P10331875A0523|4 17|dimer interface
P10332733A0000|3 21|paramyxovirus fusion
P10333481A1102|13 28|deletion analysis
P10333526A0459|3 11|hTERT gene
P10333529A0277|4 14|betaAPP mRNA
P10334888A0960|2 13|reperfusion B
P10336495A0547|4 13|repression
P10339552A0361|5 16|present study
P10339566A0602|0 5|Spc42p
P10340447A0424|3 21|average coefficients
P10340883A1266|3 10|5-year OS
P10341219A0481|12 32|heparin lyase treatment
P10342511A0909|3 13|coefficient
P10342536A0954|23 36|protein content
P10342829A0236|24 28|GnRHR
P10342829A1370|0 29|Competitive mobility shift assays
P10343189A0911|0 4|Grade
P10344736A0796|0 19|CDK4 kinase activities
P10347144A0516|3 13|recombinant
P10347197A0502|0 8|Induction
P10347203A0832|0 20|Serine phosphorylation
P10347220A1477|33 58|entire three-component yeast
P10347839A0434|3 12|IC50 values
P10348859A0292|16 36|potential binding sites
P10349084T0000|14 44|Epstein-Barr virus seropositivity
P10349443A0358|3 9|results
P10350027A0942|0 10|Amisulpride
P10350454A0000|0 3|MutY
P10350484A0346|3 10|kinetics
P10350638A0000|0 6|Latexin
P10353073A0118|0 17|Regression analyses
P10353880A0257|54 60|infants
P10355085A1119|0 6|Subsets
P10355536A0172|3 11|median age
P10355910A0369|0 21|Developmental follow-up
P10357751A0866|5 14|whole group
P10358031A0303|16 20|cells
P10358075A0984|0 4|DAF16
P10358079A0391|8 51|neu differentiation factor-induced heterodimers
P10358080A1114|8 20|linker regions
P10358080T0000|0 9|Modulation
P10358083A0263|4 21|functional analyses
P10358138A0672|5 11|results
P10359014A1077|18 42|Fra-2 phosphorylation sites
P10359575A0317|46 54|FcalphaRI
P10359603A0430|0 4|Vac1p
P10359663A0425|3 35|heterologous transcriptional system
P10359663A1280|2 23|co-transfection studies
P10359664A0579|15 19|sites
P10359673A0000|3 15|yeast LPD1 gene
P10359792A0610|13 23|mild defects
P10360454A0916|11 33|serum TNF-a concentration
P10360839A1338|36 52|individual members
P10360947A1113|9 32|fluorescence spectroscopy
P10361038A0281|15 30|similar locations
P10362652A0350|4 12|carbachol
P10362652A1456|0 18|Dominant negative Sos
P10362897A0545|0 6|RESULTS
P10363517A0401|12 22|such lesions
P10364076A0429|5 11|regions
P10364159A0813|14 22|questions
P10364163A0092|0 2|Hrs
P10364202A0646|3 14|coexpression
P10364314A0919|5 14|subgenomes
P10364319A0109|0 1|Cp
P10364425A0610|5 15|indications
P10364523A0826|4 15|exon trapping
P10364523T0000|0 42|Campomelic dysplasia translocation breakpoints
P10365883A1355|7 27|common characteristics
P10366446A0893|1 17|coiled-coil domain
P10366503A0812|0 16|Binding affinities
P10366503A1506|11 19|terminase
P10366559A0605|3 15|hybrid viruses
P10366722T0000|0 3|cDNA
P10367240A1354|12 27|cryopreservation
P10367385A0000|1 27|liquid chromatographic method
P10367460A0191|3 16|FCMS conditions
P10367646A0569|0 14|Severe hemolysis
P10369418A0644|0 3|EMSA
P10369625A0942|0 16|Optimal monitoring
P10369757A0000|3 27|major transcription factors
P10369775A0178|10 25|protein fragments
P10369926A0251|3 6|exon
P10369965A0000|3 13|Aa-Pri2 gene
P10370675A0649|3 12|main causes
P10370778A0000|5 26|new aromatase inhibitors
P10371097A0963|0 10|CONCLUSIONS
P10372627A0530|7 14|injuries
P10373029A0204|3 20|femoral artery/vein
P10373507A0680|0 8|SRFDelta5
P10373523A0924|2 16|serum-free media
P10374632A0818|3 9|potency
P10374632A0897|0 9|CONCLUSION
P10375107A1138|0 10|Progression
P10375638A0859|0 8|Mutations
P10375640A0153|18 35|nucleotide sequence
P10375694T0000|0 14|Corticostriatal
P10375718A0000|0 26|Basic fibroblast growth factor
P10376065A0881|4 10|filters
P10376446A0000|2 13|healthy women
P10376873A0706|5 10|sgRNA2
P10376874A0759|5 27|single mutational defects
P10376877A0611|0 6|Removal
P10376991A0977|0 2|Ras
P10377345A0740|0 36|Green fluorescent protein-tagged UNC-49B
P10377438A0647|19 22|UBC9
P10378989A0000|36 53|spontaneous reports
P10379547A0000|0 8|Molecules
P10379899A0446|3 15|major findings
P10379942A0956|27 34|residues
P10379942T0000|0 13|Identification
P10380232A0000|0 8|OBJECTIVE
P10380659A0545|0 11|Baseline data
P10380800A0194|16 25|nucleotide
P10380878A0542|0 9|Consistent
P10380890A0619|11 19|sequences
P10381257A0000|26 32|metaxin
P10381377T0000|0 15|Molecular cloning
P10381570A1355|0 3|Slp1
P10383764A1809|3 9|results
P10383966A0000|3 27|penicillin binding proteins
P10384129A0000|0 7|TCR alpha
P10385384A0654|0 13|Similar results
P10385395A0000|3 24|high density lipoprotein
P10385915A1341|0 6|D3S1261
P10388670A1976|3 13|percentages
P10390158A1150|0 13|Point mutations
P10390538T0000|1 37|human Raf-responsive zinc-finger protein
P10391075A0000|16 26|autopsy case
P10391246A0756|12 16|MOM-4
P10391277A0000|0 9|BACKGROUND
P10391903T0000|0 3|Gab2
P10392266A0111|13 30|cutaneous xanthomas
P10392669A0935|22 30|incidence
P10392710A1000|0 13|Lung mesenchyme
P10392900A1020|3 12|activation
P10392903A0000|3 31|bovine papillomavirus E2 protein
P10392903A0889|0 19|E2 point mutants unable
P10392914A0000|0 17|BACKGROUND/PURPOSE
P10393192A0792|0 21|Neurospora crassa CYT-18
P10393197A0543|0 3|DDP1
P10393201A0654|16 35|human DNA repair system
P10393251A0283|3 10|PAC clone
P10393251T0000|0 7|Sequence
P10393422A0476|7 8|kb
P10393910A0705|0 23|Site-directed mutagenesis
P10393969A0000|3 24|infected cell protein no.
P10394116T0000|0 15|Wrist measurement
P10394900A1166|0 23|G-box-directed expression
P10394919A1058|7 22|element necessary
P10395199A0792|4 7|scFv
P10395283A0960|28 35|activin A
P10395378A1198|53 74|HA envelope glycoprotein
P10395827A1297|19 40|parallel beta helix model
P10395908A0236|24 41|315-residue protein
P10395911A0288|0 15|Characterisation
P10395920A1424|5 11|results
P10396343A0754|10 23|high proportion
P10396343T0000|1 22|multi-centre evaluation
P10396793A0815|0 6|Results
P10397257A1142|0 10|Mutagenesis
P10398286A0678|5 11|Scheffe
P10398682A0365|3 18|crystal structure
P10399136A0389|0 6|Ozagrel
P10400032A0304|3 14|latter method
P10400593A1084|11 15|PvirE
P10400712A0000|0 23|Simian parainfluenza virus
P10400712A0577|16 24|functions
P10400757A0000|0 4|CXCR4
P10400757A1498|21 32|better detail
P10400760A0663|3 9|results
P10400774A0240|0 1|y.
P10400785A0912|0 1|SM
P10400794T0000|0 13|Identification
P10402022A0432|0 13|Auditory clicks
P10402467T0000|0 21|Myosin light chain kinase
P10403575A1401|3 12|inhibition
P10403690A0000|3 28|prospective randomized study
P10403839A0140|5 23|sequence information
P10403839A1459|0 9|Comparison
P10405635A0374|3 27|transcriptional activities
P10406047A1244|18 39|significant differences
P10406122T0000|1 26|13-bp cis-regulatory element
P10406459A0000|25 52|platelet-derived growth factor
P10406462A1127|40 44|SRC-1
P10406464A0687|11 32|mTRAP100 coprecipitates
P10406465A0589|23 25|VDR
P10406466A0000|0 40|Classical ligand-activated nuclear receptors
P10406843A1265|0 9|Expression
P10406954A0715|0 21|Chemical stability tests
P10407184A0149|2 15|overexpression
P10407184A0520|3 19|functional studies
P10407269A0000a|5 6|bp
P10407269A0000b|5 6|bp
P10407985A0574|0 4|G-CSF
P10409656A1016|0 13|Overexpression
P10409699A0292|0 4|Human
P10409724A1021|0 9|Activation
P10409730A0597|3 15|transcription
P10409741A0382|19 31|mutant alleles
P10409749T0000|0 3|Role
P10409755A1846|10 11|Ca
P10411139A0887|0 11|Accumulation
P10411139A1344|3 9|results
P10411140A0499|17 25|125-nt RNA
P10411160T0000|3 11|mysteries
P10413604A0063|28 48|cAMP-dependent kinases
P10413607A0085|37 97|other extracellular matrix molecules pepsin-solubilized collagen VI
P10413662A0193|1 21|recombinant derivative
P10413676A0000|0 2|FAK
P10413676A0595|0 9|Expression
P10413676A1193|4 26|dominant-negative effect
P10414451A0093|8 20|young patients
P10416429A0221|0 5|DESIGN
P10416558A0000|0 6|PURPOSE
P10417331A1008|3 8|enzyme
P10417703A1326|19 25|results
P10419006A0378|0 20|Epidemiologic evidence
P10419521A0136|15 32|elongation activity
P10422291A0572|12 35|IgA lambda multiple myeloma
P10422342A0535|3 17|radiation burden
P10422468A0524|17 28|malformation
P10423156A0265|0 11|TaV particles
P10423193A1309|0 9|CONCLUSION
P10423292A0782|10 25|bp upstream region
P10425094A1006|10 19|relaxivity
P10425445T0000|0 8|Structure
P10426450A1458|0 16|Bacterial recovery
P10426878A0367|3 9|results
P10427654A0000|38 68|additional diagnostic laparoscopy
P10428091A0322|18 35|state-specific MMRs
P10428294A0227|0 21|Preheparin LPL mass level
P10428759A0743|11 47|insulin-induced receptor kinase activity
P10428811A0628|0 4|Cat-1
P10428811A1067|0 10|Cat proteins
P10428862A0834|0 29|Immunoprecipitation experiments
P10429184A0000|0 8|Expansins
P10429740A0000|23 38|clinical evidence
P10429946A0473|3 18|responsive region
P10429946A0988|22 66|B-Myb-glutathionine S-transferase fusion protein
P10430421T0000|0 17|APOE-epsilon4 count
P10430580A0000|0 5|Repair
P10430583A0000|1 16|new DNA repair gene
P10430883A0000|5 24|mucus-secreting cells
P10430886A0838|3 19|C-terminal mutants
P10430890A1059|5 12|elongin C
P10430944A1298|16 32|JAK/STAT signaling
P10430980A0465|11 13|men
P10433729A1559|0 1|A.
P10433970A0279|0 5|Spfkh1
P10435595A0203|3 20|molecular mechanism
P10436016A0337|0 12|Gel filtration
P10437043A0164|0 6|METHODS
P10438540A1185|14 43|several regulatory domain mutants
P10438593A0000|3 34|human immunodeficiency virus type-1
P10438607A0330|10 14|SEBPs
P10438627A0885|0 15|Identity elements
P10438924A1009|2 24|insulin-responsive cells
P10438924T0000|3 22|B cell antigen receptor
P10438941A1197|0 23|Fewer recombination events
P10438950A0580|0 3|IL-1
P10439040A0658|15 23|role eIF4E
P10440923A0684|0 7|Analysis
P10441243A0443|0 6|RESULTS
P10441449X1212|0 8|Copyright
P10441483A0454|0 20|Oligonucleotide probes
P10441506A0098|0 6|PKNbeta
P10442493A0815|2 9|baseline
P10443990A0000|0 9|BACKGROUND
P10444597A0586|23 31|induction
P10444813A0448|3 19|symptomatic relief
P10445161A1565|13 35|no-adverse-effect-level
P10445506A0073|17 41|gigantic sperm several times
P10445945T0000|0 16|John leonard dawson
P10446131A0132|0 16|PDGF A-chain levels
P10446149A0809|0 4|M-Ras
P10446206A0000|0 14|Deletion mapping
P10446833T0000|0 26|Microcirculatory oxygenation
P10446910A0147|0 7|Analysis
P10446912A0883|29 38|mechanisms
P10446998A0375|14 28|differentiation
P10446998A0955|0 23|Adipocyte differentiation
P10446998T0000|0 13|Transformation
P10447593A0144|3 12|core enzyme
P10447597A1004|3 14|Cr.psbA-4 ORF
P10448036A0748|16 20|zf4-6
P10448095A0865|3 25|STAT protein accumulation
P10448285A1035|3 17|median durations
P10448440T0020|10 29|scientific psychiatry
P10448902A0921|0 27|Myocardial antioxidant enzymes
P10449072A0560|3 12|second goal
P10449899A0881|5 18|overall results
P10450815A0180|3 22|present investigation
P10451209A0000|0 8|OBJECTIVE
P10452306A0502|0 7|Patients
P10452951A0000|0 22|Nuclear hormone receptors
P10452991A0331|5 9|cells
P10453006A0000|0 9|Sequencing
P10453006A0478|12 21|homologues
P10453248A0094|9 12|Udry
P10453371A0640|0 5|Weight
P10453721A0445|1 23|limited sampling strategy
P10454533A0859|0 10|Interaction
P10454540A0392|3 23|amino acid changes D206A
P10454550A0960|0 27|Previous experimental evidence
P10454557A0000|12 16|yeast
P10454557A0975|5 11|results
P10454561A0594|5 16|present study
P10454568A0815|3 25|Complete Grb10 expression
P10454570A0846|16 61|distinct mitogen-activated protein kinase pathways
P10455087A1400|0 10|CONCLUSIONS
P10455143T0000|0 19|Interdomain signaling
P10455183A0530|14 18|xtRNA
P10455183A0930|18 24|results
P10455189A0104|2 7|B cells
P10455189A0427|3 43|calcitonin-induced tyrosine phosphorylation
P10457075A1198|0 36|Independent protrudor muscle stimulation
P10458905A0000|40 77|1.7-Mb sequence-ready YAC/BAC clone contig
P10458907A0543|3 13|human RAD30B
P10458914A0674|0 7|Analysis
P10459809A1262|8 25|matrix distribution
P10460015A0465|7 12|months
P10460171A0842|0 19|Viscosity experiments
P10460172A0823|0 20|Velocity sedimentation
P10463057A0534|7 22|expression levels
P10463242A0316|2 4|EEG
P10464185T0000|0 24|Molecular characterization
P10464250A0275|6 12|FASEB J.
P10464291A0597|0 7|IL-1beta
P10464302A1109b|3 13|recruitment
P10464310A0218|0 31|Transient tyrosine phosphorylation
P10466306A0000|0 46|ECG-gated myocardial Technetium-99m sestamibi SPECT
P10466825T0000|0 3|Role
P10467004A0116|3 11|intron RNA
P10467004A0683|3 8|intron
P10467403A0000|3 31|Trk/Nerve Growth Factor receptor
P10467465T0000|16 34|significance testing
P10468033T0000|0 13|Chemical uptake
P10468585A0980|4 13|DNA binding
P10469140A0336|28 62|potential NF-kappaB-like sites present
P10469174A0678|0 25|N-terminal sequence analysis
P10469656T0000|3 21|nucleosomal response
P10470220A1011|21 33|cutoff-levels
P10471587A0239|7 13|strains
P10471696A0734|0 10|Null alleles
P10471721A0141|0 22|Recent molecular analysis
P10471743A0000|1 4|cDNA
P10471746A1102|7 10|MyoD
P10472314A0717|0 6|RESULTS
P10472836A0189|0 9|Feed intake
P10473589A0189|3 11|N terminus
P10473598A0691|0 5|Skn-1a
P10473623A0081|2 20|early Xenopus embryos
P10474898A0629|36 56|evolutionary synthesis
P10475610A1289|0 4|Natl.
P10475972A0269|14 21|outbreak
P10476970A0542|15 26|novel isoform
P10477545T0000|3 12|B-oligomer
P10477583A0000a|16 30|B cell Ag receptor
P10477583A0000b|16 30|B cell Ag receptor
P10477597A0126|0 4|TRAF2
P10477599T0000|2 29|activation-responsive element
P10477620A0580|0 42|Cytokine-induced NF-kappa B DNA binding activity
P10477748A1076|10 13|p193
P10478275A1230|3 12|main issues
P10478844A1604|0 13|Cotransfection
P10478848A0331|0 3|SF-1
P10479025A0528|13 21|locations
P10479382A1098|14 20|results
P10479492A0000|0 8|OBJECTIVE
P10480937A0000|1 35|novel Drosophila A kinase anchor protein
P10482516A1158|7 26|transcription results
P10482516T0000|3 14|RNA stem-loop
P10482565A0469|0 35|Single-alanine-substitution mutations
P10482620A1009|29 41|transcription
P10483124T0000|0 29|Regional insertional mutagenesis
P10483945A0641|0 6|RESULTS
P10484695A0791|5 21|NART-R performance
P10484818A0292|9 13|areas
P10485353T0000|0 64|Natural Haemophilus influenzae type b capsular polysaccharide antibodies
P10485470A0242|24 26|Sp1
P10485585A0175|0 6|Galoyan
P10486210A0126|39 64|human aldehyde reductase gene
P10487040A0453|0 26|Immunohistochemical staining
P10487217A0735|3 9|C2C-Prx
P10487307A0768|17 31|surgery patients
P10487744T0000|1 27|tyrosine-based sorting signal
P10487753A0788|3 11|injection
P10487759A0630|5 28|transgenic Xenopus embryos
P10487760A0336|18 30|such cofactors
P10487762A0252|0 3|NuA4
P10487921A0132|0 16|ATF1 transcription
P10487953A0765|3 10|patients
P10488087A0340|0 7|Mutation
P10488088T0000|0 25|Insulin-like growth factor-I
P10488129T0058|0 8|Synthesis
P10488147A1176|0 13|Identification
P10488148A0111|0 8|NF-kappaB
P10488148A1267|5 11|studies
P10488148T0000|0 31|ERK MAP kinase links cytokine signals
P10488337T0000|1 31|human nuclear-localized chaperone
P10488875A0000|0 22|Clinical differentiation
P10489680A0927|0 9|Sputum IL-8
P10489822T0000|0 10|Montelukast
P10490065T0000|0 8|Treatment
P10490604A0601|22 32|kinase-dead
P10490609A0413|0 12|Substitutions
P10490639A0000|26 30|PHO85
P10490662A0431|0 6|Mutants
P10490662A0819|7 17|SPT activity
P10490816A0000|0 8|Mutations
P10490822A1167|5 11|results
P10490826T0000|0 3|EB-1
P10490835T0000|0 55|Protein kinase A-Ialpha subunit-directed antisense inhibition
P10490843A0159|0 3|BCL6
P10490955T0000|0 3|Beta
P10491133A0365|0 8|Optical CD
P10491187T0000|3 26|phosphotransferase system
P10491213A0263|0 18|Serum concentrations
P10492127A0914|15 39|intravenous administration
P10492169A0939|36 48|unrelated ESTs
P10493203T0000|0 14|Prognostic value
P10493575T0000|0 16|Structural changes
P10493580A1126|13 17|Gly84
P10493876A0000|3 19|solution structure
P10495573A0365|5 14|sildenafil
P10496161A0503|0 14|Serum antibodies
P10496284A0115|10 31|encephalopathy episodes
P10496303A1968|0 10|CONCLUSIONS
P10496388A1956a|9 20|nonperfusion
P10496388A1956b|9 20|nonperfusion
P10496553A1004|3 13|healing rate
P10497117A0358|3 7|P mRNA
P10497199A0559|1 13|genetic screen
P10497262A0000|15 29|single-copy gene
P10497800A0000|3 8|MMPI-A
P10497874A0925|5 13|other hand
P10498616A0157|1 10|G22V mutant
P10498616A1280|0 13|Mammalian M-Ras
P10498706A1219|32 35|PecS
P10498717A1048|5 16|observations
P10499121A0542|7 32|experienced hearing aid users
P10499357A0439|0 10|SCOB testing
P10501034A0839|0 27|Ribonuclease protection assays
P10501656A1415|0 21|Differential expression
P10501936T0000|0 11|Inactivation
P10501965A0879|0 11|Several genes
P10501969A1329|3 9|results
P10502216A0289|32 39|efficacy
P10502402A0129|9 25|cell-surface TRAIL
P10502402A0533|8 30|pharmacologic inhibitors
P10502434A0367|4 11|February
P10502434A0604|6 13|patients
P10502522A0000|0 23|Defective provirus genomes
P10503540A0602|11 21|primer pairs
P10503812A1450|1 30|population pharmacokinetic study
P10504332A0701|0 20|Immunofluoresence data
P10505694A0000|0 13|Interleukin-12
P10505694A0739|0 14|IL-12 production
P10506143A0610|2 10|HeLa cells
P10506160A0297|0 1|J.
P10508522A1598|3 9|results
P10509768A1118|14 38|saturated fatty acids intake
P10510295A0606|11 41|ethanol repression autoregulation
P10510379A0105|1 26|crucial transcription factor
P10511216A0654|0 10|CONCLUSIONS
P10511554T0000|7 18|high-density
P10512699A0364|4 12|machinery
P10512699T0000|0 19|High-level expression
P10512857A0000|2 13|Wnt signaling
P10512882A0137|0 7|Assembly
P10513756A0584|3 5|EPV
P10513922A1237|24 43|significant increases
P10514493A0199|5 37|SO-induced neuronal differentiation
P10514808T0000|0 17|Cortical dysplasias
P10516011A0471|28 41|peptide mapping
P10516026A0270|4 13|HERV-K type
P10516072A0146|0 3|Duch
P10516738A0925|5 15|time-points
P10516878T0000|0 11|Modification
P10517666A1069|0 24|High-affinity binding sites
P10517672A1417|7 19|73-bp fragment
P10517675A0809|0 18|Western blot analysis
P10518496A0952|0 10|Aggregation
P10518502T0000|0 4|nos-1
P10518561A0261|8 25|upstream regulators
P10518561A0885|0 23|Efficient phosphorylation
P10518822A1037|0 9|CONCLUSION
P10518937A0572|3 20|expression analysis
P10518956A0137|5 25|thyroid hormone changes
P10518956A1212|0 6|ESS type
P10520800A0307|0 6|METHODS
P10521345A0202|0 20|Paleoceanographic data
P10521443A0486|21 32|IR activation
P10521447A0606|19 19|B
P10521447A1190|12 25|overexpression
P10521450A0437|10 22|Akt activation
P10521509A0000|0 9|Regulators
P10521544T0000|0 6|Cloning
P10521796A0872|3 5|ORs
P10523319A0209|16 20|Dbp5p
P10523520A0986|8 20|nematode genes
P10523634A1404|1 6|subset
P10523640A0367|11 27|Src tyrosine kinase
P10523647A0000|3 25|transcription factor CHOP
P10523647A1001|5 8|CHOP
P10523663A0404|4 8|motif
P10523674A0000|0 7|RNase MRP
P10524258A0286|32 41|FGFR-1 gene
P10524258T0000|0 9|Regulation
P10525413A1408|3 18|backbone dynamics
P10526670A0236|0 2|Rac
P10526670A1828|9 27|specific ICE/caspase
P10527106A0384|0 8|OBJECTIVE
P10527158T0000|3 9|AL-R8 SI
P10527180A0869|0 6|RESULTS
P10527426A0521|12 29|SBEI gene transcript
P10527475A0643|5 13|rare MNGCs
P10528035A1102|2 8|percent
P10529198A0068|3 27|C-terminal catalytic domain
P10529354A0375|3 12|proteasome
P10531334A0525|2 7|assays
P10531340A1275|0 1|R.
P10531342A0348|3 18|N-terminal domain
P10531342A1111|35 54|proteophosphoglycans
P10531360A0958|28 32|cells
P10531446A0203|0 9|Neuregulin
P10532354A1374|3 9|results
P10532805A0792|2 10|PC12 cells
P10532805A1084|3 16|PC12 cell mutant
P10533066A0758|0 12|TSC1 mutations
P10533066A1197|6 13|patients
P10534048A0297|3 16|first algorithm
P10534402A0126|12 15|cDNA
P10534402A0659|0 5|RT-PCR
P10534691A0542|0 6|Animals
P10535715A0268|3 5|RMR
P10536125A0093|0 10|Oseltamivir
P10536369A0662|2 23|gel mobility shift assays
P10536369A1280|3 20|relative importance
P10536788A0931|7 7|d
P10540015A0664|0 11|C-SP duration
P10540292A1179|20 36|spv virulence genes
P10540553A0980|0 17|Intensive synthesis
P10540915A0697|0 19|Tracheal transsection
P10541432A0185|0 27|Kinase-deficient erbB proteins
P10541550A0487|5 22|immunolocalization
P10541865A1301|10 31|homozygous co-deletions
P10542237A0357|15 28|aortic explants
P10542249A0415|0 16|Albumin expression
P10542260A0832|17 35|proteolytic activity
P10542269A0000|0 18|Amyloid beta-protein
P10542274A1376|14 23|activation
P10542277A0000|3 15|importin alpha
P10542281A0382|12 16|G1-G2
P10542281A2021|3 9|results
P10543270A1054|7 24|i.v. steroid therapy
P10543727A0282|17 21|sites
P10543728A0358|3 16|tumorigenic E1A
P10543730A0000|3 31|yeast C-type cyclin Ume3p/Srb11p
P10543949A0686|16 17|S1
P10544037A0617|0 3|FZD4
P10544088A0308|3 38|NF-kappaB responsive reporter construct
P10544089A1208|3 16|RNA transcripts
P10544113A0293|0 25|EIAV LTR sequence variability
P10545192T0000|0 38|Phosphatidylinositol 3-kinase requirement
P10545248A0567|13 20|enhancer
P10545281A0836|25 35|immunogenic
P10548434A1549|15 29|striking ability
P10548622A0906|15 31|paracervical block
P10548722A0099|3 6|loci
P10549354A1782|13 39|APC wild-type colon carcinomas
P10549354A2371|0 16|Similar mechanisms
P10549912A0136|32 72|previous inferior acute myocardial infarction
P10550139A0191|0 7|PATIENTS
P10550571A0000|0 6|PURPOSE
P10550574A1038|12 35|nonhematologic toxicities
P10551788A0229|0 5|LHbeta
P10551796T0000|0 9|Regulation
P10551816A0162|0 10|Human LTBP-1
P10551848A0000|4 15|earlier study
P10551867A0350|16 32|amino acid residues
P10551879T0000|0 38|Cyclic AMP-dependent protein kinase binding
P10552357A1936|0 10|CONCLUSIONS
P10553551A0000|0 17|Factor XI deficiency
P10553959A0812|3 16|Ishasha samples
P10554946A0082|3 22|more traditional SERMS
P10555079A0254|0 1|Ti
P10555285A1065|28 44|duplication events
P10555964A0778|0 1|S.
P10556028A0292|3 11|cop region
P10556029A0852|0 11|WA constructs
P10556033A0000|3 18|RFX protein family
P10556044A0913|0 6|Binding
P10556046A0328|20 31|antagonistic
P10556063A0092|5 11|kinases
P10556089A0901|19 23|etr-1
P10556145A1034|0 9|Gentamicin
P10556263A1035|0 10|CONCLUSIONS
P10556595A0391|25 38|mutant recN gene
P10556751A0758|24 49|potential transmission rates
P10557008T0000|0 8|Detection
P10557072A0127|34 43|human cDNAs
P10557072A0418|0 3|ULKs
P10557072A1218|5 11|results
P10557308A0000|0 16|Connector enhancer
P10559207A0207|2 17|simpler organisms
P10559303A0000|0 16|Epstein-Barr virus
P10559320A0080|3 20|amino-terminal half
P10559324A0716|10 22|recombinant Ad
P10559364A0846|2 5|HCMV
P10560014A0000|0 10|Macroscopic
P10560997A1072|0 9|CONCLUSION
P10561095A2141|8 18|reoperation
P10561153A0225|16 24|carcinoma
P10561251A0000|0 6|PURPOSE
P10561460A0615|3 17|GPI anchor moiety
P10561546A0000|13 40|novel 100-kDa mammalian protein
P10562418A0238|0 22|Insulin-regulated events
P10562456T0000|0 16|Regulatory regions
P10562495A0188|8 19|most SFV genes
P10563212A0514|21 38|SF-36 questionnaire
P10563605A0773|40 43|IENF
P10563789A1951|26 42|F beta alpha/CG beta
P10563836A1234|11 29|AP-2 binding activity
P10564231A0315|0 8|N. van Hoek
P10564280A0140|16 52|tyrosine-phosphorylated nuclear protein
P10564472A0853|5 11|mutants
P10564474T0000|0 18|PhoP-PhoQ homologues
P10564479A0384|0 7|Deletion
P10564484A0859|4 13|constructs
P10564495A0444|19 29|Opa proteins
P10564593A0428|0 3|FISH
P10564593A1618|3 9|MXR gene
P10564939A0981|11 17|smoking
P10566630A0371|0 29|Serum insulin-like growth factor I
P10566862A0000|0 9|BACKGROUND
P10567430A0785|0 16|Additional studies
P10567524T0000|3 21|elm1 kinase functions
P10567533A0818|0 19|Reverse transcription
P10567538A1028|14 38|acetyltransferase activity
P10567581A0119|3 29|proliferation-specific HNF-3
P10567582A1334|11 15|CtBP1
P10567589A1268|3 19|multiple functions
P10568275A0679|20 25|sea ice
P10568455A0000|20 34|single injection
P10568728A1445|10 28|serum creatine kinase
P10568744A0728|19 23|sites
P10570262A0000|0 9|Activation
P10570996A1213|1 20|phylogenetic analysis
P10571047A1009|0 30|Several 7SL RNA-encoding sequences
P10571474A0571|0 6|Results
P10572087A0326|15 28|binding partner
P10572130A1623|5 11|results
P10572131A0000|0 16|Klebsiella oxytoca
P10572866A0481|0 14|Marked hemolysis
P10573781A0631|0 6|Studies
P10574913A1108|22 56|GRK-mediated receptor phosphorylation
P10574929A0583|7 30|subcellular fractionation
P10574982A1075|0 14|Supershift EMSAs
P10574992A0901|11 20|E1A binding
P10575231A0355|0 7|Analysis
P10575545A0147|15 19|CACCC
P10575642T0000|0 12|Skin pH changes
P10576177A0308|55 74|straightforward range
P10576545A0926|17 44|potent regulatory DNA cassettes
P10578528A0730|46 48|EEG
P10579331A1225|3 9|results
P10579722T0000|0 14|Phosphorylation
P10580071A0436|7 14|patients
P10580438A0508|2 34|electrophoretic mobility shift assay
P10582831T0000|0 8|Syndromes
P10584138T0001|0 13|Cytoprotection
P10584704A0913|0 26|Immunohistochemical staining
P10585311A0494|0 7|Patients
P10585311A1542|0 27|Residual urinary abnormalities
P10585417A1412|14 24|differences
P10585440A0204|37 48|FAK homologue
P10585453A1029|10 19|Pit-1 sites
P10585463A0859|0 29|Recombinant prenylcysteine lyase
P10585480A0157|17 30|third SH3 domain
P10585480A0265|0 13|Point mutations
P10585491A0945|2 23|gel mobility shift assays
P10585808A0000|0 26|Mycoplasma hominis infections
P10586074A0129|30 46|plasmid constructs
P10586107A0160|24 28|types
P10586115A0477|24 53|major pro-inflammatory cytokines
P10586626A0607|0 20|Demyelinating diseases
P10587460A0302|11 34|minimal VDRE binding domain
P10587461A0341|4 23|induced-fit mechanism
P10587576A0596|5 8|REPs
P10588946A0432|25 49|novel OSBP-related proteins
P10589562A1208|20 28|inability
P10589711A1228|11 24|narZ expression
P10590092A0124|8 17|mechanisms
P10590368X0000|2 21|radical trachelectomy
P10591633A0138|1 8|key event
P10591933A0798|13 16|Type
P10591976A0317|0 11|Measurements
P10591990A0178|10 47|DSM-IV paranoid schizophrenic in-patients
P10592791A0370|16 23|TECRA kit
P10592791T0001|0 9|Comparison
P10592824A1157|10 22|high frequency
P10593939A0747|28 64|protein-protein interaction experiments
P10593950A1113|10 12|WT1
P10594130A0652|11 16|hearts
P10594239A0614|0 7|Tih1 maps
P10594239T0000|1 41|novel pleckstrin homology-related gene family
P10594903A0000|21 41|reactive nanoparticles
P10595315A0344|9 30|minimal negative effects
P10596955A1032|13 32|renal failure patients
P10597222A1371|23 25|p27
P10597223A0339|0 8|Transient
P10597232A0000|3 23|RET/PTC3 rearrangement
P10597317A1156|0 8|Apoptosis
P10598101A0000|15 32|bZIP protein Opaque2
P10598101A0754|3 16|mEmBP-1 protein
P10598316A1534|0 2|GHB
P10599013A0505|11 16|deaths
P10599727A1567|8 9|GH
P10600171A1066|23 36|responsiveness
P10600171A1432|0 25|Higher CYP3A23 basal activity
P10601280A0674|14 34|TPA-responsive element
P10601290A0742|35 54|cell surface stability
P10601335A0892|0 13|Redistribution
P10601344A1653|16 40|biochemical activity assays
P10601410A0977|40 43|IVIg
P10601606A0152|3 21|rhabdomyosarcoma R1H
P10601747A0482|0 7|Relative
P10602419A1253|5 22|synergistic effects
P10602502A0422|7 16|Tob protein
P10602507A0652|3 20|coordinate increase
P10602516A0182|11 13|SLK
P10602838A0127|13 20|patients
P10603349A1667|3 25|signalling molecules Wnt1
P10604246A0523|0 10|STUDY DESIGN
P10604583T0000|0 14|Albumin dialysis
P10604945A0731|4 31|artificial promoter constructs
P10606245A0906|0 13|Overexpression
P10606272A1241|0 8|Injection
P10606515A0389|4 10|domains
P10606664A0000|0 18|Snail family proteins
P10607566A0880|0 9|Consistent
P10607899A0605|0 15|Sequence analysis
P10607900T0000|0 21|Sak kinase gene structure
P10608053A0923|0 11|Thrombolysis
P10608893A0727|0 6|Similar
P10610716A1127|13 32|new missense mutations
P10611225A1127|37 41|eIF4A
P10611228A1388|3 23|DAP5/p86 apoptotic form
P10611235A1927|20 26|key step
P10611242A0541|0 9|Consistent
P10611320A0816|59 71|proven CAK gene
P10611353A0458|0 11|Northern blot
P10612044A1180|42 56|AP-4 binding site
P10612505A1317|37 48|power greater
P10612773A1210|0 10|CONCLUSIONS
P10612805A0716|10 26|genetic alteration
P10612918A0318|3 10|problems
P10613816X0000|0 6|Statins
P10613843A0107|14 21|products
P10613863T0000|3 23|VirR response regulator
P10613874A0663|0 6|Cloning
P10614676A0000|0 8|Objective
P10614857A0584|0 16|Leukocyte cultures
P10616948A0998|5 21|BF ECT group the-age
P10617126A1005|0 19|Histological analysis
P10617144A0386|3 9|extents
P10617232A0393|0 11|Serum HBV-DNA
P10617613A1192|0 3|Chem
P10618645A0750|0 15|Maximum induction
P10619062T0000|0 23|Haycocknema perplexum n. g.
P10619169A0411|0 3|Rams
P10619254A1055|0 12|Animal studies
P10619353T0000|0 3|Role
P10620010A1155|0 9|CONCLUSION
P10620335A0749|16 18|AHR
P10620777A1399|0 7|AB004534
P10622574A0000|3 12|prevalence
P10622576A0552|0 4|Clear
P10623758A0947|6 12|latency
P10623804A0808|4 22|alternative approach
P10624787A0432|19 38|normal renal functions
P10625438A1429|5 11|tissues
P10625494A1059|5 11|results
P10625683A0091|4 12|receptors
P10625721T0101|0 10|Hypothermia
P10627518A0544|3 22|synergistic effect due
P10627532A0739|21 21|R
P10627834A0178|3 23|US commercial cultivars
P10628490T0000|0 6|Anatomy
P10628748A0344|8 17|activation
P10628748A0746|0 7|Deletion
P10628750A0298|26 29|APRE
P10628750T0000|0 10|Angiotensin
P10628755A0000|0 15|Synthetic ligands
P10628971A0824|15 21|mutants
P10628971A1165|19 25|mutants
P10629035A0827|3 20|single strandedness
P10629176A0887|11 16|CaMig1
P10629938A1352|15 30|wide distribution
P10630471T0000|2 10|ASIC-chip
P10630630A0614|8 18|calphostin C
P10633075A1111|0 11|Preimmune IgG
P10633499A1306|0 22|Arhythmacanthus Yamaguti
P10634007A0202|17 37|acetaminophen overdose
P10635209A0419|9 20|conditioning
P10637149A0806|0 9|Downstream
P10637230A0332|19 23|c-myc
P10637238A0291|0 40|Eastern Cooperative Oncology Group trial E3186
P10637337A0545|15 23|DNA repair
P10638607A0000|5 12|articles
P10639585A0157|0 6|Studies
P10640683A0204|0 11|NDRF/NeuroD2
P10640683A0670|0 26|Transient transfection assays
P10640701T0000|3 23|Pax2/5/8-binding sites
P10640734A0190|4 26|tyrosine phosphorylation
P10641037A1371|0 7|AF154055
P10641688A0341|0 8|Alignment
P10642524A0156|3 24|concomitant interaction
P10642531A2322|0 21|Competition experiments
P10642889A0393|0 15|Sequence analysis
P10643313A0345|5 22|i.v. administration
P10644357A0935|5 11|results
P10644414T0000|0 21|Differential expression
P10644753A0725|8 15|isoforms
P10644760A0000|3 17|differentiation
P10644760A0956|0 7|Analysis
P10645921A0000|0 9|BACKGROUND
P10645921A1320|0 21|Multivariate predictors
P10646820T0000|23 37|lymphadenectomy
P10646863A0838|0 13|Overexpression
P10647177A0599|3 12|RNA aptamer
P10647633A1685|31 49|anatomical sphincter
P10647817T0000|0 8|Isolation
P10647859A0000|13 38|mechanical inhibitory effect
P10648020A0151|0 6|METHODS
P10648211A0000|0 26|Neuronal signaling properties
P10648489A1117|0 8|Treatment
P10648619A0000|35 61|specific TATA-binding protein
P10649449A0413|3 11|sequences
P10649456A1061|3 8|clones
P10649738A0953|3 10|episodes
P10650104X0284|0 8|Copyright
P10650938T0000|3 18|estrogen receptor
P10650939A0789|0 8|Induction
P10650939A1542|2 14|myometrial SMC
P10650958A1315|0 7|Element B
P10651076T0000|0 13|High resolution
P10651805A1600|0 17|Stable transfection
P10651805T0000|0 15|Characterization
P10652093A0139|0 18|Electron microscopic
P10652102A0620|22 27|dosage
P10652228A0759|13 22|activation
P10652324A0177|26 40|collagen binding
P10652362A0933|32 47|carboxyl terminus
P10652800A0984|3 23|insulin therapy regimen
P10653359A1297|0 8|Scmh1 maps
P10653400A0000|3 15|applicability
P10653550A1120|0 18|Hyaluronan treatment
P10653693A0429|20 25|issues
P10653693A0903|3 12|RING finger
P10653697A0133|0 5|Actins
P10653733A0596|7 13|domains
P10654032A1133|0 3|JPEG
P10655164A0546|18 47|current systematic uncertainties
P10655230A0685|9 24|yeast counterpart
P10656154A0722|4 8|women
P10656161A0316|0 2|MBI
P10656802A1724|7 19|long insertion
P10657238A0541|0 22|Transfection experiments
P10657658A0165|0 13|Further studies
P10657899A0685|0 11|Pretreatment
P10658425A1567|10 29|subclinical infection
P10658445A0208|0 6|METHODS
P10658588A0304|0 26|Desmethylferrochloroquine 1a
P10660069A0819|3 19|rrd1,2delta mutant
P10660304A0522|0 6|Members
P10660604A0748|7 22|CARbeta/RXRalpha
P10660676A0000|0 15|Zebrafish cyclops
P10662550A0679|5 8|SOX8
P10662614A0000|3 20|genome organization
P10662614A0972|3 17|two-hybrid assay
P10663558T0000|0 27|Diverse endogenous light chains
P10664876A0000|0 8|Patch test
P10665308T0001|0 9|Mechanisms
P10665798A0598|22 33|serum enzymes
P10665949A1131|3 19|partial farm budget
P10666222A0330|14 48|full-length murine survivin cDNA clones
P10666238A1322|8 16|induction
P10666253A1291|10 22|stabilization
P10666509A0494|0 34|Ischemia-induced biphasic arrhythmias
P10667597A0668|0 2|ZK7
P10668701A1311|0 9|CONCLUSION
P10669319A1722|2 20|definite conclusions
P10669594A0000|21 28|fimbrins
P10669594A0969|2 15|marked contrast
P10669596A0430|0 15|Productive growth
P10669633A0391|29 47|molecular mechanisms
P10669736A0903|9 26|2.4-fold difference
P10669751T0000|0 54|Multiple mitogen-activated protein kinase signaling pathways
P10670358A0143|0 10|Dermatology
P10671224A0254|5 16|present study
P10671519A0641|0 22|Protein sequence analysis
P10671520T0000|0 15|Molecular cloning
P10671554A0492|10 27|amino acid sequences
P10671606A0884|4 23|chemical shift imaging
P10672433A0199|31 51|subjective measurement
P10672899A0078|0 3|Acad
P10673335X0782|0 8|Copyright
P10673426A0168|11 11|R
P10674395A0262|57 80|reproductive neuropeptide
P10674484A0633|20 34|combined lesions
P10675154T0000|0 13|Extreme potency
P10675331A0600|11 15|c-Src
P10675610A0279|0 4|MSSPs
P10677214A1045|3 14|wild type MutT
P10677214A2842|0 16|Structural changes
P10677297A0933|50 57|nonsense
P10678144A0509|5 8|i.v.
P10678968A1096|0 7|Immunity
P10679015A0216|22 28|studies
P10679065A0711|0 15|BCR cross-linking
P10679065A1217|0 9|Activation
P10679190A0693|24 47|upstream open reading frame
P10679649A0311|0 6|METHODS
P10679781A1183|4 31|bp Glucocorticoid Response Unit
P10679922A1110|2 17|somatic mutations
P10681520A0525|0 7|Ras-GRF1
P10681562A0263|4 31|complete PPARgamma antagonists
P10681588A0899a|0 3|EMSA
P10681588A0899b|0 3|EMSA
P10681679A0220|22 33|solid portion
P10682570A0453|0 2|LPO
P10683072T0000|0 30|Sustained ventricular tachycardia
P10683244A0939|14 17|NBF1
P10683244A1860|18 28|experiments
P10683244X2359|0 8|Copyright
P10683259A0774|0 18|Sulfhydryl titration
P10683989A0251|5 25|nitric oxide inhalation
P10684069A0508|3 9|results
P10684097A0175|5 26|4-month old SD female rats
P10684111A1411|32 51|extracellular factors
P10684265T0000|0 19|Covalent modification
P10684304A1242|21 21|U
P10684534A0634|0 8|Protamine
P10684646A0224|13 27|common mechanism
P10684660A1266|0 9|Comparison
P10684941A0722|18 32|complementarity
P10684967A0000|0 5|NKX2.1
P10687366A0000|0 19|National abortion laws
P10687855A1197|0 9|Expression
P10687855T0000|0 41|Mouse growth hormone transcription factor Zn-16
P10687862A1980|3 26|CCAAT core sequence mutants
P10687945A0000|0 10|Deglutition
P10688639A1310|4 13|repression
P10688646A0535|6 28|human erythroid K562 cells
P10688660A0992|32 34|CBP
P10688661A0237|3 23|cognate binding protein
P10688663A0207|0 6|Removal
P10688666A1010|22 35|ASK1 activation
P10690702A0065|0 6|OUTCOME
P10690725A1037|3 15|other patients
P10690866A0783|3 12|variations
P10691972T0000|0 15|Characterization
P10692167A0364|38 60|preliminary observations
P10692374A1873|5 11|results
P10692433A0000|3 24|transcription factor E2F
P10693246A0252|2 25|two-field nodal dissection
P10693314A0521|8 15|patients
P10694189A0469|11 13|MIB
P10694210A0385|3 18|regional blockade
P10694511A0570|18 21|yam8
P10694605A1327|10 30|overall infection rates
P10694609A0309|0 5|Static
P10695685T0000|0 17|Antipyretic therapy
P10696007A1325|27 45|C2-C3 disk morphology
P10698516T0000|0 2|KFC
P10698937T0000|0 4|TIP30
P10698974A0951|15 28|human STAG3 gene
P10699354A0557|0 11|Reaction time
P10699653A0967|16 19|rats
P10699684A0661|12 16|Zelen
P10699896A0455|0 6|RESULTS
P10700262A0000|0 23|Selective visual attention
P10701534A0164|22 50|left-sided low-frequency tremor
P10702241A0357|11 19|a1 isoform
P10702253A0357|9 15|cloning
P10702285A0855|30 30|G
P10702389A1148|2 10|endemic BL
P10702794A1495|26 29|ERK2
P10702926T0089|0 13|Cross-reaction
P10703633A0747|0 15|Strontium nitrate
P10704196A1051|3 32|pCMBS-reactive sulfhydryl groups
P10704283A0649a|0 7|Analysis
P10704285A0536|0 11|Human AP-2rep
P10704338A0354|13 25|deeper insight
P10704410T0000|0 15|Clb/Cdc28 kinases
P10704499A0682|14 25|PC12-E2 cells
P10704853T0000|0 15|Cooperative roles
P10704975A0479|0 16|Thiopentone sodium
P10705380A0629|34 51|Xretpos transcripts
P10705783A0433|5 14|other cases
P10706475A0644|27 30|DSPP
P10706513A0843|6 19|grave prognosis
P10706688A0376|11 22|TCR signaling
P10706736A1091|5 12|patients
P10706887A0281|15 15|%
P10706887A1457|19 27|decreases
P10708243A0000|27 54|non-organ-specific antibodies
P10708424A0800|0 12|Manganese ions
P10708769A0433|3 6|Mif1
P10709705T0000|0 28|Rigid point feature registration
P10710499A0000|0 11|Methysergide
P10710742T0000|0 24|Serum leptin concentrations
P10710985T0000|7 14|families
P10711674A0000|0 6|PURPOSE
P10712512A0506|0 5|Ste18p
P10712599A0349|15 19|IRF-1
P10712618A0181|2 29|amino-acid sequence comparison
P10713083A0170|0 5|Unique
P10713083A0560|13 24|genetic assay
P10713155A0151|14 33|IIIa pre-mRNA splicing
P10713161A0985|0 11|Inactivation
P10713175A1399|16 22|results
P10713176A0422|0 16|Cyclin A expression
P10713176A0885|0 19|D-cyclin-cdk activity
P10713239A0988|0 9|CONCLUSION
P10713453A0172|30 50|monoclonal antibody Q18
P10714985A1057|2 23|RNA boundary experiments
P10715322A0000|0 12|Gene silencing
P10715325A0834|3 12|AtERF genes
P10715602A0149|0 6|Animals
P10717612A0000|0 9|BACKGROUND
P10720434A0291|9 17|injection
P10721698A1195|35 56|dodecamer repeat located
P10721704A1155|13 31|genomic organization
P10721704X0000|0 7|Analysis
P10721714A1087|0 33|Electrophoretic mobility shift assays
P10721717A0676|0 3|Fgd3
P10721726T0000|0 15|Molecular cloning
P10722063A0328|3 12|HPLC method
P10722509A0392|5 12|patients
P10722661A0146|0 3|CYC2
P10722661A0406|13 16|CYC2
P10722737A1726|5 12|findings
P10723723A0781|16 28|mouse promoter
P10723727A0713|31 36|intron
P10724436A0085|11 48|enriched U3O8 standard reference materials
P10724483A0540|13 31|positive cAMP control
P10724519A1185|28 41|regulatory RNAs
P10725017A0673|19 42|middleware-based approach
P10725382A0398|0 15|Sequence analyses
P10725433A0543|1 8|mutation
P10727247A0461|17 23|cloning
P10727413A1244|12 23|binding sites
P10727426A1280|3 16|kinase activity
P10727428A0000|8 10|MAP
P10727433A0560|0 11|Transfection
P10727433T0000|0 9|Regulation
P10727511A0294|0 7|Molecule
P10727515A1202|0 11|Coactivation
P10728945A0233|0 7|Patients
P10728986A0000|3 21|Wnt signaling pathway
P10729151A1160|4 11|mutation
P10729155A0653|5 26|icosahaedral MVMi capsid
P10729220A0000|6 19|contiguous IGF2
P10729220A1569|3 23|asymmetric methylation
P10729221A0798|18 35|expression patterns
P10730292T0000|0 22|Early treatment mechanics
P10730763A1491|0 13|Preliminary use
P10731411A0958|37 49|residues other
P10731926A0775|0 14|Advanced adenoma
P10732669A0510|2 16|transient assays
P10732669A1336|0 6|Results
P10733569A0364|5 17|mammalian HSFs
P10733581A1391|12 32|concomitant expression
P10733591A0146|9 29|many downstream targets
P10733591A0533|0 9|Expression
P10733880X1783|0 8|Copyright
P10734312A0503|19 33|Shc localization
P10735272A0649|0 15|Southern blotting
P10735848A1440|0 3|RegA
P10736161T0000|0 6|Enzyme I
P10736223A1227|31 43|transcription
P10737366A0280|20 30|intrathecal
P10738139A0681|0 15|Molecular mimicry
P10739408A0896|0 16|Family environment
P10739671A0136|2 35|electrophoresis mobility shift assays
P10740602A0141|0 10|STUDY DESIGN
P10741850A0452|0 27|Electrophile Response Elements
P10741947T0000|1 12|new technique
P10742114A0486|0 3|Dll3
P10742216A0555|0 7|Schlegel
P10743608A1154|0 15|TbRAB31 behaviour
P10743719A0223|3 9|early dg
P10744026A0000|0 9|Invertases
P10744749A0315|16 34|molecular mechanisms
P10744749T0000|3 42|human T cell leukemia/lymphotropic virus type
P10744974T0000|0 14|Phosphorylation
P10745563A0409|12 22|hyperplasia
P10747053A1102|3 11|cell cycle
P10747099A0507|0 28|Extracellular-regulated kinase
P10747782A0390|0 10|Proteolysis
P10747879A0607|17 40|CCR5 cis-regulatory region
P10747890A1096|5 11|results
P10747987A0658|3 20|recombinant enzymes
P10748054T0048|1 7|pathway
P10748113A0187|14 29|second RIM protein
P10748125A0000|0 10|Inhibitor-1
P10748164A1284|0 16|Scanning mutations
P10748175A0000|3 12|substrates
P10748194T0000|0 16|Synaptic targeting
P10748204A0238|6 7|J.
P10748672A0130|0 4|Bites
P10749145T0000|25 36|PCPH proteins
P10749166A0991|5 11|results
P10749849A0000|2 19|important mechanism
P10749932A0000|0 7|Paxillin
P10750020A0843|5 26|growth factor activation
P10750021A0728|22 56|deletion promoter-reporter constructs
P10750524A0724|0 6|RESULTS
P10751398A1135|14 26|transcription
P10752450A0288|25 52|self-applied fluoride products
P10752475A1376|5 11|studies
P10752807A1598|0 9|CONCLUSION
P10753553T0000|0 8|Phenazone
P10754312A0798|3 12|solubility
P10756007A0575|9 29|identical RBE sequences
P10756007A1512|0 9|EM analysis
P10756020A0571|35 56|vaccinia virus particles
P10756032A0599|6 32|dimethyl sulfate footprinting
P10756094A0671|11 14|STSs
P10756100A0457|10 17|mutation
P10756225A1464|0 9|CONCLUSION
P10757975A0509|0 3|Biol
P10757983A0733|20 30|CRS sequence
P10758289A0141|0 6|METHODS
P10758489A0206|28 31|ICK2
P10758726T0000|0 13|Systemic impact
P10759693A0201|0 6|METHODS
P10760109A1050|3 12|prevalence
P10760132A1169|28 42|high temperature
P10760169A1142|3 22|second functional pair
P10760950A1133|1 23|distinct staining pattern
P10761263A1108|4 12|Newcastle
P10762254A0954|3 5|MMA
P10762348A0269|5 19|phosphorylation
P10763823A0824|0 13|Overexpression
P10763827A1158|13 38|multiple senescence pathways
P10764150A0000|15 23|abilities
P10764574A0718|0 10|Application
P10764729A1846|3 22|complete cDNA sequence
P10764760T0000|0 14|Transactivation
P10764802A1258|20 36|alpha-helix domain
P10764970A1009|21 45|quinupristin/dalfopristin
P10765095A0308|31 42|PRL secretion
P10766246A0000|0 24|Integrin adhesion receptors
P10766493T0000|0 12|Recombination
P10766556T0000|3 21|somatoform conundrum
P10767091A0133|0 24|Intra-operative ultrasound
P10767251A1046|0 10|CONCLUSIONS
P10767338T0000|0 19|Hailey-Hailey disease
P10767553A0100|0 2|Hex
P10767560A0105|18 43|structural characterization
P10769144A0000|3 5|CRE
P10770041A0731|0 11|Kidney length
P10770065A0264|3 15|clinical stage
P10770471T0000|0 10|Benztropine
P10771528T0036|18 36|alkaline phosphatase
P10771709A0291|3 12|physicians
P10772856X1492|0 8|Copyright
P10772977A0222|0 24|Viral cell-to-cell movement
P10773351A0672|0 8|Induction
P10773455A1268|17 43|proximal GATA-1-binding sites
P10773458A0000|0 6|SNAP-23
P10773667A0351|3 11|HMG domain
P10773951A0000|0 2|IgM
P10775038A0142|23 36|Wee1 regulation
P10775267A0363|0 21|Retroviral transduction
P10775585A0754|0 12|Ab-MLV strains
P10775623A0120|3 12|codon usage
P10777217A0536|3 20|p53-homolog p73beta
P10777499A0883|0 6|Results
P10777586A1022|0 21|Co-immunoprecipitation
P10777669A0582|3 12|ZNF274 gene
P10778740A1493|3 27|C-terminal Cdk2 truncations
P10778757A0000|17 31|molecular nature
P10779313A1842|21 34|atrial myocytes
P10779329T0000|0 3|Slap
P10779352T0000|0 13|Identification
P10779508A0452|2 6|DNase
P10779508A0897|17 27|coactivator
P10779508T0000|0 36|Estrogen receptor-related receptor alpha
P10780018A0539|9 21|current models
P10780518A1270|3 9|effects
P10780764A0722|3 14|median levels
P10780883T0000|0 5|Kaposi
P10781109T0000|0 7|Specific
P10781423A0993|0 9|Comparison
P10781541A1063|3 31|additional cis-acting sequences
P10781552A0000|0 27|Purple photosynthetic bacteria
P10781604A0827|12 28|synthetic peptides
P10781611A1023|12 40|bone marrow-derived macrophages
P10781990A0455|0 13|T1-weighted MRI
P10782640A0444|29 47|aberration constants
P10782989A0575|45 81|correct amino-terminal DNA binding domain
P10784367A0133|0 5|METHOD
P10784393A0000|0 14|Marrow dysplasia
P10785294A0720|10 36|non-acceptable inlays/onlays
P10785668A0000|3 8|plants
P10785880A0947|0 9|CONCLUSION
P10786671A0182|3 19|rate-limiting step
P10786742A0670|5 16|control group
P10787437A1616|11 25|element proximal
P10787804T0000|0 13|AMDA white paper
P10788320A1034|5 12|proteins
P10788476A0891|0 9|Antibodies
P10788480T0000|0 9|Regulation
P10790390X0000|0 6|Genetic
P10791251A0110|16 24|many kinds
P10791819A0771|14 22|likely due
P10791901A0609|0 11|Transduction
P10792583A0000|0 9|Regulation
P10792718T0000|0 13|Identification
P10793143A1533|10 24|mutant defective
P10793991A0569|8 24|relative longevity
P10794405A0000|3 17|structural study
P10794936A0241|3 15|recovery rates
P10795098A0253|0 26|Cerebral vasculitis secondary
P10796465A0373|0 16|SELECTION CRITERIA
P10796486A0817|0 16|SELECTION CRITERIA
P10797125A0000|23 49|progestin-mediated increases
P10797586A0402|3 8|models
P10798607A1359|19 35|phagocytic killing
P10799501A1391|5 11|studies
P10799576A0196|0 1|M.
P10799590A0431|0 21|Jkappa DNA-binding sites
P10799595A1454|9 11|YY1
P10799863T0000|0 17|Sequential cleavage
P10799879T0000|0 6|Cloning
P10801244A0578|0 13|Vancomycin data
P10801330A1714|8 10|Cas
P10801482A0968|14 16|p65
P10801809T0000|0 24|Transcriptional regulation
P10801860A0000|3 9|Siglecs
P10802669A1434|15 36|biochemical explanation
P10802909A0478|0 26|PATIENTS OR OTHER PARTICIPANTS
P10804379T0001|0 5|Update
P10805286A0233|5 16|present study
P10805286A0914|12 28|PCI mRNA expression
P10805390A0340|27 38|measurements
P10805729A0987|3 15|stoichiometry
P10805737T0000|0 17|Mutational analysis
P10805738A0799|0 11|Much evidence
P10805739A0343|26 41|complex formation
P10805739A0640|13 29|nonsense mutations
P10805747A0633|11 19|mutations
P10805823A1920|0 10|CONCLUSIONS
P10807900A0933|5 18|non-cirrhotics
P10807903A0362|0 4|D5/D1
P10809233A0606|0 7|Modeling
P10810083A1283|3 28|serine-threonine kinase gene
P10810294A0730|0 13|Stat activation
P10810745A0677|0 6|HFA 134a
P10811079A0555|0 6|RESULTS
P10811079A1277|5 21|SPP2 screening test
P10811804A0000|0 23|Mitogen-activated protein
P10811804A0800|0 9|Consistent
P10811908A0938|0 24|HPLC phosphopeptide mapping
P10812294X0000|7 16|entire diet
P10814989T0000|0 23|Hepatitis C virus infection
P10815410A0000|3 14|immune system
P10815807A1271|24 36|transcription
P10817754T0000|0 2|H19
P10819327T0000|0 14|C. elegans KLP-11
P10820829T0000|0 9|Flavonoids
P10820904A0000|0 9|BACKGROUND
P10821836A0842|5 32|natural antisense S transcripts
P10822117A1386|5 26|such adjustment possible
P10823630A1124|21 30|effacement
P10823837A1213|10 19|compatible
P10823961A0664|3 11|C terminus
P10824485A0393|3 10|patients
P10824958A1109|9 21|dietary energy
P10825000A1245|3 24|gene amplification model
P10825200T0000|0 8|Hierarchy
P10825293T0000|11 16|dimers
P10825294A0473|11 20|OC promoter
P10826861A0000|3 34|monoclonal immunoglobulin products
P10826946A1198|0 12|Investigation
P10827885T0059|0 11|Double-blind
P10827952A0158|18 25|TAFII250
P10828022A0877|0 18|Endostatin treatment
P10828319A0342|10 16|analogs
P10828591A0080|3 12|transcript
P10828751A2258|3 15|real challenge
P10829973T0000|0 24|Iodine deficiency disorders
P10830395A0408|3 18|network evolution
P10831972A0744|0 6|RESULTS
P10831972A1091|0 9|CONCLUSION
P10833461A0603|19 41|P-1 artificial chromosome
P10833486A0598|0 2|Age
P10834707A1533|12 29|significant amounts
P10834781A0693|11 22|elderly group
P10835355A0225|18 38|zinc finger protein Gis1
P10835485A0941|13 15|SH3
P10835732A0911|2 12|differences
P10836542A0363|6 6|%
P10836786A0516|33 43|RNA subunits
P10837126A1004|5 9|genes
P10838139A1447|14 24|Ha-ras codon
P10838399A0525|0 18|False positive PET FDG
P10838531A0675|0 10|Tumor stages
P10839470A1148|22 41|percentage reductions
P10839547A0978|0 9|Consistent
P10839593A0000|0 8|OBJECTIVE
P10840001A0188|0 18|Mucin gene expression
P10841537A0669|23 29|regions
P10841593A0780|27 36|% reduction
P10841601T0000|0 9|Paper alert
P10843716A0406|3 15|tryptase locus
P10843810A0802|3 14|cellular part
P10845522A0000|0 8|OBJECTIVE
P10846054A0573|0 17|Mutational analyses
P10846069T0000|0 3|Role
P10848605T0000|0 14|Phosphorylation
P10848848A0413|0 6|RESULTS
P10848993A0000|0 19|Genomic DNA sequencing
P10850329A0248|0 3|IL-2
P10850453A0713|21 35|antisense Ha-Ras
P10850453A1292|32 49|prostate carcinomas
P10850719A0680|0 12|Vbeta segments
P10850849A0730|3 20|oral administration
P10850942A0989|28 42|gastric emptying
P10850997A1016|11 32|H-NS negative regulation
P10851089A1248|5 7|SAG
P10851267A0000|0 2|E2F
P10851745A0624|21 33|negative moods
P10852221A0422|34 47|graft recipient
P10852460A0170|3 15|relationships
P10852485A0477|0 12|Chinese Spring
P10852953A0000|0 13|Investigations
P10853059X0751|0 7|Karger AG
P10853778A0316|6 21|surgery bone cysts
P10853850A1103|0 10|Urinary LTE4
P10854004A0788|0 7|Basal FVR
P10854699A0424|5 15|FGF-AS cDNAs
P10855690A0870|19 25|results
P10855793A1418|0 15|Characterization
P10855796A1160|14 36|RNA hybridization studies
P10856298A0798|0 11|Transfection
P10856491A0178|0 6|SETTING
P10856805T0000|0 29|Improving fissure sealant quality
P10857215A0000|3 24|Menopause-Rating-Scale
P10857215A0806|3 7|MRS II
P10857262A0186|22 35|fruA transcript
P10857751A0304|14 26|mouse ortholog
P10858355A0920|0 11|Sparfloxacin
P10858988A0786|0 2|ECP
P10860131A0847|0 15|Tolterodine users
P10860196A0876|5 23|unsupervised program
P10860752A1601|18 28|putative RNA
P10860827A0399|0 7|Deletion
P10860846A0480|0 16|Functional studies
P10861080A0433|5 22|adenoviral transfer
P10861086A0259|2 26|reconstitution experiments
P10861086A0904|11 32|c-Src-derived construct
P10861906A0999|3 20|delta srb10 mutation
P10861906A1479|15 37|environmental conditions
P10861909A0502|3 12|pJR vectors
P10862289A0289|1 3|GUT
P10863048A0000|11 15|acute
P10863352T0001|0 12|Franz Schubert
P10864271A0504|3 9|results
P10864496A0401|3 40|equilibrium dissociation binding constant
P10864641A1400|5 11|results
P10864989A0484|0 6|RESULTS
P10865422A0138|16 28|serum ferritin
P10865838A0000|0 30|Vascular endothelial growth factor
P10865940A0000|3 44|antioxidant agent pyrrolidine dithiocarbamate
P10866323A0666|19 25|effects
P10866677A1839|0 33|Phd antibody-immunoreactive peptides
P10866689A0295|5 7|pRb
P10866886A1277|22 32|conjunction
P10867199A0230|15 35|morphological criteria
P10867496T0001|0 16|Neurofibromatosis
P10868488A0921|5 27|premating period male rate
P10869076A1384|5 11|results
P10869465A1054|6 18|hybridization
P10870043A0621|22 32|GnRH agonist
P10870391T0034|0 9|Prevention
P10871045A1221|18 26|C/EBPbeta
P10871347A0477|0 15|Mutation analysis
P10871379A0261|6 9|VP16
P10871412A0369|8 23|successive rounds
P10871615A0368|0 1|G.
P10871842A0988|3 9|results
P10872473A2286|3 15|ATR-X syndrome
P10872535A0000|0 3|AIMS
P10872756A1325|2 10|NASCIS III
P10872827A0000|0 16|Penicillin acylase
P10872831A0000|1 6|murine
P10872851A0714|7 9|LCx
P10873158A0000|0 9|Activation
P10873286X0000|0 11|GAP JUNCTIONS
P10873386A0000|45 53|mouse gene
P10873387A0816|19 27|human gene
P10873388A0623|7 23|human Rhotekin cDNA
P10874044A0647|10 22|co-expression
P10874151A0000|0 9|BACKGROUND
P10878398A0542|2 21|hemodialyzed patients
P10878606A0876|23 38|neural structures
P10878675A1278|0 9|CONCLUSION
P10878944A0000|0 52|ID-PaGIA diphtheria toxin polymer particle diagnostic agent
P10880486A0790|18 37|EMS-induced mutations
P10880702A0966|13 19|results
P10881275T0000|10 24|serum IgM binding
P10882163A1077|0 17|Objective responses
P10882213A0163|0 5|Topics
P10882462T0000|12 28|tissue engineering
P10882850A0000|0 11|Endonuclease
P10884978A0633|3 10|duration
P10885708T0000|8 23|bile duct blockage
P10885731A0915|39 57|synthesis conditions
P10885750A0236|35 48|normal function
P10886067A0520|3 15|outer diameter
P10887912A0740|7 10|MVBF
P10887921A0718|0 10|CONCLUSIONS
P10888570A0678|3 16|total alkaloids
P10889399A0243|3 22|detection success rate
P10890911A0470|17 21|Smad3
P10891093A0000|3 23|transmembrane topology
P10891266A0421|0 4|ACE-2
P10891286A0000|0 6|Members
P10891399A1185|15 24|activation
P10891441A0871|13 36|pTyr317 Shc phosphopeptide
P10891489A0152|32 46|HMG-I/Y proteins
P10891632A0435|3 34|naltrexone/lofexidine combination
P10892300A0268|3 15|first symptoms
P10892823A1040|0 8|Screening
P10893243T0000|0 24|Transcriptional regulation
P10893258T0000|11 25|protein response
P10894149T0000|0 3|PNRC
P10894816A0836|0 6|Studies
P10894886A0375|21 26|subset
P10895417A0000|18 25|epidural
P10895417A0669|9 17|EPI-C0401
P10895851A0696|0 16|Bailey Instruments
P10896008A0531|0 11|PARTICIPANTS
P10896859A0000|11 26|water deprivation
P10896859A0838|12 21|major cause
P10897233A1057|0 9|CONCLUSION
P10897973T0001|0 24|Antithrombin III deficiency
P10898795A0527|0 12|Specific class
P10899128A0661|9 20|first example
P10899142A0000|17 24|Berkeley
P10900129A0138|0 26|Degenerate primers homologous
P10900269A0396|4 8|cells
P10901133A0381|0 15|Methyllevamisole
P10902348A0566|0 15|Resistance ratios
P10903440A0515|4 22|transcripts specific
P10903495A0533|3 21|gel retardation assay
P10903583T0000|0 10|Reliability
P10903733A0540|0 31|Coimmunoprecipitation experiments
P10903837A1208|8 15|RINX gene
P10903843A0447|3 25|chromosomal localization
P10903877A0879|0 9|Activation
P10904191A0000|3 14|present study
P10905349A0329|0 5|Mus81p
P10905349A0609|0 19|Double mutant analysis
P10905352A0000|3 20|linear plasmid pCLU1
P10906176A0000|3 15|repetitive ETn
P10906317A0351|6 30|main experimental variables
P10906999T0000|16 17|NO
P10907348A0508|0 22|Biochemical examinations
P10907971A0806|0 11|Atorvastatin
P10907971T0000|0 25|Pharmacoeconomic assessment
P10908317A1459|22 29|E domains
P10908364A0000|0 4|G-DNA
P10908462A3159|18 20|NRT
P10908478A0717|0 16|SELECTION CRITERIA
P10908822A0519|1 1|%
P10909973A1508|22 26|GLP-1
P10910073A0876|10 25|PDGFbetaR fusions
P10910439A1196|0 10|CONCLUSIONS
P10910908A0767|27 51|PI3K-Akt activation pathway
P10913094A0424|4 15|DNA fragments
P10913172A0442|21 36|NTP-binding motif
P10913276A0510|3 37|carboxyl-terminal proline-rich domain
P10913276A0684|4 29|transient expression studies
P10913304A0894|3 18|distinct Ets mRNAs
P10913304A1180|2 13|kb transcript
P10915728A0216|6 21|eligible patients
P10915780A1063|0 18|Wnt-1 overexpression
P10917402T0000|0 10|Intravenous
P10918059A0569|0 7|Deletion
P10918164A0878|0 25|Logistic regression analysis
P10918440T0000|0 28|Erythema exsudativum multiforme
P10918572A0794|0 2|VaI
P10918572A1547|5 16|interactions
P10918596A0000|26 38|p53 C-terminus
P10918599A0071|12 27|full-length E2F-3
P10918612A0000|3 24|transcription factor Jun
P10918943T0000|0 20|Developmental toxicity
P10918948A0110|17 39|main bioactive metabolite
P10919971A0606|36 53|neutrophil response
P10920186A0528|25 42|stem-loop templates
P10920906A0759|0 9|CONCLUSION
P10921197A0179|0 11|Measurements
P10924061A0588|0 9|Activation
P10925159A1353|7 12|MARTA1
P10925207A0634|12 16|exons
P10926776A0731|9 20|PDP1 isoforms
P10928179A0101|3 18|optimum technique
P10928337A0590|0 16|Partial correction
P10928477A0764|28 42|PFA-100 analyzer
P10930526A0174|21 36|molecular cloning
P10931524A0313|12 29|regulatory activity
P10931927A0655|7 20|oligomer duplex
P10931950A0869|0 3|Cdk2
P10931960A0630|9 26|avirulence activity
P10932196A0359|0 8|Mutations
P10932329A0597|18 22|cecum
P10932527A0947|13 14|HD
P10932527T0000|21 44|haemodialysate Solcoseryl
P10932679A0049|15 28|little evidence
P10933154A1118|5 12|findings
P10933728A1398|5 11|results
P10933732A0000|3 8|genome
P10934073A1433|12 22|limitations
P10934310A0698|0 12|DATA SYNTHESIS
P10934640A1114|0 9|TB bone area
P10934751T0001|0 12|CREST syndrome
P10935488A1033|0 11|Troglitazone
P10935880A1049|0 6|Viruses
P10936051T0000|3 49|RS447 human megasatellite tandem repetitive sequence
P10936920A0105|0 17|Previous experience
P10938102A0265|36 42|targets
P10938102A1359|62 64|NS1
P10938102T0000|0 39|Eukaryotic translation initiation factor 4GI
P10938105A0000|0 7|Splicing
P10938109A1361|12 16|cells
P10938113A0388|48 59|isoforms Vav2
P10938120A1093|0 24|Transcriptional regulation
P10938130A0338|0 24|X-ray crystallographic data
P10938135A0259|12 15|SMRT
P10938556A0248|14 33|ketamine-treated rats
P10939030A0986|3 13|differences
P10939785A0540|0 7|Patients
P10940413A1153|3 9|results
P10940553A0912|5 11|regions
P10940557A1687|13 27|putative CF1/USP
P10940562A0379|0 15|Sequence analysis
P10940562T0000|0 6|Genomic
P10940892A0573|3 37|distinct recessive susceptibility loci
P10942587A0981|19 38|phosphorylation state
P10942599A1298|0 22|Further characterization
P10943891A1062|12 24|U6-U57 mutants
P10944466A0451|33 42|WNT-2B gene
P10945010T0001|9 20|daunorubicin
P10945781A0412|9 24|Aeromonas strains
P10946303A0000|0 8|TNF-alpha
P10947274A0839|3 13|therapy time
P10947840A0762|0 3|Mis3
P10950398T0100|0 19|Losartan Intervention
P10950415A0866|0 9|CONCLUSION
P10950924A0393|0 2|RNA
P10950935A0111|12 23|manipulation
P10951579A1238|5 21|gamma-irradiation
P10951848A0230|0 11|Mobilization
P10952828A2638|16 46|cardiovascular magnetic resonance
P10954093A0000|1 23|degenerate DNA transposon
P10954525A1161|21 23|Tax
P10954564A1262|21 36|functional domain
P10954913A0152|1 26|2.3-kb full-length cDNA clone
P10955313A0000|0 5|PLUS-3
P10955913A0827|4 8|HIT II
P10955998A1124|25 43|glycosylase activity
P10958271A0365|0 6|METHODS
P10958456A0529|4 8|cDNAs
P10958673A0142|4 25|intracellular signaling
P10958688A0265|1 23|Y. lipolytica Kar2p mutant
P10958698A0280|33 53|systematic mutagenesis
P10958698A0485|3 9|spacing
P10959676A0200|3 7|bases
P10959838A0153|2 14|invertebrates
P10961046A0342|0 13|Platelet counts
P10961585A0273|3 16|manifestations
P10962564A0883|1 26|beta2 RARE reporter construct
P10962593A0580|0 23|Non-poliomyelitis AFP rate
P10962738A0000|0 12|Consciousness
P10962881A0900|0 10|Multiparity
P10963577T0016|0 6|Picture
P10963735A0193|39 53|oxidative stress
P10963735A0651|0 27|Indirect plasma parameters such
P10964833A1696|11 22|participants
P10964995A2152|46 50|women
P10965135A0735|0 15|Promoter activity
P10965135A1207|3 9|results
P10965830A0305|0 12|INTERVENTIONS
P10965905A1618|7 29|GH-induced Akt activation
P10965905T0000|0 45|Insulin receptor substrate-1-mediated enhancement
P10967361A0000|0 33|Functional magnetic resonance imaging
P10967531A1025|20 24|aorta
P10967890A1120|3 9|results
P10970048A0352|27 33|RH level
P10972688A1272|2 19|long-term follow-up
P10972894A0488|0 15|Genomic libraries
P10972980A0295|2 17|several cell lines
P10972990A0196|3 28|tumor-suppressor protein p53
P10972990A0526|0 9|Abrogation
P10972990A0966|0 18|Cytogenetic analysis
P10972990A1518|5 11|results
P10973151A0883|19 43|new epidemiological profile
P10973385A1423|2 9|patients
P10973400A0664|0 6|RESULTS
P10974541A0389|11 25|K562 cDNA library
P10975465A0134|3 21|human cDNA clone NFBD1
P10976413A0514|0 6|RESULTS
P10980416T0000|0 27|Parathyroid hormone regulation
P10981094A0779|0 18|Recent target BP goals
P10982076A0000|7 49|continuous community-based morbidity recording
P10982143A0346|3 8|muskox
P10982391A0425|12 21|NPF repeats
P10982825A0363|49 63|Mot3 binding site
P10983344A0000|22 31|diagnosing
P10983857A0923|0 17|Mucosal application
P10983979T0000|0 20|Functional recognition
P10984122A0911|13 17|cells
P10987280A0604|3 19|amino acid sequence
P10987301A0332|54 83|active G protein-coupled receptor
P10989777A1286|2 17|specific subgroup
P10991383A0289|5 11|lattice
P10991648T0000|21 30|horizontal
P10992299A0745|17 23|members
P10992983T0000|28 44|sexual orientation
P10993773A0717|12 18|further
P10993787A0369|11 13|MAP
P10995121A0569|0 7|Analysis
P10995751A0093|28 62|CCAAAT/enhancer-binding protein-beta
P10997330A0361|0 19|Northern blot analysis
P10997863A0753|5 15|TLE patients
P10997904A1258|3 15|Spo0F residues
P10998679A0500|3 20|psychologic factors
P10999205A0607|13 29|spatial resolution
P10999301A0000|0 21|Quantitative evaluation
P10999369A0192|14 22|amplitude
P11000203A0752|5 13|mutations
P11000250A0200|0 4|LMP-1
P11000266T0000|0 13|Identification
P11000521A0588|8 37|intracellular signaling pathways
P11002236A0328|0 6|METHODS
P11003471A1149|0 19|Phylogenetic analysis
P11003641A0811|11 33|Fcp1p-binding motif KEFGK
P11003652A0961|5 11|results
P11003653A0198|0 7|Deletion
P11003669A0000|12 18|rat gene
P11003805A0443|0 6|Studies
P11003807A0303|0 7|Symptoms
P11004369A0000|0 8|OBJECTIVE
P11005808A1082|5 11|results
P11005831A0242|5 9|cDNAs
P11006283A1180|0 18|Recombinant AROM-p64
P11006284T0000|3 27|protein-tyrosine kinase fer
P11006331A0319|3 19|variable phenotype
P11007509A1271|5 17|PMR target area
P11007777A0813|0 7|Analysis
P11007949A1395|20 38|inactivation mutants
P11007949A1607|35 37|ILK
P11007954A0170|3 35|growth factor receptor-bound protein
P11007961A0930|0 8|Mutations
P11007968A0255|25 27|dxr
P11008139T0000|0 17|Perceptual learning
P11008420A0580|3 10|detector
P11011139A0000|32 46|SIN4 gene product
P11012568A0192|0 29|Primary adrenal hypersensitivity
P11012671A0576|12 40|noncanonical C/EBP-binding site
P11012680A0676|0 12|Src activation
P11012680A1020|11 35|PLCgamma inhibitory peptide
P11013079A0927|0 30|Multiple transcription start sites
P11014197A0339|7 24|inhibitor scaffolds
P11014213A1019|31 38|arsenite
P11014215A1092|16 30|deletion studies
P11014465A0479|3 9|mean day
P11014821T0000|3 21|LAMMER protein kinase
P11015197A0310|15 22|cysteine
P11015200A0156|6 7|J.
P11016014A0181|0 9|HYPOTHESIS
P11016724A0536|2 7|group B
P11016737A0275|0 30|Post-operative functional outcome
P11016850A0423|9 19|DNA fragment
P11016954A0438|0 3|AGO1
P11017876A0787|0 31|Intracellular localization studies
P11018028A0263|34 60|cAMP-dependent protein kinase
P11018264A0397|0 29|Reporter gene expression analyses
P11019257A0159|10 16|3T1-3T2
P11020375A0134|11 36|1-day-old Ross broiler chicks
P11023074A1105|32 33|CC
P11023832A1038|15 21|results
P11023853A0188|24 40|weather conditions
P11023934A0855|0 2|L/H
P11024026A0133|3 17|high selectivity
P11024036A0984|19 29|fibroblasts
P11024047A0626|0 9|Expression
P11024182A0781|0 11|Normal alpha1
P11024300A1579|0 5|Nature
P11025367A1009|0 12|Abnormalities
P11027027A0061|2 16|Sunset Yellow FCF
P11027267A0752|0 7|Polysome
P11027274A1682|29 55|PI 3-kinase catalytic activity
P11027280A0536|0 8|Cam kinase
P11027289A0000|25 34|suppressor
P11027289A0321|26 44|arginine-rich motifs
P11027294A0483|26 57|histone acetyltransferase activity
P11027724A0335|0 17|Recombinant BRI1-KD
P11027833A0362|0 11|Flow cytomery
P11028131A1374|0 14|Further research
P11028131T0000|0 17|Cost-effectiveness
P11028944A1020|7 10|Cmax
P11029045A0000|0 14|Hyperactivation
P11029262T0000|0 4|Diary
P11029458A0000|0 4|Cells
P11029459A0000|12 29|growth factor-beta1
P11029467T0000|0 26|Vasoactive intestinal peptide
P11029656A0640|0 2|Mn2
P11029700A0295|5 6|Pt
P11029700A0746|18 31|pull-down assay
P11029704A0378|2 18|transient analysis
P11030066A0142|3 33|major neurological manifestations
P11030476A0685|0 5|Spores
P11030744A0763|0 13|Overexpression
P11031252A0646|3 10|LMW FGF-2
P11031366T0001|0 17|Helicobacter pylori
P11031773A0174|31 39|capsaicin
P11032599T0000|12 26|recommendations
P11032677A0230|0 16|Prominent findings
P11034392A1072|33 56|multiple survival pathways
P11034547A0674|8 11|Arix
P11034547A1355|27 30|Arix
P11034933A0389|0 6|METHODS
P11035037A0183|3 24|N-terminal small segment
P11035867A0000|0 8|OBJECTIVE
P11036786A0628|12 18|results
P11036938A1162|12 33|hypothalamic expression
P11036939A2149|0 2|Dsh
P11037759T0000|0 13|Catch-up growth
P11037823A1134|0 10|CONCLUSIONS
P11038042A0948|0 9|Escalation
P11038118A0000|0 12|Methyl formate
P11038317A0000|3 35|small monomeric GTP-binding proteins
P11038366A1322|18 28|methylation
P11038366A1417|5 15|methylation
P11039341A0180|36 58|temporal characteristics
P11039780A0770|3 9|authors
P11040101A1180|14 20|results
P11040219A0548|0 6|Binding
P11041308A0156|3 10|subjects
P11042197A0386|0 2|Lys
P11042199A0572|0 8|Elevation
P11042204A0186|3 14|present study
P11042703A0875|4 7|BFDS
P11043469A0440|5 27|probable border sequences
P11044097A0422|13 26|recombinant HMG
P11044097T0000|0 25|High-mobility-group protein
P11044105A0616|7 23|cis-acting element
P11045180A1892|0 10|Leptinaemia
P11045607A0239|3 14|RACE analysis
P11046146A1202|5 20|diamide treatment
P11046148A0716|0 4|LMP2A
P11046153A1052|8 28|Tax-mediated apoptosis
P11046517A0619|3 9|results
P11048832A0271|0 5|Fisher
P11049241A0659|0 6|RESULTS
P11049889A1271|0 18|Thromboelastography
P11050084A0000|0 13|High expression
P11050084A0888|27 35|PPARalpha
P11050168A1185|5 11|results
P11051364A0890|0 6|RESULTS
P11051370A1906|0 7|Response
P11053009A0000|0 6|Aspirin
P11053263A0200|12 17|clones
P11053370A0708|0 9|Expression
P11054011A1685|0 10|CONCLUSIONS
P11054341A0599|0 6|RESULTS
P11054539A0114|26 30|exons
P11054565A0654|7 16|p190-B exon
P11054571A0230|3 23|entire human teneurin-1
P11054970A0282|3 23|plexiform neurofibroma
P11055513A0564|2 16|general lookback
P11055786A0306|11 19|algorithm
P11056007A0224|16 30|extra amino acids
P11056019A0926|0 3|MED1
P11058008A0159|11 19|instances
P11058119A0957|5 11|results
P11058120A0256|10 16|factors
P11058132A0264|8 16|total CDSs
P11058406A0447|0 19|Tobramycin-loaded SLN
P11059492A0376|0 8|Bacteriol
P11059777A0813|0 64|Terminal deoxynucleotidyl transferase-mediated nick end labeling assays
P11059786A0682|0 19|VEGF promoter activity
P11059786T0000|0 28|Epidermal growth factor receptor
P11062047A1208|5 9|IHHNV
P11062067A0000|0 28|Stress-activated protein kinase
P11062068T0000|0 18|Catalytic activation
P11062257A0977|8 24|class C-Vps complex
P11062274T0000|8 18|intravenous
P11062705A0658|43 47|ATF-2
P11063127A0000|0 17|Signal transduction
P11063169T0000|0 14|Botulinum toxin A
P11063252A0437|0 4|Exon A
P11063742A0000|0 8|NF-kappaB
P11064829T0058|0 24|Cardiovascular risk factors
P11066245T0000|20 35|compliance review
P11067797A1306|0 10|CONCLUSIONS
P11067928A0532|8 11|mAbs
P11069011A0224|0 13|SSF experiments
P11069075T0000|0 15|Characterization
P11069223A0593|0 7|Patients
P11069307A0546|0 9|Inhibition
P11069756A2618|0 12|Abbreviations
P11069788A0531|4 23|ventilator-dependent
P11069791A0226|5 20|eligible subjects
P11069825A0530|12 16|cases
P11069897A1112|5 11|results
P11069999A1602|3 9|U17/U16
P11070007A0136|0 12|Transcription
P11070056A0704|3 17|Cili-2 sequences
P11070078A1153|4 18|dynamic response
P11071651A1308|16 39|RARalpha-specific pathway
P11071789T0000|2 11|more better
P11071852A0297|18 23|SOCS-3
P11071924A0588|18 20|SH2
P11071974A0155|13 19|effects
P11072155A0764|9 34|weak significant correlation
P11072388T0000|0 15|Acute feasibility
P11073163A0131|14 35|proteasomal degradation
P11073218A0800|3 17|sixth nucleotide
P11073539A0866|0 17|Functional analysis
P11073870A0375|0 7|Patients
P11073919A0631|13 29|amino acid residues
P11073954A0337|3 10|Psc2 cDNA
P11074003A0741|3 9|results
P11074210A0623|3 12|QT interval
P11075678A0298|3 13|wavenumbers
P11075929A1657|14 27|strong evidence
P11075944A0691|11 14|npm3
P11076860A0872|0 10|Experiments
P11078726X0000|0 28|Stoichiometric phosphorylation
P11080796A0883|18 31|mutant cell line
P11080796A1277|3 25|Tax/IKKgamma interaction
P11081962T0000|10 13|AFLP
P11082185A0415|24 32|novel type
P11082587X0000|0 6|Effects
P11082715X0001|0 24|Simultaneous determination
P11083154A0881|3 7|males
P11083358A1071|0 9|CONCLUSION
P11083432A0332|7 12|groups
P11083868A0386|0 9|DNA binding
P11084022A1178|13 25|ALK7 signaling
P11084334A0590|3 14|swa2-1 allele
P11084556T0000|0 10|Association
P11084649A0497|10 21|older embryos
P11085267A0562|0 13|Transformation
P11085600A0123|3 9|authors
P11086872A0000|0 8|Influence
P11087141A0977|0 15|Detailed analysis
P11088635A0200|1 37|thermal Kubo-Martin-Schwinger condition
P11089911A1267|3 25|non-homologous sequences
P11090172A0612|3 12|time course
P11090272A1240|3 15|transcription
P11090762A0527|0 6|RESULTS
P11092770A0238|3 12|extraction
P11092809A0823|14 20|results
P11092850A1023|7 33|16S rRNA gene sequence analysis
P11092886A0341|13 37|protein kinase A stimulation
P11093745A0563|7 22|putative HNF3 site
P11094066A0505|4 28|transcriptional regulation
P11094066A1194|19 30|observations
P11094072A0842|0 4|DNase
P11094072A1234|14 18|c-Myb
P11094073A0000|17 25|new member
P11094075A0257|26 37|reexpression
P11094087T0000|19 22|Rnd3
P11094091A0000|16 38|transcription factor CREB
P11094109A0600|0 6|RESULTS
P11094590A0617|6 11|fields
P11095248A0423|9 25|mammalian proteins
P11095248A1523|0 11|NH2-terminal
P11095981A0254|22 33|cis-elements
P11096662T0000|0 8|Tranilast
P11097040A0000|3 12|objectives
P11097079A0525|12 18|further
P11098217A0674|3 11|Aie1 locus
P11098420A0175|0 19|Psychiatric disorders
P11099377T0000|0 15|Molecular cloning
P11100515A0282|0 16|Thyrotoxicosis due
P11101008A0649|0 14|Chaperones/HSPs
P11101847A0159|0 18|Oncogenic signalling
P11102367A1170|23 33|conclusions
P11102458A0000|30 52|initial characterization
P11103472A0802|0 7|Children
P11103601T0025|5 9|UMDNJ
P11103792A0755|0 13|Overexpression
P11105129T0000|0 26|Antimicrobial Susceptibility
P11105716A0782|0 9|CONCLUSION
P11105717A0123|0 6|METHODS
P11106216A0918|5 16|COPD patients
P11106428A0635|24 40|synthetic proteins
P11106667A1061|5 11|Pet111p
P11106668A0875|12 23|transfection
P11107637X0001|21 32|double bounds
P11108151A0560|0 27|Ang II-induced fibronectin mRNA
P11108374A1466|0 5|Acoust
P11108523A0326|0 10|Video images
P11108548A0710|0 16|MS characteristics
P11108616A0000|0 8|Young fish
P11108720A0124|0 3|S6K2
P11108720A1130|0 11|Pretreatment
P11108839A0401|0 5|T cells
P11110040A0000|0 9|Ketanserin
P11110528A0414|19 33|2D axial sequence
P11111051A0051|26 30|Tip60
P11112417A1126|15 38|multiple MLSN1 transcripts
P11112438X0847|0 8|Copyright
P11112700A1936|0 6|Plectin
P11112700T0000|0 15|Characterization
P11112790A0989|5 11|results
P11113179A0541|22 25|SRC1
P11113179A1020|36 43|residues
P11113199A0800|5 7|MEK
P11113201A1114|0 3|Pmt2
P11113546A0728|0 11|Fecal samples
P11113692A0169|34 44|risk factors
P11113822A0999|7 23|quadrants positive
P11113823A0197|4 8|cases
P11114294A0075|0 14|Previous studies
P11114521A0282|0 9|Regulation
P11114718A0349|12 27|mouse fibroblasts
P11114924A0808|0 3|ORFA
P11116084A0000|0 10|Mouse Impact
P11116131A0863|5 9|cells
P11116148A0741|0 18|Coexpression studies
P11117263A0570|10 28|graminaceous species
P11117523A0650|11 32|high COUP-TFI expression
P11117826A0788|7 9|PET
P11118062A1691|31 42|localization
P11118438A0411|29 34|MdPin1
P11118440T0000|0 22|Differential association
P11118619A0835|8 16|other data
P11118712A1296|4 22|sensitivity analysis
P11119611A0428|0 5|ORFK10
P11120441A1193|15 23|believers
P11121043A0074|2 8|Xenopus
P11121118A0075|13 26|unique variants
P11121118T0000|0 18|Genomic organization
P11121397A0587|3 17|present findings
P11121434A0915|0 9|Inhibition
P11121490A0000|3 37|transcription factor CHOP/GADD153 gene
P11122381A0908|0 7|Addition
P11122588A0549|0 18|MAIN OUTCOME MEASURES
P11123054T0000|0 31|Paraneoplastic rheumatic syndromes
P11123089A0362|18 34|recent information
P11123316T0000|0 17|Tec kinase signaling
P11123701A0442|0 14|Current evidence
P11123912A0306|17 29|free SH2 domain
P11124024A1098|28 32|sites
P11124902X1337|0 8|Copyright
P11125151T0000|0 17|Nucleotide sequence
P11125363A0525|0 7|Patients
P11125411A0857|4 20|untreated patients
P11125872A0133|33 42|compound RP
P11126275A1068|9 14|levels
P11126353A0582|0 6|RESULTS
P11126806A0206|8 15|sequelae
P11127161T0000|0 8|Bupropion
P11127200A1024|6 28|natural dominant negative
P11127250A1111|8 17|mg/kg daily
P11127955X0001|0 14|Adjuvant therapy
P11128312A1238|9 30|significant differences
P11128925A0000|0 9|BACKGROUND
P11129515A0000|3 13|prospective
P11129724A0904|0 6|Studies
P11131321T0000|0 6|Effects
P11131634A0955|0 7|NF kappa B
P11132063A0250|11 28|treatment exposures
P11132148A0162|13 34|locus-specific residues
P11132195A0000|18 27|parameters
P11132790A0609|3 16|standard method
P11133741A0617|0 3|NiCl
P11133830A0174|0 9|Engagement
P11133927T0000|0 7|Validity
P11133986A0350|0 14|Previous studies
P11134033A0000|3 18|murine int-6 locus
P11134033A0639|2 13|int6 deletion
P11134351A1405|13 18|MIP-2A
P11134508A0317|10 25|transgenic plants
P11134822A0629|11 11|P
P11137296A0923|4 31|transcription initiation sites
P11137296A1216|0 8|PFK-A mRNA
P11137367A0297|9 25|Toshiba IIDR system
P11137551A0437|2 13|whole sardine
P11138009A1032|26 34|mutations
P11138231T0000|0 6|Closeup
P11138694A0000|1 3|18F
P11139148A0421|30 44|murine homologue
P11139336A0257|3 23|molecular associations
P11139469A0402|0 4|Ang II
P11139473A0696|0 15|Promoter analysis
P11139567A1440|0 22|LH/CG receptor activation
P11139605A0811|0 15|Deletion analysis
P11139974A0762|0 10|Termination
P11140472A0497|12 18|results
P11141003T0000|0 6|Changes
P11142380A0389|0 7|Nuclease
P11143384A0267|0 8|Tele-Talk
P11145562A0000|1 14|marked decrease
P11145562A0468|3 13|P69 cell line
P11145563A0202|22 38|human StAR promoter
P11145563A0303|0 9|Expression
P11145566A0000|10 40|high-density lipoprotein receptor
P11145571A0788|0 25|IFN-stimulated gene factor-3
P11145590A0217|25 43|molecular mechanisms
P11145717A0936|3 25|epitope-protected lysine
P11145743A0170|15 33|molecular regulation
P11145813A0668|0 16|Regional blood blow
P11145887A1393|0 9|Activation
P11145955A0189|14 50|ligand-activated estrogen receptor alpha
P11146961T0000|0 17|Perfusion technique
P11148042A1258|7 14|mixtures
P11148589A1124|0 10|CONCLUSIONS
P11149472A1257|10 30|NP/NMP4/CIZ expression
P11150114T0000|0 8|Chlamydia
P11150315A0226|1 13|novel approach
P11150315A0844|0 2|NGF
P11150315A1126|0 2|NGF
P11150439A0701|0 16|Energy expenditure
P11151826T0000|0 7|Workload
P11152070A0573|3 10|actA gene
P11152081A0413|8 16|mmol SDS/l
P11152283A0223|27 29|NGF
P11152344A0416|4 10|animals
P11152451A0529|3 29|Schistosoma mansoni homologue
P11152451A1580|24 30|SmSmad2
P11152521A0181|0 31|Intact Flag-tagged protein products
P11152963A0000|0 9|Expression
P11153302A0000|0 22|Naltrexone hydrochloride
P11154491A0322|0 6|METHODS
P11155096A0222|0 6|METHODS
P11156303A1098|13 37|ventriculopleural shunting
P11156413T0000|0 9|Derivation
P11156484A0223|0 10|TBARS levels
P11156618T0000|0 19|Long-range comparison
P11156789A1669|28 46|other possible causes
P11157035A1405|3 11|utilities
P11157334A1107|0 7|Serum PTH
P11157763T0000|0 8|Structure
P11157774A0789|0 22|Hypomorphic dSLBP alleles
P11157784A0141|11 19|DGCR6 gene
P11157879A0192|0 6|METHODS
P11158236A0000|0 16|Nerve growth factor
P11158288T0000|0 10|Recruitment
P11158290A0728|23 29|serines
P11158295A0158|30 41|kinase domain
P11158310A0993|24 27|ERSF
P11158324A1073|11 20|phenotypes
P11158326A1032|5 11|effects
P11158337A0000|3 22|gonadotrope-specific
P11158456A0223|0 6|METHODS
P11159081A1155|7 11|cases
P11159363A1251|0 10|Methylation
P11160096A1067|5 13|mutations
P11160280A1275|7 33|IFN-gamma-induced expression
P11160307A0394|13 21|wH22xeGFP
P11160656A0000|0 9|Inactivity
P11160683A1220|17 26|reciprocal
P11160688A1726|3 17|metabolic events
P11160721A0932|0 21|Transient transfections
P11160732A0464|0 11|Vector stocks
P11160732A1199|0 21|Quantitative PCR studies
P11160738A1414|8 31|anti-interferon functions
P11160742A0696|4 4|Z
P11160860A0662|27 39|IkappaB kinase
P11160896A0713|0 24|Immunofluorescence studies
P11160902A0962|13 16|TFOs
P11160929T0000|0 13|Rapid evolution
P11161455A1286|0 19|Southern blot analysis
P11161720X1294|0 8|Copyright
P11161793A1033|22 37|receptor isoforms
P11161816A0851|17 28|similarities
P11162278A0629|0 13|Mental rotation
P11162576A0213|38 71|corresponding alternative first exons
P11162666A0442|3 28|glucose/insulin stimulation
P11162936A2727|26 32|ligands
P11163932A0000|0 15|Behavioural tests
P11163968A0152|5 15|present work
P11164078A0833|4 14|animal model
P11166478T0000|0 9|Peripheral
P11166863A0167|13 13|%
P11167019A1249|3 6|TATA
P11167111A0957|13 40|higher lung function parameters
P11167778T0000|8 29|antithrombin deficiency
P11168366A0569|26 40|genomic fragment
P11168422A0248|6 11|Nature
P11168446T0000|9 31|erythropoietin synthesis
P11168588T0000|0 9|Expression
P11169080T0000|35 43|ignorance
P11169113A0555|22 24|p16
P11169149A0097|24 28|SNTCS
P11170476A1546|3 24|extraordinary stability
P11171118A0836|0 19|High-affinity binding
P11171320A0894|0 11|Coexpression
P11172610A0508|10 12|p73
P11172944A0548|0 6|RESULTS
P11172944A0826|26 47|significant correlation
P11175333A0336|5 41|immunochemical co-precipitation methods
P11176098A0342|0 6|METHODS
P11176290T0000|0 13|Identification
P11177538A0655|0 13|Tumor cell lines
P11177686A0243|0 8|Treatment
P11178248A1042|21 51|differential screening techniques
P11178696A0301|0 13|Serial US images
P11178765A0642|16 22|effects
P11179272T0000|0 14|Cytomegalovirus
P11179400T0000|0 8|Responses
P11179664T0000|0 11|Architecture
P11179668A0869|29 36|proteins
P11179687A0280|14 45|tyrosine dephosphorylating enzymes
P11179687A1118|3 12|Ig-related
P11179689A0000|3 15|Sox gene family
P11179956A1818|10 16|results
P11180027A1306|0 20|Respiratory parameters
P11180255A0776|12 28|previous arguments
P11180688A0000|11 29|maximum oxygen uptake
P11181516A0119|14 55|deletion insulin promoter-reporter constructs
P11181525T0000|3 18|androgen receptor
P11181531A0464|1 14|major mechanism
P11181548A0214|13 45|important cis-DNA regulatory element
P11181564A0733|15 19|genes
P11181995A1093|0 7|Analysis
P11182520A0889|3 23|corresponding genotype
P11182746A0872|13 20|patients
P11185475T0034|2 8|Caveman
P11187016T0000|0 15|Multistage models
P11188971A0000|3 16|revitalization
P11188993A0298|0 6|Corneal
P11189314A1000|5 11|results
P11191208A0000|0 18|Multidrug resistance
P11191365A0682|0 13|Susceptibility
P11193045A1193|26 33|gradient
P11193666A1269|15 33|subsequent outbreaks
P11193704A0000|0 30|Contagious bovine pleuropneumonia
P11194101A0532|0 16|Baseline BMD values
P11194147A1496|17 34|red rice cultivation
P11194183A0866|21 33|terminal hairs
P11195338A0494|0 16|Ectopic expression
P11195401A1030|0 18|High plasma AVP levels
P11196191A1789|7 30|T47D breast carcinoma cells
P11196199T0000|0 13|Human homologue
P11196340A1046|3 22|immunological methods
P11197288A0855|0 11|Most patients
P11197328T0000|0 6|Binding
P11197549A0748|0 6|RESULTS
P11197926A0000|0 9|BACKGROUND
P11198053T0000|0 11|Acute effects
P11198289T0000|9 26|serum ceruloplasmin
P11198385A0000|1 14|microsporidian
P11198424T0000|0 15|Molecular cloning
P11200568A0830|0 4|Blood
P11201250A0849|0 21|Plasma DHE concentration
P11202434T0000|0 27|Single amino acid substitutions
P11202705A1112|0 11|Implications
P11203702A1307|5 10|Xlim-1
P11204897A0797|20 29|absorption
P11207216A0296|3 18|bovine PGHS-2 cDNA
P11207216A0719|15 24|PGHS-2 mRNA
P11207261A1421|0 17|Functional analysis
P11207269A0745|0 16|Anti-nucleolin mAb
P11207282A0729|12 27|stable expression
P11207288A0897|0 12|Substitutions
P11207308A0999|10 17|curcumin
P11207609A0994|26 34|QKTT motif
P11208017A0070|1 9|cDNA clone
P11208814A0673|0 9|Consistent
P11209100A0069|9 31|antimicrobial properties
P11209814A0243|42 69|morphological characteristics
P11210401A0000|0 21|Sevelamer hydrochloride
P11210401A0544|3 25|pharmacokinetic profiles
P11210839A0282|6 22|PO3 administration
P11210988T0000|25 32|patients
P11211759A0165|0 7|Patients
P11211936A1490|3 13|present data
P11212249A0993|3 9|effects
P11212327A1564|0 12|Recent studies
P11213342A0492|0 6|RESULTS
P11214177A1125|19 27|antisense
P11214354A1104|0 12|VE-DEF animals
P11215622A0949|0 7|Grippers
P11218739A0811|0 9|Transition
P11220166A0616|3 20|contrasting effects
P11220306A0911|0 5|HexA71
P11220306A1753|0 13|Multiple copies
P11220486A0686|1 1|%
P11220487T0000|0 15|Systematic review
P11220857T0000|0 3|CHAP
P11221836A0981|20 25|fusion
P11221845A0295|23 39|methylation status
P11221845A0800|3 17|Genescan program
P11221845A1370|0 19|Northern blot analysis
P11221845A1713|0 8|Treatment
P11222387A1497|9 24|nontoxic compound
P11222639A1273|5 11|results
P11222720A1699|14 17|RPMS
P11223131A0000|0 15|Folate metabolism
P11223153A0533|3 11|BFA System
P11223164A0000|0 8|Retinoids
P11223186A1095|0 14|Transactivation
P11223199A0751|5 11|results
P11223240A0655|10 30|Menin1 gene transcripts
P11223246A0359|0 15|Sequence analysis
P11223255A1034|14 36|consensus amino acid motif
P11223256A1212|34 47|flanking region
P11223257A0404|0 5|OsBBPI
P11223938X1218|0 8|Copyright
P11224226A0000|3 9|effects
P11226228A0899|8 15|plasmids
P11226752A0750|2 28|mammalian tissue culture cells
P11227039A0953|0 15|Multiparous women
P11227182A1475|3 9|authors
P11227484T0000|0 24|Fluorimetric determination
P11230145A0732|3 9|results
P11230169A0480|6 16|novel method
P11230534A0688|20 32|DEAH helicases
P11230889A1151|3 7|cases
P11231287A0158|16 45|human neuroblastoma cells SK-N-SH
P11232947A1451|0 30|Prophylactic lymph node dissection
P11233643A0000|13 23|clinical use
P11234223A1451|13 23|antibiotics
P11235335T0000|8 10|HIV
P11235777A0878|2 12|Klinefelter
P11235817A0000|3 32|histamine H1 receptor antagonists
P11236056A0374|0 9|Conclusion
P11237038A0889|1 6|subset
P11237491A0000|0 3|AIMS
P11237598A0962|3 32|homologous active-site framework
P11238105A0959|0 4|Cells
P11238375A0617|11 14|RhoA
P11238402A0191|10 41|several heme-responsive mechanisms
P11238405A0817|2 8|strains
P11238447A0524|7 20|binding studies
P11238586A0000|0 16|Structural studies
P11238882A0157|26 29|eIF6
P11238884A0892|0 13|Mice homozygous
P11238916A0838|27 32|PTP phi
P11238947A0636|1 16|single base change
P11239184A1340|0 16|Baseline variables
P11239529A0981|0 7|IL-1beta
P11240600A0523|1 19|complete drug history
P11241166A0677|0 13|TaqMan analysis
P11241215A0566|3 17|mutant receptors
P11241243A0693|3 9|authors
P11241332A0393|53 69|fixation strengths
P11241356T0000|0 26|Constitutive phosphorylation
P11241672T0000|0 6|Cloning
P11243306A0961|0 10|CONCLUSIONS
P11243336A0000|0 9|GafChromic
P11243494A0833|0 6|RESULTS
P11243777A0000|0 22|Cis-acting CCAAT elements
P11243980A0510|11 18|patients
P11244568A0506|3 8|Gap69C
P11244733A0782|0 4|Cases
P11245986T0000|1 33|novel growth-related nuclear protein
P11246679A0000|0 8|OBJECTIVE
P11246887A0000|26 49|cholesteryl ester transfer
P11247663A1447|3 10|families
P11248463A0187|3 13|blood levels
P11248626T0000|0 7|Efficacy
P11250196A0455|4 12|two-motif
P11250942A0626|0 17|Deletional analyses
P11251083T0000|0 8|Mechanism
P11251104A0526|15 27|alpha-amylase
P11251252A0494|0 17|3D image-processing
P11251276A0793|8 15|patients
P11251697T0000|0 33|Direct superoxide scavenging activity
P11251951A0000|0 9|BACKGROUND
P11254134A0648|9 12|PTax
P11254504A0766|11 24|promoter region
P11254713A1029|21 23|Tat
P11254864T0000|0 7|Adjuvant
P11255035A0331|6 25|other progenitor cells
P11255252A0961|1 18|minimal ER3 sequence
P11255423A0211|0 8|OBJECTIVE
P11256845A0340|2 17|economic analysis
P11256944A1144|15 26|soluble forms
P11256962A0233|0 15|Sequence analysis
P11257870A0000|3 14|present study
P11258906A0743|2 27|DNA strand exchange reactions
P11259347A0000|0 20|Anecdotal observations
P11259503A0212|0 17|Forskolin treatment
P11259593A1094|0 7|Analysis
P11260468A1179|3 9|results
P11260662X0000|0 1|A.
P11263622A0683|0 6|RESULTS
P11263664A1085|19 22|SIP1
P11263664T0000|0 3|SIP1
P11264176A0181|0 4|B-myb
P11264177T0000|0 17|Nucleotide sequence
P11264182A0000|0 27|Human T-cell leukemia virus type
P11264372T0000|0 11|Requirements
P11264375A0000|3 22|human cytomegalovirus
P11264561A0167|0 8|OBJECTIVE
P11265853A0000|3 9|Novacor
P11266184A0000|0 7|Atheroma
P11266194A0743|0 18|Body fat distribution
P11266227A0295|3 11|flux rates
P11266540A0328|18 51|known mammalian Groucho family members
P11266558A1470|24 43|transcription extract
P11266615A0258|25 36|major domains
P11267679A0102|6 20|bp EcoRI fragment
P11268459A0167|14 25|present study
P11268887A1174|7 24|misinterpretations
P11271297T0000|0 13|Nephrotoxicity
P11273995A1148|12 32|normal control subjects
P11274109A0129|0 6|Acetoin
P11274149A0625|0 17|Mutational analysis
P11274179A0610|8 14|studies
P11274184A0000|0 3|Nrf2
P11274184A1068|5 11|results
P11274357A0724|5 13|other hand
P11274368A0469|41 56|protein synthesis
P11274368A0818|0 7|Deletion
P11274563T0000|0 14|Fetal lung volume
P11275986A0091|5 16|gene products
P11276426A0501|8 12|Mmip1
P11277913T0000|20 37|untranslated region
P11278286A0456|2 19|SN-48 neuronal cells
P11278286A1083|0 47|Corticosteroid-mediated transcriptional inhibition
P11278290A1220|7 11|Smad2
P11278310A1516|16 37|kinase-deficient mutant
P11278390A0632|0 49|Reverse transcriptase-polymerase chain reaction assays
P11278400A0668|4 13|pancreatic
P11278440A0095|0 2|SV1
P11278461A0637|0 19|Polyclonal antibodies
P11278488T0000|3 16|v-Src SH3 domain
P11278521A0849|1 26|20-base pair oligonucleotide
P11278563A0917|0 15|Deletion analyses
P11278583A0873|0 10|Mutagenesis
P11278594A0618|13 27|human propeptide
P11278604A0300|12 31|biantennary N-glycans
P11278610A0902|14 20|SOCS box
P11278671T0000|0 27|Neuron-specific Bcl-2 homology
P11278713A1054|8 26|10-nucleotide region
P11278819A0565|0 17|Sequence comparison
P11278848A1316|12 19|SB203580
P11278855A0205|32 34|TLS
P11278870A0123|0 7|Analysis
P11278928A1634|7 20|mutational data
P11279038A0194|0 10|WRN helicase
P11279086A1350|20 28|ADAM-TS12
P11279108T0000|0 6|Binding
P11279207A0904|14 20|results
P11279217A0273|0 3|Biol
P11279324A0710|12 18|infarct
P11279385A3917|1 29|new echocardiographic technique
P11279720A0844|0 16|SELECTION CRITERIA
P11280495A1330|0 10|CONCLUSIONS
P11280799A1025|11 28|exogenous PTHrP1-34
P11281201T0000|0 19|Deterministic effects
P11281268A0000|0 31|Unusual two-domain arginine kinases
P11282029A0075|3 35|mouse platelet-derived growth factor
P11282088A0837|0 10|Baseline MBF
P11282394A0841|2 25|preferential VH/VL-chains
P11282395A0530|31 44|RAG1/2 proteins
P11282395A1073|25 46|significant differences
P11282433T0000|0 4|Phase
P11282761A0531|0 18|Oral supplementation
P11283010A0701|4 13|activation
P11283014A0921|3 9|results
P11283168A0738|3 28|independent transgenic lines
P11283256A0258|21 30|native MRCK
P11283354A0548|25 31|pathway
P11285054A0781|0 17|Regression analyses
P11285235A0466|8 12|TRPS1
P11285329A0682|6 8|% CI
P11286833A0959|5 12|patients
P11287555A1057|3 16|Delta6CCI virus
P11287578A1311|0 8|Secretion
P11287579A1084|7 12|mutant
P11287611A0802|6 14|PPARgamma
P11287623A0286|24 79|Ras-activated Raf-MEK-extracellular signal-regulated kinase
P11287654A0150|0 3|PABP
P11288208A0712|0 7|Children
P11288930A0000|3 21|reproductive effects
P11289135A0975|0 9|Coexposure
P11289149A0658|8 17|EWS protein
P11290415A0288|5 16|present study
P11290906T0000|0 21|Tumor-like accumulation
P11291552A0156|0 6|METHODS
P11292335A0852|18 24|dnaE173
P11292839A0531|3 15|transcription
P11292844A0081|0 2|HSF
P11294895A0292|24 28|spo20
P11295470A0954|20 40|linkage disequilibrium
P11295523A0218|5 11|numbers
P11295760A1374|0 20|Specimen mass reduction
P11296288A1107|18 27|derivative
P11296442A0565|13 20|tube size
P11297419A0894|2 6|F222W
P11297514A0218|3 23|recessive hos1 mutation
P11297545A0948|0 17|Stable transfection
P11297866A0484|18 28|I. argentina
P11298326A0677|16 36|duplicated Vkappa genes
P11301189A1396|14 33|ubiquitous expression
P11302072A0508|3 9|results
P11302566A1318|8 26|affective flattening
P11302704T0000|0 19|Homo-oligomerisation
P11303027A0954|16 29|complex network
P11303638A0559|4 20|NEU overexpression
P11303890A0996|14 34|blind therapeutic doses
P11305129T0000|0 6|Effects
P11306101A0000|5 18|RACE techniques
P11306463A0383|1 8|mutation
P11306511A1476|86 94|mdm2 mRNAs
P11306845A0168|0 22|Histological examination
P11308851A0333|13 28|response function
P11308877A0213|20 32|periodic input
P11309077A0953|4 10|strains
P11309373A0783|0 7|Analysis
P11309389A0273|26 36|proteolysis
P11309400T0000|0 6|Effects
P11309677A0000|1 38|comprehensive neuropsychological battery
P11309678A0489|0 31|Reverse transcription-PCR analysis
P11310937A0548|0 6|RESULTS
P11311153T0000|20 40|factor V Leiden mutation
P11311464A0362|5 13|disorders
P11311480A0079|0 15|Sural nerve biopsy
P11311550A0253|9 33|transcriptional regulation
P11311563A0423|8 15|CCAAT box
P11311687A0231|3 8|JHRLSS
P11311909A0938|22 29|aneurysm
P11311980A1049|0 3|GABA
P11312108A2853|0 3|Raes
P11312120A1311|0 25|NF-kappaB pathway activation
P11312326A0169|7 9|rev
P11312584X1846|0 8|Copyright
P11313249T0000|1 61|novel myeloid-restricted zebrafish CCAAT/enhancer-binding protein
P11313342A0224|25 44|alanine substitutions
P11313386A0704|0 18|SH2D1A protein levels
P11313398A0687|0 20|Cross-linking FcalphaR
P11313946A0449|0 7|RPM/RGL3
P11313946T0000|1 22|novel potential effector
P11313961A1323|3 6|mice
P11314030A1264|3 9|results
P11314046A0000|0 6|Cyclins
P11314373T0000|0 17|Evidence-based care
P11314428A0651|11 32|osteo-retentive ability
P11315633A0920|3 14|cleavage site
P11316127A0485|3 8|%SVend
P11317256A0361|9 16|isolates
P11318363A0085|0 5|DESIGN
P11318608A0669|0 29|Human brain cDNA library screening
P11318608A1155|0 11|Transfection
P11319098A0164|5 9|genes
P11319880A1108|0 8|Rapamycin
P11321187A0355|14 35|seropositive MS patients
P11323411A0505|0 21|Far Western blot analysis
P11323419T0000|0 15|Molecular cloning
P11323716A0413|3 12|UBA domains
P11324516A0159|14 38|intrathecal administration
P11325195A0661|3 4|R2
P11325391A0498|8 12|doses
P11325685A1624|0 30|Intravenous L-carnitine treatment
P11325944A0511|0 17|Elevated expression
P11327292A0190|4 17|unique location
P11327698A0191|14 16|PKC
P11327858A0087|10 24|novel mechanisms
P11328699A0000|5 33|free-swimming rotatory test mice
P11328853A0644|0 10|Examination
P11331589A0113|3 12|MSL complex
P11331596A0710|0 3|Prrp
P11331604A0267|0 4|Srb10
P11331613A0827|0 16|Consistent effects
P11333263A0240|1 9|new intron
P11333268A1521|36 47|interactions
P11334124A0903|1 23|log-linear dose-response
P11335116A1099|0 19|Bandshift experiments
P11335710A0320|11 20|pronounced
P11336211A0132|3 17|iterative method
P11336698A0075|15 18|Rsc3
P11337859A0651|3 5|COD
P11340048A0432|17 31|high correlation
P11340080A0096|10 17|proteins
P11340085A0211|47 53|regions
P11340516A0509|0 8|Tolerance
P11340525A0737|5 12|patients
P11341349T0000|0 14|Early indicators
P11341405A0146|6 15|POPULATION
P11341405A1154|0 10|CONCLUSIONS
P11341828A0744|0 5|Linear
P11342479A0430|0 6|METHODS
P11344530A0320|0 10|Percentages
P11345435A0199|17 29|RNA subdomains
P11345445A0533|2 18|Cd-spiked OECD soil
P11347201X0001|0 16|Nutritional status
P11348318A0940|14 20|adjunct
P11349796A0950|0 11|Measurements
P11350038A0459|28 37|distal half
P11350165A1606|0 6|Changes
P11350175A0173|22 28|members
P11350812A0829|0 9|Inhibition
P11350957A0457|0 8|PACAP mRNA
P11350982A0560|16 28|first evidence
P11352423A0084|3 19|radial forearm flap
P11352663A0138|15 36|nontumorigenic Ad5 cells
P11352671A0492|17 31|reverse genetics
P11353392A1127|3 12|frameshift
P11353770A0085|14 27|latter activity
P11353774A0255|27 42|characterization
P11354406A1373|11 31|CSF outflow conductance
P11354975A0850|1 10|new species
P11355576A1125|3 9|cyclins
P11355615A0766|0 18|Additional education
P11355668T0000|0 24|Proliferative vasculopathy
P11356214A0794|15 22|hardness
P11356716A0372|2 18|18-kb genomic clone
P11356835A0000|33 49|regulatory network
P11356853A0429|2 10|Ka13 cells
P11356853A0554|0 15|Mutation analyses
P11356853A0873|0 6|Members
P11357063A0138|0 11|Descriptions
P11357063A1053|7 34|consensus mammalian LHbeta gene
P11358801A1046|15 24|situations
P11358958A0878|0 9|Expression
P11358962A0344|0 4|Foxp1
P11359568T0000|0 16|Molecular analysis
P11359827T0000|0 12|Immunological
P11359907A0099|0 23|Several dozen HIF-1 targets
P11360190A0178|24 26|Tax
P11361338A0093|0 33|Most yeast peroxisomal matrix proteins
P11361338A0447|8 22|PEX5-TPR domains
P11361493T0000|0 4|HIV-1
P11367523A1684|0 24|Immunofixation experiments
P11367523A2624|8 18|C4B proteins
P11368363A0129|25 44|transcription factors
P11368363A1103|3 22|human protein sequence
P11368787A0180|0 30|Promoter transcriptional activity
P11368901A0327|21 37|mouse BCNT proteins
P11368911T0000|0 22|Molecular identification
P11368914T0071|19 23|exons
P11369066A1210|0 10|CONCLUSIONS
P11369106A0428|0 13|Recent advances
P11369410A0949|3 17|first hypothesis
P11369453A1083|20 33|protein binding
P11369700A0074|0 2|CSR
P11369700A0616|6 15|manuscript
P11369759A0605|0 3|Cell
P11370174A0447|3 26|mean serum creatinine level
P11371115A0962|18 25|biopsies
P11371160A0193|16 36|nucleotides equivalent
P11371160A0854|20 41|canonical anticodon loop
P11371343A0125|15 23|cell cycle
P11371417A0744|0 20|Mechanical ventilation
P11372882A1143|0 8|Maternal p
P11372959A1447|0 25|Multiple regression analysis
P11373277A0812|27 50|adenoviral oncoprotein E1A
P11374051A0437|0 20|Additional factors such
P11374559A0103|0 10|SERS spectra
P11374866X0914|0 8|Copyright
P11375392T0000|3 14|core promoter
P11376007A0584|14 40|phosphorylation-induced loss
P11376119A0346|3 11|first exon
P11376134A1506|5 15|corrections
P11376165T0000|0 2|FLP
P11376279A0000|9 55|three-station three-dimensional magnetic resonance
P11376687A0344|1 28|single nucleotide polymorphism
P11376946A0000|3 17|previous studies
P11377975A0898|13 36|Arg1-expressing COS1 cells
P11378898A0164|0 3|ORF1
P11379106A0372|43 67|deammonification processes
P11380028A0000|44 50|methods
P11380370A0000|23 33|skin lesions
P11380837A1505|0 12|Interventions
P11381094A0797|11 16|stonin
P11382701A0688|4 21|partial transection
P11382948A0793|13 33|USPIO-enhanced MRI data
P11383860A0661|3 8|images
P11384225A0634|12 29|expression cassette
P11384229A1669|11 22|N63S mutation
P11384576A1132|11 26|severe vision loss
P11384880A0719|17 25|induction
P11385840A1684|12 23|RTC algorithm
P11387208T0000|0 33|SKP1-SnRK protein kinase interactions
P11387351A0092|0 7|PATIENTS
P11387940A0647|3 10|severity
P11387950X0001|0 16|Experimental study
P11389077A0000|10 43|receptor-mediated signaling pathways
P11389085A0290|0 6|TT cells
P11389085A1032|0 9|Inhibition
P11390395A1018|13 28|HMGI-C expression
P11390581A1203|1 14|central finding
P11390650A0562|0 26|Additional deletion mutations
P11390663A1400|8 16|profiling
P11390684A1170|0 7|Evidence
P11391303A0807|5 7|LHR
P11391303A1023|0 10|CONCLUSIONS
P11391531A1157|0 7|Mutation
P11391793A0856|14 30|genomic complexity
P11392306T0000|0 13|Online teaching
P11392772A0182|19 31|biotechnology
P11393463A0274|0 3|Data
P11393791A1153|0 19|Northern blot analysis
P11395469A1373|7 14|mutation
P11396685A0477|12 18|results
P11397652A0381|0 9|Guidelines
P11398134A1565|13 19|obesity
P11398899A1183|0 3|Fans
P11399064T0000|0 13|Autoregulation
P11399834T0000|3 11|first case
P11400644A0435|15 27|uncertainties
P11401105T0000|0 9|Gabapentin
P11401611A1703|0 10|CONCLUSIONS
P11402674T0000|0 28|Newcastle disease antibody titre
P11403173A0192|10 17|patients
P11403663A0359|0 6|Net lift
P11403719A1257|3 9|results
P11404010A0235|11 19|triplexes
P11404016A1922|3 14|co-existence
P11404019A0532|26 41|mGSTM2 regulation
P11404312A0660|10 17|pmol/24 h
P11406007A0292|0 16|SELECTION CRITERIA
P11406025A0204|0 9|OBJECTIVES
P11406277A0598|28 35|elements
P11406642A0792|12 16|cases
P11407289A1507|0 10|CONCLUSIONS
P11407448A0815|3 9|results
P11407650A0661|0 12|Hypercalcemia
P11408099A0518|0 7|Positive
P11408338A1686|21 23|PSP
P11408575A0000|35 41|mitosis
P11408591A0000|29 38|hyaluronan
P11408604A1440|3 9|results
P11408774X0893|0 7|Karger AG
P11409425A0000|12 24|plasma samples
P11410110A0190|0 3|NIRS
P11410563A0363|2 23|dominant clinical factor
P11410664A0963|37 70|human breast carcinoma MDA-MB231 cells
P11410679A0000|3 21|selective alteration
P11411198A0711|0 15|Colorectal cancer
P11411623T0000|0 8|Influence
P11411961A0735|0 24|Keratoconjunctivitis sicca
P11413148A0573|0 14|STAT5A mutations
P11413277A1121|13 31|primary chemotherapy
P11413310A0148|0 5|RANTES
P11413319A0000|0 12|Reovirus mRNAs
P11413641A0373|0 7|Analyses
P11413760A0000|0 9|Myasthenia
P11414754X1099|0 8|Copyright
P11415633A1253|8 15|postural
P11415952A0369|0 5|Angina
P11415958A0000|5 14|past decade
P11416012A1982|8 41|more specific PKA-dependent mediation
P11416012A2511|16 29|convergent role
P11416012T0000|0 33|Concerted transcriptional activation
P11416132A1351|5 11|studies
P11416144A1324|3 10|findings
P11416260A0000|1 18|computerized method
P11416393A0000|4 13|modalities
P11416650T0000|8 27|Systolic Hypertension
P11416737T0000|0 4|Ga-67
P11416879A1589|0 23|Arterial blood gas tensions
P11418130A0499|11 33|homologous loxP sequences
P11418662A0917|3 19|N-terminal portion
P11419938T0000|0 20|Conformational changes
P11420612A0303|3 12|complement
P11422200A0000|0 34|Granulocyte colony-stimulating factor
P11422757A0737|5 15|individuals
P11423991A1393|17 31|toxic p53 mutants
P11424992A0712|17 36|psychiatric diagnoses
P11425076A0364|28 45|physiological flows
P11425877A1026|0 4|Cells
P11427329A1077|16 20|FPS-R
P11427611A0000|3 16|susceptibility
P11428276A0352|3 5|Van
P11428283A0228|1 17|5-month-old infant
P11428435A0446|0 5|DESIGN
P11428487T0000|0 17|Pulmonary vein varix
P11428897A0318|0 21|Biochemical experiments
P11429702A0917|24 46|serum-starved conditions
P11430042A0000|19 40|Stille coupling reaction
P11430976X0000|0 12|Special issues
P11431348A0000|0 11|Interactions
P11431472A0540|0 17|Low affinity binding
P11431857A0186|3 10|students
P11432112A0000|0 6|PURPOSE
P11432748T0000|0 9|Regulation
P11432776A0421|0 7|Northern
P11433014A0683|25 34|nucleosome
P11433018A0756|20 38|proper direct binding
P11433024A0260|0 9|Telomerase
P11433379A0000|0 2|SIT
P11434084A0508|11 20|patients DD
P11435428A0000|0 28|Cytosolic acetyl-CoA synthetase
P11435517A0396|0 19|Ileal digestibilities
P11435560A1322|29 38|HFV R region
P11435578A0760|5 8|TxRE
P11435578A2231|20 33|reconstitution
P11435605A0587|0 23|Site-directed mutagenesis
P11435688A0262|4 12|subfamily
P11435983T0000|0 8|Tolerance
P11437439A0201|3 18|promoter activity
P11437660A1219|0 11|Substitution
P11438651A1365|5 27|replication fork movement
P11438654A1237|5 12|findings
P11438666A0555|13 29|novel mouse protein
P11438838A0788|3 16|other inhibitor
P11439343A0785|12 15|MPc3
P11441163T0000|0 9|Foreigners
P11441311X0001|0 15|Long-term results
P11441952A0414|4 7|days
P11441974A0320|31 51|pulmonary hemolymph PO2
P11443509A0293|0 5|DESIGN
P11443999A0573|0 19|Mean Hg concentrations
P11444762A0373|8 29|many different proposals
P11445008A0816|3 7|assay
P11447490A0598|18 25|effusion
P11448051A0093|40 72|constant small intestine transit time
P11449014A0000|0 13|STUDY OBJECTIVE
P11450490A0565|3 46|median preoperative best-corrected visual acuity
P11450776T0000|1 8|rare case
P11451447A0205|0 4|Gimpl
P11451682A0190|3 21|present chemotherapy
P11451995T0000|0 10|Topological
P11454004T0000|0 17|Hormonal regulation
P11454190A0000|0 14|BACKGROUND/AIMS
P11454239A0478|0 18|Statistical Analysis
P11454703A0000|3 41|telomerase RNA-protein complex responsible
P11456259A0142|3 7|titer
P11457139A0604|3 9|results
P11459048A0485|27 39|uncertainties
P11459304T0078|0 19|Enantiomer separation
P11459794A1172|0 10|TE-671 cells
P11459960A1109|23 41|separable components
P11459962A0785|27 31|genes
P11460035A0548|5 12|last case
P11461595A0000|16 31|reaction kinetics
P11462004A0886|12 17|Vp1 DBD
P11462004A1500|5 13|nonviable
P11462024A0306|0 2|Zhu
P11462952A1040|7 19|gastrin levels
P11463359A0167|18 32|phorbol ester PMA
P11463834A0606|7 25|deletion mutagenesis
P11464997A0566|0 12|Such knowledge
P11465518A0000|0 9|BACKGROUND
P11465655A0439|5 12|next week
P11465844T0000|0 3|Lack
P11466227A1665|13 20|AS-oligo
P11467349A0452|7 21|challenging task
P11468958A0122|11 17|results
P11469701A0377|3 15|novel approach
P11469737A1791|12 25|isokinetic test
P11469853A0702|21 35|domain shuffling
P11469853A1053|22 36|further evidence
P11469926T0000|0 25|Breast cancer risk assessment
P11469970A0873|0 7|Patients
P11470914A0305|13 16|Rac1
P11471077A0382|0 6|RESULTS
P11471231A0964|16 23|patients
P11472523A0535|0 9|CONCLUSION
P11472696A0387|3 13|differences
P11473254A0000|0 3|NaeI
P11473261A0587|0 3|Mss4
P11474642A1451|3 12|decrements
P11478627A0573|3 22|desirability function
P11479104A0446|21 52|positive anti-cardiolipin antibody
P11479501A0744|0 6|RESULTS
P11480490A0443|9 33|electrocardiographic signs
P11480497T0000|0 6|Effects
P11480555A0928|15 22|ceramide
P11481625A0202|23 30|subjects
P11484028T0000|2 14|cross purposes
P11484578A1132|0 9|CONCLUSION
P11486032A1261|8 27|transcription factors
P11486141A0424|0 10|Many factors
P11486399A0000|16 25|ifosfamide
P11486476A0147|1 16|prospective trial
P11486476A1512|0 22|Cardiac markers troponin T
P11489597A0379|2 12|termination
P11489597A0561|3 15|maternal death
P11490862A0141|5 22|further development
P11494391A0579|3 9|results
P11495833T0000|39 43|means
P11495920A0504|1 18|1-base pair mismatch
P11496495A0000|3 9|authors
P11496617A0301|0 6|METHODS
P11498795A0716|4 18|slow progression
P11500377A0518|2 8|mammals
P11500512A0000|3 16|human ABCG1 gene
P11500571A0976|7 24|abundant expression
P11500913A1238|0 11|C/EBPbeta LIP
P11502738A1457|0 15|Identical effects
P11502758A0869|5 12|findings
P11502778A0941|9 18|elderly men
P11504545A0393|0 38|Competition electrophoretic mobility shift
P11504709A0981|25 43|inducible expression
P11505407A0461|0 6|RESULTS
P11509266A0955|2 47|Cox proportional hazards regression adenocarcinoma
P11509615T0000|0 27|Phosphatidylinositol 3-kinase
P11509673A0574|5 23|stable transfectants
P11511544T0000|3 12|loop domain
P11512925A0000|0 16|EXAFS measurements
P11513121T0000|0 15|Progressive study
P11513180A1257|8 12|cases
P11513579A0372|8 23|two-hybrid system
P11516890A0236|24 38|cytochrome P-450
P11517190A0352|0 7|Analysis
P11517190T0000|0 20|Novel intronic promoter
P11517269A0472|0 4|Pitx2
P11517399A0858|3 10|patterns
P11517445A0221|9 13|cases
P11518505A0107|54 70|particular tissues
P11518868A0559|34 54|nonsexual risk behavior
P11519466A0196|0 15|Low-selenium diet
P11520436A0705|5 14|BALB/c mice
P11521191A0000|28 50|adenoviral 12S E1A protein
P11522431A0673|3 12|prevalence
P11522584A0882|0 14|Diffuse myalgias
P11522626A1374|12 29|hormonal regulation
P11522658A0086|25 44|ErbB1/ErbB2 signaling
P11522658A0870|18 32|phosphorylation
P11523446A0523|0 2|ICA
P11524015A0937|18 23|BZAP45
P11524815A0753|0 16|Local control rates
P11524823X0001|0 6|Utility
P11525102A0970|14 30|systematic reviews
P11525486A0350|14 22|CaCO3-CO2
P11525640A0560|0 9|Inhibition
P11528127A1402|5 13|GC content
P11528253X1211|0 8|Copyright
P11528500A0571|2 9|mutation
P11529914T0000|0 8|NF-kappaB
P11530684A0667|5 15|nerve injury
P11530829A0000|45 56|ECG simulator
P11532556A0000|0 38|Subacute diencephalic angioencephalopathy
P11532856A1175|0 4|Third
P11533238A1137|0 7|Mutation
P11533340A1285|10 30|significant difference
P11533863A0125|5 14|single case
P11534132A0219|12 24|search engines
P11534900A0000|3 8|binary
P11535014A1157|7 18|above results
P11535140T0000|0 19|Audiological findings
P11535532A0189|3 29|deubiquitinating enzyme DUB-2
P11535832A0586|3 9|isoform
P11536063A0178|0 19|Pulmonary embolectomy
P11538437A0568|2 15|such conditions
P11539522A0612|3 16|NAUSICAA system
P11540991A0127|22 28|effects
P11542677A0411|37 50|Generic Systems
P11542780A0086|0 34|Different thermoluminescent detectors
P11543154T0000|0 8|Responses
P11543317A0203|55 63|detectors
P11543662A0562|8 11|gstC
P11545594A1556|23 32|Myb domains
P11547819A0532|0 6|METHODS
P11548027A0163|13 33|performance indicators
P11550795A2583|0 13|Overexpression
P11552058A0235|4 6|ICP
P11552058A0833|0 13|Other therapies
P11552724A0527|0 10|CONCLUSIONS
P11552922A0361|0 14|CYP2C19 genotype
P11553091A1472|3 9|results
P11553704A0674|0 10|Similar data
P11554469A1386|5 12|analyses
P11554566A0668|3 19|hatcher incubators
P11554566A0833|6 19|companies sites
P11554727A0890|3 21|mutation experiments
P11555516A0639|0 12|Cardiac output
P11555669A0464|0 9|Experience
P11555669A0983|19 26|sections
P11556809A2085|17 46|CYP71D20-encoded enzyme activity
P11557127A0991|13 16|NF-Y
P11559366T0000|0 37|E2F1-mediated transcriptional inhibition
P11559547T0000|0 24|Transcriptional regulation
P11559564A0459|0 5|NB-506
P11559789A0314|26 51|replication-deficient virus
P11559821A1315|0 15|DNA binding assays
P11560292A0557|17 36|categorical structure
P11560509T0000|0 13|DNA recognition
P11560990A0272|0 15|E47 protein levels
P11560992A0000|3 54|dual specificity kinases mitogen-activated protein kinase
P11560992A0651|0 17|SAPK/JNK activation
P11560992A1184|5 8|MKK7
P11561623A0897|3 40|small copepod Pseudonychocamptus proximus
P11561626A0197|13 28|aqueous solutions
P11562278A0169|0 3|Many
P11562870A0892|3 13|probability
P11564871A1184|5 11|results
P11564893A1068|21 32|conformation
P11565747A1020|0 3|Data
P11566874T0000|1 16|split motor domain
P11566948A1217|2 28|hypertensive nephrosclerosis
P11566961A0472|0 18|Body weight reduction
P11566996A1391|17 20|uvrA
P11568988A0960|3 21|best regression model
P11569800T0000|0 21|Temperature measurement
P11569900A0660|0 13|APC-resistance
P11569949A2087|0 4|Zarix
P11570735A1097|0 6|RESULTS
P11570820T0000|4 15|casein kinase
P11572377T0000|0 2|Use
P11572388A0000|21 27|results
P11572467A0658|7 15|blood clot
P11572467T0000|0 9|Management
P11573771T0000|0 5|Effect
P11573891A0525|0 6|RESULTS
P11574088A1687|30 47|pancreas transplant
P11574105A0727|0 7|Patients
P11575109A0214|9 35|baseline clinical examination
P11575977A1133|8 15|patients
P11576158A1371|5 16|TVD-patients
P11576776T0081|5 17|dynamic moduli
P11577094A1226|5 12|findings
P11578685A0077|0 5|ICAM-1
P11579100T0000|0 21|Phosphotyrosyl peptides
P11580173A0181|0 16|Plane wave geometry
P11580301A1161|14 25|HCV arthritis
P11580757A0304|0 6|METHODS
P11580941A0815|0 6|RESULTS
P11583428A0191|2 4|Exp
P11583621A0301|0 30|Several distinct apoptotic stimuli
P11583880T0000|0 25|Endovascular aneurysm repair
P11584107T0000|0 25|Chronic nutritional diseases
P11584328A0532|0 15|Drug interactions
P11585856A0285|0 6|METHODS
P11586096A0699|9 19|differences
P11587514A0758|11 27|abi1-1 gene product
P11587980A1039|2 15|children unable
P11589568A0744|9 13|yeast
P11589779T0000|0 5|HTLV-1
P11590364A1056|11 29|beta5L splice variant
P11592315A0325|0 8|PROCEDURE
P11592532A0188|0 6|METHODS
P11593394A0000|12 28|growth factor-beta
P11595170A0582|0 8|Alignment
P11595176T0000|3 18|genomic structure
P11595478A1014|0 18|Hp positive relatives
P11595813A0633|0 19|Peripheral metabolism
P11595840A0000|3 8|uptake
P11596104A0614|0 19|Northern blot analysis
P11596838A1357|28 48|fluticasone propionate
P11597185A0477|7 58|space-discrete/continuous metapopulation dynamic models
P11597936A0570|5 15|CAD patients
P11599079A1040|3 30|corresponding orifice voltages
P11599797A0732|0 6|RESULTS
P11599840A0813|3 8|moduli
P11600252A0795|3 4|LA
P11600314A0000|0 24|Direct current polarography
P11600365A0471|7 28|gram-positive organisms
P11600467A1436|20 40|significant alteration
P11602353A0770|13 21|HNF-3 beta
P11603271T0001|8 14|vertigo
P11604152A0526|3 6|MABP
P11605207T0001|0 8|Treatment
P11605598A0785|0 9|Hepatitis B
P11606538A1002|1 16|twelfth insertion
P11614398T0000|1 14|peculiar people
P11626110T0000|3 11|Available
P11639485A0478|4 13|unique work
P11642687T0000|0 9|Comparison
P11653491T0000|0 17|Disciplinary action
P11669281A0653|0 21|Epithelial cytotoxicity
P11669476A0346|0 23|Pro-inflammatory cytokine
P11675912A0131|49 68|analgesic preparation
P11676899A0704|7 26|important risk factors
P11677363A0775|7 22|important finding
P11677839A0876|23 30|patients
P11678437A0000|11 26|crude oil spillage
P11679441A0429|0 12|NO metabolites
P11680835A0756|5 21|base-case analysis
P11683558A0446|9 16|migrants
P11684665A0000|0 21|C. elegans embryogenesis
P11685047A0301|9 25|chromogenic method
P11685284X0000|1 12|Diabetologia
P11686239A0464|5 20|flanking sequence
P11686378A0326|18 24|reactor
P11687083A0218|0 9|OBJECTIVES
P11687180A3209|5 12|long term
P11687352A0215|0 6|METHODS
P11687517A1619|2 6|ISREs
P11687737A0000|0 9|BACKGROUND
P11687869A0000|1 16|38-year-old woman
P11689217T0000|0 30|Cholesteryl ester transfer protein
P11691585A1174|0 33|Electrophoretic mobility shift assays
P11691585T0000|3 18|hcKrox gene family
P11692004A1200|33 60|comprehensive clinical studies
P11693461A1649|5 19|utilisation data
P11695481A0310|8 17|conditions
P11697760A0000|28 32|boron
P11703464A0560|12 30|control subjects rCBF
P11703558A0000|0 10|Doxorubicin
P11704380A1608|3 11|event rate
P11704829A0312|0 23|Subtraction hybridization
P11705093A2016|10 27|vitamin D3 analogues
P11706668A0000|0 9|Hydrocoele
P11706949T0000|0 12|Growth hormone
P11707977A0750|5 13|other hand
P11708032A0183|28 56|hepatic intra-arterial infusion
P11708362A0889|3 15|astronaut crew
P11708431A0904|8 15|patients
P11708761A1388|32 40|arguments
P11709561T0000|0 4|Phase
P11709890T0000|0 28|Hepatitis A infected food handler
P11710233T0000|0 8|Hydrogels
P11710685A0994a|14 19|subset
P11710685A0994b|14 19|subset
P11711701A0602|3 27|nuclear medicine physicians
P11714429X0000|2 20|clopidogrel superior
P11715079A1016|17 30|proprioception
P11716043A0380|22 29|patients
P11716441A0585|0 2|ISS
P11718197A1282|42 51|sternotomy
P11722993A0276|0 10|Paul Monagle
P11723500X0000|1 8|Clinical
P11723511A0780|9 23|gestational risk
P11723675A1022|3 10|severity
P11723928A0294|29 44|river reclamation
P11724510T0000|0 17|Physical principles
P11726022A0909|5 11|results
P11726068A0539|0 3|Rind
P11726164A0215|2 13|major concern
P11726262A0692|0 22|Lactate accumulation peak
P11726413A1756|12 20|clearance
P11726574A1304|5 11|results
P11727073A0842|0 9|CONCLUSION
P11727209A0502|3 10|patients
P11728771A0187|50 65|contrast material
P11730182A0984|22 43|significant correlation
P11730262A0874|13 22|Dutch study
P11730712A0416|0 16|Treadmill training
P11732088A0471|20 40|false positive readings
P11732417A0571|3 34|cut-off percentage positivity value
P11736254A0000|43 56|solvable models
P11736792A0204|9 20|semen samples
P11737056A0680|6 14|timepoint
P11737158A1517|0 21|Modality-specific areas
P11737900A0700|27 35|plasma COP
P11738404A0120|5 22|chemical structures
P11740571A0114|4 9|toxins
P11740806X0810|0 14|Saunders Company
P11741259A1233|16 36|pH-sensitive particles
P11741554T0000|0 9|Comparison
P11742432A0798|7 13|results
P11743360A2491|0 10|Acute stress
P11743612A1179|0 7|Patients
P11744290T0045|1 9|Cactaceae
P11744953A0878|0 10|Skin cancers
P11752821A1365|0 9|CONCLUSION
P11755894A0466|16 34|opioid naive patients
P11760398A0553|0 6|METHODS
P11760796A0698|0 7|Evidence
P11761601A0133|1 15|computer program
P11763176A0918|10 23|severe decrease
P11764062A0000|3 29|Penn State Worry Questionnaire
P11764226A0798|0 13|Classification
P11765448A0588|9 23|X-ray projection
P11766747A0000|23 38|pathologic review
P11768467A0000|0 21|Pyrethroid insecticides
P11769229A0357|3 20|sorption mechanisms
P11771979A1141|11 17|spatial
P11773168A0915|3 23|5-year overall survival
P11773921A0397|0 6|METHODS
P11775180A0379|0 29|Traditional surgical exploration
P11775301A0797|27 42|depression scores
P11776922A0830|11 19|sclerosis
P11777575A0363|30 39|bulgaricus
P11777632A1678|0 1|AF
P11778044A0000|8 43|joint probability density distributions
P11778804A0179|0 8|Frequency
P11781615A0000|0 30|Chronic graft-versus-host disease
P11782218A0349|10 23|white-on-white
P11783457A0000|0 12|Preservatives
P11785085X0001|0 18|Comparative analysis
P11785827A0986|3 9|results
P11786248A1162|0 10|Consumption
P11786945A0958|0 15|Actuarial freedom
P11787041A0167|0 16|Mental development
P11787322X0001|0 8|Influence
P11787720A1313|25 38|slight decrease
P11787746A0374|0 9|Vitrectomy
P11789206A1182|0 10|CONCLUSIONS
P11789216T0001|0 6|Effects
P11790897T0000|0 16|Proteomic patterns
P11791292A0193|48 60|neural network
P11791571T0000|1 48|high-efficiency cross-flow micronebulizer interface
P11791585A0287|3 12|electrodes
P11791853A0532|3 21|experimental results
P11792586A0290|0 12|Cyclic loading
P11793172A0545|3 23|weight-bearing surface
P11793614A0000|0 8|OBJECTIVE
P11796977T0000|0 7|Postdocs
P11800119A0814|3 17|design principle
P11800586A1090|10 17|DPPD gene
P11800878T0000|0 13|Dynamic imaging
P11801459T0000|0 7|Efficacy
P11802580A0000|3 33|General Practice Research Database
P11802601A0107|19 25|results
P11803325A0868|7 21|DC cardioversion
P11804081A0552|5 10|August
P11804100A0365a|17 29|disappearance
P11804100A0365b|17 29|disappearance
P11804510A0730|0 5|Losses
P11806132A0253|3 13|TB incidence
P11810685A0147|16 39|displacement distribution
P11811743A0800|26 34|retention
P11811825A0972|3 9|results
P11815644A0081|3 25|physical characteristics
P11816458A0319|11 18|Examples
P11816779A0343|3 13|drug packets
P11818675X0897|0 7|Karger AG
P11819326A0000|0 2|AIM
P11821098A0269|0 17|MAIN OUTCOME MEASURE
P11822790A0907|13 25|total SIP score
P11822811A0319|0 4|Group
P11824701A0894|0 7|Patients
P11824801A0661|14 25|continuation
P11825801A1212|11 32|tumor-related mortality
P11826141T0000|0 17|Dissociable effects
P11828186A0239|33 35|men
P11830544A0335|0 8|Herceptin
P11831512A0468|11 14|pigs
P11832019A0668|0 10|CONCLUSIONS
P11833863A0987|22 34|apnea duration
P11834476A1187|13 28|large animal model
P11835109A0000|77 97|health-related quality
P11836046A0549|43 44|mg
P11836303A0518|0 7|TNFalpha
P11836303A1191|38 56|prenatal disturbance
P11837409A0584|3 10|two-wave
P11838058A0084|0 6|METHODS
P11838102T0001|0 6|Wegener
P11840365A0949|9 25|significant effect
P11842037A0327|7 24|analytic precisions
P11842728X0001|18 32|schistosomiasis
P11843252A0907|1 18|global response rate
P11844591A0329|14 25|new parameter
P11844812A0915|12 21|ng/mL model
P11845547A0449|0 18|Potential treatments
P11846167A0000|0 7|Selenium
P11846187A0894|3 21|GT-foreign-pictures
P11847580T0000|0 25|Emphysematous cholecystitis
P11849417A0900|0 2|Age
P11849796A0452|0 6|RESULTS
P11851941A0372|19 49|radiolabelled serumalbumin method
P11852907A0871|3 30|equilibrium phosphorus content
P11853943A0122|3 21|long-term prediction
P11858256A0102|7 26|considerable research
P11858548A0241|43 46|mono
P11858635A0896|20 34|general property
P11859400A0229|13 20|efficacy
P11859943A0150|3 8|adults
P11860097A1695|0 3|Data
P11860723A0182|1 10|mail survey
P11860876A0409|0 12|HIV-1 C subtype
P11861092A0730|5 11|plateau
P11862350T0000|1 16|comparative study
P11863811A0259|21 33|Nusselt number
P11864173T0000|0 4|Viral
P11865218A0069|0 8|Treatment
P11866130A0419|11 20|benzocaine
P11867388A0502|3 4|EC
P11870646A0668|12 23|such analyses
P11872359A0000|21 37|insulin resistance
P11872570T0000|0 7|Dementia
P11873003X0000|0 13|HIV-1 infection
P11874637A0212|14 40|active antiretroviral therapy
P11875695A0718|0 3|Time
P11876937A0261|0 6|Heparin
P11879108A0719|0 17|MAIN OUTCOME MEASURE
P11881268A0000|55 98|meaningful exercise self-efficacy questionnaire
P11881923A1256|0 9|Neutrophil
P11882054A0568|0 7|Adjacent
P11882054A1250|8 23|close correlation
P11882747A0354|0 1|CD
P11883682A0162|18 27|monitoring
P11883763A1062|3 13|large fluxes
P11884014A0665|0 25|Rigorous treatment protocols
P11885053A1897|30 35|Volkan
P11885737A1713|23 40|spermatozoa/microl
P11886473A0796|0 13|Gastritis score
P11887803A1455|3 15|mean thickness
P11888183A0541|1 15|further analysis
P11888867A0000|0 9|BACKGROUND
P11890354A0000|0 16|Genetics Institute
P11890438A0838|0 7|Patients
P11893403A0252|0 7|Elements
P11893767A0356|3 15|mass-specific
P11894605A1429|0 13|INTERPRETATION
P11895024A1054|4 8|cases
P11895184A0000|12 15|rats
P11897449A0566|13 34|earliest activation site
P11897888A0590|0 11|Urine samples
P11897950A0617|0 10|CONCLUSIONS
P11898018T0000|0 13|Data management
P11898797A0124|31 36|levels
P11899479A0122|11 16|smears
P11899489A0119|3 9|effects
P11900770T0000|19 28|incentives
P11902068T0000|3 12|CKD patient
P11902738A0185|0 7|PATIENTS
P11902781A0550|0 13|Concentrations
P11904017A0000|8 32|pathophysiological process
P11907691A0214|3 14|orientations
P11908529A0553|3 9|results
P11909404A0000|0 11|Nodal domains
P11910310A0279|0 5|DESIGN
P11910344A1119|0 10|CONCLUSIONS
P11911552A0776|2 9|patients
P11912261A0284|0 17|Calcimimetic agents
P11912677A0281|4 15|such analysis
P11913427A0290|3 10|subjects
P11915436A0491|11 24|incidence rates
P11917061A0922|3 15|only predictor
P11917882A0326|8 25|morphological study
P11920455X1195|0 8|Copyright
P11920896A0298|30 31|DR
P11921126A1196|15 20|PDQ-39
